words,sentence_id,labels
Debrisoquine,0,B-ChemicalEntity
phenotype,0,O
and,0,O
the,0,O
pharmacokinetics,0,O
and,0,O
beta-2,0,B-GeneOrGeneProduct
receptor,0,I-GeneOrGeneProduct
pharmacodynamics,0,O
of,0,O
metoprolol,0,B-ChemicalEntity
and,0,O
its,0,O
enantiomers,0,O
.,0,O
The,1,O
metabolism,1,O
of,1,O
the,1,O
cardioselective,1,O
beta-blocker,1,O
metoprolol,1,B-ChemicalEntity
is,1,O
under,1,O
genetic,1,O
control,1,O
of,1,O
the,1,O
debrisoquine/sparteine,1,B-ChemicalEntity
type,1,O
.,1,O
The,2,O
two,2,O
metabolic,2,O
phenotypes,2,O
",",2,O
extensive,2,O
(,2,O
EM,2,O
),2,O
and,2,O
poor,2,O
metabolizers,2,O
(,2,O
PM,2,O
),2,O
",",2,O
show,2,O
different,2,O
stereoselective,2,O
metabolism,2,O
",",2,O
resulting,2,O
in,2,O
apparently,2,O
higher,2,O
beta-1,2,B-GeneOrGeneProduct
adrenoceptor,2,I-GeneOrGeneProduct
antagonistic,2,O
potency,2,O
of,2,O
racemic,2,O
metoprolol,2,B-ChemicalEntity
in,2,O
EMs,2,O
.,2,O
We,3,O
investigated,3,O
if,3,O
the,3,O
latter,3,O
also,3,O
applies,3,O
to,3,O
the,3,O
beta-2,3,B-GeneOrGeneProduct
adrenoceptor,3,I-GeneOrGeneProduct
antagonism,3,O
by,3,O
metoprolol,3,B-ChemicalEntity
.,3,O
The,4,O
drug,4,O
effect,4,O
studied,4,O
was,4,O
the,4,O
antagonism,4,O
by,4,O
metoprolol,4,B-ChemicalEntity
of,4,O
terbutaline-induced,4,B-ChemicalEntity
hypokalemia,4,B-DiseaseOrPhenotypicFeature
.,4,O
By,5,O
using,5,O
pharmacokinetic,5,O
pharmacodynamic,5,O
modeling,5,O
the,5,O
pharmacodynamics,5,O
of,5,O
racemic,5,O
metoprolol,5,B-ChemicalEntity
and,5,O
the,5,O
active,5,O
S-isomer,5,O
",",5,O
were,5,O
quantitated,5,O
in,5,O
EMs,5,O
and,5,O
PMs,5,O
in,5,O
terms,5,O
of,5,O
IC50,5,O
values,5,O
",",5,O
representing,5,O
metoprolol,5,B-ChemicalEntity
plasma,5,O
concentrations,5,O
resulting,5,O
in,5,O
half-maximum,5,O
receptor,5,O
occupancy,5,O
.,5,O
Six,6,O
EMs,6,O
received,6,O
0.5,6,O
mg,6,O
of,6,O
terbutaline,6,B-ChemicalEntity
s.c.,6,O
on,6,O
two,6,O
different,6,O
occasions,6,O
:,6,O
1,6,O
),6,O
1,6,O
hr,6,O
after,6,O
administration,6,O
of,6,O
a,6,O
placebo,6,O
and,6,O
2,6,O
),6,O
1,6,O
hr,6,O
after,6,O
150,6,O
mg,6,O
of,6,O
metoprolol,6,B-ChemicalEntity
p.o,6,O
.,6,O
Five,7,O
PMs,7,O
were,7,O
studied,7,O
according,7,O
to,7,O
the,7,O
same,7,O
protocol,7,O
",",7,O
except,7,O
for,7,O
a,7,O
higher,7,O
terbutaline,7,B-ChemicalEntity
dose,7,O
(,7,O
0.75,7,O
mg,7,O
),7,O
on,7,O
day,7,O
2,7,O
.,7,O
Blood,8,O
samples,8,O
for,8,O
the,8,O
analysis,8,O
of,8,O
plasma,8,O
potassium,8,B-ChemicalEntity
",",8,O
terbutaline,8,B-ChemicalEntity
",",8,O
metoprolol,8,B-ChemicalEntity
(,8,O
racemic,8,O
",",8,O
R-,8,O
and,8,O
S-isomer,8,O
),8,O
",",8,O
and,8,O
alpha-hydroxymetoprolol,8,B-ChemicalEntity
concentrations,8,O
were,8,O
taken,8,O
at,8,O
regular,8,O
time,8,O
intervals,8,O
",",8,O
during,8,O
8,8,O
hr,8,O
after,8,O
metoprolol,8,B-ChemicalEntity
.,8,O
In,9,O
PMs,9,O
",",9,O
metoprolol,9,B-ChemicalEntity
increased,9,O
the,9,O
terbutaline,9,B-ChemicalEntity
area,9,O
under,9,O
the,9,O
plasma,9,O
concentration,9,O
vs.,9,O
time,9,O
curve,9,O
(,9,O
+67,9,O
%,9,O
),9,O
.,9,O
Higher,10,O
metoprolol/alpha-hydroxymetoprolol,10,B-ChemicalEntity
ratios,10,O
in,10,O
PMs,10,O
were,10,O
predictive,10,O
for,10,O
higher,10,O
R-/S-isomer,10,O
ratios,10,O
of,10,O
unchanged,10,O
drug,10,O
.,10,O
There,11,O
was,11,O
a,11,O
difference,11,O
in,11,O
metoprolol,11,B-ChemicalEntity
potency,11,O
with,11,O
higher,11,O
racemic,11,O
metoprolol,11,B-ChemicalEntity
IC50,11,O
values,11,O
in,11,O
PMs,11,O
(,11,O
72,11,O
+/-,11,O
7,11,O
ng.ml-1,11,O
),11,O
than,11,O
EMs,11,O
(,11,O
42,11,O
+/-,11,O
8,11,O
ng.ml-1,11,O
",",11,O
P,11,O
less,11,O
than,11,O
.001,11,O
),11,O
.,11,O
(,12,O
ABSTRACT,12,O
TRUNCATED,12,O
AT,12,O
250,12,O
WORDS,12,O
),12,O
Molecular,13,O
and,13,O
phenotypic,13,O
analysis,13,O
of,13,O
patients,13,B-OrganismTaxon
with,13,O
deletions,13,O
within,13,O
the,13,O
deletion-rich,13,O
region,13,O
of,13,O
the,13,O
Duchenne,13,B-GeneOrGeneProduct
muscular,13,I-GeneOrGeneProduct
dystrophy,13,I-GeneOrGeneProduct
(,13,I-GeneOrGeneProduct
DMD,13,I-GeneOrGeneProduct
),13,I-GeneOrGeneProduct
gene,13,I-GeneOrGeneProduct
.,13,O
Eighty,14,O
unrelated,14,O
individuals,14,O
with,14,O
Duchenne,14,B-DiseaseOrPhenotypicFeature
muscular,14,I-DiseaseOrPhenotypicFeature
dystrophy,14,I-DiseaseOrPhenotypicFeature
(,14,O
DMD,14,B-DiseaseOrPhenotypicFeature
),14,O
or,14,O
Becker,14,B-DiseaseOrPhenotypicFeature
muscular,14,I-DiseaseOrPhenotypicFeature
dystrophy,14,I-DiseaseOrPhenotypicFeature
(,14,O
BMD,14,B-DiseaseOrPhenotypicFeature
),14,O
were,14,O
found,14,O
to,14,O
have,14,O
deletions,14,O
in,14,O
the,14,O
major,14,O
deletion-rich,14,O
region,14,O
of,14,O
the,14,O
DMD,14,B-GeneOrGeneProduct
locus,14,O
.,14,O
This,15,O
region,15,O
includes,15,O
the,15,O
last,15,O
five,15,O
exons,15,O
detected,15,O
by,15,O
cDNA5b-7,15,O
",",15,O
all,15,O
exons,15,O
detected,15,O
by,15,O
cDNA8,15,O
",",15,O
and,15,O
the,15,O
first,15,O
two,15,O
exons,15,O
detected,15,O
by,15,O
cDNA9,15,O
.,15,O
These,16,O
80,16,O
individuals,16,O
account,16,O
for,16,O
approximately,16,O
75,16,O
%,16,O
of,16,O
109,16,O
deletions,16,O
of,16,O
the,16,O
gene,16,O
",",16,O
detected,16,O
among,16,O
181,16,O
patients,16,B-OrganismTaxon
analyzed,16,O
with,16,O
the,16,O
entire,16,O
dystrophin,16,B-GeneOrGeneProduct
cDNA,16,O
.,16,O
Endpoints,17,O
for,17,O
many,17,O
of,17,O
these,17,O
deletions,17,O
were,17,O
further,17,O
characterized,17,O
using,17,O
two,17,O
genomic,17,O
probes,17,O
",",17,O
p20,17,O
(,17,O
DXS269,17,O
;,17,O
Wapenaar,17,O
et,17,O
al,17,O
.,17,O
),17,O
and,18,O
GMGX11,18,O
(,18,O
DXS239,18,O
;,18,O
present,18,O
paper,18,O
),18,O
.,18,O
Clinical,19,O
findings,19,O
are,19,O
presented,19,O
for,19,O
all,19,O
80,19,O
patients,19,B-OrganismTaxon
allowing,19,O
a,19,O
correlation,19,O
of,19,O
phenotypic,19,O
severity,19,O
with,19,O
the,19,O
genotype,19,O
.,19,O
Thirty-eight,20,O
independent,20,O
patients,20,B-OrganismTaxon
were,20,O
old,20,O
enough,20,O
to,20,O
be,20,O
classified,20,O
as,20,O
DMD,20,B-DiseaseOrPhenotypicFeature
",",20,O
BMD,20,B-DiseaseOrPhenotypicFeature
",",20,O
or,20,O
intermediate,20,O
phenotype,20,O
and,20,O
had,20,O
deletions,20,O
of,20,O
exons,20,O
with,20,O
sequenced,20,O
intron/exon,20,O
boundaries,20,O
.,20,O
Of,21,O
these,21,O
",",21,O
eight,21,O
BMD,21,B-DiseaseOrPhenotypicFeature
patients,21,B-OrganismTaxon
and,21,O
one,21,O
intermediate,21,O
patient,21,B-OrganismTaxon
had,21,O
gene,21,O
deletions,21,O
predicted,21,O
to,21,O
leave,21,O
the,21,O
reading,21,O
frame,21,O
intact,21,O
",",21,O
while,21,O
21,21,O
DMD,21,B-DiseaseOrPhenotypicFeature
patients,21,B-OrganismTaxon
",",21,O
7,21,O
intermediate,21,O
patients,21,B-OrganismTaxon
",",21,O
and,21,O
1,21,O
BMD,21,B-DiseaseOrPhenotypicFeature
patient,21,B-OrganismTaxon
had,21,O
gene,21,O
deletions,21,O
predicted,21,O
to,21,O
disrupt,21,O
the,21,O
reading,21,O
frame,21,O
.,21,O
Thus,22,O
",",22,O
with,22,O
two,22,O
exceptions,22,O
",",22,O
frameshift,22,O
deletions,22,O
of,22,O
the,22,O
gene,22,O
resulted,22,O
in,22,O
more,22,O
severe,22,O
phenotype,22,O
than,22,O
did,22,O
in-frame,22,O
deletions,22,O
.,22,O
This,23,O
is,23,O
in,23,O
agreement,23,O
with,23,O
recent,23,O
findings,23,O
by,23,O
Baumbach,23,O
et,23,O
al,23,O
.,23,O
and,24,O
Koenig,24,O
et,24,O
al,24,O
.,24,O
but,25,O
is,25,O
in,25,O
contrast,25,O
to,25,O
findings,25,O
",",25,O
by,25,O
Malhotra,25,O
et,25,O
al,25,O
.,25,O
at,26,O
the,26,O
5,26,O
',26,O
end,26,O
of,26,O
the,26,O
gene,26,O
.,26,O
Nefiracetam,27,B-ChemicalEntity
(,27,O
DM-9384,27,B-ChemicalEntity
),27,O
reverses,27,O
apomorphine-induced,27,B-ChemicalEntity
amnesia,27,B-DiseaseOrPhenotypicFeature
of,27,O
a,27,O
passive,27,O
avoidance,27,O
response,27,O
:,27,O
delayed,27,O
emergence,27,O
of,27,O
the,27,O
memory,27,O
retention,27,O
effects,27,O
.,27,O
Nefiracetam,28,B-ChemicalEntity
is,28,O
a,28,O
novel,28,O
pyrrolidone,28,B-ChemicalEntity
derivative,28,O
which,28,O
attenuates,28,O
scopolamine-induced,28,B-ChemicalEntity
learning,28,B-DiseaseOrPhenotypicFeature
and,28,I-DiseaseOrPhenotypicFeature
post-training,28,I-DiseaseOrPhenotypicFeature
consolidation,28,I-DiseaseOrPhenotypicFeature
deficits,28,I-DiseaseOrPhenotypicFeature
.,28,O
Given,29,O
that,29,O
apomorphine,29,B-ChemicalEntity
inhibits,29,O
passive,29,O
avoidance,29,O
retention,29,O
when,29,O
given,29,O
during,29,O
training,29,O
or,29,O
in,29,O
a,29,O
defined,29,O
10-12h,29,O
post-training,29,O
period,29,O
",",29,O
we,29,O
evaluated,29,O
the,29,O
ability,29,O
of,29,O
nefiracetam,29,B-ChemicalEntity
to,29,O
attenuate,29,O
amnesia,29,B-DiseaseOrPhenotypicFeature
induced,29,O
by,29,O
dopaminergic,29,B-ChemicalEntity
agonism,29,I-ChemicalEntity
.,29,O
A,30,O
step-down,30,O
passive,30,O
avoidance,30,O
paradigm,30,O
was,30,O
employed,30,O
and,30,O
nefiracetam,30,B-ChemicalEntity
(,30,O
3,30,O
mg/kg,30,O
),30,O
and,30,O
apomorphine,30,B-ChemicalEntity
(,30,O
0.5,30,O
mg/kg,30,O
),30,O
were,30,O
given,30,O
alone,30,O
or,30,O
in,30,O
combination,30,O
during,30,O
training,30,O
and,30,O
at,30,O
the,30,O
10-12h,30,O
post-training,30,O
period,30,O
of,30,O
consolidation,30,O
.,30,O
Co-administration,31,O
of,31,O
nefiracetam,31,B-ChemicalEntity
and,31,O
apomorphine,31,B-ChemicalEntity
during,31,O
training,31,O
or,31,O
10h,31,O
thereafter,31,O
produced,31,O
no,31,O
significant,31,O
anti-amnesic,31,O
effect,31,O
.,31,O
However,32,O
",",32,O
administration,32,O
of,32,O
nefiracetam,32,B-ChemicalEntity
during,32,O
training,32,O
completely,32,O
reversed,32,O
the,32,O
amnesia,32,B-DiseaseOrPhenotypicFeature
induced,32,O
by,32,O
apomorphine,32,B-ChemicalEntity
at,32,O
the,32,O
10h,32,O
post-training,32,O
time,32,O
and,32,O
the,32,O
converse,32,O
was,32,O
also,32,O
true,32,O
.,32,O
These,33,O
effects,33,O
were,33,O
not,33,O
mediated,33,O
by,33,O
a,33,O
dopaminergic,33,O
mechanism,33,O
as,33,O
nefiracetam,33,B-ChemicalEntity
",",33,O
at,33,O
millimolar,33,O
concentrations,33,O
",",33,O
failed,33,O
to,33,O
displace,33,O
either,33,O
[,33,O
3H,33,B-ChemicalEntity
],33,O
SCH,33,B-ChemicalEntity
23390,33,I-ChemicalEntity
or,33,O
[,33,O
3H,33,B-ChemicalEntity
],33,O
spiperone,33,B-ChemicalEntity
binding,33,O
from,33,O
D1,33,B-GeneOrGeneProduct
or,33,I-GeneOrGeneProduct
D2,33,I-GeneOrGeneProduct
dopamine,33,I-GeneOrGeneProduct
receptor,33,I-GeneOrGeneProduct
subtypes,33,O
",",33,O
respectively,33,O
.,33,O
It,34,O
is,34,O
suggested,34,O
that,34,O
nefiracetam,34,B-ChemicalEntity
augments,34,O
molecular,34,O
processes,34,O
in,34,O
the,34,O
early,34,O
stages,34,O
of,34,O
events,34,O
which,34,O
ultimately,34,O
lead,34,O
to,34,O
consolidation,34,O
of,34,O
memory,34,O
.,34,O
Pethidine-associated,35,B-ChemicalEntity
seizure,35,B-DiseaseOrPhenotypicFeature
in,35,O
a,35,O
healthy,35,O
adolescent,35,O
receiving,35,O
pethidine,35,B-ChemicalEntity
for,35,O
postoperative,35,B-DiseaseOrPhenotypicFeature
pain,35,I-DiseaseOrPhenotypicFeature
control,35,O
.,35,O
A,36,O
healthy,36,O
17-year-old,36,O
male,36,O
received,36,O
standard,36,O
intermittent,36,O
doses,36,O
of,36,O
pethidine,36,B-ChemicalEntity
via,36,O
a,36,O
patient-controlled,36,B-OrganismTaxon
analgesia,36,O
(,36,O
PCA,36,O
),36,O
pump,36,O
for,36,O
management,36,O
of,36,O
postoperative,36,B-DiseaseOrPhenotypicFeature
pain,36,I-DiseaseOrPhenotypicFeature
control,36,O
.,36,O
Twenty-three,37,O
h,37,O
postoperatively,37,O
he,37,O
developed,37,O
a,37,O
brief,37,O
self-limited,37,O
seizure,37,B-DiseaseOrPhenotypicFeature
.,37,O
Both,38,O
plasma,38,O
pethidine,38,B-ChemicalEntity
and,38,O
norpethidine,38,B-ChemicalEntity
were,38,O
elevated,38,O
in,38,O
the,38,O
range,38,O
associated,38,O
with,38,O
clinical,38,O
manifestations,38,O
of,38,O
central,38,O
nervous,38,O
system,38,O
excitation,38,O
.,38,O
No,39,O
other,39,O
risk,39,O
factors,39,O
for,39,O
CNS,39,O
toxicity,39,B-DiseaseOrPhenotypicFeature
were,39,O
identified,39,O
.,39,O
This,40,O
method,40,O
allowed,40,O
frequent,40,O
self-dosing,40,O
of,40,O
pethidine,40,B-ChemicalEntity
at,40,O
short,40,O
time,40,O
intervals,40,O
and,40,O
rapid,40,O
accumulation,40,O
of,40,O
pethidine,40,B-ChemicalEntity
and,40,O
norpethidine,40,B-ChemicalEntity
.,40,O
The,41,O
routine,41,O
use,41,O
of,41,O
pethidine,41,B-ChemicalEntity
via,41,O
PCA,41,O
even,41,O
for,41,O
a,41,O
brief,41,O
postoperative,41,B-DiseaseOrPhenotypicFeature
analgesia,41,I-DiseaseOrPhenotypicFeature
should,41,O
be,41,O
reconsidered,41,O
.,41,O
Single-strand,42,O
conformation,42,O
polymorphism,42,O
analysis,42,O
of,42,O
the,42,O
FMR1,42,B-GeneOrGeneProduct
gene,42,O
in,42,O
autistic,42,B-DiseaseOrPhenotypicFeature
and,42,O
mentally,42,B-DiseaseOrPhenotypicFeature
retarded,42,I-DiseaseOrPhenotypicFeature
children,42,O
in,42,O
Japan,42,O
.,42,O
Fragile,43,B-DiseaseOrPhenotypicFeature
X,43,I-DiseaseOrPhenotypicFeature
syndrome,43,I-DiseaseOrPhenotypicFeature
is,43,O
one,43,O
of,43,O
the,43,O
most,43,O
common,43,O
causes,43,O
of,43,O
mental,43,B-DiseaseOrPhenotypicFeature
retardation,43,I-DiseaseOrPhenotypicFeature
in,43,O
males,43,O
",",43,O
and,43,O
patients,43,B-OrganismTaxon
with,43,O
fragile,43,B-DiseaseOrPhenotypicFeature
X,43,I-DiseaseOrPhenotypicFeature
syndrome,43,I-DiseaseOrPhenotypicFeature
occasionally,43,O
develop,43,O
autism,43,B-DiseaseOrPhenotypicFeature
.,43,O
It,44,O
is,44,O
usually,44,O
caused,44,O
by,44,O
an,44,O
expansion,44,O
of,44,O
the,44,O
trinucleotide,44,O
repeat,44,O
in,44,O
the,44,O
5'-untranslated,44,O
region,44,O
of,44,O
the,44,O
FMR1,44,B-GeneOrGeneProduct
gene,44,O
",",44,O
but,44,O
in,44,O
a,44,O
small,44,O
number,44,O
of,44,O
patients,44,B-OrganismTaxon
deletions,44,O
and,44,O
point,44,O
mutations,44,O
have,44,O
been,44,O
identified,44,O
.,44,O
We,45,O
screened,45,O
all,45,O
17,45,O
exons,45,O
of,45,O
the,45,O
FMR1,45,B-GeneOrGeneProduct
gene,45,O
for,45,O
mutations,45,O
in,45,O
90,45,O
autistic,45,B-DiseaseOrPhenotypicFeature
or,45,O
mentally,45,B-DiseaseOrPhenotypicFeature
retarded,45,I-DiseaseOrPhenotypicFeature
children,45,O
using,45,O
polymerase,45,O
chain,45,O
reaction,45,O
(,45,O
PCR,45,O
),45,O
-single,45,O
strand,45,O
conformation,45,O
polymorphism,45,O
(,45,O
SSCP,45,O
),45,O
analysis,45,O
.,45,O
No,46,O
mutations,46,O
were,46,O
found,46,O
in,46,O
76,46,O
male,46,O
patients,46,B-OrganismTaxon
.,46,O
However,47,O
",",47,O
one,47,O
female,47,O
patient,47,B-OrganismTaxon
was,47,O
heterozygous,47,O
for,47,O
a,47,O
normal,47,O
allele,47,O
and,47,O
a,47,O
mutant,47,O
allele,47,O
with,47,O
an,47,O
A,47,B-SequenceVariant
to,47,I-SequenceVariant
C,47,I-SequenceVariant
substitution,47,I-SequenceVariant
at,47,I-SequenceVariant
nucleotide,47,I-SequenceVariant
879,47,I-SequenceVariant
in,47,O
exon,47,O
9,47,O
.,47,O
This,48,O
mutation,48,O
was,48,O
not,48,O
found,48,O
in,48,O
50,48,O
controls,48,O
.,48,O
Reverse,49,O
transcription-PCR,49,O
revealed,49,O
that,49,O
a,49,O
large,49,O
proportion,49,O
of,49,O
the,49,O
mutant,49,O
transcripts,49,O
were,49,O
spliced,49,O
aberrantly,49,O
",",49,O
causing,49,O
premature,49,O
termination,49,O
of,49,O
the,49,O
protein,49,O
synthesis,49,O
.,49,O
Although,50,O
uncommon,50,O
",",50,O
point,50,O
mutations,50,O
in,50,O
the,50,O
FMR1,50,B-GeneOrGeneProduct
gene,50,O
may,50,O
be,50,O
a,50,O
cause,50,O
of,50,O
autism,50,B-DiseaseOrPhenotypicFeature
and,50,O
mental,50,B-DiseaseOrPhenotypicFeature
retardation,50,I-DiseaseOrPhenotypicFeature
in,50,O
Japanese,50,O
patients,50,B-OrganismTaxon
.,50,O
Organophosphate-induced,51,B-ChemicalEntity
convulsions,51,B-DiseaseOrPhenotypicFeature
and,51,O
prevention,51,O
of,51,O
neuropathological,51,B-DiseaseOrPhenotypicFeature
damages,51,I-DiseaseOrPhenotypicFeature
.,51,O
Such,52,O
organophosphorus,52,B-ChemicalEntity
(,52,O
OP,52,B-ChemicalEntity
),52,O
compounds,52,O
as,52,O
diisopropylfluorophosphate,52,B-ChemicalEntity
(,52,O
DFP,52,B-ChemicalEntity
),52,O
",",52,O
sarin,52,B-ChemicalEntity
and,52,O
soman,52,B-ChemicalEntity
are,52,O
potent,52,O
inhibitors,52,O
of,52,O
acetylcholinesterases,52,B-GeneOrGeneProduct
(,52,O
AChEs,52,B-GeneOrGeneProduct
),52,O
and,52,O
butyrylcholinesterases,52,B-GeneOrGeneProduct
(,52,O
BChEs,52,B-GeneOrGeneProduct
),52,O
.,52,O
The,53,O
acute,53,O
toxicity,53,B-DiseaseOrPhenotypicFeature
of,53,O
OPs,53,B-ChemicalEntity
is,53,O
the,53,O
result,53,O
of,53,O
their,53,O
irreversible,53,O
binding,53,O
with,53,O
AChEs,53,B-GeneOrGeneProduct
in,53,O
the,53,O
central,53,O
nervous,53,O
system,53,O
(,53,O
CNS,53,O
),53,O
",",53,O
which,53,O
elevates,53,O
acetylcholine,53,B-ChemicalEntity
(,53,O
ACh,53,B-ChemicalEntity
),53,O
levels,53,O
.,53,O
The,54,O
protective,54,O
action,54,O
of,54,O
subcutaneously,54,O
(,54,O
SC,54,O
),54,O
administered,54,O
antidotes,54,O
or,54,O
their,54,O
combinations,54,O
in,54,O
DFP,54,B-ChemicalEntity
(,54,O
2.0,54,O
mg/kg,54,O
BW,54,O
),54,O
intoxication,54,O
was,54,O
studied,54,O
in,54,O
9-10-weeks-old,54,O
Han-Wistar,54,O
male,54,O
rats,54,B-OrganismTaxon
.,54,O
The,55,O
rats,55,B-OrganismTaxon
received,55,O
AChE,55,B-GeneOrGeneProduct
reactivator,55,O
pralidoxime-2-chloride,55,B-ChemicalEntity
(,55,O
2PAM,55,B-ChemicalEntity
),55,O
(,55,O
30.0,55,O
mg/kg,55,O
BW,55,O
),55,O
",",55,O
anticonvulsant,55,O
diazepam,55,B-ChemicalEntity
(,55,O
2.0,55,O
mg/kg,55,O
BW,55,O
),55,O
",",55,O
A,55,B-GeneOrGeneProduct
(,55,I-GeneOrGeneProduct
1,55,I-GeneOrGeneProduct
),55,I-GeneOrGeneProduct
-adenosine,55,I-GeneOrGeneProduct
receptor,55,I-GeneOrGeneProduct
agonist,55,O
N,55,B-ChemicalEntity
(,55,I-ChemicalEntity
6,55,I-ChemicalEntity
),55,I-ChemicalEntity
-cyclopentyl,55,I-ChemicalEntity
adenosine,55,I-ChemicalEntity
(,55,O
CPA,55,B-ChemicalEntity
),55,O
(,55,O
2.0,55,O
mg/kg,55,O
BW,55,O
),55,O
",",55,O
NMDA-receptor,55,B-GeneOrGeneProduct
antagonist,55,O
dizocilpine,55,B-ChemicalEntity
maleate,55,I-ChemicalEntity
(,55,O
+-MK801,55,O
hydrogen,55,I-ChemicalEntity
maleate,55,I-ChemicalEntity
),55,O
(,55,O
2.0,55,O
mg/kg,55,O
BW,55,O
),55,O
or,55,O
their,55,O
combinations,55,O
with,55,O
cholinolytic,55,O
drug,55,O
atropine,55,B-ChemicalEntity
sulfate,55,I-ChemicalEntity
(,55,O
50.0,55,O
mg/kg,55,O
BW,55,O
),55,O
immediately,55,O
or,55,O
30,55,O
min,55,O
after,55,O
the,55,O
single,55,O
SC,55,O
injection,55,O
of,55,O
DFP,55,B-ChemicalEntity
.,55,O
The,56,O
control,56,O
rats,56,B-OrganismTaxon
received,56,O
atropine,56,B-ChemicalEntity
sulfate,56,I-ChemicalEntity
",",56,O
but,56,O
also,56,O
saline,56,O
and,56,O
olive,56,B-ChemicalEntity
oil,56,I-ChemicalEntity
instead,56,O
of,56,O
other,56,O
antidotes,56,O
and,56,O
DFP,56,B-ChemicalEntity
",",56,O
respectively,56,O
.,56,O
All,57,O
rats,57,B-OrganismTaxon
were,57,O
terminated,57,O
either,57,O
24,57,O
h,57,O
or,57,O
3,57,O
weeks,57,O
after,57,O
the,57,O
DFP,57,B-ChemicalEntity
injection,57,O
.,57,O
The,58,O
rats,58,B-OrganismTaxon
treated,58,O
with,58,O
DFP-atropine,58,B-ChemicalEntity
showed,58,O
severe,58,O
typical,58,O
OP-induced,58,B-ChemicalEntity
toxicity,58,B-DiseaseOrPhenotypicFeature
signs,58,O
.,58,O
When,59,O
CPA,59,B-ChemicalEntity
",",59,O
diazepam,59,B-ChemicalEntity
or,59,O
2PAM,59,B-ChemicalEntity
was,59,O
given,59,O
immediately,59,O
after,59,O
DFP-atropine,59,B-ChemicalEntity
",",59,O
these,59,O
treatments,59,O
prevented,59,O
",",59,O
delayed,59,O
or,59,O
shortened,59,O
the,59,O
occurrence,59,O
of,59,O
serious,59,O
signs,59,O
of,59,O
poisoning,59,B-DiseaseOrPhenotypicFeature
.,59,O
Atropine-MK801,60,B-ChemicalEntity
did,60,O
not,60,O
offer,60,O
any,60,O
additional,60,O
protection,60,O
against,60,O
DFP,60,B-ChemicalEntity
toxicity,60,B-DiseaseOrPhenotypicFeature
.,60,O
In,61,O
conclusion,61,O
",",61,O
CPA,61,B-ChemicalEntity
",",61,O
diazepam,61,B-ChemicalEntity
and,61,O
2PAM,61,B-ChemicalEntity
in,61,O
combination,61,O
with,61,O
atropine,61,B-ChemicalEntity
prevented,61,O
the,61,O
occurrence,61,O
of,61,O
serious,61,O
signs,61,O
of,61,O
poisoning,61,B-DiseaseOrPhenotypicFeature
and,61,O
thus,61,O
reduced,61,O
the,61,O
toxicity,61,B-DiseaseOrPhenotypicFeature
of,61,O
DFP,61,B-ChemicalEntity
in,61,O
rat,61,B-OrganismTaxon
.,61,O
CRYBA3/A1,62,B-GeneOrGeneProduct
gene,62,O
mutation,62,O
associated,62,O
with,62,O
suture-sparing,62,O
autosomal,62,B-DiseaseOrPhenotypicFeature
dominant,62,I-DiseaseOrPhenotypicFeature
congenital,62,I-DiseaseOrPhenotypicFeature
nuclear,62,I-DiseaseOrPhenotypicFeature
cataract,62,I-DiseaseOrPhenotypicFeature
:,62,O
a,62,O
novel,62,O
phenotype,62,O
.,62,O
PURPOSE,63,O
:,63,O
To,63,O
identify,63,O
the,63,O
genetic,63,B-DiseaseOrPhenotypicFeature
defect,63,I-DiseaseOrPhenotypicFeature
leading,63,O
to,63,O
the,63,O
congenital,63,B-DiseaseOrPhenotypicFeature
nuclear,63,I-DiseaseOrPhenotypicFeature
cataract,63,I-DiseaseOrPhenotypicFeature
affecting,63,O
a,63,O
large,63,O
five-generation,63,O
Swiss,63,O
family,63,O
.,63,O
METHODS,64,O
:,64,O
Family,64,O
history,64,O
and,64,O
clinical,64,O
data,64,O
were,64,O
recorded,64,O
.,64,O
The,65,O
phenotype,65,O
was,65,O
documented,65,O
by,65,O
both,65,O
slit,65,O
lamp,65,O
and,65,O
Scheimpflug,65,O
photography,65,O
.,65,O
One,66,O
cortical,66,O
lens,66,O
was,66,O
evaluated,66,O
by,66,O
electron,66,O
microscopy,66,O
after,66,O
cataract,66,B-DiseaseOrPhenotypicFeature
extraction,66,O
.,66,O
Lenticular,67,O
phenotyping,67,O
and,67,O
genotyping,67,O
were,67,O
performed,67,O
independently,67,O
with,67,O
short,67,O
tandem,67,O
repeat,67,O
polymorphism,67,O
.,67,O
Linkage,68,O
analysis,68,O
was,68,O
performed,68,O
",",68,O
and,68,O
candidate,68,O
genes,68,O
were,68,O
PCR,68,O
amplified,68,O
and,68,O
screened,68,O
for,68,O
mutations,68,O
on,68,O
both,68,O
strands,68,O
using,68,O
direct,68,O
sequencing,68,O
.,68,O
RESULTS,69,O
:,69,O
Affected,69,O
individuals,69,O
had,69,O
a,69,O
congenital,69,B-DiseaseOrPhenotypicFeature
nuclear,69,I-DiseaseOrPhenotypicFeature
lactescent,69,I-DiseaseOrPhenotypicFeature
cataract,69,I-DiseaseOrPhenotypicFeature
in,69,O
both,69,O
eyes,69,O
.,69,O
Linkage,70,O
was,70,O
observed,70,O
on,70,O
chromosome,70,O
17,70,O
for,70,O
DNA,70,O
marker,70,O
D17S1857,70,O
(,70,O
lod,70,O
score,70,O
:,70,O
3.44,70,O
at,70,O
theta,70,O
=,70,O
0,70,O
),70,O
.,70,O
Direct,71,O
sequencing,71,O
of,71,O
CRYBA3/A1,71,B-GeneOrGeneProduct
",",71,O
which,71,O
maps,71,O
to,71,O
the,71,O
vicinity,71,O
",",71,O
revealed,71,O
an,71,O
in-frame,71,O
3-bp,71,B-SequenceVariant
deletion,71,I-SequenceVariant
in,71,O
exon,71,O
4,71,O
(,71,O
279delGAG,71,B-SequenceVariant
),71,O
.,71,O
This,72,O
mutation,72,O
involved,72,O
a,72,O
deletion,72,B-SequenceVariant
of,72,I-SequenceVariant
glycine-91,72,I-SequenceVariant
",",72,O
cosegregated,72,O
in,72,O
all,72,O
affected,72,O
individuals,72,O
",",72,O
and,72,O
was,72,O
not,72,O
observed,72,O
in,72,O
unaffected,72,O
individuals,72,O
or,72,O
in,72,O
250,72,O
normal,72,O
control,72,O
subjects,72,O
from,72,O
the,72,O
same,72,O
ethnic,72,O
background,72,O
.,72,O
Electron,73,O
microscopy,73,O
showed,73,O
that,73,O
cortical,73,O
lens,73,O
fiber,73,O
morphology,73,O
was,73,O
normal,73,O
.,73,O
CONCLUSIONS,74,O
:,74,O
The,74,O
DeltaG91,74,B-SequenceVariant
mutation,74,O
in,74,O
CRYBA3/A1,74,B-GeneOrGeneProduct
is,74,O
associated,74,O
with,74,O
an,74,O
autosomal,74,B-DiseaseOrPhenotypicFeature
dominant,74,I-DiseaseOrPhenotypicFeature
congenital,74,I-DiseaseOrPhenotypicFeature
nuclear,74,I-DiseaseOrPhenotypicFeature
lactescent,74,I-DiseaseOrPhenotypicFeature
cataract,74,I-DiseaseOrPhenotypicFeature
.,74,O
A,75,O
splice,75,O
mutation,75,O
(,75,O
IVS3+1G/A,75,B-SequenceVariant
),75,O
in,75,O
this,75,O
gene,75,O
has,75,O
been,75,O
reported,75,O
in,75,O
a,75,O
zonular,75,B-DiseaseOrPhenotypicFeature
cataract,75,I-DiseaseOrPhenotypicFeature
with,75,O
sutural,75,O
opacities,75,O
.,75,O
These,76,O
results,76,O
indicate,76,O
phenotypic,76,O
heterogeneity,76,O
related,76,O
to,76,O
mutations,76,O
in,76,O
this,76,O
gene,76,O
.,76,O
Urinary,77,B-DiseaseOrPhenotypicFeature
bladder,77,I-DiseaseOrPhenotypicFeature
cancer,77,I-DiseaseOrPhenotypicFeature
in,77,O
Wegener,77,B-DiseaseOrPhenotypicFeature
's,77,I-DiseaseOrPhenotypicFeature
granulomatosis,77,I-DiseaseOrPhenotypicFeature
:,77,O
risks,77,O
and,77,O
relation,77,O
to,77,O
cyclophosphamide,77,B-ChemicalEntity
.,77,O
OBJECTIVE,78,O
:,78,O
To,78,O
assess,78,O
and,78,O
characterise,78,O
the,78,O
risk,78,O
of,78,O
bladder,78,B-DiseaseOrPhenotypicFeature
cancer,78,I-DiseaseOrPhenotypicFeature
",",78,O
and,78,O
its,78,O
relation,78,O
to,78,O
cyclophosphamide,78,B-ChemicalEntity
",",78,O
in,78,O
patients,78,B-OrganismTaxon
with,78,O
Wegener,78,B-DiseaseOrPhenotypicFeature
's,78,I-DiseaseOrPhenotypicFeature
granulomatosis,78,I-DiseaseOrPhenotypicFeature
.,78,O
METHODS,79,O
:,79,O
In,79,O
the,79,O
population,79,O
based,79,O
",",79,O
nationwide,79,O
Swedish,79,O
Inpatient,79,B-OrganismTaxon
Register,79,O
a,79,O
cohort,79,O
of,79,O
1065,79,O
patients,79,B-OrganismTaxon
with,79,O
Wegener,79,B-DiseaseOrPhenotypicFeature
's,79,I-DiseaseOrPhenotypicFeature
granulomatosis,79,I-DiseaseOrPhenotypicFeature
",",79,O
1969-95,79,O
",",79,O
was,79,O
identified,79,O
.,79,O
Through,80,O
linkage,80,O
with,80,O
the,80,O
Swedish,80,O
Cancer,80,B-DiseaseOrPhenotypicFeature
Register,80,O
",",80,O
all,80,O
subjects,80,O
in,80,O
this,80,O
cohort,80,O
diagnosed,80,O
with,80,O
bladder,80,B-DiseaseOrPhenotypicFeature
cancer,80,I-DiseaseOrPhenotypicFeature
were,80,O
identified,80,O
.,80,O
Nested,81,O
within,81,O
the,81,O
cohort,81,O
",",81,O
a,81,O
matched,81,O
case-control,81,O
study,81,O
was,81,O
performed,81,O
to,81,O
estimate,81,O
the,81,O
association,81,O
between,81,O
cyclophosphamide,81,B-ChemicalEntity
and,81,O
bladder,81,B-DiseaseOrPhenotypicFeature
cancer,81,I-DiseaseOrPhenotypicFeature
using,81,O
odds,81,O
ratios,81,O
(,81,O
ORs,81,O
),81,O
as,81,O
relative,81,O
risk,81,O
.,81,O
In,82,O
the,82,O
cohort,82,O
the,82,O
cumulative,82,O
risk,82,O
of,82,O
bladder,82,B-DiseaseOrPhenotypicFeature
cancer,82,I-DiseaseOrPhenotypicFeature
after,82,O
Wegener,82,B-DiseaseOrPhenotypicFeature
's,82,I-DiseaseOrPhenotypicFeature
granulomatosis,82,I-DiseaseOrPhenotypicFeature
",",82,O
and,82,O
the,82,O
relative,82,O
prevalence,82,O
of,82,O
a,82,O
history,82,O
of,82,O
bladder,82,B-DiseaseOrPhenotypicFeature
cancer,82,I-DiseaseOrPhenotypicFeature
at,82,O
the,82,O
time,82,O
of,82,O
diagnosis,82,O
of,82,O
Wegener,82,B-DiseaseOrPhenotypicFeature
's,82,I-DiseaseOrPhenotypicFeature
granulomatosis,82,I-DiseaseOrPhenotypicFeature
",",82,O
were,82,O
also,82,O
estimated,82,O
.,82,O
RESULTS,83,O
:,83,O
The,83,O
median,83,O
cumulative,83,O
doses,83,O
of,83,O
cyclophosphamide,83,B-ChemicalEntity
among,83,O
cases,83,O
(,83,O
n,83,O
=,83,O
11,83,O
),83,O
and,83,O
controls,83,O
(,83,O
n,83,O
=,83,O
25,83,O
),83,O
were,83,O
113,83,O
g,83,O
and,83,O
25,83,O
g,83,O
",",83,O
respectively,83,O
.,83,O
The,84,O
risk,84,O
of,84,O
bladder,84,B-DiseaseOrPhenotypicFeature
cancer,84,I-DiseaseOrPhenotypicFeature
doubled,84,O
for,84,O
every,84,O
10,84,O
g,84,O
increment,84,O
in,84,O
cyclophosphamide,84,B-ChemicalEntity
(,84,O
OR,84,O
=,84,O
2.0,84,O
",",84,O
95,84,O
%,84,O
confidence,84,O
interval,84,O
(,84,O
CI,84,O
),84,O
0.8,84,O
to,84,O
4.9,84,O
),84,O
.,84,O
Treatment,85,O
duration,85,O
longer,85,O
than,85,O
1,85,O
year,85,O
was,85,O
associated,85,O
with,85,O
an,85,O
eightfold,85,O
increased,85,O
risk,85,O
(,85,O
OR,85,O
=,85,O
7.7,85,O
",",85,O
95,85,O
%,85,O
CI,85,O
0.9,85,O
to,85,O
69,85,O
),85,O
.,85,O
The,86,O
absolute,86,O
risk,86,O
for,86,O
bladder,86,B-DiseaseOrPhenotypicFeature
cancer,86,I-DiseaseOrPhenotypicFeature
in,86,O
the,86,O
cohort,86,O
reached,86,O
10,86,O
%,86,O
16,86,O
years,86,O
after,86,O
diagnosis,86,O
of,86,O
Wegener,86,B-DiseaseOrPhenotypicFeature
's,86,I-DiseaseOrPhenotypicFeature
granulomatosis,86,I-DiseaseOrPhenotypicFeature
",",86,O
and,86,O
a,86,O
history,86,O
of,86,O
bladder,86,B-DiseaseOrPhenotypicFeature
cancer,86,I-DiseaseOrPhenotypicFeature
was,86,O
(,86,O
non-significantly,86,O
),86,O
twice,86,O
as,86,O
common,86,O
as,86,O
expected,86,O
at,86,O
the,86,O
time,86,O
of,86,O
diagnosis,86,O
of,86,O
Wegener,86,B-DiseaseOrPhenotypicFeature
's,86,I-DiseaseOrPhenotypicFeature
granulomatosis,86,I-DiseaseOrPhenotypicFeature
.,86,O
CONCLUSION,87,O
:,87,O
The,87,O
results,87,O
indicate,87,O
a,87,O
dose-response,87,O
relationship,87,O
between,87,O
cyclophosphamide,87,B-ChemicalEntity
and,87,O
the,87,O
risk,87,O
of,87,O
bladder,87,B-DiseaseOrPhenotypicFeature
cancer,87,I-DiseaseOrPhenotypicFeature
",",87,O
high,87,O
cumulative,87,O
risks,87,O
in,87,O
the,87,O
entire,87,O
cohort,87,O
",",87,O
and,87,O
also,87,O
the,87,O
possibility,87,O
of,87,O
risk,87,O
factors,87,O
operating,87,O
even,87,O
before,87,O
Wegener,87,B-DiseaseOrPhenotypicFeature
's,87,I-DiseaseOrPhenotypicFeature
granulomatosis,87,I-DiseaseOrPhenotypicFeature
.,87,O
Cardioprotective,88,O
effect,88,O
of,88,O
tincture,88,B-ChemicalEntity
of,88,I-ChemicalEntity
Crataegus,88,I-ChemicalEntity
on,88,O
isoproterenol-induced,88,B-ChemicalEntity
myocardial,88,B-DiseaseOrPhenotypicFeature
infarction,88,I-DiseaseOrPhenotypicFeature
in,88,O
rats,88,B-OrganismTaxon
.,88,O
Tincture,89,B-ChemicalEntity
of,89,I-ChemicalEntity
Crataegus,89,I-ChemicalEntity
(,89,O
TCR,89,B-ChemicalEntity
),89,O
",",89,O
an,89,O
alcoholic,89,B-ChemicalEntity
extract,89,I-ChemicalEntity
of,89,I-ChemicalEntity
the,89,I-ChemicalEntity
berries,89,I-ChemicalEntity
of,89,I-ChemicalEntity
hawthorn,89,I-ChemicalEntity
(,89,O
Crataegus,89,B-ChemicalEntity
oxycantha,89,I-ChemicalEntity
),89,O
",",89,O
is,89,O
used,89,O
in,89,O
herbal,89,O
and,89,O
homeopathic,89,O
medicine,89,O
.,89,O
The,90,O
present,90,O
study,90,O
was,90,O
done,90,O
to,90,O
investigate,90,O
the,90,O
protective,90,O
effect,90,O
of,90,O
TCR,90,B-ChemicalEntity
on,90,O
experimentally,90,O
induced,90,O
myocardial,90,B-DiseaseOrPhenotypicFeature
infarction,90,I-DiseaseOrPhenotypicFeature
in,90,O
rats,90,B-OrganismTaxon
.,90,O
Pretreatment,91,O
of,91,O
TCR,91,B-ChemicalEntity
",",91,O
at,91,O
a,91,O
dose,91,O
of,91,O
0.5,91,O
mL/100,91,O
g,91,O
bodyweight,91,O
per,91,O
day,91,O
",",91,O
orally,91,O
for,91,O
30,91,O
days,91,O
",",91,O
prevented,91,O
the,91,O
increase,91,O
in,91,O
lipid,91,B-ChemicalEntity
peroxidation,91,O
and,91,O
activity,91,O
of,91,O
marker,91,O
enzymes,91,O
observed,91,O
in,91,O
isoproterenol-induced,91,B-ChemicalEntity
rats,91,B-OrganismTaxon
(,91,O
85,91,O
mg,91,O
kg,91,O
(,91,O
-1,91,O
),91,O
s.,91,O
c.,91,O
for,91,O
2,91,O
days,91,O
at,91,O
an,91,O
interval,91,O
of,91,O
24,91,O
h,91,O
),91,O
.,91,O
TCR,92,B-ChemicalEntity
prevented,92,O
the,92,O
isoproterenol-induced,92,B-ChemicalEntity
decrease,92,O
in,92,O
antioxidant,92,O
enzymes,92,O
in,92,O
the,92,O
heart,92,O
and,92,O
increased,92,O
the,92,O
rate,92,O
of,92,O
ADP-stimulated,92,B-ChemicalEntity
oxygen,92,B-ChemicalEntity
uptake,92,O
and,92,O
respiratory,92,O
coupling,92,O
ratio,92,O
.,92,O
TCR,93,B-ChemicalEntity
protected,93,O
against,93,O
pathological,93,O
changes,93,O
induced,93,O
by,93,O
isoproterenol,93,B-ChemicalEntity
in,93,O
rat,93,B-OrganismTaxon
heart,93,O
.,93,O
The,94,O
results,94,O
show,94,O
that,94,O
pretreatment,94,O
with,94,O
TCR,94,B-ChemicalEntity
may,94,O
be,94,O
useful,94,O
in,94,O
preventing,94,O
the,94,O
damage,94,O
induced,94,O
by,94,O
isoproterenol,94,B-ChemicalEntity
in,94,O
rat,94,B-OrganismTaxon
heart,94,O
.,94,O
Fine,95,O
mapping,95,O
and,95,O
identification,95,O
of,95,O
a,95,O
candidate,95,O
gene,95,O
SSH1,95,B-GeneOrGeneProduct
in,95,O
disseminated,95,B-DiseaseOrPhenotypicFeature
superficial,95,I-DiseaseOrPhenotypicFeature
actinic,95,I-DiseaseOrPhenotypicFeature
porokeratosis,95,I-DiseaseOrPhenotypicFeature
.,95,O
Disseminated,96,B-DiseaseOrPhenotypicFeature
superficial,96,I-DiseaseOrPhenotypicFeature
actinic,96,I-DiseaseOrPhenotypicFeature
porokeratosis,96,I-DiseaseOrPhenotypicFeature
(,96,O
DSAP,96,B-DiseaseOrPhenotypicFeature
),96,O
is,96,O
an,96,O
uncommon,96,O
autosomal,96,O
dominant,96,O
chronic,96,O
keratinization,96,B-DiseaseOrPhenotypicFeature
disorder,96,I-DiseaseOrPhenotypicFeature
",",96,O
characterized,96,O
by,96,O
multiple,96,O
superficial,96,O
keratotic,96,B-DiseaseOrPhenotypicFeature
lesions,96,I-DiseaseOrPhenotypicFeature
surrounded,96,O
by,96,O
a,96,O
slightly,96,O
raised,96,O
keratotic,96,O
border,96,O
.,96,O
Thus,97,O
far,97,O
",",97,O
although,97,O
two,97,O
loci,97,O
for,97,O
DSAP,97,B-DiseaseOrPhenotypicFeature
have,97,O
been,97,O
identified,97,O
",",97,O
the,97,O
genetic,97,O
basis,97,O
and,97,O
pathogenesis,97,O
of,97,O
this,97,O
disorder,97,O
have,97,O
not,97,O
been,97,O
elucidated,97,O
yet,97,O
.,97,O
In,98,O
this,98,O
study,98,O
",",98,O
we,98,O
performed,98,O
a,98,O
genome-wide,98,O
linkage,98,O
analysis,98,O
in,98,O
three,98,O
Chinese,98,O
affected,98,O
families,98,O
and,98,O
localized,98,O
the,98,O
gene,98,O
in,98,O
an,98,O
8.0,98,O
cM,98,O
interval,98,O
defined,98,O
by,98,O
D12S330,98,O
and,98,O
D12S354,98,O
on,98,O
chromosome,98,O
12,98,O
.,98,O
Upon,99,O
screening,99,O
30,99,O
candidate,99,O
genes,99,O
",",99,O
we,99,O
identified,99,O
a,99,O
missense,99,O
mutation,99,O
",",99,O
p.Ser63Asn,99,B-SequenceVariant
in,99,O
SSH1,99,B-GeneOrGeneProduct
in,99,O
one,99,O
family,99,O
",",99,O
a,99,O
frameshift,99,O
mutation,99,O
",",99,O
p.Ser19CysfsX24,99,B-SequenceVariant
in,99,O
an,99,O
alternative,99,O
variant,99,O
(,99,O
isoform,99,O
f,99,O
),99,O
of,99,O
SSH1,99,B-GeneOrGeneProduct
in,99,O
another,99,O
family,99,O
",",99,O
and,99,O
a,99,O
frameshift,99,O
mutation,99,O
",",99,O
p.Pro27ProfsX54,99,B-SequenceVariant
in,99,O
the,99,O
same,99,O
alternative,99,O
variant,99,O
in,99,O
one,99,O
non-familial,99,O
case,99,O
with,99,O
DSAP,99,B-DiseaseOrPhenotypicFeature
.,99,O
SSH1,100,B-GeneOrGeneProduct
encodes,100,O
a,100,O
phosphatase,100,O
that,100,O
plays,100,O
a,100,O
pivotal,100,O
role,100,O
in,100,O
actin,100,O
dynamics,100,O
.,100,O
Our,101,O
data,101,O
suggested,101,O
that,101,O
cytoskeleton,101,O
disorganization,101,O
in,101,O
epidermal,101,O
cells,101,O
is,101,O
likely,101,O
associated,101,O
with,101,O
the,101,O
pathogenesis,101,O
of,101,O
DSAP,101,B-DiseaseOrPhenotypicFeature
.,101,O
Influence,102,O
of,102,O
interleukin,102,B-GeneOrGeneProduct
12B,102,I-GeneOrGeneProduct
(,102,O
IL12B,102,B-GeneOrGeneProduct
),102,O
polymorphisms,102,O
on,102,O
spontaneous,102,O
and,102,O
treatment-induced,102,O
recovery,102,O
from,102,O
hepatitis,102,B-DiseaseOrPhenotypicFeature
C,102,I-DiseaseOrPhenotypicFeature
virus,102,I-DiseaseOrPhenotypicFeature
infection,102,I-DiseaseOrPhenotypicFeature
.,102,O
BACKGROUND/AIMS,103,O
:,103,O
Interleukin-12,103,B-GeneOrGeneProduct
(,103,O
IL-12,103,B-GeneOrGeneProduct
),103,O
governs,103,O
the,103,O
Th1-type,103,O
immune,103,O
response,103,O
",",103,O
affecting,103,O
the,103,O
spontaneous,103,O
and,103,O
treatment-induced,103,O
recovery,103,O
from,103,O
HCV-infection,103,B-DiseaseOrPhenotypicFeature
.,103,O
We,104,O
investigated,104,O
whether,104,O
the,104,O
IL12B,104,B-GeneOrGeneProduct
polymorphisms,104,O
within,104,O
the,104,O
promoter,104,O
region,104,O
(,104,O
4,104,B-SequenceVariant
bp,104,I-SequenceVariant
insertion/deletion,104,I-SequenceVariant
),104,O
and,104,O
the,104,O
3'-UTR,104,O
(,104,O
1188-A/C,104,B-SequenceVariant
),104,O
",",104,O
which,104,O
have,104,O
been,104,O
reported,104,O
to,104,O
influence,104,O
IL-12,104,B-GeneOrGeneProduct
synthesis,104,O
",",104,O
are,104,O
associated,104,O
with,104,O
the,104,O
outcome,104,O
of,104,O
HCV,104,B-DiseaseOrPhenotypicFeature
infection,104,I-DiseaseOrPhenotypicFeature
.,104,O
METHODS,105,O
:,105,O
We,105,O
analyzed,105,O
186,105,O
individuals,105,O
with,105,O
spontaneous,105,O
HCV,105,B-OrganismTaxon
clearance,105,O
",",105,O
501,105,O
chronically,105,O
HCV,105,B-DiseaseOrPhenotypicFeature
infected,105,I-DiseaseOrPhenotypicFeature
patients,105,B-OrganismTaxon
",",105,O
and,105,O
217,105,O
healthy,105,O
controls,105,O
.,105,O
IL12B,106,B-GeneOrGeneProduct
3'-UTR,106,O
and,106,O
promoter,106,O
genotyping,106,O
was,106,O
performed,106,O
by,106,O
Taqman-based,106,O
assays,106,O
with,106,O
allele-specific,106,O
oligonucleotide,106,B-ChemicalEntity
probes,106,O
and,106,O
PCR-based,106,O
allele-specific,106,O
DNA-amplification,106,O
",",106,O
respectively,106,O
.,106,O
RESULTS,107,O
:,107,O
The,107,O
proportion,107,O
of,107,O
IL12B,107,B-GeneOrGeneProduct
promoter,107,O
and,107,O
3'-UTR,107,O
genotypes,107,O
did,107,O
not,107,O
differ,107,O
significantly,107,O
between,107,O
the,107,O
different,107,O
cohorts,107,O
.,107,O
However,108,O
",",108,O
HCV,108,B-DiseaseOrPhenotypicFeature
genotype,108,I-DiseaseOrPhenotypicFeature
1-infected,108,I-DiseaseOrPhenotypicFeature
patients,108,B-OrganismTaxon
with,108,O
high,108,O
baseline,108,O
viremia,108,B-DiseaseOrPhenotypicFeature
carrying,108,O
the,108,O
IL12B,108,B-GeneOrGeneProduct
3'-UTR,108,O
1188-C-allele,108,B-SequenceVariant
showed,108,O
significantly,108,O
higher,108,O
sustained,108,O
virologic,108,O
response,108,O
(,108,O
SVR,108,O
),108,O
rates,108,O
(,108,O
25.3,108,O
%,108,O
vs.,108,O
46,108,O
%,108,O
vs.,108,O
54.5,108,O
%,108,O
for,108,O
A/A,108,O
",",108,O
A/C,108,O
and,108,O
C/C,108,O
),108,O
due,108,O
to,108,O
reduced,108,O
relapse,108,O
rates,108,O
(,108,O
24.2,108,O
%,108,O
vs.,108,O
12,108,O
%,108,O
vs.,108,O
zero,108,O
%,108,O
for,108,O
A/A,108,O
",",108,O
A/C,108,O
and,108,O
C/C,108,O
),108,O
.,108,O
CONCLUSIONS,109,O
:,109,O
IL12B,109,B-GeneOrGeneProduct
3'-UTR,109,O
1188-C-allele,109,B-SequenceVariant
carriers,109,O
appear,109,O
to,109,O
be,109,O
capable,109,O
of,109,O
responding,109,O
more,109,O
efficiently,109,O
to,109,O
antiviral,109,O
combination,109,O
therapy,109,O
as,109,O
a,109,O
consequence,109,O
of,109,O
a,109,O
reduced,109,O
relapse,109,O
rate,109,O
.,109,O
No,110,O
association,110,O
of,110,O
IL12B,110,B-GeneOrGeneProduct
polymorphisms,110,O
and,110,O
self-limited,110,O
HCV,110,B-DiseaseOrPhenotypicFeature
infection,110,I-DiseaseOrPhenotypicFeature
could,110,O
be,110,O
demonstrated,110,O
.,110,O
A,111,O
novel,111,O
SCN5A,111,B-GeneOrGeneProduct
mutation,111,O
manifests,111,O
as,111,O
a,111,O
malignant,111,O
form,111,O
of,111,O
long,111,B-DiseaseOrPhenotypicFeature
QT,111,I-DiseaseOrPhenotypicFeature
syndrome,111,I-DiseaseOrPhenotypicFeature
with,111,O
perinatal,111,O
onset,111,O
of,111,O
tachycardia/bradycardia,111,B-DiseaseOrPhenotypicFeature
.,111,O
OBJECTIVE,112,O
:,112,O
Congenital,112,O
long,112,B-DiseaseOrPhenotypicFeature
QT,112,I-DiseaseOrPhenotypicFeature
syndrome,112,I-DiseaseOrPhenotypicFeature
(,112,O
LQTS,112,B-DiseaseOrPhenotypicFeature
),112,O
with,112,O
in,112,O
utero,112,O
onset,112,O
of,112,O
the,112,O
rhythm,112,O
disturbances,112,O
is,112,O
associated,112,O
with,112,O
a,112,O
poor,112,O
prognosis,112,O
.,112,O
In,113,O
this,113,O
study,113,O
we,113,O
investigated,113,O
a,113,O
newborn,113,O
patient,113,B-OrganismTaxon
with,113,O
fetal,113,O
bradycardia,113,B-DiseaseOrPhenotypicFeature
",",113,O
2:1,113,O
atrioventricular,113,B-DiseaseOrPhenotypicFeature
block,113,I-DiseaseOrPhenotypicFeature
and,113,O
ventricular,113,B-DiseaseOrPhenotypicFeature
tachycardia,113,I-DiseaseOrPhenotypicFeature
soon,113,O
after,113,O
birth,113,O
.,113,O
METHODS,114,O
:,114,O
Mutational,114,O
analysis,114,O
and,114,O
DNA,114,O
sequencing,114,O
were,114,O
conducted,114,O
in,114,O
a,114,O
newborn,114,O
.,114,O
The,115,O
2:1,115,O
atrioventricular,115,B-DiseaseOrPhenotypicFeature
block,115,I-DiseaseOrPhenotypicFeature
improved,115,O
to,115,O
1:1,115,O
conduction,115,O
only,115,O
after,115,O
intravenous,115,O
lidocaine,115,B-ChemicalEntity
infusion,115,O
or,115,O
a,115,O
high,115,O
dose,115,O
of,115,O
mexiletine,115,B-ChemicalEntity
",",115,O
which,115,O
also,115,O
controlled,115,O
the,115,O
ventricular,115,B-DiseaseOrPhenotypicFeature
tachycardia,115,I-DiseaseOrPhenotypicFeature
.,115,O
RESULTS,116,O
:,116,O
A,116,O
novel,116,O
",",116,O
spontaneous,116,O
LQTS-3,116,B-DiseaseOrPhenotypicFeature
mutation,116,O
was,116,O
identified,116,O
in,116,O
the,116,O
transmembrane,116,O
segment,116,O
6,116,O
of,116,O
domain,116,O
IV,116,O
of,116,O
the,116,O
Na,116,B-GeneOrGeneProduct
(,116,I-GeneOrGeneProduct
v,116,I-GeneOrGeneProduct
),116,I-GeneOrGeneProduct
1.5,116,I-GeneOrGeneProduct
cardiac,116,O
sodium,116,B-ChemicalEntity
channel,116,O
",",116,O
with,116,O
a,116,O
G,116,B-SequenceVariant
--,116,I-SequenceVariant
>,116,I-SequenceVariant
A,116,I-SequenceVariant
substitution,116,I-SequenceVariant
at,116,I-SequenceVariant
codon,116,I-SequenceVariant
1763,116,I-SequenceVariant
",",116,O
which,116,O
changed,116,O
a,116,O
valine,116,B-SequenceVariant
(,116,I-SequenceVariant
GTG,116,I-SequenceVariant
),116,I-SequenceVariant
to,116,I-SequenceVariant
a,116,I-SequenceVariant
methionine,116,I-SequenceVariant
(,116,I-SequenceVariant
ATG,116,I-SequenceVariant
),116,I-SequenceVariant
.,116,O
The,117,O
proband,117,O
was,117,O
heterozygous,117,O
but,117,O
the,117,O
mutation,117,O
was,117,O
absent,117,O
in,117,O
the,117,O
parents,117,O
and,117,O
the,117,O
sister,117,O
.,117,O
Expression,118,O
of,118,O
this,118,O
mutant,118,O
channel,118,O
in,118,O
tsA201,118,B-CellLine
mammalian,118,O
cells,118,O
by,118,O
site-directed,118,O
mutagenesis,118,O
revealed,118,O
a,118,O
persistent,118,O
tetrodotoxin-sensitive,118,B-ChemicalEntity
but,118,O
lidocaine-resistant,118,B-ChemicalEntity
current,118,O
that,118,O
was,118,O
associated,118,O
with,118,O
a,118,O
positive,118,O
shift,118,O
of,118,O
the,118,O
steady-state,118,O
inactivation,118,O
curve,118,O
",",118,O
steeper,118,O
activation,118,O
curve,118,O
and,118,O
faster,118,O
recovery,118,O
from,118,O
inactivation,118,O
.,118,O
We,119,O
also,119,O
found,119,O
a,119,O
similar,119,O
electrophysiological,119,O
profile,119,O
for,119,O
the,119,O
neighboring,119,O
V1764M,119,B-SequenceVariant
mutant,119,O
.,119,O
But,120,O
",",120,O
the,120,O
other,120,O
neighboring,120,O
I1762A,120,B-SequenceVariant
mutant,120,O
had,120,O
no,120,O
persistent,120,O
current,120,O
and,120,O
was,120,O
still,120,O
associated,120,O
with,120,O
a,120,O
positive,120,O
shift,120,O
of,120,O
inactivation,120,O
.,120,O
CONCLUSIONS,121,O
:,121,O
These,121,O
findings,121,O
suggest,121,O
that,121,O
the,121,O
Na,121,B-GeneOrGeneProduct
(,121,I-GeneOrGeneProduct
v,121,I-GeneOrGeneProduct
),121,I-GeneOrGeneProduct
1.5/V1763M,121,O
channel,121,O
dysfunction,121,O
and,121,O
possible,121,O
neighboring,121,O
mutants,121,O
contribute,121,O
to,121,O
a,121,O
persistent,121,O
inward,121,O
current,121,O
due,121,O
to,121,O
altered,121,O
inactivation,121,O
kinetics,121,O
and,121,O
clinically,121,O
congenital,121,O
LQTS,121,B-DiseaseOrPhenotypicFeature
with,121,O
perinatal,121,O
onset,121,O
of,121,O
arrhythmias,121,B-DiseaseOrPhenotypicFeature
that,121,O
responded,121,O
to,121,O
lidocaine,121,B-ChemicalEntity
and,121,O
mexiletine,121,B-ChemicalEntity
.,121,O
Common,122,O
BRCA2,122,B-GeneOrGeneProduct
variants,122,O
and,122,O
modification,122,O
of,122,O
breast,122,B-DiseaseOrPhenotypicFeature
and,122,I-DiseaseOrPhenotypicFeature
ovarian,122,I-DiseaseOrPhenotypicFeature
cancer,122,I-DiseaseOrPhenotypicFeature
risk,122,O
in,122,O
BRCA1,122,B-GeneOrGeneProduct
mutation,122,O
carriers,122,O
.,122,O
The,123,O
HH,123,O
genotype,123,O
of,123,O
the,123,O
nonconservative,123,O
amino,123,O
acid,123,O
substitution,123,O
polymorphism,123,O
N372H,123,B-SequenceVariant
in,123,O
the,123,O
BRCA2,123,B-GeneOrGeneProduct
gene,123,O
was,123,O
reported,123,O
to,123,O
be,123,O
associated,123,O
with,123,O
a,123,O
1.3-,123,O
to,123,O
1.5-fold,123,O
increase,123,O
in,123,O
risk,123,O
of,123,O
both,123,O
breast,123,B-DiseaseOrPhenotypicFeature
and,123,I-DiseaseOrPhenotypicFeature
ovarian,123,I-DiseaseOrPhenotypicFeature
cancer,123,I-DiseaseOrPhenotypicFeature
.,123,O
As,124,O
these,124,O
studies,124,O
concerned,124,O
sporadic,124,O
cancer,124,B-DiseaseOrPhenotypicFeature
cases,124,O
",",124,O
we,124,O
investigated,124,O
whether,124,O
N372H,124,B-SequenceVariant
and,124,O
another,124,O
common,124,O
variant,124,O
located,124,O
in,124,O
the,124,O
5'-untranslated,124,O
region,124,O
(,124,O
203G,124,B-SequenceVariant
>,124,I-SequenceVariant
A,124,I-SequenceVariant
),124,O
of,124,O
the,124,O
BRCA2,124,B-GeneOrGeneProduct
gene,124,O
modify,124,O
breast,124,B-DiseaseOrPhenotypicFeature
or,124,I-DiseaseOrPhenotypicFeature
ovarian,124,I-DiseaseOrPhenotypicFeature
cancer,124,I-DiseaseOrPhenotypicFeature
risk,124,O
in,124,O
BRCA1,124,B-GeneOrGeneProduct
mutation,124,O
carriers,124,O
.,124,O
The,125,O
study,125,O
includes,125,O
778,125,O
women,125,B-OrganismTaxon
carrying,125,O
a,125,O
BRCA1,125,B-GeneOrGeneProduct
germ-line,125,O
mutation,125,O
belonging,125,O
to,125,O
403,125,O
families,125,O
.,125,O
The,126,O
two,126,O
BRCA2,126,B-GeneOrGeneProduct
variants,126,O
were,126,O
analyzed,126,O
by,126,O
the,126,O
TaqMan,126,O
allelic,126,O
discrimination,126,O
technique,126,O
.,126,O
Genotypes,127,O
were,127,O
analyzed,127,O
by,127,O
disease-free,127,O
survival,127,O
analysis,127,O
using,127,O
a,127,O
Cox,127,O
proportional,127,O
hazards,127,O
model,127,O
.,127,O
We,128,O
found,128,O
no,128,O
evidence,128,O
of,128,O
a,128,O
significant,128,O
modification,128,O
of,128,O
breast,128,B-DiseaseOrPhenotypicFeature
cancer,128,I-DiseaseOrPhenotypicFeature
penetrance,128,O
in,128,O
BRCA1,128,B-GeneOrGeneProduct
mutation,128,O
carriers,128,O
by,128,O
either,128,O
polymorphism,128,O
.,128,O
In,129,O
respect,129,O
of,129,O
ovarian,129,B-DiseaseOrPhenotypicFeature
cancer,129,I-DiseaseOrPhenotypicFeature
risk,129,O
",",129,O
we,129,O
also,129,O
saw,129,O
no,129,O
effect,129,O
with,129,O
the,129,O
N372H,129,B-SequenceVariant
variant,129,O
but,129,O
we,129,O
did,129,O
observe,129,O
a,129,O
borderline,129,O
association,129,O
with,129,O
the,129,O
5'-untranslated,129,O
region,129,O
203A,129,B-SequenceVariant
allele,129,O
(,129,O
hazard,129,O
ratio,129,O
",",129,O
1.43,129,O
;,129,O
CI,129,O
",",129,O
1.01-2.00,129,O
),129,O
.,129,O
In,130,O
contrast,130,O
to,130,O
the,130,O
result,130,O
of,130,O
Healey,130,O
et,130,O
al,130,O
.,130,O
on,131,O
newborn,131,O
females,131,O
and,131,O
adult,131,O
female,131,O
controls,131,O
",",131,O
we,131,O
found,131,O
no,131,O
departure,131,O
from,131,O
Hardy-Weinberg,131,O
equilibrium,131,O
in,131,O
the,131,O
distribution,131,O
of,131,O
N372H,131,B-SequenceVariant
alleles,131,O
for,131,O
our,131,O
female,131,O
BRCA1,131,B-GeneOrGeneProduct
carriers,131,O
.,131,O
We,132,O
conclude,132,O
that,132,O
if,132,O
these,132,O
single-nucleotide,132,O
polymorphisms,132,O
do,132,O
modify,132,O
the,132,O
risk,132,O
of,132,O
cancer,132,B-DiseaseOrPhenotypicFeature
in,132,O
BRCA1,132,B-GeneOrGeneProduct
mutation,132,O
carriers,132,O
",",132,O
their,132,O
effects,132,O
are,132,O
not,132,O
significantly,132,O
larger,132,O
than,132,O
that,132,O
of,132,O
N372H,132,B-SequenceVariant
previously,132,O
observed,132,O
in,132,O
the,132,O
general,132,O
population,132,O
.,132,O
The,133,O
activation,133,O
of,133,O
spinal,133,O
N-methyl-D-aspartate,133,B-GeneOrGeneProduct
receptors,133,I-GeneOrGeneProduct
may,133,O
contribute,133,O
to,133,O
degeneration,133,O
of,133,O
spinal,133,O
motor,133,O
neurons,133,O
induced,133,O
by,133,O
neuraxial,133,O
morphine,133,B-ChemicalEntity
after,133,O
a,133,O
noninjurious,133,O
interval,133,O
of,133,O
spinal,133,B-DiseaseOrPhenotypicFeature
cord,133,I-DiseaseOrPhenotypicFeature
ischemia,133,I-DiseaseOrPhenotypicFeature
.,133,O
We,134,O
investigated,134,O
the,134,O
relationship,134,O
between,134,O
the,134,O
degeneration,134,O
of,134,O
spinal,134,O
motor,134,O
neurons,134,O
and,134,O
activation,134,O
of,134,O
N-methyl-d-aspartate,134,B-GeneOrGeneProduct
(,134,I-GeneOrGeneProduct
NMDA,134,I-GeneOrGeneProduct
),134,I-GeneOrGeneProduct
receptors,134,I-GeneOrGeneProduct
after,134,O
neuraxial,134,O
morphine,134,B-ChemicalEntity
following,134,O
a,134,O
noninjurious,134,O
interval,134,O
of,134,O
aortic,134,B-DiseaseOrPhenotypicFeature
occlusion,134,I-DiseaseOrPhenotypicFeature
in,134,O
rats,134,B-OrganismTaxon
.,134,O
Spinal,135,B-DiseaseOrPhenotypicFeature
cord,135,I-DiseaseOrPhenotypicFeature
ischemia,135,I-DiseaseOrPhenotypicFeature
was,135,O
induced,135,O
by,135,O
aortic,135,B-DiseaseOrPhenotypicFeature
occlusion,135,I-DiseaseOrPhenotypicFeature
for,135,O
6,135,O
min,135,O
with,135,O
a,135,O
balloon,135,O
catheter,135,O
.,135,O
In,136,O
a,136,O
microdialysis,136,O
study,136,O
",",136,O
10,136,O
muL,136,O
of,136,O
saline,136,O
(,136,O
group,136,O
C,136,O
;,136,O
n,136,O
=,136,O
8,136,O
),136,O
or,136,O
30,136,O
mug,136,O
of,136,O
morphine,136,B-ChemicalEntity
(,136,O
group,136,O
M,136,O
;,136,O
n,136,O
=,136,O
8,136,O
),136,O
was,136,O
injected,136,O
intrathecally,136,O
(,136,O
IT,136,O
),136,O
0.5,136,O
h,136,O
after,136,O
reflow,136,O
",",136,O
and,136,O
30,136,O
mug,136,O
of,136,O
morphine,136,B-ChemicalEntity
(,136,O
group,136,O
SM,136,O
;,136,O
n,136,O
=,136,O
8,136,O
),136,O
or,136,O
10,136,O
muL,136,O
of,136,O
saline,136,O
(,136,O
group,136,O
SC,136,O
;,136,O
n,136,O
=,136,O
8,136,O
),136,O
was,136,O
injected,136,O
IT,136,O
0.5,136,O
h,136,O
after,136,O
sham,136,O
operation,136,O
.,136,O
Microdialysis,137,O
samples,137,O
were,137,O
collected,137,O
preischemia,137,O
",",137,O
before,137,O
IT,137,O
injection,137,O
",",137,O
and,137,O
at,137,O
2,137,O
",",137,O
4,137,O
",",137,O
8,137,O
",",137,O
24,137,O
",",137,O
and,137,O
48,137,O
h,137,O
of,137,O
reperfusion,137,O
(,137,O
after,137,O
IT,137,O
injection,137,O
),137,O
.,137,O
Second,138,O
",",138,O
we,138,O
investigated,138,O
the,138,O
effect,138,O
of,138,O
IT,138,O
MK-801,138,B-ChemicalEntity
(,138,O
30,138,O
mug,138,O
),138,O
on,138,O
the,138,O
histopathologic,138,O
changes,138,O
in,138,O
the,138,O
spinal,138,O
cord,138,O
after,138,O
morphine-induced,138,B-ChemicalEntity
spastic,138,B-DiseaseOrPhenotypicFeature
paraparesis,138,I-DiseaseOrPhenotypicFeature
.,138,O
After,139,O
IT,139,O
morphine,139,B-ChemicalEntity
",",139,O
the,139,O
cerebrospinal,139,O
fluid,139,O
(,139,O
CSF,139,O
),139,O
glutamate,139,B-ChemicalEntity
concentration,139,O
was,139,O
increased,139,O
in,139,O
group,139,O
M,139,O
relative,139,O
to,139,O
both,139,O
baseline,139,O
and,139,O
group,139,O
C,139,O
(,139,O
P,139,O
<,139,O
0.05,139,O
),139,O
.,139,O
This,140,O
increase,140,O
persisted,140,O
for,140,O
8,140,O
hrs,140,O
.,140,O
IT,141,O
MK-801,141,B-ChemicalEntity
significantly,141,O
reduced,141,O
the,141,O
number,141,O
of,141,O
dark-stained,141,O
alpha-motoneurons,141,O
after,141,O
morphine-induced,141,B-ChemicalEntity
spastic,141,B-DiseaseOrPhenotypicFeature
paraparesis,141,I-DiseaseOrPhenotypicFeature
compared,141,O
with,141,O
the,141,O
saline,141,O
group,141,O
.,141,O
These,142,O
data,142,O
indicate,142,O
that,142,O
IT,142,O
morphine,142,B-ChemicalEntity
induces,142,O
spastic,142,B-DiseaseOrPhenotypicFeature
paraparesis,142,I-DiseaseOrPhenotypicFeature
with,142,O
a,142,O
concomitant,142,O
increase,142,O
in,142,O
CSF,142,O
glutamate,142,B-ChemicalEntity
",",142,O
which,142,O
is,142,O
involved,142,O
in,142,O
NMDA,142,B-GeneOrGeneProduct
receptor,142,I-GeneOrGeneProduct
activation,142,O
.,142,O
We,143,O
suggest,143,O
that,143,O
opioids,143,B-ChemicalEntity
may,143,O
be,143,O
neurotoxic,143,B-DiseaseOrPhenotypicFeature
in,143,O
the,143,O
setting,143,O
of,143,O
spinal,143,B-DiseaseOrPhenotypicFeature
cord,143,I-DiseaseOrPhenotypicFeature
ischemia,143,I-DiseaseOrPhenotypicFeature
via,143,O
NMDA,143,B-GeneOrGeneProduct
receptor,143,I-GeneOrGeneProduct
activation,143,O
.,143,O
Pheochromocytoma,144,B-DiseaseOrPhenotypicFeature
unmasked,144,O
by,144,O
amisulpride,144,B-ChemicalEntity
and,144,O
tiapride,144,B-ChemicalEntity
.,144,O
OBJECTIVE,145,O
:,145,O
To,145,O
describe,145,O
the,145,O
unmasking,145,O
of,145,O
pheochromocytoma,145,B-DiseaseOrPhenotypicFeature
in,145,O
a,145,O
patient,145,B-OrganismTaxon
treated,145,O
with,145,O
amisulpride,145,B-ChemicalEntity
and,145,O
tiapride,145,B-ChemicalEntity
.,145,O
CASE,146,O
SUMMARY,146,O
:,146,O
A,146,O
42-year-old,146,O
white,146,O
man,146,B-OrganismTaxon
developed,146,O
acute,146,O
hypertension,146,B-DiseaseOrPhenotypicFeature
with,146,O
severe,146,O
headache,146,B-DiseaseOrPhenotypicFeature
and,146,O
vomiting,146,B-DiseaseOrPhenotypicFeature
2,146,O
hours,146,O
after,146,O
the,146,O
first,146,O
doses,146,O
of,146,O
amisulpride,146,B-ChemicalEntity
100,146,O
mg,146,O
and,146,O
tiapride,146,B-ChemicalEntity
100,146,O
mg,146,O
.,146,O
Both,147,O
drugs,147,O
were,147,O
immediately,147,O
discontinued,147,O
",",147,O
and,147,O
the,147,O
patient,147,B-OrganismTaxon
recovered,147,O
after,147,O
subsequent,147,O
nicardipine,147,B-ChemicalEntity
and,147,O
verapamil,147,B-ChemicalEntity
treatment,147,O
.,147,O
Abdominal,148,O
ultrasound,148,O
showed,148,O
an,148,O
adrenal,148,O
mass,148,O
",",148,O
and,148,O
postoperative,148,O
histologic,148,O
examination,148,O
confirmed,148,O
the,148,O
diagnosis,148,O
of,148,O
pheochromocytoma,148,B-DiseaseOrPhenotypicFeature
.,148,O
DISCUSSION,149,O
:,149,O
Drug-induced,149,O
symptoms,149,O
of,149,O
pheochromocytoma,149,B-DiseaseOrPhenotypicFeature
are,149,O
often,149,O
associated,149,O
with,149,O
the,149,O
use,149,O
of,149,O
substituted,149,O
benzamide,149,B-ChemicalEntity
drugs,149,I-ChemicalEntity
",",149,O
but,149,O
the,149,O
underlying,149,O
mechanism,149,O
is,149,O
unknown,149,O
.,149,O
In,150,O
our,150,O
case,150,O
",",150,O
use,150,O
of,150,O
the,150,O
Naranjo,150,O
probability,150,O
scale,150,O
indicated,150,O
a,150,O
possible,150,O
relationship,150,O
between,150,O
the,150,O
hypertensive,150,B-DiseaseOrPhenotypicFeature
crisis,150,O
and,150,O
amisulpride,150,B-ChemicalEntity
and,150,O
tiapride,150,B-ChemicalEntity
therapy,150,O
.,150,O
CONCLUSIONS,151,O
:,151,O
As,151,O
of,151,O
March,151,O
24,151,O
",",151,O
2005,151,O
",",151,O
this,151,O
is,151,O
the,151,O
first,151,O
reported,151,O
case,151,O
of,151,O
amisulpride-,151,B-ChemicalEntity
and,151,O
tiapride-induced,151,B-ChemicalEntity
hypertensive,151,B-DiseaseOrPhenotypicFeature
crisis,151,O
in,151,O
a,151,O
patient,151,B-OrganismTaxon
with,151,O
pheochromocytoma,151,B-DiseaseOrPhenotypicFeature
.,151,O
Physicians,152,O
and,152,O
other,152,O
healthcare,152,O
professionals,152,O
should,152,O
be,152,O
aware,152,O
of,152,O
this,152,O
potential,152,O
adverse,152,O
effect,152,O
of,152,O
tiapride,152,B-ChemicalEntity
and,152,O
amisulpride,152,B-ChemicalEntity
.,152,O
Association,153,O
of,153,O
sporadic,153,B-DiseaseOrPhenotypicFeature
chondrocalcinosis,153,I-DiseaseOrPhenotypicFeature
with,153,O
a,153,O
-4-basepair,153,B-SequenceVariant
G-to-A,153,I-SequenceVariant
transition,153,O
in,153,O
the,153,O
5'-untranslated,153,O
region,153,O
of,153,O
ANKH,153,B-GeneOrGeneProduct
that,153,O
promotes,153,O
enhanced,153,O
expression,153,O
of,153,O
ANKH,153,B-GeneOrGeneProduct
protein,153,O
and,153,O
excess,153,O
generation,153,O
of,153,O
extracellular,153,O
inorganic,153,B-ChemicalEntity
pyrophosphate,153,I-ChemicalEntity
.,153,O
OBJECTIVE,154,O
:,154,O
Certain,154,O
mutations,154,O
in,154,O
ANKH,154,B-GeneOrGeneProduct
",",154,O
which,154,O
encodes,154,O
a,154,O
multiple-pass,154,O
transmembrane,154,O
protein,154,O
that,154,O
regulates,154,O
inorganic,154,B-ChemicalEntity
pyrophosphate,154,I-ChemicalEntity
(,154,O
PPi,154,B-ChemicalEntity
),154,O
transport,154,O
",",154,O
are,154,O
linked,154,O
to,154,O
autosomal-dominant,154,B-DiseaseOrPhenotypicFeature
familial,154,I-DiseaseOrPhenotypicFeature
chondrocalcinosis,154,I-DiseaseOrPhenotypicFeature
.,154,O
This,155,O
study,155,O
investigated,155,O
the,155,O
potential,155,O
for,155,O
ANKH,155,B-GeneOrGeneProduct
sequence,155,O
variants,155,O
to,155,O
promote,155,O
sporadic,155,O
chondrocalcinosis,155,B-DiseaseOrPhenotypicFeature
.,155,O
METHODS,156,O
:,156,O
ANKH,156,B-GeneOrGeneProduct
variants,156,O
identified,156,O
by,156,O
genomic,156,O
sequencing,156,O
were,156,O
screened,156,O
for,156,O
association,156,O
with,156,O
chondrocalcinosis,156,B-DiseaseOrPhenotypicFeature
in,156,O
128,156,O
patients,156,B-OrganismTaxon
with,156,O
severe,156,O
sporadic,156,O
chondrocalcinosis,156,B-DiseaseOrPhenotypicFeature
or,156,O
pseudogout,156,B-DiseaseOrPhenotypicFeature
and,156,O
in,156,O
ethnically,156,O
matched,156,O
healthy,156,O
controls,156,O
.,156,O
The,157,O
effects,157,O
of,157,O
specific,157,O
variants,157,O
on,157,O
expression,157,O
of,157,O
common,157,O
markers,157,O
were,157,O
evaluated,157,O
by,157,O
in,157,O
vitro,157,O
transcription/translation,157,O
.,157,O
The,158,O
function,158,O
of,158,O
these,158,O
variants,158,O
was,158,O
studied,158,O
in,158,O
transfected,158,O
human,158,B-OrganismTaxon
immortalized,158,O
CH-8,158,B-CellLine
articular,158,O
chondrocytes,158,O
.,158,O
RESULTS,159,O
:,159,O
Sporadic,159,B-DiseaseOrPhenotypicFeature
chondrocalcinosis,159,I-DiseaseOrPhenotypicFeature
was,159,O
associated,159,O
with,159,O
a,159,O
G-to-A,159,B-SequenceVariant
transition,159,O
in,159,O
the,159,O
ANKH,159,B-GeneOrGeneProduct
5'-untranslated,159,O
region,159,O
(,159,O
5'-UTR,159,O
),159,O
at,159,O
4,159,O
bp,159,O
upstream,159,O
of,159,O
the,159,O
start,159,O
codon,159,O
(,159,O
in,159,O
homozygotes,159,O
of,159,O
the,159,O
minor,159,O
allele,159,O
",",159,O
genotype,159,O
relative,159,O
risk,159,O
6.0,159,O
",",159,O
P,159,O
=,159,O
0.0006,159,O
;,159,O
overall,159,O
genotype,159,O
association,159,O
P,159,O
=,159,O
0.02,159,O
),159,O
.,159,O
This,160,O
-4-bp,160,O
transition,160,O
",",160,O
as,160,O
well,160,O
as,160,O
2,160,O
mutations,160,O
previously,160,O
linked,160,O
with,160,O
familial,160,B-DiseaseOrPhenotypicFeature
and,160,I-DiseaseOrPhenotypicFeature
sporadic,160,I-DiseaseOrPhenotypicFeature
chondrocalcinosis,160,I-DiseaseOrPhenotypicFeature
(,160,O
+14,160,B-SequenceVariant
bp,160,I-SequenceVariant
C-to-T,160,I-SequenceVariant
and,160,O
C-terminal,160,O
GAG,160,B-SequenceVariant
deletion,160,I-SequenceVariant
",",160,O
respectively,160,O
),160,O
",",160,O
but,160,O
not,160,O
the,160,O
French,160,O
familial,160,B-DiseaseOrPhenotypicFeature
chondrocalcinosis,160,I-DiseaseOrPhenotypicFeature
kindred,160,O
143-bp,160,B-SequenceVariant
T-to-C,160,I-SequenceVariant
mutation,160,O
",",160,O
increased,160,O
reticulocyte,160,O
ANKH,160,B-GeneOrGeneProduct
transcription/ANKH,160,O
translation,160,O
in,160,O
vitro,160,O
.,160,O
Transfection,161,O
of,161,O
complementary,161,O
DNA,161,O
for,161,O
both,161,O
the,161,O
wild-type,161,O
ANKH,161,B-GeneOrGeneProduct
and,161,O
the,161,O
-4-bp,161,O
ANKH,161,B-GeneOrGeneProduct
protein,161,O
variant,161,O
promoted,161,O
increased,161,O
extracellular,161,O
PPi,161,B-ChemicalEntity
in,161,O
CH-8,161,B-CellLine
cells,161,O
",",161,O
but,161,O
unexpectedly,161,O
",",161,O
these,161,O
ANKH,161,B-GeneOrGeneProduct
mutants,161,O
had,161,O
divergent,161,O
effects,161,O
on,161,O
the,161,O
expression,161,O
of,161,O
extracellular,161,O
PPi,161,B-ChemicalEntity
and,161,O
the,161,O
chondrocyte,161,O
hypertrophy,161,B-DiseaseOrPhenotypicFeature
marker,161,O
",",161,O
type,161,B-GeneOrGeneProduct
X,161,I-GeneOrGeneProduct
collagen,161,I-GeneOrGeneProduct
.,161,O
CONCLUSION,162,O
:,162,O
A,162,O
subset,162,O
of,162,O
sporadic,162,B-DiseaseOrPhenotypicFeature
chondrocalcinosis,162,I-DiseaseOrPhenotypicFeature
appears,162,O
to,162,O
be,162,O
heritable,162,O
via,162,O
a,162,O
-4-bp,162,B-SequenceVariant
G-to-A,162,I-SequenceVariant
ANKH,162,B-GeneOrGeneProduct
5'-UTR,162,O
transition,162,O
that,162,O
up-regulates,162,O
expression,162,O
of,162,O
ANKH,162,B-GeneOrGeneProduct
and,162,O
extracellular,162,O
PPi,162,B-ChemicalEntity
in,162,O
chondrocyte,162,O
cells,162,O
.,162,O
Distinct,163,O
ANKH,163,B-GeneOrGeneProduct
mutations,163,O
associated,163,O
with,163,O
heritable,163,O
chondrocalcinosis,163,B-DiseaseOrPhenotypicFeature
may,163,O
promote,163,O
disease,163,O
by,163,O
divergent,163,O
effects,163,O
on,163,O
extracellular,163,O
PPi,163,B-ChemicalEntity
and,163,O
chondrocyte,163,O
hypertrophy,163,B-DiseaseOrPhenotypicFeature
",",163,O
which,163,O
is,163,O
likely,163,O
to,163,O
mediate,163,O
differences,163,O
in,163,O
the,163,O
clinical,163,O
phenotypes,163,O
and,163,O
severity,163,O
of,163,O
the,163,O
disease,163,O
.,163,O
Vitamin,164,B-GeneOrGeneProduct
D-binding,164,I-GeneOrGeneProduct
protein,164,I-GeneOrGeneProduct
gene,164,O
polymorphism,164,O
association,164,O
with,164,O
IA-2,164,B-GeneOrGeneProduct
autoantibodies,164,O
in,164,O
type,164,B-DiseaseOrPhenotypicFeature
1,164,I-DiseaseOrPhenotypicFeature
diabetes,164,I-DiseaseOrPhenotypicFeature
.,164,O
BACKGROUND,165,O
:,165,O
Vitamin,165,B-GeneOrGeneProduct
D-binding,165,I-GeneOrGeneProduct
protein,165,I-GeneOrGeneProduct
(,165,O
DBP,165,B-GeneOrGeneProduct
),165,O
is,165,O
the,165,O
main,165,O
systemic,165,O
transporter,165,O
of,165,O
1.25,165,B-ChemicalEntity
(,165,I-ChemicalEntity
OH,165,I-ChemicalEntity
),165,I-ChemicalEntity
2D3,165,I-ChemicalEntity
and,165,O
is,165,O
essential,165,O
for,165,O
its,165,O
cellular,165,O
endocytosis,165,O
.,165,O
There,166,O
are,166,O
two,166,O
known,166,O
polymorphisms,166,O
in,166,O
exon,166,O
11,166,O
of,166,O
the,166,O
DBP,166,B-GeneOrGeneProduct
gene,166,O
resulting,166,O
in,166,O
amino,166,O
acid,166,O
variants,166,O
:,166,O
GAT,166,B-SequenceVariant
--,166,I-SequenceVariant
>,166,I-SequenceVariant
GAG,166,I-SequenceVariant
substitution,166,I-SequenceVariant
replaces,166,I-SequenceVariant
aspartic,166,I-SequenceVariant
acid,166,I-SequenceVariant
by,166,I-SequenceVariant
glutamic,166,I-SequenceVariant
acid,166,I-SequenceVariant
in,166,I-SequenceVariant
codon,166,I-SequenceVariant
416,166,I-SequenceVariant
;,166,O
and,166,O
ACG,166,B-SequenceVariant
--,166,I-SequenceVariant
>,166,I-SequenceVariant
AAG,166,I-SequenceVariant
substitution,166,I-SequenceVariant
in,166,I-SequenceVariant
codon,166,I-SequenceVariant
420,166,I-SequenceVariant
leads,166,O
to,166,O
an,166,O
exchange,166,O
of,166,O
threonine,166,B-SequenceVariant
for,166,I-SequenceVariant
lysine,166,I-SequenceVariant
.,166,O
These,167,O
DBP,167,B-GeneOrGeneProduct
variants,167,O
lead,167,O
to,167,O
differences,167,O
in,167,O
the,167,O
affinity,167,O
for,167,O
1.25,167,B-ChemicalEntity
(,167,I-ChemicalEntity
OH,167,I-ChemicalEntity
),167,I-ChemicalEntity
2D3,167,I-ChemicalEntity
.,167,O
Correlations,168,O
between,168,O
DBP,168,B-GeneOrGeneProduct
alleles,168,O
and,168,O
type,168,B-DiseaseOrPhenotypicFeature
1,168,I-DiseaseOrPhenotypicFeature
diabetes,168,I-DiseaseOrPhenotypicFeature
have,168,O
been,168,O
described,168,O
in,168,O
different,168,O
populations,168,O
.,168,O
Therefore,169,O
",",169,O
we,169,O
investigated,169,O
the,169,O
polymorphism,169,O
in,169,O
codon,169,O
416,169,O
of,169,O
the,169,O
DBP,169,B-GeneOrGeneProduct
gene,169,O
for,169,O
an,169,O
association,169,O
with,169,O
autoimmune,169,O
markers,169,O
of,169,O
type,169,B-DiseaseOrPhenotypicFeature
1,169,I-DiseaseOrPhenotypicFeature
diabetes,169,I-DiseaseOrPhenotypicFeature
.,169,O
DESIGN,170,O
AND,170,O
METHODS,170,O
:,170,O
The,170,O
present,170,O
analysis,170,O
was,170,O
a,170,O
case,170,O
control,170,O
study,170,O
.,170,O
110,171,O
patients,171,B-OrganismTaxon
",",171,O
68,171,O
controls,171,O
",",171,O
and,171,O
115,171,O
first-degree,171,O
relatives,171,O
were,171,O
genotyped,171,O
for,171,O
the,171,O
DBP,171,B-GeneOrGeneProduct
polymorphism,171,O
in,171,O
codon,171,O
416,171,O
.,171,O
DNA,172,O
typing,172,O
of,172,O
DBP,172,B-GeneOrGeneProduct
locus,172,O
was,172,O
performed,172,O
by,172,O
the,172,O
PCR-restriction,172,O
fragment,172,O
length,172,O
polymorphism,172,O
method,172,O
(,172,O
RFLP,172,O
),172,O
.,172,O
RESULTS,173,O
:,173,O
The,173,O
frequencies,173,O
of,173,O
the,173,O
Asp/Glu,173,O
and,173,O
Glu/Glu,173,O
were,173,O
significantly,173,O
increased,173,O
in,173,O
diabetic,173,B-DiseaseOrPhenotypicFeature
subjects,173,O
with,173,O
detectable,173,O
IA-2,173,B-GeneOrGeneProduct
antibodies,173,O
(,173,O
P,173,O
<,173,O
0.01,173,O
),173,O
.,173,O
On,174,O
the,174,O
contrary,174,O
",",174,O
the,174,O
DBP,174,B-GeneOrGeneProduct
Glu-containing,174,O
genotype,174,O
was,174,O
not,174,O
accompanied,174,O
by,174,O
differences,174,O
in,174,O
the,174,O
prevalence,174,O
of,174,O
GAD65,174,B-GeneOrGeneProduct
antibodies,174,O
.,174,O
These,175,O
finding,175,O
supports,175,O
a,175,O
role,175,O
of,175,O
the,175,O
vitamin,175,B-ChemicalEntity
D,175,I-ChemicalEntity
endocrine,175,O
system,175,O
in,175,O
the,175,O
autoimmune,175,O
process,175,O
of,175,O
type,175,B-DiseaseOrPhenotypicFeature
1,175,I-DiseaseOrPhenotypicFeature
diabetes,175,I-DiseaseOrPhenotypicFeature
.,175,O
No,176,O
Evidence,176,O
for,176,O
BRAF,176,B-GeneOrGeneProduct
as,176,O
a,176,O
melanoma/nevus,176,B-DiseaseOrPhenotypicFeature
susceptibility,176,O
gene,176,O
.,176,O
Somatic,177,O
mutations,177,O
of,177,O
BRAF,177,B-GeneOrGeneProduct
have,177,O
been,177,O
identified,177,O
in,177,O
both,177,O
melanoma,177,B-DiseaseOrPhenotypicFeature
tumors,177,I-DiseaseOrPhenotypicFeature
and,177,O
benign,177,O
nevi,177,B-DiseaseOrPhenotypicFeature
.,177,O
Germ,178,O
line,178,O
mutations,178,O
in,178,O
BRAF,178,B-GeneOrGeneProduct
have,178,O
not,178,O
been,178,O
identified,178,O
as,178,O
causal,178,O
in,178,O
families,178,O
predisposed,178,O
to,178,O
melanoma,178,B-DiseaseOrPhenotypicFeature
.,178,O
However,179,O
",",179,O
a,179,O
recent,179,O
study,179,O
suggested,179,O
that,179,O
a,179,O
BRAF,179,B-GeneOrGeneProduct
haplotype,179,O
was,179,O
associated,179,O
with,179,O
risk,179,O
of,179,O
sporadic,179,B-DiseaseOrPhenotypicFeature
melanoma,179,I-DiseaseOrPhenotypicFeature
in,179,O
men,179,B-OrganismTaxon
.,179,O
Polymorphisms,180,O
or,180,O
other,180,O
variants,180,O
in,180,O
the,180,O
BRAF,180,B-GeneOrGeneProduct
gene,180,O
may,180,O
therefore,180,O
act,180,O
as,180,O
candidate,180,O
low-penetrance,180,O
genes,180,O
for,180,O
nevus/melanoma,180,B-DiseaseOrPhenotypicFeature
susceptibility,180,O
.,180,O
We,181,O
hypothesized,181,O
that,181,O
promoter,181,O
variants,181,O
would,181,O
be,181,O
the,181,O
most,181,O
likely,181,O
candidates,181,O
for,181,O
determinants,181,O
of,181,O
risk,181,O
.,181,O
Using,182,O
denaturing,182,O
high-pressure,182,O
liquid,182,O
chromatography,182,O
and,182,O
sequencing,182,O
",",182,O
we,182,O
screened,182,O
peripheral,182,O
blood,182,O
DNA,182,O
from,182,O
184,182,O
familial,182,B-DiseaseOrPhenotypicFeature
melanoma,182,I-DiseaseOrPhenotypicFeature
cases,182,O
for,182,O
BRAF,182,B-GeneOrGeneProduct
promoter,182,O
variants,182,O
.,182,O
We,183,O
identified,183,O
a,183,O
promoter,183,O
insertion/deletion,183,O
in,183,O
linkage,183,O
disequilibrium,183,O
with,183,O
the,183,O
previously,183,O
described,183,O
BRAF,183,B-GeneOrGeneProduct
polymorphism,183,O
in,183,O
intron,183,O
11,183,O
(,183,O
rs1639679,183,B-SequenceVariant
),183,O
reported,183,O
to,183,O
be,183,O
associated,183,O
with,183,O
melanoma,183,B-DiseaseOrPhenotypicFeature
susceptibility,183,O
in,183,O
males,183,O
.,183,O
We,184,O
therefore,184,O
investigated,184,O
the,184,O
contribution,184,O
of,184,O
this,184,O
BRAF,184,B-GeneOrGeneProduct
polymorphism,184,O
to,184,O
melanoma,184,B-DiseaseOrPhenotypicFeature
susceptibility,184,O
in,184,O
581,184,O
consecutively,184,O
recruited,184,O
incident,184,O
cases,184,O
",",184,O
258,184,O
incident,184,O
cases,184,O
in,184,O
a,184,O
study,184,O
of,184,O
late,184,O
relapse,184,O
",",184,O
673,184,O
female,184,O
general,184,O
practitioner,184,O
controls,184,O
",",184,O
and,184,O
the,184,O
184,184,O
familial,184,O
cases,184,O
.,184,O
We,185,O
found,185,O
no,185,O
statistically,185,O
significant,185,O
difference,185,O
in,185,O
either,185,O
genotype,185,O
or,185,O
allele,185,O
frequencies,185,O
between,185,O
cases,185,O
and,185,O
controls,185,O
overall,185,O
or,185,O
between,185,O
male,185,O
and,185,O
female,185,O
cases,185,O
for,185,O
the,185,O
BRAF,185,B-GeneOrGeneProduct
polymorphism,185,O
in,185,O
the,185,O
two,185,O
incident,185,O
case,185,O
series,185,O
.,185,O
Our,186,O
results,186,O
therefore,186,O
suggest,186,O
that,186,O
the,186,O
BRAF,186,B-GeneOrGeneProduct
polymorphism,186,O
is,186,O
not,186,O
significantly,186,O
associated,186,O
with,186,O
melanoma,186,B-DiseaseOrPhenotypicFeature
and,186,O
the,186,O
promoter,186,O
insertion/deletion,186,O
linked,186,O
with,186,O
the,186,O
polymorphism,186,O
is,186,O
not,186,O
a,186,O
causal,186,O
variant,186,O
.,186,O
In,187,O
addition,187,O
",",187,O
we,187,O
found,187,O
that,187,O
there,187,O
was,187,O
no,187,O
association,187,O
between,187,O
the,187,O
BRAF,187,B-GeneOrGeneProduct
genotype,187,O
and,187,O
mean,187,O
total,187,O
number,187,O
of,187,O
banal,187,O
or,187,O
atypical,187,O
nevi,187,B-DiseaseOrPhenotypicFeature
in,187,O
either,187,O
the,187,O
cases,187,O
or,187,O
controls,187,O
.,187,O
Growth-associated,188,B-GeneOrGeneProduct
protein,188,I-GeneOrGeneProduct
43,188,I-GeneOrGeneProduct
expression,188,O
in,188,O
hippocampal,188,O
molecular,188,O
layer,188,O
of,188,O
chronic,188,O
epileptic,188,B-DiseaseOrPhenotypicFeature
rats,188,B-OrganismTaxon
treated,188,O
with,188,O
cycloheximide,188,B-ChemicalEntity
.,188,O
PURPOSE,189,O
:,189,O
GAP43,189,B-GeneOrGeneProduct
has,189,O
been,189,O
thought,189,O
to,189,O
be,189,O
linked,189,O
with,189,O
mossy,189,O
fiber,189,O
sprouting,189,O
(,189,O
MFS,189,O
),189,O
in,189,O
various,189,O
experimental,189,O
models,189,O
of,189,O
epilepsy,189,B-DiseaseOrPhenotypicFeature
.,189,O
To,190,O
investigate,190,O
how,190,O
GAP43,190,B-GeneOrGeneProduct
expression,190,O
(,190,O
GAP43-ir,190,B-GeneOrGeneProduct
),190,O
correlates,190,O
with,190,O
MFS,190,O
",",190,O
we,190,O
assessed,190,O
the,190,O
intensity,190,O
(,190,O
densitometry,190,O
),190,O
and,190,O
extension,190,O
(,190,O
width,190,O
),190,O
of,190,O
GAP43-ir,190,B-GeneOrGeneProduct
in,190,O
the,190,O
inner,190,O
molecular,190,O
layer,190,O
of,190,O
the,190,O
dentate,190,O
gyrus,190,O
(,190,O
IML,190,O
),190,O
of,190,O
rats,190,B-OrganismTaxon
subject,190,O
to,190,O
status,190,B-DiseaseOrPhenotypicFeature
epilepticus,190,I-DiseaseOrPhenotypicFeature
induced,190,O
by,190,O
pilocarpine,190,B-ChemicalEntity
(,190,O
Pilo,190,B-ChemicalEntity
),190,O
",",190,O
previously,190,O
injected,190,O
or,190,O
not,190,O
with,190,O
cycloheximide,190,B-ChemicalEntity
(,190,O
CHX,190,B-ChemicalEntity
),190,O
",",190,O
which,190,O
has,190,O
been,190,O
shown,190,O
to,190,O
inhibit,190,O
MFS,190,O
.,190,O
METHODS,191,O
:,191,O
CHX,191,B-ChemicalEntity
was,191,O
injected,191,O
before,191,O
the,191,O
Pilo,191,B-ChemicalEntity
injection,191,O
in,191,O
adult,191,O
Wistar,191,O
rats,191,B-OrganismTaxon
.,191,O
The,192,O
Pilo,192,B-ChemicalEntity
group,192,O
was,192,O
injected,192,O
with,192,O
the,192,O
same,192,O
drugs,192,O
",",192,O
except,192,O
for,192,O
CHX,192,B-ChemicalEntity
.,192,O
Animals,193,O
were,193,O
killed,193,O
between,193,O
30,193,O
and,193,O
60,193,O
days,193,O
later,193,O
",",193,O
and,193,O
brain,193,O
sections,193,O
were,193,O
processed,193,O
for,193,O
GAP43,193,B-GeneOrGeneProduct
immunohistochemistry,193,O
.,193,O
RESULTS,194,O
:,194,O
Densitometry,194,O
showed,194,O
no,194,O
significant,194,O
difference,194,O
regarding,194,O
GAP43-ir,194,B-GeneOrGeneProduct
in,194,O
the,194,O
IML,194,O
between,194,O
Pilo,194,B-ChemicalEntity
",",194,O
CHX+Pilo,194,B-ChemicalEntity
",",194,O
and,194,O
control,194,O
groups,194,O
.,194,O
However,195,O
",",195,O
the,195,O
results,195,O
of,195,O
the,195,O
width,195,O
of,195,O
the,195,O
GAP43-ir,195,B-GeneOrGeneProduct
band,195,O
in,195,O
the,195,O
IML,195,O
showed,195,O
that,195,O
CHX+Pilo,195,B-ChemicalEntity
and,195,O
control,195,O
animals,195,O
had,195,O
a,195,O
significantly,195,O
larger,195,O
band,195,O
(,195,O
p,195,O
=,195,O
0.03,195,O
),195,O
as,195,O
compared,195,O
with,195,O
that,195,O
in,195,O
the,195,O
Pilo,195,B-ChemicalEntity
group,195,O
.,195,O
CONCLUSIONS,196,O
:,196,O
Our,196,O
current,196,O
finding,196,O
that,196,O
animals,196,O
in,196,O
the,196,O
CHX+Pilo,196,B-ChemicalEntity
group,196,O
have,196,O
a,196,O
GAP43-ir,196,B-GeneOrGeneProduct
band,196,O
in,196,O
the,196,O
IML,196,O
",",196,O
similar,196,O
to,196,O
that,196,O
of,196,O
controls,196,O
",",196,O
reinforces,196,O
prior,196,O
data,196,O
on,196,O
the,196,O
blockade,196,O
of,196,O
MFS,196,O
in,196,O
these,196,O
animals,196,O
.,196,O
The,197,O
change,197,O
in,197,O
GAP43-ir,197,B-GeneOrGeneProduct
present,197,O
in,197,O
Pilo-treated,197,B-ChemicalEntity
animals,197,O
was,197,O
a,197,O
thinning,197,O
of,197,O
the,197,O
band,197,O
to,197,O
a,197,O
very,197,O
narrow,197,O
layer,197,O
just,197,O
above,197,O
the,197,O
granule,197,O
cell,197,O
layer,197,O
that,197,O
is,197,O
likely,197,O
to,197,O
be,197,O
associated,197,O
with,197,O
the,197,O
loss,197,O
of,197,O
hilar,197,O
cell,197,O
projections,197,O
that,197,O
express,197,O
GAP-43,197,B-GeneOrGeneProduct
.,197,O
Allelic,198,O
expression,198,O
imbalance,198,O
of,198,O
human,198,B-OrganismTaxon
mu,198,B-GeneOrGeneProduct
opioid,198,I-GeneOrGeneProduct
receptor,198,I-GeneOrGeneProduct
(,198,O
OPRM1,198,B-GeneOrGeneProduct
),198,O
caused,198,O
by,198,O
variant,198,O
A118G,198,B-SequenceVariant
.,198,O
As,199,O
a,199,O
primary,199,O
target,199,O
for,199,O
opioid,199,O
drugs,199,O
and,199,O
peptides,199,O
",",199,O
the,199,O
mu,199,B-GeneOrGeneProduct
opioid,199,I-GeneOrGeneProduct
receptor,199,I-GeneOrGeneProduct
(,199,O
OPRM1,199,B-GeneOrGeneProduct
),199,O
plays,199,O
a,199,O
key,199,O
role,199,O
in,199,O
pain,199,B-DiseaseOrPhenotypicFeature
perception,199,O
and,199,O
addiction,199,O
.,199,O
Genetic,200,O
variants,200,O
of,200,O
OPRM1,200,B-GeneOrGeneProduct
have,200,O
been,200,O
implicated,200,O
in,200,O
predisposition,200,O
to,200,O
drug,200,B-DiseaseOrPhenotypicFeature
addiction,200,I-DiseaseOrPhenotypicFeature
",",200,O
in,200,O
particular,200,O
the,200,O
single,200,O
nucleotide,200,O
polymorphism,200,O
A118G,200,B-SequenceVariant
",",200,O
leading,200,O
to,200,O
an,200,O
N40D,200,B-SequenceVariant
substitution,200,O
",",200,O
with,200,O
an,200,O
allele,200,O
frequency,200,O
of,200,O
10-32,200,O
%,200,O
",",200,O
and,200,O
uncertain,200,O
functions,200,O
.,200,O
We,201,O
have,201,O
measured,201,O
allele-specific,201,O
mRNA,201,O
expression,201,O
of,201,O
OPRM1,201,B-GeneOrGeneProduct
in,201,O
human,201,B-OrganismTaxon
autopsy,201,O
brain,201,O
tissues,201,O
",",201,O
using,201,O
A118G,201,B-SequenceVariant
as,201,O
a,201,O
marker,201,O
.,201,O
In,202,O
8,202,O
heterozygous,202,O
samples,202,O
measured,202,O
",",202,O
the,202,O
A118,202,B-SequenceVariant
mRNA,202,O
allele,202,O
was,202,O
1.5-2.5-fold,202,O
more,202,O
abundant,202,O
than,202,O
the,202,O
G118,202,B-SequenceVariant
allele,202,O
.,202,O
Transfection,203,O
into,203,O
Chinese,203,B-OrganismTaxon
hamster,203,I-OrganismTaxon
ovary,203,O
cells,203,O
of,203,O
a,203,O
cDNA,203,O
representing,203,O
only,203,O
the,203,O
coding,203,O
region,203,O
of,203,O
OPRM1,203,B-GeneOrGeneProduct
",",203,O
carrying,203,O
adenosine,203,B-SequenceVariant
",",203,I-SequenceVariant
guanosine,203,I-SequenceVariant
",",203,I-SequenceVariant
cytidine,203,I-SequenceVariant
",",203,I-SequenceVariant
and,203,I-SequenceVariant
thymidine,203,I-SequenceVariant
in,203,I-SequenceVariant
position,203,I-SequenceVariant
118,203,I-SequenceVariant
",",203,O
resulted,203,O
in,203,O
1.5-fold,203,O
lower,203,O
mRNA,203,O
levels,203,O
only,203,O
for,203,O
OPRM1-G118,203,B-GeneOrGeneProduct
",",203,O
and,203,O
more,203,O
than,203,O
10-fold,203,O
lower,203,O
OPRM1,203,B-GeneOrGeneProduct
protein,203,O
levels,203,O
",",203,O
measured,203,O
by,203,O
Western,203,O
blotting,203,O
and,203,O
receptor,203,O
binding,203,O
assay,203,O
.,203,O
After,204,O
transfection,204,O
and,204,O
inhibition,204,O
of,204,O
transcription,204,O
with,204,O
actinomycin,204,B-ChemicalEntity
D,204,I-ChemicalEntity
",",204,O
analysis,204,O
of,204,O
mRNA,204,O
turnover,204,O
failed,204,O
to,204,O
reveal,204,O
differences,204,O
in,204,O
mRNA,204,O
stability,204,O
between,204,O
A118,204,B-SequenceVariant
and,204,O
G118,204,B-SequenceVariant
alleles,204,O
",",204,O
indicating,204,O
a,204,O
defect,204,O
in,204,O
transcription,204,O
or,204,O
mRNA,204,O
maturation,204,O
.,204,O
These,205,O
results,205,O
indicate,205,O
that,205,O
OPRM1-G118,205,B-GeneOrGeneProduct
is,205,O
a,205,O
functional,205,O
variant,205,O
with,205,O
deleterious,205,O
effects,205,O
on,205,O
both,205,O
mRNA,205,O
and,205,O
protein,205,O
yield,205,O
.,205,O
Clarifying,206,O
the,206,O
functional,206,O
relevance,206,O
of,206,O
polymorphisms,206,O
associated,206,O
with,206,O
susceptibility,206,O
to,206,O
a,206,O
complex,206,O
disorder,206,O
such,206,O
as,206,O
drug,206,B-DiseaseOrPhenotypicFeature
addiction,206,I-DiseaseOrPhenotypicFeature
provides,206,O
a,206,O
foundation,206,O
for,206,O
clinical,206,O
association,206,O
studies,206,O
.,206,O
In,207,O
vivo,207,O
evidences,207,O
suggesting,207,O
the,207,O
role,207,O
of,207,O
oxidative,207,O
stress,207,O
in,207,O
pathogenesis,207,O
of,207,O
vancomycin-induced,207,B-ChemicalEntity
nephrotoxicity,207,B-DiseaseOrPhenotypicFeature
:,207,O
protection,207,O
by,207,O
erdosteine,207,B-ChemicalEntity
.,207,O
The,208,O
aims,208,O
of,208,O
this,208,O
study,208,O
were,208,O
to,208,O
examine,208,O
vancomycin,208,B-ChemicalEntity
(,208,O
VCM,208,B-ChemicalEntity
),208,O
-induced,208,O
oxidative,208,O
stress,208,O
that,208,O
promotes,208,O
production,208,O
of,208,O
reactive,208,B-ChemicalEntity
oxygen,208,I-ChemicalEntity
species,208,I-ChemicalEntity
(,208,O
ROS,208,B-ChemicalEntity
),208,O
and,208,O
to,208,O
investigate,208,O
the,208,O
role,208,O
of,208,O
erdosteine,208,B-ChemicalEntity
",",208,O
an,208,O
expectorant,208,O
agent,208,O
",",208,O
which,208,O
has,208,O
also,208,O
antioxidant,208,B-ChemicalEntity
properties,208,O
",",208,O
on,208,O
kidney,208,O
tissue,208,O
against,208,O
the,208,O
possible,208,O
VCM-induced,208,B-ChemicalEntity
renal,208,B-DiseaseOrPhenotypicFeature
impairment,208,I-DiseaseOrPhenotypicFeature
in,208,O
rats,208,B-OrganismTaxon
.,208,O
Rats,209,B-OrganismTaxon
were,209,O
divided,209,O
into,209,O
three,209,O
groups,209,O
:,209,O
sham,209,O
",",209,O
VCM,209,B-ChemicalEntity
and,209,O
VCM,209,B-ChemicalEntity
plus,209,O
erdosteine,209,B-ChemicalEntity
.,209,O
VCM,210,B-ChemicalEntity
was,210,O
administrated,210,O
intraperitoneally,210,O
(,210,O
i.p,210,O
.,210,O
),210,O
with,211,O
200mgkg,211,O
(,211,O
-1,211,O
),211,O
twice,211,O
daily,211,O
for,211,O
7,211,O
days,211,O
.,211,O
Erdosteine,212,B-ChemicalEntity
was,212,O
administered,212,O
orally,212,O
.,212,O
VCM,213,B-ChemicalEntity
administration,213,O
to,213,O
control,213,O
rats,213,B-OrganismTaxon
significantly,213,O
increased,213,O
renal,213,O
malondialdehyde,213,B-ChemicalEntity
(,213,O
MDA,213,B-ChemicalEntity
),213,O
and,213,O
urinary,213,O
N-acetyl-beta-d-glucosaminidase,213,B-GeneOrGeneProduct
(,213,O
NAG,213,B-GeneOrGeneProduct
",",213,O
a,213,O
marker,213,O
of,213,O
renal,213,B-DiseaseOrPhenotypicFeature
tubular,213,I-DiseaseOrPhenotypicFeature
injury,213,I-DiseaseOrPhenotypicFeature
),213,O
excretion,213,O
but,213,O
decreased,213,O
superoxide,213,B-ChemicalEntity
dismutase,213,I-ChemicalEntity
(,213,O
SOD,213,B-ChemicalEntity
),213,O
and,213,O
catalase,213,B-GeneOrGeneProduct
(,213,O
CAT,213,B-GeneOrGeneProduct
),213,O
activities,213,O
.,213,O
Erdosteine,214,B-ChemicalEntity
administration,214,O
with,214,O
VCM,214,B-ChemicalEntity
injections,214,O
caused,214,O
significantly,214,O
decreased,214,O
renal,214,O
MDA,214,B-ChemicalEntity
and,214,O
urinary,214,O
NAG,214,B-GeneOrGeneProduct
excretion,214,O
",",214,O
and,214,O
increased,214,O
SOD,214,B-ChemicalEntity
activity,214,O
",",214,O
but,214,O
not,214,O
CAT,214,B-GeneOrGeneProduct
activity,214,O
in,214,O
renal,214,O
tissue,214,O
when,214,O
compared,214,O
with,214,O
VCM,214,B-ChemicalEntity
alone,214,O
.,214,O
Erdosteine,215,B-ChemicalEntity
showed,215,O
histopathological,215,O
protection,215,O
against,215,O
VCM-induced,215,B-ChemicalEntity
nephrotoxicity,215,B-DiseaseOrPhenotypicFeature
.,215,O
There,216,O
were,216,O
a,216,O
significant,216,O
dilatation,216,O
of,216,O
tubular,216,O
lumens,216,O
",",216,O
extensive,216,O
epithelial,216,O
cell,216,O
vacuolization,216,O
",",216,O
atrophy,216,B-DiseaseOrPhenotypicFeature
",",216,O
desquamation,216,B-DiseaseOrPhenotypicFeature
",",216,O
and,216,O
necrosis,216,B-DiseaseOrPhenotypicFeature
in,216,O
VCM-treated,216,B-ChemicalEntity
rats,216,B-OrganismTaxon
more,216,O
than,216,O
those,216,O
of,216,O
the,216,O
control,216,O
and,216,O
the,216,O
erdosteine,216,B-ChemicalEntity
groups,216,O
.,216,O
Erdosteine,217,B-ChemicalEntity
caused,217,O
a,217,O
marked,217,O
reduction,217,O
in,217,O
the,217,O
extent,217,O
of,217,O
tubular,217,O
damage,217,O
.,217,O
It,218,O
is,218,O
concluded,218,O
that,218,O
oxidative,218,O
tubular,218,O
damage,218,O
plays,218,O
an,218,O
important,218,O
role,218,O
in,218,O
the,218,O
VCM-induced,218,B-ChemicalEntity
nephrotoxicity,218,B-DiseaseOrPhenotypicFeature
and,218,O
the,218,O
modulation,218,O
of,218,O
oxidative,218,O
stress,218,O
with,218,O
erdosteine,218,B-ChemicalEntity
reduces,218,O
the,218,O
VCM-induced,218,B-ChemicalEntity
kidney,218,B-DiseaseOrPhenotypicFeature
damage,218,I-DiseaseOrPhenotypicFeature
both,218,O
at,218,O
the,218,O
biochemical,218,O
and,218,O
histological,218,O
levels,218,O
.,218,O
rTMS,219,O
of,219,O
supplementary,219,O
motor,219,O
area,219,O
modulates,219,O
therapy-induced,219,O
dyskinesias,219,B-DiseaseOrPhenotypicFeature
in,219,O
Parkinson,219,B-DiseaseOrPhenotypicFeature
disease,219,I-DiseaseOrPhenotypicFeature
.,219,O
The,220,O
neural,220,O
mechanisms,220,O
and,220,O
circuitry,220,O
involved,220,O
in,220,O
levodopa-induced,220,B-ChemicalEntity
dyskinesia,220,B-DiseaseOrPhenotypicFeature
are,220,O
unclear,220,O
.,220,O
Using,221,O
repetitive,221,O
transcranial,221,O
magnetic,221,O
stimulation,221,O
(,221,O
rTMS,221,O
),221,O
over,221,O
the,221,O
supplementary,221,O
motor,221,O
area,221,O
(,221,O
SMA,221,O
),221,O
in,221,O
a,221,O
group,221,O
of,221,O
patients,221,B-OrganismTaxon
with,221,O
advanced,221,O
Parkinson,221,B-DiseaseOrPhenotypicFeature
disease,221,I-DiseaseOrPhenotypicFeature
",",221,O
the,221,O
authors,221,O
investigated,221,O
whether,221,O
modulation,221,O
of,221,O
SMA,221,O
excitability,221,O
may,221,O
result,221,O
in,221,O
a,221,O
modification,221,O
of,221,O
a,221,O
dyskinetic,221,B-DiseaseOrPhenotypicFeature
state,221,O
induced,221,O
by,221,O
continuous,221,O
apomorphine,221,B-ChemicalEntity
infusion,221,O
.,221,O
rTMS,222,O
at,222,O
1,222,O
Hz,222,O
was,222,O
observed,222,O
to,222,O
markedly,222,O
reduce,222,O
drug-induced,222,B-DiseaseOrPhenotypicFeature
dyskinesias,222,I-DiseaseOrPhenotypicFeature
",",222,O
whereas,222,O
5-Hz,222,O
rTMS,222,O
induced,222,O
a,222,O
slight,222,O
but,222,O
not,222,O
significant,222,O
increase,222,O
.,222,O
Characterization,223,O
of,223,O
Bietti,223,B-DiseaseOrPhenotypicFeature
crystalline,223,I-DiseaseOrPhenotypicFeature
dystrophy,223,I-DiseaseOrPhenotypicFeature
patients,223,B-OrganismTaxon
with,223,O
CYP4V2,223,B-GeneOrGeneProduct
mutations,223,O
.,223,O
PURPOSE,224,O
:,224,O
Mutations,224,O
of,224,O
the,224,O
CYP4V2,224,B-GeneOrGeneProduct
gene,224,O
",",224,O
a,224,O
novel,224,O
family,224,O
member,224,O
of,224,O
the,224,O
cytochrome,224,B-GeneOrGeneProduct
P450,224,I-GeneOrGeneProduct
genes,224,O
on,224,O
chromosome,224,O
4q35,224,O
",",224,O
have,224,O
recently,224,O
been,224,O
identified,224,O
in,224,O
patients,224,B-OrganismTaxon
with,224,O
Bietti,224,B-DiseaseOrPhenotypicFeature
crystalline,224,I-DiseaseOrPhenotypicFeature
dystrophy,224,I-DiseaseOrPhenotypicFeature
(,224,O
BCD,224,B-DiseaseOrPhenotypicFeature
),224,O
.,224,O
The,225,O
aim,225,O
of,225,O
this,225,O
study,225,O
was,225,O
to,225,O
investigate,225,O
the,225,O
spectrum,225,O
of,225,O
mutations,225,O
in,225,O
this,225,O
gene,225,O
in,225,O
BCD,225,B-DiseaseOrPhenotypicFeature
patients,225,B-OrganismTaxon
from,225,O
Singapore,225,O
",",225,O
and,225,O
to,225,O
characterize,225,O
their,225,O
phenotype,225,O
.,225,O
METHODS,226,O
:,226,O
Nine,226,O
patients,226,B-OrganismTaxon
with,226,O
BCD,226,B-DiseaseOrPhenotypicFeature
from,226,O
six,226,O
families,226,O
were,226,O
recruited,226,O
into,226,O
the,226,O
study,226,O
.,226,O
The,227,O
11,227,O
exons,227,O
of,227,O
the,227,O
CYP4V2,227,B-GeneOrGeneProduct
gene,227,O
were,227,O
amplified,227,O
from,227,O
genomic,227,O
DNA,227,O
of,227,O
patients,227,B-OrganismTaxon
by,227,O
polymerase,227,O
chain,227,O
reaction,227,O
and,227,O
then,227,O
sequenced,227,O
.,227,O
Detailed,228,O
characterization,228,O
of,228,O
the,228,O
patients,228,B-OrganismTaxon
',228,O
phenotype,228,O
was,228,O
performed,228,O
with,228,O
fundal,228,O
photography,228,O
",",228,O
visual,228,O
field,228,O
testing,228,O
",",228,O
fundal,228,O
fluorescein,228,O
angiography,228,O
",",228,O
and,228,O
electroretinography,228,O
(,228,O
ERG,228,O
),228,O
.,228,O
RESULTS,229,O
:,229,O
Three,229,O
pathogenic,229,O
mutations,229,O
were,229,O
identified,229,O
;,229,O
two,229,O
mutations,229,O
",",229,O
S482X,229,B-SequenceVariant
and,229,O
K386T,229,B-SequenceVariant
",",229,O
were,229,O
novel,229,O
and,229,O
found,229,O
in,229,O
three,229,O
patients,229,B-OrganismTaxon
.,229,O
The,230,O
third,230,O
mutation,230,O
",",230,O
a,230,O
previously,230,O
identified,230,O
15-bp,230,B-SequenceVariant
deletion,230,I-SequenceVariant
that,230,O
included,230,O
the,230,O
3,230,O
',230,O
splice,230,O
site,230,O
for,230,O
exon,230,O
7,230,O
",",230,O
was,230,O
found,230,O
in,230,O
all,230,O
nine,230,O
patients,230,B-OrganismTaxon
",",230,O
with,230,O
six,230,O
patients,230,B-OrganismTaxon
carrying,230,O
the,230,O
deletion,230,O
in,230,O
the,230,O
homozygous,230,O
state,230,O
.,230,O
Haplotype,231,O
analysis,231,O
in,231,O
patients,231,B-OrganismTaxon
and,231,O
controls,231,O
indicated,231,O
a,231,O
founder,231,O
effect,231,O
for,231,O
this,231,O
deletion,231,O
mutation,231,O
in,231,O
exon,231,O
7,231,O
.,231,O
Clinical,232,O
heterogeneity,232,O
was,232,O
present,232,O
in,232,O
the,232,O
patients,232,B-OrganismTaxon
.,232,O
Compound,233,O
heterozygotes,233,O
for,233,O
the,233,O
deletion,233,O
in,233,O
exon,233,O
7,233,O
seemed,233,O
to,233,O
have,233,O
more,233,O
severe,233,O
disease,233,O
compared,233,O
to,233,O
patients,233,B-OrganismTaxon
homozygous,233,O
for,233,O
the,233,O
deletion,233,O
.,233,O
There,234,O
was,234,O
good,234,O
correlation,234,O
between,234,O
clinical,234,O
stage,234,O
of,234,O
disease,234,O
and,234,O
ERG,234,O
changes,234,O
",",234,O
but,234,O
age,234,O
did,234,O
not,234,O
correlate,234,O
with,234,O
disease,234,O
severity,234,O
.,234,O
CONCLUSIONS,235,O
:,235,O
This,235,O
study,235,O
identified,235,O
novel,235,O
mutations,235,O
in,235,O
the,235,O
CYP4V2,235,B-GeneOrGeneProduct
gene,235,O
as,235,O
a,235,O
cause,235,O
of,235,O
BCD,235,B-DiseaseOrPhenotypicFeature
.,235,O
A,236,O
high,236,O
carrier,236,O
frequency,236,O
for,236,O
the,236,O
15-bp,236,B-SequenceVariant
deletion,236,I-SequenceVariant
in,236,O
exon,236,O
7,236,O
may,236,O
exist,236,O
in,236,O
the,236,O
Singapore,236,O
population,236,O
.,236,O
Phenotype,237,O
characterization,237,O
showed,237,O
clinical,237,O
heterogeneity,237,O
",",237,O
and,237,O
age,237,O
did,237,O
not,237,O
correlate,237,O
with,237,O
disease,237,O
severity,237,O
.,237,O
Polymorphisms,238,O
of,238,O
the,238,O
DNA,238,O
mismatch,238,B-GeneOrGeneProduct
repair,238,I-GeneOrGeneProduct
gene,238,O
HMSH2,238,B-GeneOrGeneProduct
in,238,O
breast,238,B-DiseaseOrPhenotypicFeature
cancer,238,I-DiseaseOrPhenotypicFeature
occurence,238,O
and,238,O
progression,238,O
.,238,O
The,239,O
response,239,O
of,239,O
the,239,O
cell,239,O
to,239,O
DNA,239,O
damage,239,O
and,239,O
its,239,O
ability,239,O
to,239,O
maintain,239,O
genomic,239,O
stability,239,O
by,239,O
DNA,239,O
repair,239,O
are,239,O
crucial,239,O
in,239,O
preventing,239,O
cancer,239,B-DiseaseOrPhenotypicFeature
initiation,239,I-DiseaseOrPhenotypicFeature
and,239,O
progression,239,O
.,239,O
Therefore,240,O
",",240,O
polymorphism,240,O
of,240,O
DNA,240,O
repair,240,O
genes,240,O
may,240,O
affect,240,O
the,240,O
process,240,O
of,240,O
carcinogenesis,240,B-DiseaseOrPhenotypicFeature
.,240,O
The,241,O
importance,241,O
of,241,O
genetic,241,O
variability,241,O
of,241,O
the,241,O
components,241,O
of,241,O
mismatch,241,B-GeneOrGeneProduct
repair,241,I-GeneOrGeneProduct
(,241,O
MMR,241,B-GeneOrGeneProduct
),241,O
genes,241,O
is,241,O
well,241,O
documented,241,O
in,241,O
colorectal,241,B-DiseaseOrPhenotypicFeature
cancer,241,I-DiseaseOrPhenotypicFeature
",",241,O
but,241,O
little,241,O
is,241,O
known,241,O
about,241,O
its,241,O
role,241,O
in,241,O
breast,241,B-DiseaseOrPhenotypicFeature
cancer,241,I-DiseaseOrPhenotypicFeature
.,241,O
hMSH2,242,B-GeneOrGeneProduct
is,242,O
one,242,O
of,242,O
the,242,O
crucial,242,O
proteins,242,O
of,242,O
MMR,242,B-GeneOrGeneProduct
.,242,O
We,243,O
performed,243,O
a,243,O
case-control,243,O
study,243,O
to,243,O
test,243,O
the,243,O
association,243,O
between,243,O
two,243,O
polymorphisms,243,O
in,243,O
the,243,O
hMSH2,243,B-GeneOrGeneProduct
gene,243,O
:,243,O
an,243,O
A,243,B-SequenceVariant
--,243,I-SequenceVariant
>,243,I-SequenceVariant
G,243,I-SequenceVariant
transition,243,I-SequenceVariant
at,243,I-SequenceVariant
127,243,I-SequenceVariant
position,243,I-SequenceVariant
producing,243,O
an,243,O
Asn,243,B-SequenceVariant
--,243,I-SequenceVariant
>,243,I-SequenceVariant
Ser,243,I-SequenceVariant
substitution,243,I-SequenceVariant
at,243,I-SequenceVariant
codon,243,I-SequenceVariant
127,243,I-SequenceVariant
(,243,O
the,243,O
Asn127Ser,243,B-SequenceVariant
polymorphism,243,O
),243,O
and,243,O
a,243,O
G,243,B-SequenceVariant
--,243,I-SequenceVariant
>,243,I-SequenceVariant
A,243,I-SequenceVariant
transition,243,I-SequenceVariant
at,243,I-SequenceVariant
1032,243,I-SequenceVariant
position,243,I-SequenceVariant
resulting,243,O
in,243,O
a,243,O
Gly,243,B-SequenceVariant
--,243,I-SequenceVariant
>,243,I-SequenceVariant
Asp,243,I-SequenceVariant
change,243,I-SequenceVariant
at,243,I-SequenceVariant
codon,243,I-SequenceVariant
322,243,I-SequenceVariant
(,243,O
the,243,O
Gly322Asp,243,B-SequenceVariant
polymorphism,243,O
),243,O
and,243,O
breast,243,B-DiseaseOrPhenotypicFeature
cancer,243,I-DiseaseOrPhenotypicFeature
risk,243,O
and,243,O
cancer,243,B-DiseaseOrPhenotypicFeature
progression,243,O
.,243,O
Genotypes,244,O
were,244,O
determined,244,O
in,244,O
DNA,244,O
from,244,O
peripheral,244,O
blood,244,O
lymphocytes,244,O
of,244,O
150,244,O
breast,244,B-DiseaseOrPhenotypicFeature
cancer,244,I-DiseaseOrPhenotypicFeature
patients,244,B-OrganismTaxon
and,244,O
150,244,O
age-matched,244,O
women,244,B-OrganismTaxon
(,244,O
controls,244,O
),244,O
by,244,O
restriction,244,O
fragment,244,O
length,244,O
polymorphism,244,O
and,244,O
allele-specific,244,O
PCR,244,O
.,244,O
We,245,O
did,245,O
not,245,O
observe,245,O
any,245,O
correlation,245,O
between,245,O
studied,245,O
polymorphisms,245,O
and,245,O
breast,245,B-DiseaseOrPhenotypicFeature
cancer,245,I-DiseaseOrPhenotypicFeature
progression,245,O
evaluated,245,O
by,245,O
node-metastasis,245,O
",",245,O
tumor,245,B-DiseaseOrPhenotypicFeature
size,245,O
and,245,O
Bloom-Richardson,245,O
grading,245,O
.,245,O
A,246,O
strong,246,O
association,246,O
between,246,O
breast,246,B-DiseaseOrPhenotypicFeature
cancer,246,I-DiseaseOrPhenotypicFeature
occurrence,246,O
and,246,O
the,246,O
Gly/Gly,246,O
phenotype,246,O
of,246,O
the,246,O
Gly322Asp,246,B-SequenceVariant
polymorphism,246,O
(,246,O
odds,246,O
ratio,246,O
8.39,246,O
;,246,O
95,246,O
%,246,O
confidence,246,O
interval,246,O
1.44-48.8,246,O
),246,O
was,246,O
found,246,O
.,246,O
Therefore,247,O
",",247,O
MMR,247,B-GeneOrGeneProduct
may,247,O
play,247,O
a,247,O
role,247,O
in,247,O
the,247,O
breast,247,B-DiseaseOrPhenotypicFeature
carcinogenesis,247,I-DiseaseOrPhenotypicFeature
and,247,O
the,247,O
Gly322Asp,247,B-SequenceVariant
polymorphism,247,O
of,247,O
the,247,O
hMSH2,247,B-GeneOrGeneProduct
gene,247,O
may,247,O
be,247,O
considered,247,O
as,247,O
a,247,O
potential,247,O
marker,247,O
in,247,O
breast,247,B-DiseaseOrPhenotypicFeature
cancer,247,I-DiseaseOrPhenotypicFeature
.,247,O
Array-based,248,O
comparative,248,O
genomic,248,O
hybridization,248,O
analysis,248,O
reveals,248,O
recurrent,248,O
chromosomal,248,O
alterations,248,O
and,248,O
prognostic,248,O
parameters,248,O
in,248,O
primary,248,B-DiseaseOrPhenotypicFeature
cutaneous,248,I-DiseaseOrPhenotypicFeature
large,248,I-DiseaseOrPhenotypicFeature
B-cell,248,I-DiseaseOrPhenotypicFeature
lymphoma,248,I-DiseaseOrPhenotypicFeature
.,248,O
PURPOSE,249,O
:,249,O
To,249,O
evaluate,249,O
the,249,O
clinical,249,O
relevance,249,O
of,249,O
genomic,249,O
aberrations,249,O
in,249,O
primary,249,B-DiseaseOrPhenotypicFeature
cutaneous,249,I-DiseaseOrPhenotypicFeature
large,249,I-DiseaseOrPhenotypicFeature
B-cell,249,I-DiseaseOrPhenotypicFeature
lymphoma,249,I-DiseaseOrPhenotypicFeature
(,249,O
PCLBCL,249,B-DiseaseOrPhenotypicFeature
),249,O
.,249,O
PATIENTS,250,B-OrganismTaxon
AND,250,O
METHODS,250,O
:,250,O
Skin,250,O
biopsy,250,O
samples,250,O
of,250,O
31,250,O
patients,250,B-OrganismTaxon
with,250,O
a,250,O
PCLBCL,250,B-DiseaseOrPhenotypicFeature
classified,250,O
as,250,O
either,250,O
primary,250,B-DiseaseOrPhenotypicFeature
cutaneous,250,I-DiseaseOrPhenotypicFeature
follicle,250,I-DiseaseOrPhenotypicFeature
center,250,I-DiseaseOrPhenotypicFeature
lymphoma,250,I-DiseaseOrPhenotypicFeature
(,250,O
PCFCL,250,B-DiseaseOrPhenotypicFeature
;,250,O
n,250,O
=,250,O
19,250,O
),250,O
or,250,O
PCLBCL,250,B-DiseaseOrPhenotypicFeature
",",250,O
leg,250,O
type,250,O
(,250,O
n,250,O
=,250,O
12,250,O
),250,O
",",250,O
according,250,O
to,250,O
the,250,O
WHO-European,250,O
Organisation,250,O
for,250,O
Research,250,O
and,250,O
Treatment,250,O
of,250,O
Cancer,250,B-DiseaseOrPhenotypicFeature
(,250,O
EORTC,250,O
),250,O
classification,250,O
",",250,O
were,250,O
investigated,250,O
using,250,O
array-based,250,O
comparative,250,O
genomic,250,O
hybridization,250,O
",",250,O
fluorescence,250,O
in,250,O
situ,250,O
hybridization,250,O
(,250,O
FISH,250,O
),250,O
",",250,O
and,250,O
examination,250,O
of,250,O
promoter,250,O
hypermethylation,250,O
.,250,O
RESULTS,251,O
:,251,O
The,251,O
most,251,O
recurrent,251,O
alterations,251,O
in,251,O
PCFCL,251,B-DiseaseOrPhenotypicFeature
were,251,O
high-level,251,O
DNA,251,O
amplifications,251,O
at,251,O
2p16.1,251,O
(,251,O
63,251,O
%,251,O
),251,O
and,251,O
deletion,251,O
of,251,O
chromosome,251,O
14q32.33,251,O
(,251,O
68,251,O
%,251,O
),251,O
.,251,O
FISH,252,O
analysis,252,O
confirmed,252,O
c-REL,252,B-GeneOrGeneProduct
amplification,252,O
in,252,O
patients,252,B-OrganismTaxon
with,252,O
gains,252,O
at,252,O
2p16.1,252,O
.,252,O
In,253,O
PCLBCL,253,B-DiseaseOrPhenotypicFeature
",",253,O
leg,253,O
type,253,O
",",253,O
most,253,O
prominent,253,O
aberrations,253,O
were,253,O
a,253,O
high-level,253,O
DNA,253,O
amplification,253,O
of,253,O
18q21.31-q21.33,253,O
(,253,O
67,253,O
%,253,O
),253,O
",",253,O
including,253,O
the,253,O
BCL-2,253,B-GeneOrGeneProduct
and,253,O
MALT1,253,B-GeneOrGeneProduct
genes,253,O
as,253,O
confirmed,253,O
by,253,O
FISH,253,O
",",253,O
and,253,O
deletions,253,O
of,253,O
a,253,O
small,253,O
region,253,O
within,253,O
9p21.3,253,O
containing,253,O
the,253,O
CDKN2A,253,B-GeneOrGeneProduct
",",253,O
CDKN2B,253,B-GeneOrGeneProduct
",",253,O
and,253,O
NSG-x,253,B-GeneOrGeneProduct
genes,253,O
.,253,O
Homozygous,254,O
deletion,254,O
of,254,O
9p21.3,254,O
was,254,O
detected,254,O
in,254,O
five,254,O
of,254,O
12,254,O
patients,254,B-OrganismTaxon
with,254,O
PCLBCL,254,B-DiseaseOrPhenotypicFeature
",",254,O
leg,254,O
type,254,O
",",254,O
but,254,O
in,254,O
zero,254,O
of,254,O
19,254,O
patients,254,B-OrganismTaxon
with,254,O
PCFCL,254,B-DiseaseOrPhenotypicFeature
.,254,O
Complete,255,O
methylation,255,O
of,255,O
the,255,O
promoter,255,O
region,255,O
of,255,O
the,255,O
CDKN2A,255,B-GeneOrGeneProduct
gene,255,O
was,255,O
demonstrated,255,O
in,255,O
one,255,O
PCLBCL,255,B-DiseaseOrPhenotypicFeature
",",255,O
leg,255,O
type,255,O
",",255,O
patient,255,B-OrganismTaxon
with,255,O
hemizygous,255,O
deletion,255,O
",",255,O
in,255,O
one,255,O
patient,255,B-OrganismTaxon
without,255,O
deletion,255,O
",",255,O
but,255,O
in,255,O
zero,255,O
of,255,O
19,255,O
patients,255,B-OrganismTaxon
with,255,O
PCFCL,255,B-DiseaseOrPhenotypicFeature
.,255,O
Seven,256,O
of,256,O
seven,256,O
PCLBCL,256,B-DiseaseOrPhenotypicFeature
",",256,O
leg,256,O
type,256,O
",",256,O
patients,256,B-OrganismTaxon
with,256,O
deletion,256,O
of,256,O
9p21.3,256,O
and/or,256,O
complete,256,O
methylation,256,O
of,256,O
CDKN2A,256,B-GeneOrGeneProduct
died,256,O
as,256,O
a,256,O
result,256,O
of,256,O
their,256,O
lymphoma,256,B-DiseaseOrPhenotypicFeature
.,256,O
CONCLUSION,257,O
:,257,O
Our,257,O
results,257,O
demonstrate,257,O
prominent,257,O
differences,257,O
in,257,O
chromosomal,257,O
alterations,257,O
between,257,O
PCFCL,257,B-DiseaseOrPhenotypicFeature
and,257,O
PCLBCL,257,B-DiseaseOrPhenotypicFeature
",",257,O
leg,257,O
type,257,O
",",257,O
that,257,O
support,257,O
their,257,O
classification,257,O
as,257,O
separate,257,O
entities,257,O
within,257,O
the,257,O
WHO-EORTC,257,O
scheme,257,O
.,257,O
Inactivation,258,O
of,258,O
CDKN2A,258,B-GeneOrGeneProduct
by,258,O
either,258,O
deletion,258,O
or,258,O
methylation,258,O
of,258,O
its,258,O
promoter,258,O
could,258,O
be,258,O
an,258,O
important,258,O
prognostic,258,O
parameter,258,O
for,258,O
the,258,O
group,258,O
of,258,O
PCLBCL,258,B-DiseaseOrPhenotypicFeature
",",258,O
leg,258,O
type,258,O
.,258,O
Daidzein,259,B-ChemicalEntity
activates,259,O
choline,259,B-GeneOrGeneProduct
acetyltransferase,259,I-GeneOrGeneProduct
from,259,O
MC-IXC,259,B-CellLine
cells,259,O
and,259,O
improves,259,O
drug-induced,259,O
amnesia,259,B-DiseaseOrPhenotypicFeature
.,259,O
The,260,O
choline,260,B-GeneOrGeneProduct
acetyltransferase,260,I-GeneOrGeneProduct
(,260,O
ChAT,260,B-GeneOrGeneProduct
),260,O
activator,260,O
",",260,O
which,260,O
enhances,260,O
cholinergic,260,O
transmission,260,O
via,260,O
an,260,O
augmentation,260,O
of,260,O
the,260,O
enzymatic,260,O
production,260,O
of,260,O
acetylcholine,260,B-ChemicalEntity
(,260,O
ACh,260,B-ChemicalEntity
),260,O
",",260,O
is,260,O
an,260,O
important,260,O
factor,260,O
in,260,O
the,260,O
treatment,260,O
of,260,O
Alzheimer,260,B-DiseaseOrPhenotypicFeature
's,260,I-DiseaseOrPhenotypicFeature
disease,260,I-DiseaseOrPhenotypicFeature
(,260,O
AD,260,B-DiseaseOrPhenotypicFeature
),260,O
.,260,O
Methanolic,261,B-ChemicalEntity
extracts,261,O
from,261,O
Pueraria,261,O
thunbergiana,261,O
exhibited,261,O
an,261,O
activation,261,O
effect,261,O
(,261,O
46,261,O
%,261,O
),261,O
on,261,O
ChAT,261,B-GeneOrGeneProduct
in,261,O
vitro,261,O
.,261,O
Via,262,O
the,262,O
sequential,262,O
isolation,262,O
of,262,O
Pueraria,262,O
thunbergiana,262,O
",",262,O
the,262,O
active,262,O
component,262,O
was,262,O
ultimately,262,O
identified,262,O
as,262,O
daidzein,262,B-ChemicalEntity
(,262,O
"4',7-dihydroxy-isoflavone",262,B-ChemicalEntity
),262,O
.,262,O
In,263,O
order,263,O
to,263,O
investigate,263,O
the,263,O
effects,263,O
of,263,O
daidzein,263,B-ChemicalEntity
from,263,O
Pueraria,263,O
thunbergiana,263,O
on,263,O
scopolamine-induced,263,B-ChemicalEntity
impairments,263,B-DiseaseOrPhenotypicFeature
of,263,I-DiseaseOrPhenotypicFeature
learning,263,I-DiseaseOrPhenotypicFeature
and,263,I-DiseaseOrPhenotypicFeature
memory,263,I-DiseaseOrPhenotypicFeature
",",263,O
we,263,O
conducted,263,O
a,263,O
series,263,O
of,263,O
in,263,O
vivo,263,O
tests,263,O
.,263,O
Administration,264,O
of,264,O
daidzein,264,B-ChemicalEntity
(,264,O
4.5,264,O
mg/kg,264,O
body,264,O
weight,264,O
),264,O
to,264,O
mice,264,B-OrganismTaxon
was,264,O
shown,264,O
significantly,264,O
to,264,O
reverse,264,O
scopolamine-induced,264,B-ChemicalEntity
amnesia,264,B-DiseaseOrPhenotypicFeature
",",264,O
according,264,O
to,264,O
the,264,O
results,264,O
of,264,O
a,264,O
Y-maze,264,O
test,264,O
.,264,O
Injections,265,O
of,265,O
scopolamine,265,B-ChemicalEntity
into,265,O
mice,265,B-OrganismTaxon
resulted,265,O
in,265,O
impaired,265,O
performance,265,O
on,265,O
Y-maze,265,O
tests,265,O
(,265,O
a,265,O
37,265,O
%,265,O
decreases,265,O
in,265,O
alternation,265,O
behavior,265,O
),265,O
.,265,O
By,266,O
way,266,O
of,266,O
contrast,266,O
",",266,O
mice,266,B-OrganismTaxon
treated,266,O
with,266,O
daidzein,266,B-ChemicalEntity
prior,266,O
to,266,O
the,266,O
scopolamine,266,B-ChemicalEntity
injections,266,O
were,266,O
noticeably,266,O
protected,266,O
from,266,O
this,266,O
performance,266,O
impairment,266,O
(,266,O
an,266,O
approximately,266,O
12,266,O
%,266,O
-21,266,O
%,266,O
decrease,266,O
in,266,O
alternation,266,O
behavior,266,O
),266,O
.,266,O
These,267,O
results,267,O
indicate,267,O
that,267,O
daidzein,267,B-ChemicalEntity
might,267,O
play,267,O
a,267,O
role,267,O
in,267,O
acetylcholine,267,B-ChemicalEntity
biosynthesis,267,O
as,267,O
a,267,O
ChAT,267,B-GeneOrGeneProduct
activator,267,O
",",267,O
and,267,O
that,267,O
it,267,O
also,267,O
ameliorates,267,O
scopolamine-induced,267,B-ChemicalEntity
amnesia,267,B-DiseaseOrPhenotypicFeature
.,267,O
Definition,268,O
and,268,O
management,268,O
of,268,O
anemia,268,B-DiseaseOrPhenotypicFeature
in,268,O
patients,268,B-OrganismTaxon
infected,268,B-DiseaseOrPhenotypicFeature
with,268,I-DiseaseOrPhenotypicFeature
hepatitis,268,I-DiseaseOrPhenotypicFeature
C,268,I-DiseaseOrPhenotypicFeature
virus,268,I-DiseaseOrPhenotypicFeature
.,268,O
Chronic,269,B-DiseaseOrPhenotypicFeature
infection,269,I-DiseaseOrPhenotypicFeature
with,269,I-DiseaseOrPhenotypicFeature
hepatitis,269,I-DiseaseOrPhenotypicFeature
C,269,I-DiseaseOrPhenotypicFeature
virus,269,I-DiseaseOrPhenotypicFeature
(,269,O
HCV,269,B-OrganismTaxon
),269,O
can,269,O
progress,269,O
to,269,O
cirrhosis,269,B-DiseaseOrPhenotypicFeature
",",269,O
hepatocellular,269,B-DiseaseOrPhenotypicFeature
carcinoma,269,I-DiseaseOrPhenotypicFeature
",",269,O
and,269,O
end-stage,269,B-DiseaseOrPhenotypicFeature
liver,269,I-DiseaseOrPhenotypicFeature
disease,269,I-DiseaseOrPhenotypicFeature
.,269,O
The,270,O
current,270,O
best,270,O
treatment,270,O
for,270,O
HCV,270,B-DiseaseOrPhenotypicFeature
infection,270,I-DiseaseOrPhenotypicFeature
is,270,O
combination,270,O
therapy,270,O
with,270,O
pegylated,270,B-GeneOrGeneProduct
interferon,270,I-GeneOrGeneProduct
and,270,O
ribavirin,270,B-ChemicalEntity
.,270,O
Although,271,O
this,271,O
regimen,271,O
produces,271,O
sustained,271,O
virologic,271,O
responses,271,O
(,271,O
SVRs,271,O
),271,O
in,271,O
approximately,271,O
50,271,O
%,271,O
of,271,O
patients,271,B-OrganismTaxon
",",271,O
it,271,O
can,271,O
be,271,O
associated,271,O
with,271,O
a,271,O
potentially,271,O
dose-limiting,271,O
hemolytic,271,B-DiseaseOrPhenotypicFeature
anemia,271,I-DiseaseOrPhenotypicFeature
.,271,O
Hemoglobin,272,B-GeneOrGeneProduct
concentrations,272,O
decrease,272,O
mainly,272,O
as,272,O
a,272,O
result,272,O
of,272,O
ribavirin-induced,272,B-ChemicalEntity
hemolysis,272,B-DiseaseOrPhenotypicFeature
",",272,O
and,272,O
this,272,O
anemia,272,B-DiseaseOrPhenotypicFeature
can,272,O
be,272,O
problematic,272,O
in,272,O
patients,272,B-OrganismTaxon
with,272,O
HCV,272,B-DiseaseOrPhenotypicFeature
infection,272,I-DiseaseOrPhenotypicFeature
",",272,O
especially,272,O
those,272,O
who,272,O
have,272,O
comorbid,272,O
renal,272,B-DiseaseOrPhenotypicFeature
or,272,I-DiseaseOrPhenotypicFeature
cardiovascular,272,I-DiseaseOrPhenotypicFeature
disorders,272,I-DiseaseOrPhenotypicFeature
.,272,O
In,273,O
general,273,O
",",273,O
anemia,273,B-DiseaseOrPhenotypicFeature
can,273,O
increase,273,O
the,273,O
risk,273,O
of,273,O
morbidity,273,O
and,273,O
mortality,273,O
",",273,O
and,273,O
may,273,O
have,273,O
negative,273,O
effects,273,O
on,273,O
cerebral,273,O
function,273,O
and,273,O
quality,273,O
of,273,O
life,273,O
.,273,O
Although,274,O
ribavirin-associated,274,B-ChemicalEntity
anemia,274,B-DiseaseOrPhenotypicFeature
can,274,O
be,274,O
reversed,274,O
by,274,O
dose,274,O
reduction,274,O
or,274,O
discontinuation,274,O
",",274,O
this,274,O
approach,274,O
compromises,274,O
outcomes,274,O
by,274,O
significantly,274,O
decreasing,274,O
SVR,274,O
rates,274,O
.,274,O
Recombinant,275,O
human,275,B-OrganismTaxon
erythropoietin,275,B-GeneOrGeneProduct
has,275,O
been,275,O
used,275,O
to,275,O
manage,275,O
ribavirin-associated,275,B-ChemicalEntity
anemia,275,B-DiseaseOrPhenotypicFeature
but,275,O
has,275,O
other,275,O
potential,275,O
disadvantages,275,O
.,275,O
Viramidine,276,B-ChemicalEntity
",",276,O
a,276,O
liver-targeting,276,O
prodrug,276,O
of,276,O
ribavirin,276,B-ChemicalEntity
",",276,O
has,276,O
the,276,O
potential,276,O
to,276,O
maintain,276,O
the,276,O
virologic,276,O
efficacy,276,O
of,276,O
ribavirin,276,B-ChemicalEntity
while,276,O
decreasing,276,O
the,276,O
risk,276,O
of,276,O
hemolytic,276,B-DiseaseOrPhenotypicFeature
anemia,276,I-DiseaseOrPhenotypicFeature
in,276,O
patients,276,B-OrganismTaxon
with,276,O
chronic,276,B-DiseaseOrPhenotypicFeature
hepatitis,276,I-DiseaseOrPhenotypicFeature
C,276,I-DiseaseOrPhenotypicFeature
.,276,O
Enhanced,277,O
isoproterenol-induced,277,B-ChemicalEntity
cardiac,277,B-DiseaseOrPhenotypicFeature
hypertrophy,277,I-DiseaseOrPhenotypicFeature
in,277,O
transgenic,277,O
rats,277,B-OrganismTaxon
with,277,O
low,277,O
brain,277,O
angiotensinogen,277,B-GeneOrGeneProduct
.,277,O
We,278,O
have,278,O
previously,278,O
shown,278,O
that,278,O
a,278,O
permanent,278,O
deficiency,278,O
in,278,O
the,278,O
brain,278,O
renin-angiotensin,278,B-GeneOrGeneProduct
system,278,O
(,278,O
RAS,278,O
),278,O
may,278,O
increase,278,O
the,278,O
sensitivity,278,O
of,278,O
the,278,O
baroreflex,278,O
control,278,O
of,278,O
heart,278,O
rate,278,O
.,278,O
In,279,O
this,279,O
study,279,O
we,279,O
aimed,279,O
at,279,O
studying,279,O
the,279,O
involvement,279,O
of,279,O
the,279,O
brain,279,O
RAS,279,O
in,279,O
the,279,O
cardiac,279,O
reactivity,279,O
to,279,O
the,279,O
beta-adrenoceptor,279,B-GeneOrGeneProduct
(,279,O
beta-AR,279,B-GeneOrGeneProduct
),279,O
agonist,279,O
isoproterenol,279,B-ChemicalEntity
(,279,O
Iso,279,B-ChemicalEntity
),279,O
.,279,O
Transgenic,280,O
rats,280,B-OrganismTaxon
with,280,O
low,280,O
brain,280,O
angiotensinogen,280,B-GeneOrGeneProduct
(,280,O
TGR,280,O
),280,O
were,280,O
used,280,O
.,280,O
In,281,O
isolated,281,O
hearts,281,O
",",281,O
Iso,281,B-ChemicalEntity
induced,281,O
a,281,O
significantly,281,O
greater,281,O
increase,281,O
in,281,O
left,281,O
ventricular,281,O
(,281,O
LV,281,O
),281,O
pressure,281,O
and,281,O
maximal,281,O
contraction,281,O
(,281,O
+dP/dt,281,O
(,281,O
max,281,O
),281,O
),281,O
in,281,O
the,281,O
TGR,281,O
than,281,O
in,281,O
the,281,O
Sprague-Dawley,281,O
(,281,O
SD,281,O
),281,O
rats,281,B-OrganismTaxon
.,281,O
LV,282,B-DiseaseOrPhenotypicFeature
hypertrophy,282,I-DiseaseOrPhenotypicFeature
induced,282,O
by,282,O
Iso,282,B-ChemicalEntity
treatment,282,O
was,282,O
significantly,282,O
higher,282,O
in,282,O
TGR,282,O
than,282,O
in,282,O
SD,282,O
rats,282,B-OrganismTaxon
(,282,O
in,282,O
g,282,O
LV,282,O
wt/100,282,O
g,282,O
body,282,O
wt,282,O
",",282,O
0.28,282,O
+/-,282,O
0.004,282,O
vs.,282,O
0.24,282,O
+/-,282,O
0.004,282,O
",",282,O
respectively,282,O
),282,O
.,282,O
The,283,O
greater,283,O
LV,283,B-DiseaseOrPhenotypicFeature
hypertrophy,283,I-DiseaseOrPhenotypicFeature
in,283,O
TGR,283,O
rats,283,B-OrganismTaxon
was,283,O
associated,283,O
with,283,O
more,283,O
pronounced,283,O
downregulation,283,O
of,283,O
beta-AR,283,B-GeneOrGeneProduct
and,283,O
upregulation,283,O
of,283,O
LV,283,O
beta-AR,283,B-GeneOrGeneProduct
kinase-1,283,I-GeneOrGeneProduct
mRNA,283,O
levels,283,O
compared,283,O
with,283,O
those,283,O
in,283,O
SD,283,O
rats,283,B-OrganismTaxon
.,283,O
The,284,O
decrease,284,O
in,284,O
the,284,O
heart,284,O
rate,284,O
(,284,O
HR,284,O
),284,O
induced,284,O
by,284,O
the,284,O
beta-AR,284,B-GeneOrGeneProduct
antagonist,284,O
metoprolol,284,B-ChemicalEntity
in,284,O
conscious,284,O
rats,284,B-OrganismTaxon
was,284,O
significantly,284,O
attenuated,284,O
in,284,O
TGR,284,O
compared,284,O
with,284,O
SD,284,O
rats,284,B-OrganismTaxon
(,284,O
-9.9,284,O
+/-,284,O
1.7,284,O
%,284,O
vs.,284,O
-18.1,284,O
+/-,284,O
1.5,284,O
%,284,O
),284,O
",",284,O
whereas,284,O
the,284,O
effect,284,O
of,284,O
parasympathetic,284,O
blockade,284,O
by,284,O
atropine,284,B-ChemicalEntity
on,284,O
HR,284,O
was,284,O
similar,284,O
in,284,O
both,284,O
strains,284,O
.,284,O
These,285,O
results,285,O
indicate,285,O
that,285,O
TGR,285,O
are,285,O
more,285,O
sensitive,285,O
to,285,O
beta-AR,285,B-GeneOrGeneProduct
agonist-induced,285,O
cardiac,285,O
inotropic,285,O
response,285,O
and,285,O
hypertrophy,285,B-DiseaseOrPhenotypicFeature
",",285,O
possibly,285,O
due,285,O
to,285,O
chronically,285,O
low,285,O
sympathetic,285,O
outflow,285,O
directed,285,O
to,285,O
the,285,O
heart,285,O
.,285,O
Atorvastatin,286,B-ChemicalEntity
prevented,286,O
and,286,O
reversed,286,O
dexamethasone-induced,286,B-ChemicalEntity
hypertension,286,B-DiseaseOrPhenotypicFeature
in,286,O
the,286,O
rat,286,B-OrganismTaxon
.,286,O
To,287,O
assess,287,O
the,287,O
antioxidant,287,B-ChemicalEntity
effects,287,O
of,287,O
atorvastatin,287,B-ChemicalEntity
(,287,O
atorva,287,B-ChemicalEntity
),287,O
on,287,O
dexamethasone,287,B-ChemicalEntity
(,287,O
dex,287,B-ChemicalEntity
),287,O
-induced,287,O
hypertension,287,B-DiseaseOrPhenotypicFeature
",",287,O
60,287,O
male,287,O
Sprague-Dawley,287,O
rats,287,B-OrganismTaxon
were,287,O
treated,287,O
with,287,O
atorva,287,B-ChemicalEntity
30,287,O
mg/kg/day,287,O
or,287,O
tap,287,O
water,287,O
for,287,O
15,287,O
days,287,O
.,287,O
Dex,288,B-ChemicalEntity
increased,288,O
systolic,288,O
blood,288,O
pressure,288,O
(,288,O
SBP,288,O
),288,O
from,288,O
109,288,O
+/-,288,O
1.8,288,O
to,288,O
135,288,O
+/-,288,O
0.6,288,O
mmHg,288,O
and,288,O
plasma,288,O
superoxide,288,B-ChemicalEntity
(,288,O
5711,288,O
+/-,288,O
284.9,288,O
saline,288,O
",",288,O
7931,288,O
+/-,288,O
392.8,288,O
U/ml,288,O
dex,288,B-ChemicalEntity
",",288,O
P,288,O
<,288,O
0.001,288,O
),288,O
.,288,O
In,289,O
this,289,O
prevention,289,O
study,289,O
",",289,O
SBP,289,O
in,289,O
the,289,O
atorva,289,B-ChemicalEntity
+,289,O
dex,289,B-ChemicalEntity
group,289,O
was,289,O
increased,289,O
from,289,O
115,289,O
+/-,289,O
0.4,289,O
to,289,O
124,289,O
+/-,289,O
1.5,289,O
mmHg,289,O
",",289,O
but,289,O
this,289,O
was,289,O
significantly,289,O
lower,289,O
than,289,O
in,289,O
the,289,O
dex-only,289,B-ChemicalEntity
group,289,O
(,289,O
P,289,O
',289,O
<,289,O
0.05,289,O
),289,O
.,289,O
Atorva,290,B-ChemicalEntity
reversed,290,O
dex-induced,290,B-ChemicalEntity
hypertension,290,B-DiseaseOrPhenotypicFeature
(,290,O
129,290,O
+/-,290,O
0.6,290,O
mmHg,290,O
",",290,O
vs.,290,O
135,290,O
+/-,290,O
0.6,290,O
mmHg,290,O
P,290,O
',290,O
<,290,O
0.05,290,O
),290,O
and,290,O
decreased,290,O
plasma,290,O
superoxide,290,B-ChemicalEntity
(,290,O
7931,290,O
+/-,290,O
392.8,290,O
dex,290,B-ChemicalEntity
",",290,O
1187,290,O
+/-,290,O
441.2,290,O
atorva,290,B-ChemicalEntity
+,290,O
dex,290,B-ChemicalEntity
",",290,O
P,290,O
<,290,O
0.0001,290,O
),290,O
.,290,O
Plasma,291,O
nitrate/nitrite,291,B-ChemicalEntity
(,291,O
NOx,291,B-ChemicalEntity
),291,O
was,291,O
decreased,291,O
in,291,O
dex-treated,291,B-ChemicalEntity
rats,291,B-OrganismTaxon
compared,291,O
to,291,O
saline-treated,291,O
rats,291,B-OrganismTaxon
(,291,O
11.2,291,O
+/-,291,O
1.08,291,O
microm,291,O
",",291,O
15.3,291,O
+/-,291,O
1.17,291,O
microm,291,O
",",291,O
respectively,291,O
",",291,O
P,291,O
<,291,O
0.05,291,O
),291,O
.,291,O
Atorva,292,B-ChemicalEntity
affected,292,O
neither,292,O
plasma,292,O
NOx,292,B-ChemicalEntity
nor,292,O
thymus,292,O
weight,292,O
.,292,O
Thus,293,O
",",293,O
atorvastatin,293,B-ChemicalEntity
prevented,293,O
and,293,O
reversed,293,O
dexamethasone-induced,293,B-ChemicalEntity
hypertension,293,B-DiseaseOrPhenotypicFeature
in,293,O
the,293,O
rat,293,B-OrganismTaxon
.,293,O
Two,294,O
novel,294,O
mutations,294,O
in,294,O
the,294,O
MEN1,294,B-GeneOrGeneProduct
gene,294,O
in,294,O
subjects,294,O
with,294,O
multiple,294,B-DiseaseOrPhenotypicFeature
endocrine,294,I-DiseaseOrPhenotypicFeature
neoplasia-1,294,I-DiseaseOrPhenotypicFeature
.,294,O
Multiple,295,B-DiseaseOrPhenotypicFeature
endocrine,295,I-DiseaseOrPhenotypicFeature
neoplasia,295,I-DiseaseOrPhenotypicFeature
type,295,I-DiseaseOrPhenotypicFeature
1,295,I-DiseaseOrPhenotypicFeature
(,295,O
MEN1,295,B-DiseaseOrPhenotypicFeature
),295,O
is,295,O
characterized,295,O
by,295,O
parathyroid,295,O
",",295,O
enteropancreatic,295,B-DiseaseOrPhenotypicFeature
endocrine,295,I-DiseaseOrPhenotypicFeature
and,295,I-DiseaseOrPhenotypicFeature
pituitary,295,I-DiseaseOrPhenotypicFeature
adenomas,295,I-DiseaseOrPhenotypicFeature
as,295,O
well,295,O
as,295,O
germline,295,O
mutation,295,O
of,295,O
the,295,O
MEN1,295,B-GeneOrGeneProduct
gene,295,O
.,295,O
We,296,O
describe,296,O
2,296,O
families,296,O
with,296,O
MEN1,296,B-GeneOrGeneProduct
with,296,O
novel,296,O
mutations,296,O
in,296,O
the,296,O
MEN1,296,B-GeneOrGeneProduct
gene,296,O
.,296,O
One,297,O
family,297,O
was,297,O
of,297,O
Turkish,297,O
origin,297,O
",",297,O
and,297,O
the,297,O
index,297,O
patient,297,B-OrganismTaxon
had,297,O
primary,297,B-DiseaseOrPhenotypicFeature
hyperparathyroidism,297,I-DiseaseOrPhenotypicFeature
(,297,O
PHPT,297,B-DiseaseOrPhenotypicFeature
),297,O
plus,297,O
a,297,O
prolactinoma,297,B-DiseaseOrPhenotypicFeature
;,297,O
three,297,O
relatives,297,O
had,297,O
PHPT,297,B-DiseaseOrPhenotypicFeature
only,297,O
.,297,O
The,298,O
index,298,O
patient,298,B-OrganismTaxon
in,298,O
the,298,O
second,298,O
family,298,O
was,298,O
a,298,O
46-yr-old,298,O
woman,298,B-OrganismTaxon
of,298,O
Chinese,298,O
origin,298,O
living,298,O
in,298,O
Taiwan,298,O
.,298,O
This,299,O
patient,299,B-OrganismTaxon
presented,299,O
with,299,O
a,299,O
complaint,299,O
of,299,O
epigastric,299,O
pain,299,B-DiseaseOrPhenotypicFeature
and,299,O
watery,299,O
diarrhea,299,B-DiseaseOrPhenotypicFeature
over,299,O
the,299,O
past,299,O
3,299,O
months,299,O
",",299,O
and,299,O
had,299,O
undergone,299,O
subtotal,299,O
parathyroidectomy,299,O
and,299,O
enucleation,299,O
of,299,O
pancreatic,299,B-DiseaseOrPhenotypicFeature
islet,299,I-DiseaseOrPhenotypicFeature
cell,299,I-DiseaseOrPhenotypicFeature
tumor,299,I-DiseaseOrPhenotypicFeature
about,299,O
10,299,O
yr,299,O
before,299,O
.,299,O
There,300,O
was,300,O
also,300,O
a,300,O
prolactinoma,300,B-DiseaseOrPhenotypicFeature
.,300,O
Sequence,301,O
analysis,301,O
of,301,O
the,301,O
MEN1,301,B-GeneOrGeneProduct
gene,301,O
from,301,O
leukocyte,301,O
genomic,301,O
DNA,301,O
revealed,301,O
heterozygous,301,O
mutations,301,O
in,301,O
both,301,O
probands,301,O
.,301,O
The,302,O
Turkish,302,O
patient,302,B-OrganismTaxon
and,302,O
her,302,O
affected,302,O
relatives,302,O
all,302,O
had,302,O
a,302,O
heterozygous,302,O
A,302,B-SequenceVariant
to,302,I-SequenceVariant
G,302,I-SequenceVariant
transition,302,I-SequenceVariant
at,302,I-SequenceVariant
codon,302,I-SequenceVariant
557,302,I-SequenceVariant
(,302,I-SequenceVariant
AAG,302,I-SequenceVariant
--,302,I-SequenceVariant
>,302,I-SequenceVariant
GAG,302,I-SequenceVariant
),302,I-SequenceVariant
of,302,O
exon,302,O
10,302,O
of,302,O
MEN1,302,B-GeneOrGeneProduct
that,302,O
results,302,O
in,302,O
a,302,O
replacement,302,O
of,302,O
lysine,302,B-SequenceVariant
by,302,I-SequenceVariant
glutamic,302,I-SequenceVariant
acid,302,I-SequenceVariant
.,302,O
The,303,O
Chinese,303,O
index,303,O
patient,303,B-OrganismTaxon
and,303,O
one,303,O
of,303,O
her,303,O
siblings,303,O
had,303,O
a,303,O
heterozygous,303,O
mutation,303,B-SequenceVariant
at,303,I-SequenceVariant
codon,303,I-SequenceVariant
418,303,I-SequenceVariant
of,303,I-SequenceVariant
exon,303,I-SequenceVariant
9,303,I-SequenceVariant
(,303,I-SequenceVariant
GAC,303,I-SequenceVariant
--,303,I-SequenceVariant
>,303,I-SequenceVariant
TAT,303,I-SequenceVariant
),303,I-SequenceVariant
that,303,O
results,303,O
in,303,O
a,303,O
substitution,303,O
of,303,O
aspartic,303,B-SequenceVariant
acid,303,I-SequenceVariant
by,303,I-SequenceVariant
tyrosine,303,I-SequenceVariant
.,303,O
In,304,O
conclusion,304,O
",",304,O
we,304,O
have,304,O
identified,304,O
2,304,O
novel,304,O
missense,304,O
mutations,304,O
in,304,O
the,304,O
MEN1,304,B-GeneOrGeneProduct
gene,304,O
.,304,O
Effect,305,O
of,305,O
alpha-tocopherol,305,B-ChemicalEntity
and,305,O
deferoxamine,305,B-ChemicalEntity
on,305,O
methamphetamine-induced,305,B-ChemicalEntity
neurotoxicity,305,B-DiseaseOrPhenotypicFeature
.,305,O
Methamphetamine,306,B-ChemicalEntity
(,306,O
MA,306,B-ChemicalEntity
),306,O
-induced,306,O
dopaminergic,306,B-ChemicalEntity
neurotoxicity,306,B-DiseaseOrPhenotypicFeature
is,306,O
believed,306,O
to,306,O
be,306,O
associated,306,O
with,306,O
the,306,O
increased,306,O
formation,306,O
of,306,O
free,306,O
radicals,306,O
.,306,O
This,307,O
study,307,O
examined,307,O
the,307,O
effect,307,O
of,307,O
alpha-tocopherol,307,B-ChemicalEntity
(,307,O
alpha-TC,307,B-ChemicalEntity
),307,O
",",307,O
a,307,O
scavenger,307,O
of,307,O
reactive,307,B-ChemicalEntity
oxygen,307,I-ChemicalEntity
species,307,I-ChemicalEntity
",",307,O
and,307,O
deferoxamine,307,B-ChemicalEntity
(,307,O
DFO,307,B-ChemicalEntity
),307,O
",",307,O
an,307,O
iron,307,B-ChemicalEntity
chelator,307,O
",",307,O
on,307,O
the,307,O
MA-induced,307,B-ChemicalEntity
neurotoxicity,307,B-DiseaseOrPhenotypicFeature
.,307,O
Male,308,O
rats,308,B-OrganismTaxon
were,308,O
treated,308,O
with,308,O
MA,308,B-ChemicalEntity
(,308,O
10,308,O
mg/kg,308,O
",",308,O
every,308,O
2,308,O
h,308,O
for,308,O
four,308,O
injections,308,O
),308,O
.,308,O
The,309,O
rat,309,B-OrganismTaxon
received,309,O
either,309,O
alpha-TC,309,B-ChemicalEntity
(,309,O
20,309,O
mg/kg,309,O
),309,O
intraperitoneally,309,O
for,309,O
3,309,O
days,309,O
and,309,O
30,309,O
min,309,O
prior,309,O
to,309,O
MA,309,B-ChemicalEntity
administration,309,O
or,309,O
DFO,309,B-ChemicalEntity
(,309,O
50,309,O
mg/kg,309,O
),309,O
subcutaneously,309,O
30,309,O
min,309,O
before,309,O
MA,309,B-ChemicalEntity
administration,309,O
.,309,O
The,310,O
concentrations,310,O
of,310,O
dopamine,310,B-ChemicalEntity
(,310,O
DA,310,B-ChemicalEntity
),310,O
",",310,O
serotonin,310,B-ChemicalEntity
and,310,O
their,310,O
metabolites,310,O
decreased,310,O
significantly,310,O
after,310,O
MA,310,B-ChemicalEntity
administration,310,O
",",310,O
which,310,O
was,310,O
inhibited,310,O
by,310,O
the,310,O
alpha-TC,310,B-ChemicalEntity
and,310,O
DFO,310,B-ChemicalEntity
pretreatment,310,O
.,310,O
alpha-TC,311,B-ChemicalEntity
and,311,O
DFO,311,B-ChemicalEntity
attenuated,311,O
the,311,O
MA-induced,311,B-ChemicalEntity
hyperthermia,311,B-DiseaseOrPhenotypicFeature
as,311,O
well,311,O
as,311,O
the,311,O
alterations,311,O
in,311,O
the,311,O
locomotor,311,O
activity,311,O
.,311,O
The,312,O
level,312,O
of,312,O
lipid,312,B-ChemicalEntity
peroxidation,312,O
was,312,O
higher,312,O
and,312,O
the,312,O
reduced,312,O
glutathione,312,B-ChemicalEntity
concentration,312,O
was,312,O
lower,312,O
in,312,O
the,312,O
MA-treated,312,B-ChemicalEntity
rats,312,B-OrganismTaxon
.,312,O
These,313,O
changes,313,O
were,313,O
significantly,313,O
attenuated,313,O
by,313,O
alpha-TC,313,B-ChemicalEntity
and,313,O
DFO,313,B-ChemicalEntity
.,313,O
This,314,O
suggests,314,O
that,314,O
alpha-TC,314,B-ChemicalEntity
and,314,O
DFO,314,B-ChemicalEntity
ameliorate,314,O
the,314,O
MA-induced,314,B-ChemicalEntity
neuronal,314,B-DiseaseOrPhenotypicFeature
damage,314,I-DiseaseOrPhenotypicFeature
by,314,O
decreasing,314,O
the,314,O
level,314,O
of,314,O
oxidative,314,O
stress,314,O
.,314,O
Intronic,315,O
deletions,315,O
in,315,O
the,315,O
SLC34A3,315,B-GeneOrGeneProduct
gene,315,O
cause,315,O
hereditary,315,B-DiseaseOrPhenotypicFeature
hypophosphatemic,315,I-DiseaseOrPhenotypicFeature
rickets,315,I-DiseaseOrPhenotypicFeature
with,315,I-DiseaseOrPhenotypicFeature
hypercalciuria,315,I-DiseaseOrPhenotypicFeature
.,315,O
CONTEXT,316,O
:,316,O
Hereditary,316,B-DiseaseOrPhenotypicFeature
hypophosphatemic,316,I-DiseaseOrPhenotypicFeature
rickets,316,I-DiseaseOrPhenotypicFeature
with,316,I-DiseaseOrPhenotypicFeature
hypercalciuria,316,I-DiseaseOrPhenotypicFeature
(,316,O
HHRH,316,B-DiseaseOrPhenotypicFeature
),316,O
is,316,O
a,316,O
rare,316,O
metabolic,316,B-DiseaseOrPhenotypicFeature
disorder,316,I-DiseaseOrPhenotypicFeature
",",316,O
characterized,316,O
by,316,O
hypophosphatemia,316,B-DiseaseOrPhenotypicFeature
and,316,O
rickets/osteomalacia,316,B-DiseaseOrPhenotypicFeature
with,316,O
increased,316,O
serum,316,O
"1,25-dihydroxyvitamin",316,B-ChemicalEntity
D,316,I-ChemicalEntity
[,316,O
"1,25-",316,B-ChemicalEntity
(,316,I-ChemicalEntity
OH,316,I-ChemicalEntity
),316,I-ChemicalEntity
(,316,I-ChemicalEntity
2,316,I-ChemicalEntity
),316,I-ChemicalEntity
D,316,I-ChemicalEntity
],316,O
resulting,316,O
in,316,O
hypercalciuria,316,B-DiseaseOrPhenotypicFeature
.,316,O
OBJECTIVE,317,O
:,317,O
Our,317,O
objective,317,O
was,317,O
to,317,O
determine,317,O
whether,317,O
mutations,317,O
in,317,O
the,317,O
SLC34A3,317,B-GeneOrGeneProduct
gene,317,O
",",317,O
which,317,O
encodes,317,O
sodium-phosphate,317,B-GeneOrGeneProduct
cotransporter,317,I-GeneOrGeneProduct
type,317,I-GeneOrGeneProduct
IIc,317,I-GeneOrGeneProduct
",",317,O
are,317,O
responsible,317,O
for,317,O
the,317,O
occurrence,317,O
of,317,O
HHRH,317,B-DiseaseOrPhenotypicFeature
.,317,O
DESIGN,318,O
AND,318,O
SETTING,318,O
:,318,O
Mutation,318,O
analysis,318,O
of,318,O
exons,318,O
and,318,O
adjacent,318,O
introns,318,O
in,318,O
the,318,O
SLC34A3,318,B-GeneOrGeneProduct
gene,318,O
was,318,O
conducted,318,O
at,318,O
an,318,O
academic,318,O
research,318,O
laboratory,318,O
and,318,O
medical,318,O
center,318,O
.,318,O
PATIENTS,319,B-OrganismTaxon
OR,319,O
OTHER,319,O
PARTICIPANTS,319,O
:,319,O
Members,319,O
of,319,O
two,319,O
unrelated,319,O
families,319,O
with,319,O
HHRH,319,B-DiseaseOrPhenotypicFeature
participated,319,O
in,319,O
the,319,O
study,319,O
.,319,O
RESULTS,320,O
:,320,O
Two,320,O
affected,320,O
siblings,320,O
in,320,O
one,320,O
family,320,O
were,320,O
homozygous,320,O
for,320,O
a,320,O
101-bp,320,B-SequenceVariant
deletion,320,I-SequenceVariant
in,320,O
intron,320,O
9,320,O
.,320,O
Haplotype,321,O
analysis,321,O
of,321,O
the,321,O
SLC34A3,321,B-GeneOrGeneProduct
locus,321,O
in,321,O
the,321,O
family,321,O
showed,321,O
that,321,O
the,321,O
two,321,O
deletions,321,O
are,321,O
on,321,O
different,321,O
haplotypes,321,O
.,321,O
An,322,O
unrelated,322,O
individual,322,O
with,322,O
HHRH,322,B-DiseaseOrPhenotypicFeature
was,322,O
a,322,O
compound,322,O
heterozygote,322,O
for,322,O
an,322,O
85-bp,322,B-SequenceVariant
deletion,322,I-SequenceVariant
in,322,O
intron,322,O
10,322,O
and,322,O
a,322,O
G-to-A,322,B-SequenceVariant
substitution,322,O
at,322,O
the,322,O
last,322,O
nucleotide,322,O
in,322,O
exon,322,O
7,322,O
.,322,O
The,323,O
intron,323,O
9,323,O
deletion,323,O
(,323,O
and,323,O
likely,323,O
the,323,O
other,323,O
two,323,O
mutations,323,O
),323,O
identified,323,O
in,323,O
this,323,O
study,323,O
causes,323,O
aberrant,323,O
RNA,323,O
splicing,323,O
.,323,O
Sequence,324,O
analysis,324,O
of,324,O
the,324,O
deleted,324,O
regions,324,O
revealed,324,O
the,324,O
presence,324,O
of,324,O
direct,324,O
repeats,324,O
of,324,O
homologous,324,O
sequences,324,O
.,324,O
CONCLUSION,325,O
:,325,O
HHRH,325,B-DiseaseOrPhenotypicFeature
is,325,O
caused,325,O
by,325,O
biallelic,325,O
mutations,325,O
in,325,O
the,325,O
SLC34A3,325,B-GeneOrGeneProduct
gene,325,O
.,325,O
Haplotype,326,O
analysis,326,O
suggests,326,O
that,326,O
the,326,O
two,326,O
intron,326,O
9,326,O
deletions,326,O
arose,326,O
independently,326,O
.,326,O
The,327,O
identification,327,O
of,327,O
three,327,O
independent,327,O
deletions,327,O
in,327,O
introns,327,O
9,327,O
and,327,O
10,327,O
suggests,327,O
that,327,O
the,327,O
SLC34A3,327,B-GeneOrGeneProduct
gene,327,O
may,327,O
be,327,O
susceptible,327,O
to,327,O
unequal,327,O
crossing,327,O
over,327,O
because,327,O
of,327,O
sequence,327,O
misalignment,327,O
during,327,O
meiosis,327,O
.,327,O
Mutations,328,O
in,328,O
the,328,O
NDP,328,B-GeneOrGeneProduct
gene,328,O
:,328,O
contribution,328,O
to,328,O
Norrie,328,B-DiseaseOrPhenotypicFeature
disease,328,I-DiseaseOrPhenotypicFeature
",",328,O
familial,328,B-DiseaseOrPhenotypicFeature
exudative,328,I-DiseaseOrPhenotypicFeature
vitreoretinopathy,328,I-DiseaseOrPhenotypicFeature
and,328,O
retinopathy,328,B-DiseaseOrPhenotypicFeature
of,328,I-DiseaseOrPhenotypicFeature
prematurity,328,I-DiseaseOrPhenotypicFeature
.,328,O
BACKGROUND,329,O
:,329,O
To,329,O
examine,329,O
the,329,O
contribution,329,O
of,329,O
mutations,329,O
within,329,O
the,329,O
Norrie,329,B-DiseaseOrPhenotypicFeature
disease,329,I-DiseaseOrPhenotypicFeature
(,329,O
NDP,329,B-GeneOrGeneProduct
),329,O
gene,329,O
to,329,O
the,329,O
clinically,329,O
similar,329,O
retinal,329,B-DiseaseOrPhenotypicFeature
diseases,329,I-DiseaseOrPhenotypicFeature
Norrie,329,I-DiseaseOrPhenotypicFeature
disease,329,I-DiseaseOrPhenotypicFeature
",",329,O
X-linked,329,B-DiseaseOrPhenotypicFeature
familial,329,I-DiseaseOrPhenotypicFeature
exudative,329,I-DiseaseOrPhenotypicFeature
vitreoretinopathy,329,I-DiseaseOrPhenotypicFeature
(,329,O
FEVR,329,B-DiseaseOrPhenotypicFeature
),329,O
",",329,O
Coat,329,B-DiseaseOrPhenotypicFeature
's,329,I-DiseaseOrPhenotypicFeature
disease,329,I-DiseaseOrPhenotypicFeature
and,329,O
retinopathy,329,B-DiseaseOrPhenotypicFeature
of,329,I-DiseaseOrPhenotypicFeature
prematurity,329,I-DiseaseOrPhenotypicFeature
(,329,O
ROP,329,B-DiseaseOrPhenotypicFeature
),329,O
.,329,O
METHODS,330,O
:,330,O
A,330,O
dataset,330,O
comprising,330,O
13,330,O
Norrie-FEVR,330,B-DiseaseOrPhenotypicFeature
",",330,O
one,330,O
Coat,330,B-DiseaseOrPhenotypicFeature
's,330,I-DiseaseOrPhenotypicFeature
disease,330,I-DiseaseOrPhenotypicFeature
",",330,O
31,330,O
ROP,330,B-DiseaseOrPhenotypicFeature
patients,330,B-OrganismTaxon
and,330,O
90,330,O
ex-premature,330,O
babies,330,O
of,330,O
<,330,O
32,330,O
weeks,330,O
',330,O
gestation,330,O
underwent,330,O
an,330,O
ophthalmologic,330,O
examination,330,O
and,330,O
were,330,O
screened,330,O
for,330,O
mutations,330,O
within,330,O
the,330,O
NDP,330,B-GeneOrGeneProduct
gene,330,O
by,330,O
direct,330,O
DNA,330,O
sequencing,330,O
",",330,O
denaturing,330,O
high-performance,330,O
liquid,330,O
chromatography,330,O
or,330,O
gel,330,O
electrophoresis,330,O
.,330,O
Controls,331,O
were,331,O
only,331,O
screened,331,O
using,331,O
denaturing,331,O
high-performance,331,O
liquid,331,O
chromatography,331,O
and,331,O
gel,331,O
electrophoresis,331,O
.,331,O
Confirmation,332,O
of,332,O
mutations,332,O
identified,332,O
was,332,O
obtained,332,O
by,332,O
DNA,332,O
sequencing,332,O
.,332,O
RESULTS,333,O
:,333,O
Evidence,333,O
for,333,O
two,333,O
novel,333,O
mutations,333,O
in,333,O
the,333,O
NDP,333,B-GeneOrGeneProduct
gene,333,O
was,333,O
presented,333,O
:,333,O
Leu103Val,333,B-SequenceVariant
in,333,O
one,333,O
FEVR,333,B-DiseaseOrPhenotypicFeature
patient,333,B-OrganismTaxon
and,333,O
His43Arg,333,B-SequenceVariant
in,333,O
monozygotic,333,O
twin,333,O
Norrie,333,B-DiseaseOrPhenotypicFeature
disease,333,I-DiseaseOrPhenotypicFeature
patients,333,B-OrganismTaxon
.,333,O
Furthermore,334,O
",",334,O
a,334,O
previously,334,O
described,334,O
14-bp,334,B-SequenceVariant
deletion,334,I-SequenceVariant
located,334,O
in,334,O
the,334,O
5,334,O
',334,O
unstranslated,334,O
region,334,O
of,334,O
the,334,O
NDP,334,B-GeneOrGeneProduct
gene,334,O
was,334,O
detected,334,O
in,334,O
three,334,O
cases,334,O
of,334,O
regressed,334,O
ROP,334,B-DiseaseOrPhenotypicFeature
.,334,O
A,335,O
second,335,O
heterozygotic,335,O
14-bp,335,B-SequenceVariant
deletion,335,I-SequenceVariant
was,335,O
detected,335,O
in,335,O
an,335,O
unaffected,335,O
ex-premature,335,O
girl,335,O
.,335,O
Only,336,O
two,336,O
of,336,O
the,336,O
13,336,O
Norrie-FEVR,336,B-DiseaseOrPhenotypicFeature
index,336,O
cases,336,O
had,336,O
the,336,O
full,336,O
features,336,O
of,336,O
Norrie,336,B-DiseaseOrPhenotypicFeature
disease,336,I-DiseaseOrPhenotypicFeature
with,336,O
deafness,336,B-DiseaseOrPhenotypicFeature
and,336,O
mental,336,B-DiseaseOrPhenotypicFeature
retardation,336,I-DiseaseOrPhenotypicFeature
.,336,O
CONCLUSION,337,O
:,337,O
Two,337,O
novel,337,O
mutations,337,O
within,337,O
the,337,O
coding,337,O
region,337,O
of,337,O
the,337,O
NDP,337,B-GeneOrGeneProduct
gene,337,O
were,337,O
found,337,O
",",337,O
one,337,O
associated,337,O
with,337,O
a,337,O
severe,337,O
disease,337,O
phenotypes,337,O
of,337,O
Norrie,337,B-DiseaseOrPhenotypicFeature
disease,337,I-DiseaseOrPhenotypicFeature
and,337,O
the,337,O
other,337,O
with,337,O
FEVR,337,B-DiseaseOrPhenotypicFeature
.,337,O
A,338,O
deletion,338,O
within,338,O
the,338,O
non-coding,338,O
region,338,O
was,338,O
associated,338,O
with,338,O
only,338,O
mild-regressed,338,O
ROP,338,B-DiseaseOrPhenotypicFeature
",",338,O
despite,338,O
the,338,O
presence,338,O
of,338,O
low,338,O
birthweight,338,O
",",338,O
prematurity,338,B-DiseaseOrPhenotypicFeature
and,338,O
exposure,338,O
to,338,O
oxygen,338,B-ChemicalEntity
.,338,O
In,339,O
full-term,339,O
children,339,O
with,339,O
retinal,339,B-DiseaseOrPhenotypicFeature
detachment,339,I-DiseaseOrPhenotypicFeature
only,339,O
15,339,O
%,339,O
appear,339,O
to,339,O
have,339,O
the,339,O
full,339,O
features,339,O
of,339,O
Norrie,339,B-DiseaseOrPhenotypicFeature
disease,339,I-DiseaseOrPhenotypicFeature
and,339,O
this,339,O
is,339,O
important,339,O
for,339,O
counselling,339,O
parents,339,O
on,339,O
the,339,O
possible,339,O
long-term,339,O
outcome,339,O
.,339,O
Gene,340,O
polymorphisms,340,O
implicated,340,O
in,340,O
influencing,340,O
susceptibility,340,O
to,340,O
venous,340,B-DiseaseOrPhenotypicFeature
and,340,I-DiseaseOrPhenotypicFeature
arterial,340,I-DiseaseOrPhenotypicFeature
thromboembolism,340,I-DiseaseOrPhenotypicFeature
:,340,O
frequency,340,O
distribution,340,O
in,340,O
a,340,O
healthy,340,O
German,340,O
population,340,O
.,340,O
Evolvement,341,O
and,341,O
progression,341,O
of,341,O
cardiovascular,341,B-DiseaseOrPhenotypicFeature
diseases,341,I-DiseaseOrPhenotypicFeature
affecting,341,O
the,341,O
venous,341,O
and,341,O
arterial,341,O
system,341,O
are,341,O
influenced,341,O
by,341,O
a,341,O
multitude,341,O
of,341,O
environmental,341,O
and,341,O
hereditary,341,O
factors,341,O
.,341,O
Many,342,O
of,342,O
these,342,O
hereditary,342,O
factors,342,O
consist,342,O
of,342,O
defined,342,O
gene,342,O
polymorphisms,342,O
",",342,O
such,342,O
as,342,O
single,342,O
nucleotide,342,O
polymorphisms,342,O
(,342,O
SNPs,342,O
),342,O
or,342,O
insertion-deletion,342,O
polymorphisms,342,O
",",342,O
which,342,O
directly,342,O
or,342,O
indirectly,342,O
affect,342,O
the,342,O
hemostatic,342,O
system,342,O
.,342,O
The,343,O
frequencies,343,O
of,343,O
individual,343,O
hemostatic,343,O
gene,343,O
polymorphisms,343,O
in,343,O
different,343,O
normal,343,O
populations,343,O
are,343,O
well,343,O
defined,343,O
.,343,O
However,344,O
",",344,O
descriptions,344,O
of,344,O
patterns,344,O
of,344,O
genetic,344,O
variability,344,O
of,344,O
a,344,O
larger,344,O
extent,344,O
of,344,O
different,344,O
factors,344,O
of,344,O
hereditary,344,B-DiseaseOrPhenotypicFeature
hypercoagulability,344,I-DiseaseOrPhenotypicFeature
in,344,O
single,344,O
populations,344,O
are,344,O
scarce,344,O
.,344,O
The,345,O
aim,345,O
of,345,O
this,345,O
study,345,O
was,345,O
i,345,O
),345,O
to,345,O
give,345,O
a,345,O
detailed,345,O
description,345,O
of,345,O
the,345,O
frequencies,345,O
of,345,O
factors,345,O
of,345,O
hereditary,345,B-DiseaseOrPhenotypicFeature
thrombophilia,345,I-DiseaseOrPhenotypicFeature
and,345,O
their,345,O
combinations,345,O
in,345,O
a,345,O
German,345,O
population,345,O
(,345,O
n,345,O
=,345,O
282,345,O
),345,O
and,345,O
ii,345,O
),345,O
to,345,O
compare,345,O
their,345,O
distributions,345,O
with,345,O
those,345,O
reported,345,O
for,345,O
other,345,O
regions,345,O
.,345,O
Variants,346,O
of,346,O
coagulation,346,O
factors,346,O
[,346,O
factor,346,B-GeneOrGeneProduct
V,346,I-GeneOrGeneProduct
1691G,346,B-SequenceVariant
>,346,I-SequenceVariant
A,346,I-SequenceVariant
(,346,O
factor,346,B-GeneOrGeneProduct
V,346,I-GeneOrGeneProduct
Leiden,346,I-GeneOrGeneProduct
),346,O
",",346,O
factor,346,B-GeneOrGeneProduct
V,346,I-GeneOrGeneProduct
4070A,346,B-SequenceVariant
>,346,I-SequenceVariant
G,346,I-SequenceVariant
(,346,O
factor,346,B-GeneOrGeneProduct
V,346,I-GeneOrGeneProduct
HR2,346,O
haplotype,346,O
),346,O
",",346,O
factor,346,B-GeneOrGeneProduct
VII,346,I-GeneOrGeneProduct
Arg353Gln,346,B-SequenceVariant
",",346,O
factor,346,B-GeneOrGeneProduct
XIII,346,I-GeneOrGeneProduct
Val34Leu,346,B-SequenceVariant
",",346,O
beta-fibrinogen,346,B-GeneOrGeneProduct
-455G,346,B-SequenceVariant
>,346,I-SequenceVariant
A,346,I-SequenceVariant
",",346,O
prothrombin,346,B-GeneOrGeneProduct
20210G,346,B-SequenceVariant
>,346,I-SequenceVariant
A,346,I-SequenceVariant
],346,O
",",346,O
coagulation,346,O
inhibitors,346,O
[,346,O
tissue,346,B-GeneOrGeneProduct
factor,346,I-GeneOrGeneProduct
pathway,346,I-GeneOrGeneProduct
inhibitor,346,I-GeneOrGeneProduct
536C,346,B-SequenceVariant
>,346,I-SequenceVariant
T,346,I-SequenceVariant
",",346,O
thrombomodulin,346,B-GeneOrGeneProduct
127G,346,B-SequenceVariant
>,346,I-SequenceVariant
A,346,I-SequenceVariant
],346,O
",",346,O
fibrinolytic,346,O
factors,346,O
[,346,O
angiotensin,346,B-GeneOrGeneProduct
converting,346,I-GeneOrGeneProduct
enzyme,346,I-GeneOrGeneProduct
intron,346,O
16,346,O
insertion/deletion,346,O
",",346,O
factor,346,B-GeneOrGeneProduct
VII-activating,346,I-GeneOrGeneProduct
protease,346,I-GeneOrGeneProduct
1601G,346,B-SequenceVariant
>,346,I-SequenceVariant
A,346,I-SequenceVariant
(,346,O
FSAP,346,B-GeneOrGeneProduct
Marburg,346,O
I,346,O
),346,O
",",346,O
plasminogen,346,B-GeneOrGeneProduct
activator,346,I-GeneOrGeneProduct
inhibitor,346,I-GeneOrGeneProduct
1-675,346,O
insertion/deletion,346,I-SequenceVariant
(,346,O
5G/4G,346,O
),346,O
",",346,O
tissue,346,B-GeneOrGeneProduct
plasminogen,346,I-GeneOrGeneProduct
activator,346,I-GeneOrGeneProduct
intron,346,O
h,346,O
deletion/insertion,346,O
],346,O
",",346,O
and,346,O
other,346,O
factors,346,O
implicated,346,O
in,346,O
influencing,346,O
susceptibility,346,O
to,346,O
thromboembolic,346,B-DiseaseOrPhenotypicFeature
diseases,346,I-DiseaseOrPhenotypicFeature
[,346,O
apolipoprotein,346,B-GeneOrGeneProduct
E2/E3/E4,346,I-GeneOrGeneProduct
",",346,I-GeneOrGeneProduct
glycoprotein,346,I-GeneOrGeneProduct
Ia,346,I-GeneOrGeneProduct
807C,346,B-SequenceVariant
>,346,I-SequenceVariant
T,346,I-SequenceVariant
",",346,O
methylenetetrahydrofolate,346,B-GeneOrGeneProduct
reductase,346,I-GeneOrGeneProduct
677C,346,B-SequenceVariant
>,346,I-SequenceVariant
T,346,I-SequenceVariant
],346,O
were,346,O
included,346,O
.,346,O
The,347,O
distribution,347,O
of,347,O
glycoprotein,347,B-GeneOrGeneProduct
Ia,347,I-GeneOrGeneProduct
807C,347,B-SequenceVariant
>,347,I-SequenceVariant
T,347,I-SequenceVariant
deviated,347,O
significantly,347,O
from,347,O
the,347,O
Hardy-Weinberg,347,O
equilibrium,347,O
",",347,O
and,347,O
a,347,O
comparison,347,O
with,347,O
previously,347,O
published,347,O
data,347,O
indicates,347,O
marked,347,O
region,347,O
and,347,O
ethnicity,347,O
dependent,347,O
differences,347,O
in,347,O
the,347,O
genotype,347,O
distributions,347,O
of,347,O
some,347,O
other,347,O
factors,347,O
.,347,O
A,348,O
novel,348,O
splicing,348,O
mutation,348,O
in,348,O
SLC12A3,348,B-GeneOrGeneProduct
associated,348,O
with,348,O
Gitelman,348,B-DiseaseOrPhenotypicFeature
syndrome,348,I-DiseaseOrPhenotypicFeature
and,348,O
idiopathic,348,B-DiseaseOrPhenotypicFeature
intracranial,348,I-DiseaseOrPhenotypicFeature
hypertension,348,I-DiseaseOrPhenotypicFeature
.,348,O
We,349,O
report,349,O
a,349,O
case,349,O
of,349,O
Gitelman,349,B-DiseaseOrPhenotypicFeature
syndrome,349,I-DiseaseOrPhenotypicFeature
(,349,O
GS,349,B-DiseaseOrPhenotypicFeature
),349,O
in,349,O
a,349,O
dizygotic,349,O
twin,349,O
who,349,O
presented,349,O
at,349,O
12,349,O
years,349,O
of,349,O
age,349,O
with,349,O
growth,349,B-DiseaseOrPhenotypicFeature
delay,349,I-DiseaseOrPhenotypicFeature
",",349,O
metabolic,349,B-DiseaseOrPhenotypicFeature
alkalosis,349,I-DiseaseOrPhenotypicFeature
",",349,O
hypomagnesemia,349,B-DiseaseOrPhenotypicFeature
and,349,O
hypokalemia,349,B-DiseaseOrPhenotypicFeature
with,349,O
inappropriate,349,O
kaliuresis,349,O
",",349,O
and,349,O
idiopathic,349,B-DiseaseOrPhenotypicFeature
intracranial,349,I-DiseaseOrPhenotypicFeature
hypertension,349,I-DiseaseOrPhenotypicFeature
with,349,O
bilateral,349,B-DiseaseOrPhenotypicFeature
papilledema,349,I-DiseaseOrPhenotypicFeature
(,349,O
pseudotumor,349,B-DiseaseOrPhenotypicFeature
cerebri,349,I-DiseaseOrPhenotypicFeature
),349,O
.,349,O
The,350,O
patient,350,B-OrganismTaxon
",",350,O
her,350,O
twin,350,O
sister,350,O
",",350,O
and,350,O
her,350,O
mother,350,O
also,350,O
presented,350,O
with,350,O
cerebral,350,B-DiseaseOrPhenotypicFeature
cavernous,350,I-DiseaseOrPhenotypicFeature
malformations,350,I-DiseaseOrPhenotypicFeature
.,350,O
Based,351,O
on,351,O
the,351,O
early,351,O
onset,351,O
and,351,O
normocalciuria,351,O
",",351,O
Bartter,351,B-DiseaseOrPhenotypicFeature
syndrome,351,I-DiseaseOrPhenotypicFeature
was,351,O
diagnosed,351,O
first,351,O
.,351,O
However,352,O
",",352,O
mutation,352,O
analysis,352,O
showed,352,O
that,352,O
the,352,O
proband,352,O
is,352,O
a,352,O
compound,352,O
heterozygote,352,O
for,352,O
2,352,O
mutations,352,O
in,352,O
SLC12A3,352,B-GeneOrGeneProduct
:,352,O
a,352,O
substitution,352,O
of,352,O
serine,352,B-SequenceVariant
by,352,I-SequenceVariant
leucine,352,I-SequenceVariant
at,352,I-SequenceVariant
amino,352,I-SequenceVariant
acid,352,I-SequenceVariant
position,352,I-SequenceVariant
555,352,I-SequenceVariant
(,352,O
p.Ser555Leu,352,B-SequenceVariant
),352,O
and,352,O
a,352,O
novel,352,O
guanine,352,B-SequenceVariant
to,352,I-SequenceVariant
cytosine,352,I-SequenceVariant
transition,352,O
at,352,O
the,352,O
5,352,O
',352,O
splice,352,O
site,352,O
of,352,O
intron,352,O
22,352,O
(,352,O
c.2633+1G,352,B-SequenceVariant
>,352,I-SequenceVariant
C,352,I-SequenceVariant
),352,O
",",352,O
providing,352,O
the,352,O
molecular,352,O
diagnosis,352,O
of,352,O
GS,352,B-DiseaseOrPhenotypicFeature
.,352,O
These,353,O
mutations,353,O
were,353,O
not,353,O
detected,353,O
in,353,O
200,353,O
normal,353,O
chromosomes,353,O
and,353,O
cosegregated,353,O
within,353,O
the,353,O
family,353,O
.,353,O
Analysis,354,O
of,354,O
complementary,354,O
DNA,354,O
showed,354,O
that,354,O
the,354,O
heterozygous,354,O
nucleotide,354,O
change,354,O
c.2633+1G,354,B-SequenceVariant
>,354,I-SequenceVariant
C,354,I-SequenceVariant
caused,354,O
the,354,O
appearance,354,O
of,354,O
2,354,O
RNA,354,O
molecules,354,O
",",354,O
1,354,O
normal,354,O
transcript,354,O
and,354,O
1,354,O
skipping,354,O
the,354,O
entire,354,O
exon,354,O
22,354,O
(,354,O
r.2521_2634del,354,B-SequenceVariant
),354,O
.,354,O
Supplementation,355,O
with,355,O
potassium,355,B-ChemicalEntity
and,355,O
magnesium,355,B-ChemicalEntity
improved,355,O
clinical,355,O
symptoms,355,O
and,355,O
resulted,355,O
in,355,O
catch-up,355,O
growth,355,O
",",355,O
but,355,O
vision,355,O
remained,355,O
impaired,355,O
.,355,O
Three,356,O
similar,356,O
associations,356,O
of,356,O
Bartter,356,B-DiseaseOrPhenotypicFeature
syndrome/GS,356,O
with,356,O
pseudotumor,356,B-DiseaseOrPhenotypicFeature
cerebri,356,I-DiseaseOrPhenotypicFeature
were,356,O
found,356,O
in,356,O
the,356,O
literature,356,O
",",356,O
suggesting,356,O
that,356,O
electrolyte,356,B-DiseaseOrPhenotypicFeature
abnormalities,356,I-DiseaseOrPhenotypicFeature
and,356,O
secondary,356,B-DiseaseOrPhenotypicFeature
aldosteronism,356,I-DiseaseOrPhenotypicFeature
may,356,O
have,356,O
a,356,O
role,356,O
in,356,O
idiopathic,356,B-DiseaseOrPhenotypicFeature
intracranial,356,I-DiseaseOrPhenotypicFeature
hypertension,356,I-DiseaseOrPhenotypicFeature
.,356,O
This,357,O
study,357,O
provides,357,O
further,357,O
evidence,357,O
for,357,O
the,357,O
phenotypical,357,O
heterogeneity,357,O
of,357,O
GS,357,B-DiseaseOrPhenotypicFeature
and,357,O
its,357,O
association,357,O
with,357,O
severe,357,O
manifestations,357,O
in,357,O
children,357,O
.,357,O
It,358,O
also,358,O
shows,358,O
the,358,O
independent,358,O
segregation,358,O
of,358,O
familial,358,B-DiseaseOrPhenotypicFeature
cavernomatosis,358,I-DiseaseOrPhenotypicFeature
and,358,O
GS,358,B-DiseaseOrPhenotypicFeature
.,358,O
Association,359,O
between,359,O
an,359,O
endoglin,359,B-GeneOrGeneProduct
gene,359,O
polymorphism,359,O
and,359,O
systemic,359,B-DiseaseOrPhenotypicFeature
sclerosis-related,359,O
pulmonary,359,B-DiseaseOrPhenotypicFeature
arterial,359,I-DiseaseOrPhenotypicFeature
hypertension,359,I-DiseaseOrPhenotypicFeature
.,359,O
Systemic,360,B-DiseaseOrPhenotypicFeature
sclerosis,360,I-DiseaseOrPhenotypicFeature
(,360,O
SSc,360,B-DiseaseOrPhenotypicFeature
),360,O
is,360,O
a,360,O
connective,360,O
tissue,360,O
disorder,360,O
characterized,360,O
by,360,O
early,360,O
generalized,360,O
microangiopathy,360,B-DiseaseOrPhenotypicFeature
with,360,O
disturbed,360,O
angiogenesis,360,O
.,360,O
Endoglin,361,B-GeneOrGeneProduct
gene,361,O
(,361,O
ENG,361,B-GeneOrGeneProduct
),361,O
encodes,361,O
a,361,O
transmembrane,361,O
glycoprotein,361,B-GeneOrGeneProduct
which,361,O
acts,361,O
as,361,O
an,361,O
accessory,361,O
receptor,361,O
for,361,O
the,361,O
transforming,361,B-GeneOrGeneProduct
growth,361,I-GeneOrGeneProduct
factor-beta,361,I-GeneOrGeneProduct
(,361,O
TGF-beta,361,B-GeneOrGeneProduct
),361,O
superfamily,361,O
",",361,O
and,361,O
is,361,O
crucial,361,O
for,361,O
maintaining,361,O
vascular,361,O
integrity,361,O
.,361,O
A,362,O
6-base,362,B-SequenceVariant
insertion,362,I-SequenceVariant
in,362,O
intron,362,O
7,362,O
(,362,O
6bINS,362,B-SequenceVariant
),362,O
of,362,O
ENG,362,B-GeneOrGeneProduct
has,362,O
been,362,O
reported,362,O
to,362,O
be,362,O
associated,362,O
with,362,O
microvascular,362,O
disturbance,362,O
.,362,O
OBJECTIVES,363,O
:,363,O
Our,363,O
objective,363,O
was,363,O
to,363,O
investigate,363,O
the,363,O
relationship,363,O
between,363,O
6bINS,363,B-SequenceVariant
and,363,O
the,363,O
vascular,363,B-DiseaseOrPhenotypicFeature
complication,363,I-DiseaseOrPhenotypicFeature
pulmonary,363,B-DiseaseOrPhenotypicFeature
arterial,363,I-DiseaseOrPhenotypicFeature
hypertension,363,I-DiseaseOrPhenotypicFeature
(,363,O
PAH,363,B-DiseaseOrPhenotypicFeature
),363,O
in,363,O
SSc,363,B-DiseaseOrPhenotypicFeature
in,363,O
a,363,O
French,363,O
Caucasian,363,O
population,363,O
.,363,O
METHODS,364,O
:,364,O
Two,364,O
hundred,364,O
eighty,364,O
SSc,364,B-DiseaseOrPhenotypicFeature
cases,364,O
containing,364,O
29/280,364,O
having,364,O
PAH,364,B-DiseaseOrPhenotypicFeature
diagnosed,364,O
by,364,O
catheterism,364,O
were,364,O
compared,364,O
with,364,O
140,364,O
patients,364,B-OrganismTaxon
with,364,O
osteoarthritis,364,B-DiseaseOrPhenotypicFeature
.,364,O
Genotyping,365,O
was,365,O
performed,365,O
by,365,O
polymerase-chain-reaction-based,365,O
fluorescence,365,O
and,365,O
direct,365,O
sequencing,365,O
of,365,O
genomic,365,O
DNA,365,O
.,365,O
RESULTS,366,O
:,366,O
The,366,O
polymorphism,366,O
was,366,O
in,366,O
Hardy-Weinberg,366,O
equilibrium,366,O
.,366,O
We,367,O
observed,367,O
a,367,O
significant,367,O
lower,367,O
frequency,367,O
of,367,O
6bINS,367,B-SequenceVariant
allele,367,O
in,367,O
SSc,367,B-DiseaseOrPhenotypicFeature
patients,367,B-OrganismTaxon
with,367,O
associated,367,O
PAH,367,B-DiseaseOrPhenotypicFeature
compared,367,O
with,367,O
controls,367,O
[,367,O
10.3,367,O
vs,367,O
23.9,367,O
%,367,O
",",367,O
P,367,O
=,367,O
0.01,367,O
;,367,O
odds,367,O
ratio,367,O
(,367,O
OR,367,O
),367,O
0.37,367,O
",",367,O
95,367,O
%,367,O
confidence,367,O
interval,367,O
(,367,O
CI,367,O
),367,O
0.15-0.89,367,O
],367,O
",",367,O
and,367,O
a,367,O
trend,367,O
in,367,O
comparison,367,O
with,367,O
SSc,367,B-DiseaseOrPhenotypicFeature
patients,367,B-OrganismTaxon
without,367,O
PAH,367,B-DiseaseOrPhenotypicFeature
(,367,O
10.3,367,O
vs,367,O
20.3,367,O
%,367,O
",",367,O
P,367,O
=,367,O
0.05,367,O
;,367,O
OR,367,O
:,367,O
0.45,367,O
",",367,O
95,367,O
%,367,O
CI,367,O
:,367,O
0.19-1.08,367,O
),367,O
.,367,O
Genotypes,368,O
carrying,368,O
allele,368,O
6bINS,368,B-SequenceVariant
were,368,O
also,368,O
less,368,O
frequent,368,O
in,368,O
SSc,368,B-DiseaseOrPhenotypicFeature
patients,368,B-OrganismTaxon
with,368,O
PAH,368,B-DiseaseOrPhenotypicFeature
than,368,O
in,368,O
controls,368,O
(,368,O
20.7,368,O
vs,368,O
42.9,368,O
%,368,O
",",368,O
P,368,O
=,368,O
0.02,368,O
),368,O
.,368,O
CONCLUSIONS,369,O
:,369,O
Thus,369,O
the,369,O
frequency,369,O
of,369,O
6bINS,369,B-SequenceVariant
differs,369,O
between,369,O
SSc,369,B-DiseaseOrPhenotypicFeature
patients,369,B-OrganismTaxon
with,369,O
or,369,O
without,369,O
PAH,369,B-DiseaseOrPhenotypicFeature
",",369,O
suggesting,369,O
the,369,O
implication,369,O
of,369,O
ENG,369,B-GeneOrGeneProduct
in,369,O
this,369,O
devastating,369,O
vascular,369,B-DiseaseOrPhenotypicFeature
complication,369,I-DiseaseOrPhenotypicFeature
of,369,O
SSc,369,B-DiseaseOrPhenotypicFeature
.,369,O
Assessment,370,O
of,370,O
a,370,O
new,370,O
non-invasive,370,O
index,370,O
of,370,O
cardiac,370,O
performance,370,O
for,370,O
detection,370,O
of,370,O
dobutamine-induced,370,B-ChemicalEntity
myocardial,370,B-DiseaseOrPhenotypicFeature
ischemia,370,I-DiseaseOrPhenotypicFeature
.,370,O
BACKGROUND,371,O
:,371,O
Electrocardiography,371,O
has,371,O
a,371,O
very,371,O
low,371,O
sensitivity,371,O
in,371,O
detecting,371,O
dobutamine-induced,371,B-ChemicalEntity
myocardial,371,B-DiseaseOrPhenotypicFeature
ischemia,371,I-DiseaseOrPhenotypicFeature
.,371,O
OBJECTIVES,372,O
:,372,O
To,372,O
assess,372,O
the,372,O
added,372,O
diagnostic,372,O
value,372,O
of,372,O
a,372,O
new,372,O
cardiac,372,O
performance,372,O
index,372,O
(,372,O
dP/dtejc,372,O
),372,O
measurement,372,O
",",372,O
based,372,O
on,372,O
brachial,372,O
artery,372,O
flow,372,O
changes,372,O
",",372,O
as,372,O
compared,372,O
to,372,O
standard,372,O
12-lead,372,O
ECG,372,O
",",372,O
for,372,O
detecting,372,O
dobutamine-induced,372,B-ChemicalEntity
myocardial,372,B-DiseaseOrPhenotypicFeature
ischemia,372,I-DiseaseOrPhenotypicFeature
",",372,O
using,372,O
Tc99m-Sestamibi,372,O
single-photon,372,O
emission,372,O
computed,372,O
tomography,372,O
as,372,O
the,372,O
gold,372,O
standard,372,O
of,372,O
comparison,372,O
to,372,O
assess,372,O
the,372,O
presence,372,O
or,372,O
absence,372,O
of,372,O
ischemia,372,B-DiseaseOrPhenotypicFeature
.,372,O
METHODS,373,O
:,373,O
The,373,O
study,373,O
group,373,O
comprised,373,O
40,373,O
patients,373,B-OrganismTaxon
undergoing,373,O
Sestamibi-SPECT/dobutamine,373,O
stress,373,O
test,373,O
.,373,O
Simultaneous,374,O
measurements,374,O
of,374,O
ECG,374,O
and,374,O
brachial,374,O
artery,374,O
dP/dtejc,374,O
were,374,O
performed,374,O
at,374,O
each,374,O
dobutamine,374,B-ChemicalEntity
level,374,O
.,374,O
In,375,O
19,375,O
of,375,O
the,375,O
40,375,O
patients,375,B-OrganismTaxon
perfusion,375,O
defects,375,O
compatible,375,O
with,375,O
ischemia,375,B-DiseaseOrPhenotypicFeature
were,375,O
detected,375,O
on,375,O
SPECT,375,O
.,375,O
The,376,O
increase,376,O
in,376,O
dP/dtejc,376,O
during,376,O
infusion,376,O
of,376,O
dobutamine,376,B-ChemicalEntity
in,376,O
this,376,O
group,376,O
was,376,O
severely,376,O
impaired,376,O
as,376,O
compared,376,O
to,376,O
the,376,O
non-ischemic,376,O
group,376,O
.,376,O
dP/dtejc,377,O
outcome,377,O
was,377,O
combined,377,O
with,377,O
the,377,O
ECG,377,O
results,377,O
",",377,O
giving,377,O
an,377,O
ECG-enhanced,377,O
value,377,O
",",377,O
and,377,O
compared,377,O
to,377,O
ECG,377,O
alone,377,O
.,377,O
RESULTS,378,O
:,378,O
The,378,O
sensitivity,378,O
improved,378,O
dramatically,378,O
from,378,O
16,378,O
%,378,O
to,378,O
79,378,O
%,378,O
",",378,O
positive,378,O
predictive,378,O
value,378,O
increased,378,O
from,378,O
60,378,O
%,378,O
to,378,O
68,378,O
%,378,O
and,378,O
negative,378,O
predictive,378,O
value,378,O
from,378,O
54,378,O
%,378,O
to,378,O
78,378,O
%,378,O
",",378,O
and,378,O
specificity,378,O
decreased,378,O
from,378,O
90,378,O
%,378,O
to,378,O
67,378,O
%,378,O
.,378,O
CONCLUSIONS,379,O
:,379,O
If,379,O
ECG,379,O
alone,379,O
is,379,O
used,379,O
for,379,O
specificity,379,O
",",379,O
the,379,O
combination,379,O
with,379,O
dP/dtejc,379,O
improved,379,O
the,379,O
sensitivity,379,O
of,379,O
the,379,O
test,379,O
and,379,O
could,379,O
be,379,O
a,379,O
cost-savings,379,O
alternative,379,O
to,379,O
cardiac,379,O
imaging,379,O
or,379,O
perfusion,379,O
studies,379,O
to,379,O
detect,379,O
myocardial,379,B-DiseaseOrPhenotypicFeature
ischemia,379,I-DiseaseOrPhenotypicFeature
",",379,O
especially,379,O
in,379,O
patients,379,B-OrganismTaxon
unable,379,O
to,379,O
exercise,379,O
.,379,O
An,380,O
extremely,380,O
rare,380,O
case,380,O
of,380,O
delusional,380,B-DiseaseOrPhenotypicFeature
parasitosis,380,I-DiseaseOrPhenotypicFeature
in,380,O
a,380,O
chronic,380,B-DiseaseOrPhenotypicFeature
hepatitis,380,I-DiseaseOrPhenotypicFeature
C,380,I-DiseaseOrPhenotypicFeature
patient,380,B-OrganismTaxon
during,380,O
pegylated,380,B-GeneOrGeneProduct
interferon,380,I-GeneOrGeneProduct
alpha-2b,380,I-GeneOrGeneProduct
and,380,O
ribavirin,380,B-ChemicalEntity
treatment,380,O
.,380,O
During,381,O
treatment,381,O
of,381,O
chronic,381,B-DiseaseOrPhenotypicFeature
hepatitis,381,I-DiseaseOrPhenotypicFeature
C,381,I-DiseaseOrPhenotypicFeature
patients,381,B-OrganismTaxon
with,381,O
interferon,381,B-GeneOrGeneProduct
and,381,O
ribavirin,381,B-ChemicalEntity
",",381,O
a,381,O
lot,381,O
of,381,O
side,381,O
effects,381,O
are,381,O
described,381,O
.,381,O
Twenty-three,382,O
percent,382,O
to,382,O
44,382,O
%,382,O
of,382,O
patients,382,B-OrganismTaxon
develop,382,O
depression,382,B-DiseaseOrPhenotypicFeature
.,382,O
A,383,O
minority,383,O
of,383,O
patients,383,B-OrganismTaxon
evolve,383,O
to,383,O
psychosis,383,B-DiseaseOrPhenotypicFeature
.,383,O
To,384,O
the,384,O
best,384,O
of,384,O
our,384,O
knowledge,384,O
",",384,O
no,384,O
cases,384,O
of,384,O
psychogenic,384,B-DiseaseOrPhenotypicFeature
parasitosis,384,I-DiseaseOrPhenotypicFeature
occurring,384,O
during,384,O
interferon,384,B-GeneOrGeneProduct
therapy,384,O
have,384,O
been,384,O
described,384,O
in,384,O
the,384,O
literature,384,O
.,384,O
We,385,O
present,385,O
a,385,O
49-year-old,385,O
woman,385,B-OrganismTaxon
who,385,O
developed,385,O
a,385,O
delusional,385,B-DiseaseOrPhenotypicFeature
parasitosis,385,I-DiseaseOrPhenotypicFeature
during,385,O
treatment,385,O
with,385,O
pegylated,385,B-GeneOrGeneProduct
interferon,385,I-GeneOrGeneProduct
alpha-2b,385,I-GeneOrGeneProduct
weekly,385,O
and,385,O
ribavirin,385,B-ChemicalEntity
.,385,O
She,386,O
complained,386,O
of,386,O
seeing,386,O
parasites,386,O
and,386,O
the,386,O
larvae,386,O
of,386,O
fleas,386,O
in,386,O
her,386,O
stools,386,O
.,386,O
This,387,O
could,387,O
not,387,O
be,387,O
confirmed,387,O
by,387,O
any,387,O
technical,387,O
examination,387,O
.,387,O
All,388,O
the,388,O
complaints,388,O
disappeared,388,O
after,388,O
stopping,388,O
pegylated,388,B-GeneOrGeneProduct
interferon,388,I-GeneOrGeneProduct
alpha-2b,388,I-GeneOrGeneProduct
and,388,O
reappeared,388,O
after,388,O
restarting,388,O
it,388,O
.,388,O
She,389,O
had,389,O
a,389,O
complete,389,O
sustained,389,O
viral,389,O
response,389,O
.,389,O
Cardiac,390,O
Angiography,390,O
in,390,O
Renally,390,O
Impaired,390,O
Patients,390,B-OrganismTaxon
(,390,O
CARE,390,O
),390,O
study,390,O
:,390,O
a,390,O
randomized,390,O
double-blind,390,O
trial,390,O
of,390,O
contrast-induced,390,B-ChemicalEntity
nephropathy,390,B-DiseaseOrPhenotypicFeature
in,390,O
patients,390,B-OrganismTaxon
with,390,O
chronic,390,B-DiseaseOrPhenotypicFeature
kidney,390,I-DiseaseOrPhenotypicFeature
disease,390,I-DiseaseOrPhenotypicFeature
.,390,O
BACKGROUND,391,O
:,391,O
No,391,O
direct,391,O
comparisons,391,O
exist,391,O
of,391,O
the,391,O
renal,391,O
tolerability,391,O
of,391,O
the,391,O
low-osmolality,391,O
contrast,391,B-ChemicalEntity
medium,391,I-ChemicalEntity
iopamidol,391,B-ChemicalEntity
with,391,O
that,391,O
of,391,O
the,391,O
iso-osmolality,391,O
contrast,391,B-ChemicalEntity
medium,391,I-ChemicalEntity
iodixanol,391,B-ChemicalEntity
in,391,O
high-risk,391,O
patients,391,B-OrganismTaxon
.,391,O
METHODS,392,O
AND,392,O
RESULTS,392,O
:,392,O
The,392,O
present,392,O
study,392,O
is,392,O
a,392,O
multicenter,392,O
",",392,O
randomized,392,O
",",392,O
double-blind,392,O
comparison,392,O
of,392,O
iopamidol,392,B-ChemicalEntity
and,392,O
iodixanol,392,B-ChemicalEntity
in,392,O
patients,392,B-OrganismTaxon
with,392,O
chronic,392,B-DiseaseOrPhenotypicFeature
kidney,392,I-DiseaseOrPhenotypicFeature
disease,392,I-DiseaseOrPhenotypicFeature
(,392,O
estimated,392,O
glomerular,392,O
filtration,392,O
rate,392,O
",",392,O
20,392,O
to,392,O
59,392,O
mL/min,392,O
),392,O
who,392,O
underwent,392,O
cardiac,392,O
angiography,392,O
or,392,O
percutaneous,392,O
coronary,392,O
interventions,392,O
.,392,O
Serum,393,O
creatinine,393,B-ChemicalEntity
(,393,O
SCr,393,B-ChemicalEntity
),393,O
levels,393,O
and,393,O
estimated,393,O
glomerular,393,O
filtration,393,O
rate,393,O
were,393,O
assessed,393,O
at,393,O
baseline,393,O
and,393,O
2,393,O
to,393,O
5,393,O
days,393,O
after,393,O
receiving,393,O
medications,393,O
.,393,O
The,394,O
primary,394,O
outcome,394,O
was,394,O
a,394,O
postdose,394,O
SCr,394,B-ChemicalEntity
increase,394,O
>,394,O
or,394,O
=,394,O
0.5,394,O
mg/dL,394,O
(,394,O
44.2,394,O
micromol/L,394,O
),394,O
over,394,O
baseline,394,O
.,394,O
Secondary,395,O
outcomes,395,O
were,395,O
a,395,O
postdose,395,O
SCr,395,B-ChemicalEntity
increase,395,O
>,395,O
or,395,O
=,395,O
25,395,O
%,395,O
",",395,O
a,395,O
postdose,395,O
estimated,395,O
glomerular,395,O
filtration,395,O
rate,395,O
decrease,395,O
of,395,O
>,395,O
or,395,O
=,395,O
25,395,O
%,395,O
",",395,O
and,395,O
the,395,O
mean,395,O
peak,395,O
change,395,O
in,395,O
SCr,395,B-ChemicalEntity
.,395,O
In,396,O
414,396,O
patients,396,B-OrganismTaxon
",",396,O
contrast,396,B-ChemicalEntity
volume,396,O
",",396,O
presence,396,O
of,396,O
diabetes,396,B-DiseaseOrPhenotypicFeature
mellitus,396,I-DiseaseOrPhenotypicFeature
",",396,O
use,396,O
of,396,O
N-acetylcysteine,396,B-ChemicalEntity
",",396,O
mean,396,O
baseline,396,O
SCr,396,B-ChemicalEntity
",",396,O
and,396,O
estimated,396,O
glomerular,396,O
filtration,396,O
rate,396,O
were,396,O
comparable,396,O
in,396,O
the,396,O
2,396,O
groups,396,O
.,396,O
SCr,397,B-ChemicalEntity
increases,397,O
>,397,O
or,397,O
=,397,O
0.5,397,O
mg/dL,397,O
occurred,397,O
in,397,O
4.4,397,O
%,397,O
(,397,O
9,397,O
of,397,O
204,397,O
patients,397,B-OrganismTaxon
),397,O
after,397,O
iopamidol,397,B-ChemicalEntity
and,397,O
6.7,397,O
%,397,O
(,397,O
14,397,O
of,397,O
210,397,O
patients,397,B-OrganismTaxon
),397,O
after,397,O
iodixanol,397,B-ChemicalEntity
(,397,O
P=0.39,397,O
),397,O
",",397,O
whereas,397,O
rates,397,O
of,397,O
SCr,397,B-ChemicalEntity
increases,397,O
>,397,O
or,397,O
=,397,O
25,397,O
%,397,O
were,397,O
9.8,397,O
%,397,O
and,397,O
12.4,397,O
%,397,O
",",397,O
respectively,397,O
(,397,O
P=0.44,397,O
),397,O
.,397,O
In,398,O
patients,398,B-OrganismTaxon
with,398,O
diabetes,398,B-DiseaseOrPhenotypicFeature
",",398,O
SCr,398,B-ChemicalEntity
increases,398,O
>,398,O
or,398,O
=,398,O
0.5,398,O
mg/dL,398,O
were,398,O
5.1,398,O
%,398,O
(,398,O
4,398,O
of,398,O
78,398,O
patients,398,B-OrganismTaxon
),398,O
with,398,O
iopamidol,398,B-ChemicalEntity
and,398,O
13.0,398,O
%,398,O
(,398,O
12,398,O
of,398,O
92,398,O
patients,398,B-OrganismTaxon
),398,O
with,398,O
iodixanol,398,B-ChemicalEntity
(,398,O
P=0.11,398,O
),398,O
",",398,O
whereas,398,O
SCr,398,B-ChemicalEntity
increases,398,O
>,398,O
or,398,O
=,398,O
25,398,O
%,398,O
were,398,O
10.3,398,O
%,398,O
and,398,O
15.2,398,O
%,398,O
",",398,O
respectively,398,O
(,398,O
P=0.37,398,O
),398,O
.,398,O
Mean,399,O
post-SCr,399,O
increases,399,O
were,399,O
significantly,399,O
less,399,O
with,399,O
iopamidol,399,B-ChemicalEntity
(,399,O
all,399,O
patients,399,B-OrganismTaxon
:,399,O
0.07,399,O
versus,399,O
0.12,399,O
mg/dL,399,O
",",399,O
6.2,399,O
versus,399,O
10.6,399,O
micromol/L,399,O
",",399,O
P=0.03,399,O
;,399,O
patients,399,B-OrganismTaxon
with,399,O
diabetes,399,B-DiseaseOrPhenotypicFeature
:,399,O
0.07,399,O
versus,399,O
0.16,399,O
mg/dL,399,O
",",399,O
6.2,399,O
versus,399,O
14.1,399,O
micromol/L,399,O
",",399,O
P=0.01,399,O
),399,O
.,399,O
CONCLUSIONS,400,O
:,400,O
The,400,O
rate,400,O
of,400,O
contrast-induced,400,B-ChemicalEntity
nephropathy,400,B-DiseaseOrPhenotypicFeature
",",400,O
defined,400,O
by,400,O
multiple,400,O
end,400,O
points,400,O
",",400,O
is,400,O
not,400,O
statistically,400,O
different,400,O
after,400,O
the,400,O
intraarterial,400,O
administration,400,O
of,400,O
iopamidol,400,B-ChemicalEntity
or,400,O
iodixanol,400,B-ChemicalEntity
to,400,O
high-risk,400,O
patients,400,B-OrganismTaxon
",",400,O
with,400,O
or,400,O
without,400,O
diabetes,400,B-DiseaseOrPhenotypicFeature
mellitus,400,I-DiseaseOrPhenotypicFeature
.,400,O
Any,401,O
true,401,O
difference,401,O
between,401,O
the,401,O
agents,401,O
is,401,O
small,401,O
and,401,O
not,401,O
likely,401,O
to,401,O
be,401,O
clinically,401,O
significant,401,O
.,401,O
Estrogen,402,B-ChemicalEntity
prevents,402,O
cholesteryl,402,B-ChemicalEntity
ester,402,I-ChemicalEntity
accumulation,402,O
in,402,O
macrophages,402,O
induced,402,O
by,402,O
the,402,O
HIV,402,B-GeneOrGeneProduct
protease,402,I-GeneOrGeneProduct
inhibitor,402,O
ritonavir,402,B-ChemicalEntity
.,402,O
Individuals,403,O
with,403,O
HIV,403,B-OrganismTaxon
can,403,O
now,403,O
live,403,O
long,403,O
lives,403,O
with,403,O
drug,403,O
therapy,403,O
that,403,O
often,403,O
includes,403,O
protease,403,O
inhibitors,403,O
such,403,O
as,403,O
ritonavir,403,B-ChemicalEntity
.,403,O
Many,404,O
patients,404,O
",",404,O
however,404,O
",",404,O
develop,404,O
negative,404,O
long-term,404,O
side,404,O
effects,404,O
such,404,O
as,404,O
premature,404,B-DiseaseOrPhenotypicFeature
atherosclerosis,404,I-DiseaseOrPhenotypicFeature
.,404,O
We,405,O
have,405,O
previously,405,O
demonstrated,405,O
that,405,O
ritonavir,405,B-ChemicalEntity
treatment,405,O
increases,405,O
atherosclerotic,405,B-DiseaseOrPhenotypicFeature
lesion,405,I-DiseaseOrPhenotypicFeature
formation,405,O
in,405,O
male,405,O
mice,405,B-OrganismTaxon
to,405,O
a,405,O
greater,405,O
extent,405,O
than,405,O
in,405,O
female,405,O
mice,405,B-OrganismTaxon
.,405,O
Furthermore,406,O
",",406,O
peripheral,406,O
blood,406,O
monocytes,406,O
isolated,406,O
from,406,O
ritonavir-treated,406,B-ChemicalEntity
females,406,O
had,406,O
less,406,O
cholesteryl,406,B-ChemicalEntity
ester,406,I-ChemicalEntity
accumulation,406,O
.,406,O
In,407,O
the,407,O
present,407,O
study,407,O
",",407,O
we,407,O
have,407,O
investigated,407,O
the,407,O
molecular,407,O
mechanisms,407,O
by,407,O
which,407,O
female,407,O
hormones,407,O
influence,407,O
cholesterol,407,B-ChemicalEntity
metabolism,407,O
in,407,O
macrophages,407,O
in,407,O
response,407,O
to,407,O
the,407,O
HIV,407,B-GeneOrGeneProduct
protease,407,I-GeneOrGeneProduct
inhibitor,407,O
ritonavir,407,B-ChemicalEntity
.,407,O
We,408,O
have,408,O
utilized,408,O
the,408,O
human,408,B-OrganismTaxon
monocyte,408,O
cell,408,O
line,408,O
",",408,O
THP-1,408,B-CellLine
as,408,O
a,408,O
model,408,O
to,408,O
address,408,O
this,408,O
question,408,O
.,408,O
Briefly,409,O
",",409,O
cells,409,O
were,409,O
differentiated,409,O
for,409,O
72,409,O
h,409,O
with,409,O
100,409,O
nM,409,O
PMA,409,O
to,409,O
obtain,409,O
a,409,O
macrophage-like,409,O
phenotype,409,O
in,409,O
the,409,O
presence,409,O
or,409,O
absence,409,O
of,409,O
1,409,O
nM,409,O
17beta-estradiol,409,B-ChemicalEntity
(,409,O
E2,409,B-ChemicalEntity
),409,O
",",409,O
100,409,O
nM,409,O
progesterone,409,B-ChemicalEntity
or,409,O
vehicle,409,O
(,409,O
0.01,409,O
%,409,O
ethanol,409,B-ChemicalEntity
),409,O
.,409,O
Cells,410,O
were,410,O
then,410,O
treated,410,O
with,410,O
30,410,O
ng/ml,410,O
ritonavir,410,B-ChemicalEntity
or,410,O
vehicle,410,O
in,410,O
the,410,O
presence,410,O
of,410,O
aggregated,410,O
LDL,410,O
for,410,O
24,410,O
h.,410,O
Cell,410,O
extracts,410,O
were,410,O
harvested,410,O
",",410,O
and,410,O
lipid,410,B-ChemicalEntity
or,410,O
total,410,O
RNA,410,O
was,410,O
isolated,410,O
.,410,O
E2,411,B-ChemicalEntity
decreased,411,O
the,411,O
accumulation,411,O
of,411,O
cholesteryl,411,B-ChemicalEntity
esters,411,I-ChemicalEntity
in,411,O
macrophages,411,O
following,411,O
ritonavir,411,B-ChemicalEntity
treatment,411,O
.,411,O
Ritonavir,412,B-ChemicalEntity
increased,412,O
the,412,O
expression,412,O
of,412,O
the,412,O
scavenger,412,O
receptor,412,O
",",412,O
CD36,412,B-GeneOrGeneProduct
mRNA,412,O
",",412,O
responsible,412,O
for,412,O
the,412,O
uptake,412,O
of,412,O
LDL,412,O
.,412,O
Additionally,413,O
",",413,O
ritonavir,413,B-ChemicalEntity
treatment,413,O
selectively,413,O
increased,413,O
the,413,O
relative,413,O
levels,413,O
of,413,O
PPARgamma,413,B-GeneOrGeneProduct
mRNA,413,O
",",413,O
a,413,O
transcription,413,O
factor,413,O
responsible,413,O
for,413,O
the,413,O
regulation,413,O
of,413,O
CD36,413,B-GeneOrGeneProduct
mRNA,413,O
expression,413,O
.,413,O
Treatment,414,O
with,414,O
E2,414,B-ChemicalEntity
",",414,O
however,414,O
",",414,O
failed,414,O
to,414,O
prevent,414,O
these,414,O
increases,414,O
at,414,O
the,414,O
mRNA,414,O
level,414,O
.,414,O
E2,415,B-ChemicalEntity
did,415,O
",",415,O
however,415,O
",",415,O
significantly,415,O
suppress,415,O
CD36,415,B-GeneOrGeneProduct
protein,415,O
levels,415,O
as,415,O
measured,415,O
by,415,O
fluorescent,415,O
immunocytochemistry,415,O
.,415,O
This,416,O
data,416,O
suggests,416,O
that,416,O
E2,416,B-ChemicalEntity
modifies,416,O
the,416,O
expression,416,O
of,416,O
CD36,416,B-GeneOrGeneProduct
at,416,O
the,416,O
level,416,O
of,416,O
protein,416,O
expression,416,O
in,416,O
monocyte-derived,416,O
macrophages,416,O
resulting,416,O
in,416,O
reduced,416,O
cholesteryl,416,B-ChemicalEntity
ester,416,I-ChemicalEntity
accumulation,416,O
following,416,O
ritonavir,416,B-ChemicalEntity
treatment,416,O
.,416,O
Somatic,417,O
and,417,O
gonadal,417,O
mosaicism,417,O
in,417,O
X-linked,417,B-DiseaseOrPhenotypicFeature
retinitis,417,I-DiseaseOrPhenotypicFeature
pigmentosa,417,I-DiseaseOrPhenotypicFeature
.,417,O
The,418,O
g.ORF15,418,B-SequenceVariant
+,418,I-SequenceVariant
652-653delAG,418,I-SequenceVariant
mutation,418,O
in,418,O
the,418,O
RPGR,418,B-GeneOrGeneProduct
gene,418,O
is,418,O
the,418,O
most,418,O
frequent,418,O
mutation,418,O
in,418,O
X-linked,418,B-DiseaseOrPhenotypicFeature
retinitis,418,I-DiseaseOrPhenotypicFeature
pigmentosa,418,I-DiseaseOrPhenotypicFeature
(,418,O
XLRP,418,B-DiseaseOrPhenotypicFeature
),418,O
.,418,O
The,419,O
objective,419,O
of,419,O
this,419,O
study,419,O
was,419,O
to,419,O
investigate,419,O
the,419,O
possibility,419,O
of,419,O
mosaicism,419,O
in,419,O
an,419,O
XLRP,419,B-DiseaseOrPhenotypicFeature
family,419,O
.,419,O
Eight,420,O
subjects,420,O
in,420,O
the,420,O
RP,420,B-DiseaseOrPhenotypicFeature
family,420,O
were,420,O
recruited,420,O
.,420,O
Blood,421,O
samples,421,O
were,421,O
collected,421,O
for,421,O
DNA,421,O
extraction,421,O
.,421,O
Haplotype,422,O
analysis,422,O
and,422,O
mutational,422,O
screening,422,O
on,422,O
the,422,O
RPGR,422,B-GeneOrGeneProduct
gene,422,O
were,422,O
performed,422,O
.,422,O
Additionally,423,O
",",423,O
samples,423,O
of,423,O
hair,423,O
follicles,423,O
and,423,O
buccal,423,O
cells,423,O
from,423,O
the,423,O
mother,423,O
of,423,O
the,423,O
proband,423,O
were,423,O
acquired,423,O
for,423,O
DNA,423,O
extraction,423,O
and,423,O
molecular,423,O
analysis,423,O
.,423,O
Phenotype,424,O
was,424,O
characterized,424,O
with,424,O
routine,424,O
ophthalmic,424,O
examination,424,O
",",424,O
Goldmann,424,O
perimetry,424,O
",",424,O
electroretinography,424,O
",",424,O
and,424,O
color,424,O
fundus,424,O
photography,424,O
.,424,O
A,425,O
g.ORF15,425,B-SequenceVariant
+,425,I-SequenceVariant
652-653delAG,425,I-SequenceVariant
mutation,425,O
was,425,O
identified,425,O
in,425,O
second-,425,O
and,425,O
third-generation,425,O
patients/carriers,425,B-OrganismTaxon
.,425,O
A,426,O
first-generation,426,O
female,426,O
",",426,O
who,426,O
was,426,O
considered,426,O
to,426,O
be,426,O
an,426,O
obligate,426,O
carrier,426,O
",",426,O
demonstrated,426,O
a,426,O
normal,426,O
phenotype,426,O
as,426,O
well,426,O
as,426,O
a,426,O
normal,426,O
genotype,426,O
in,426,O
lymphocytic,426,O
DNA,426,O
",",426,O
indicating,426,O
the,426,O
gonadal,426,O
mosaicism,426,O
;,426,O
however,426,O
",",426,O
a,426,O
heterozygous,426,O
AG-deletion,426,B-SequenceVariant
at,426,I-SequenceVariant
nucleotide,426,I-SequenceVariant
652,426,I-SequenceVariant
and,426,I-SequenceVariant
653,426,I-SequenceVariant
was,426,O
identified,426,O
in,426,O
the,426,O
genomic,426,O
DNA,426,O
of,426,O
hair,426,O
follicles,426,O
",",426,O
hair,426,O
shaft,426,O
",",426,O
and,426,O
buccal,426,O
cells,426,O
",",426,O
indicating,426,O
that,426,O
the,426,O
mutation,426,O
is,426,O
somatic,426,O
.,426,O
In,427,O
conclusion,427,O
",",427,O
we,427,O
reported,427,O
on,427,O
a,427,O
family,427,O
in,427,O
which,427,O
an,427,O
asymptomatic,427,O
woman,427,B-OrganismTaxon
with,427,O
somatic-gonadal,427,O
mosaicism,427,O
for,427,O
a,427,O
RPGR,427,B-GeneOrGeneProduct
gene,427,O
mutation,427,O
transmitted,427,O
the,427,O
mutation,427,O
to,427,O
an,427,O
asymptomatic,427,O
daughter,427,O
and,427,O
to,427,O
a,427,O
son,427,O
with,427,O
XLRP,427,B-DiseaseOrPhenotypicFeature
.,427,O
Gonadal,428,O
mosaicism,428,O
may,428,O
be,428,O
responsible,428,O
for,428,O
a,428,O
proportion,428,O
of,428,O
multiplex,428,O
or,428,O
simplex,428,O
RP,428,B-DiseaseOrPhenotypicFeature
families,428,O
",",428,O
in,428,O
which,428,O
more,428,O
than,428,O
50,428,O
%,428,O
of,428,O
all,428,O
cases,428,O
of,428,O
RP,428,B-DiseaseOrPhenotypicFeature
are,428,O
found,428,O
.,428,O
(,429,O
c,429,O
),429,O
2007,429,O
Wiley-Liss,429,O
",",429,O
Inc,429,O
.,429,O
Mutation,430,O
analysis,430,O
of,430,O
CHRNA1,430,B-GeneOrGeneProduct
",",430,O
CHRNB1,430,B-GeneOrGeneProduct
",",430,O
CHRND,430,B-GeneOrGeneProduct
",",430,O
and,430,O
RAPSN,430,B-GeneOrGeneProduct
genes,430,O
in,430,O
multiple,430,B-DiseaseOrPhenotypicFeature
pterygium,430,I-DiseaseOrPhenotypicFeature
syndrome/fetal,430,O
akinesia,430,I-DiseaseOrPhenotypicFeature
patients,430,B-OrganismTaxon
.,430,O
Multiple,431,B-DiseaseOrPhenotypicFeature
pterygium,431,I-DiseaseOrPhenotypicFeature
syndromes,431,I-DiseaseOrPhenotypicFeature
(,431,O
MPS,431,B-DiseaseOrPhenotypicFeature
),431,O
comprise,431,O
a,431,O
group,431,O
of,431,O
multiple,431,O
congenital,431,B-DiseaseOrPhenotypicFeature
anomaly,431,I-DiseaseOrPhenotypicFeature
disorders,431,I-DiseaseOrPhenotypicFeature
characterized,431,O
by,431,O
webbing,431,O
(,431,O
pterygia,431,O
),431,O
of,431,O
the,431,O
neck,431,O
",",431,O
elbows,431,O
",",431,O
and/or,431,O
knees,431,O
and,431,O
joint,431,B-DiseaseOrPhenotypicFeature
contractures,431,I-DiseaseOrPhenotypicFeature
(,431,O
arthrogryposis,431,B-DiseaseOrPhenotypicFeature
),431,O
.,431,O
MPS,432,B-DiseaseOrPhenotypicFeature
are,432,O
phenotypically,432,O
and,432,O
genetically,432,O
heterogeneous,432,O
but,432,O
are,432,O
traditionally,432,O
divided,432,O
into,432,O
prenatally,432,O
lethal,432,O
and,432,O
nonlethal,432,O
(,432,O
Escobar,432,O
),432,O
types,432,O
.,432,O
Previously,433,O
",",433,O
we,433,O
and,433,O
others,433,O
reported,433,O
that,433,O
recessive,433,O
mutations,433,O
in,433,O
the,433,O
embryonal,433,B-GeneOrGeneProduct
acetylcholine,433,I-GeneOrGeneProduct
receptor,433,I-GeneOrGeneProduct
g,433,I-GeneOrGeneProduct
subunit,433,I-GeneOrGeneProduct
(,433,O
CHRNG,433,B-GeneOrGeneProduct
),433,O
can,433,O
cause,433,O
both,433,O
lethal,433,O
and,433,O
nonlethal,433,O
MPS,433,B-DiseaseOrPhenotypicFeature
",",433,O
thus,433,O
demonstrating,433,O
that,433,O
pterygia,433,O
resulted,433,O
from,433,O
fetal,433,B-DiseaseOrPhenotypicFeature
akinesia,433,I-DiseaseOrPhenotypicFeature
.,433,O
We,434,O
hypothesized,434,O
that,434,O
mutations,434,O
in,434,O
acetylcholine,434,O
receptor-related,434,O
genes,434,O
might,434,O
also,434,O
result,434,O
in,434,O
a,434,O
MPS/fetal,434,B-DiseaseOrPhenotypicFeature
akinesia,434,I-DiseaseOrPhenotypicFeature
phenotype,434,O
and,434,O
so,434,O
we,434,O
analyzed,434,O
15,434,O
cases,434,O
of,434,O
lethal,434,O
MPS/fetal,434,B-DiseaseOrPhenotypicFeature
akinesia,434,I-DiseaseOrPhenotypicFeature
without,434,O
CHRNG,434,B-GeneOrGeneProduct
mutations,434,O
for,434,O
mutations,434,O
in,434,O
the,434,O
CHRNA1,434,B-GeneOrGeneProduct
",",434,O
CHRNB1,434,B-GeneOrGeneProduct
",",434,O
CHRND,434,B-GeneOrGeneProduct
",",434,O
and,434,O
rapsyn,434,B-GeneOrGeneProduct
(,434,O
RAPSN,434,B-GeneOrGeneProduct
),434,O
genes,434,O
.,434,O
No,435,O
CHRNA1,435,B-GeneOrGeneProduct
",",435,O
CHRNB1,435,B-GeneOrGeneProduct
",",435,O
or,435,O
CHRND,435,B-GeneOrGeneProduct
mutations,435,O
were,435,O
detected,435,O
",",435,O
but,435,O
a,435,O
homozygous,435,O
RAPSN,435,B-GeneOrGeneProduct
frameshift,435,O
mutation,435,O
",",435,O
c.1177-1178delAA,435,B-SequenceVariant
",",435,O
was,435,O
identified,435,O
in,435,O
a,435,O
family,435,O
with,435,O
three,435,O
children,435,O
affected,435,O
with,435,O
lethal,435,O
fetal,435,B-DiseaseOrPhenotypicFeature
akinesia,435,I-DiseaseOrPhenotypicFeature
sequence,435,I-DiseaseOrPhenotypicFeature
.,435,O
Previously,436,O
",",436,O
RAPSN,436,B-GeneOrGeneProduct
mutations,436,O
have,436,O
been,436,O
reported,436,O
in,436,O
congenital,436,B-DiseaseOrPhenotypicFeature
myasthenia,436,I-DiseaseOrPhenotypicFeature
.,436,O
Functional,437,O
studies,437,O
were,437,O
consistent,437,O
with,437,O
the,437,O
hypothesis,437,O
that,437,O
whereas,437,O
incomplete,437,O
loss,437,O
of,437,O
rapsyn,437,B-GeneOrGeneProduct
function,437,O
may,437,O
cause,437,O
congenital,437,B-DiseaseOrPhenotypicFeature
myasthenia,437,I-DiseaseOrPhenotypicFeature
",",437,O
more,437,O
severe,437,O
loss,437,O
of,437,O
function,437,O
can,437,O
result,437,O
in,437,O
a,437,O
lethal,437,O
fetal,437,B-DiseaseOrPhenotypicFeature
akinesia,437,I-DiseaseOrPhenotypicFeature
phenotype,437,O
.,437,O
Co-inheritance,438,O
of,438,O
a,438,O
PKD1,438,B-GeneOrGeneProduct
mutation,438,O
and,438,O
homozygous,438,O
PKD2,438,B-GeneOrGeneProduct
variant,438,O
:,438,O
a,438,O
potential,438,O
modifier,438,O
in,438,O
autosomal,438,B-DiseaseOrPhenotypicFeature
dominant,438,I-DiseaseOrPhenotypicFeature
polycystic,438,I-DiseaseOrPhenotypicFeature
kidney,438,I-DiseaseOrPhenotypicFeature
disease,438,I-DiseaseOrPhenotypicFeature
.,438,O
BACKGROUND,439,O
:,439,O
Autosomal,439,B-DiseaseOrPhenotypicFeature
dominant,439,I-DiseaseOrPhenotypicFeature
polycystic,439,I-DiseaseOrPhenotypicFeature
kidney,439,I-DiseaseOrPhenotypicFeature
disease,439,I-DiseaseOrPhenotypicFeature
(,439,O
ADPKD,439,B-DiseaseOrPhenotypicFeature
),439,O
",",439,O
which,439,O
is,439,O
caused,439,O
by,439,O
mutations,439,O
in,439,O
polycystins,439,B-GeneOrGeneProduct
1,439,I-GeneOrGeneProduct
(,439,O
PC1,439,B-GeneOrGeneProduct
),439,O
and,439,O
2,439,O
(,439,O
PC2,439,B-GeneOrGeneProduct
),439,O
",",439,O
is,439,O
one,439,O
of,439,O
the,439,O
most,439,O
commonly,439,O
inherited,439,O
renal,439,B-DiseaseOrPhenotypicFeature
diseases,439,I-DiseaseOrPhenotypicFeature
",",439,O
affecting,439,O
~1,439,O
:,439,O
1000,439,O
Caucasians,439,O
.,439,O
MATERIALS,440,O
AND,440,O
METHODS,440,O
:,440,O
We,440,O
screened,440,O
Greek,440,O
ADPKD,440,B-DiseaseOrPhenotypicFeature
patients,440,B-OrganismTaxon
with,440,O
the,440,O
denaturing,440,O
gradient,440,O
gel,440,O
electrophoresis,440,O
(,440,O
DGGE,440,O
),440,O
assay,440,O
and,440,O
direct,440,O
sequencing,440,O
.,440,O
RESULTS,441,O
:,441,O
We,441,O
identified,441,O
a,441,O
patient,441,B-OrganismTaxon
homozygous,441,O
for,441,O
a,441,O
nucleotide,441,O
change,441,O
c.1445T,441,B-SequenceVariant
>,441,I-SequenceVariant
G,441,I-SequenceVariant
",",441,O
resulting,441,O
in,441,O
a,441,O
novel,441,O
homozygous,441,O
substitution,441,O
of,441,O
the,441,O
non-polar,441,O
hydrophobic,441,O
phenylalanine,441,B-SequenceVariant
to,441,I-SequenceVariant
the,441,I-SequenceVariant
polar,441,I-SequenceVariant
hydrophilic,441,I-SequenceVariant
cysteine,441,I-SequenceVariant
in,441,I-SequenceVariant
exon,441,I-SequenceVariant
6,441,I-SequenceVariant
at,441,I-SequenceVariant
codon,441,I-SequenceVariant
482,441,I-SequenceVariant
(,441,O
p.F482C,441,B-SequenceVariant
),441,O
of,441,O
the,441,O
PKD2,441,B-GeneOrGeneProduct
gene,441,O
and,441,O
a,441,O
de-novo,441,O
PKD1,441,B-GeneOrGeneProduct
splice-site,441,O
variant,441,O
IVS21-2delAG,441,B-SequenceVariant
.,441,O
We,442,O
did,442,O
not,442,O
find,442,O
this,442,O
PKD2,442,B-GeneOrGeneProduct
variant,442,O
in,442,O
a,442,O
screen,442,O
of,442,O
280,442,O
chromosomes,442,O
of,442,O
healthy,442,O
subjects,442,O
",",442,O
supporting,442,O
its,442,O
pathogenicity,442,O
.,442,O
The,443,O
proband,443,O
's,443,O
parents,443,O
did,443,O
not,443,O
have,443,O
the,443,O
PKD1,443,B-GeneOrGeneProduct
mutation,443,O
.,443,O
Real-time,444,O
PCR,444,O
of,444,O
the,444,O
PKD2,444,B-GeneOrGeneProduct
transcript,444,O
from,444,O
a,444,O
skin,444,O
biopsy,444,O
revealed,444,O
20-fold,444,O
higher,444,O
expression,444,O
in,444,O
the,444,O
patient,444,B-OrganismTaxon
than,444,O
in,444,O
a,444,O
healthy,444,O
subject,444,O
and,444,O
was,444,O
higher,444,O
in,444,O
the,444,O
patient,444,B-OrganismTaxon
's,444,O
peripheral,444,O
blood,444,O
mononuclear,444,O
cells,444,O
(,444,O
PBMCs,444,O
),444,O
than,444,O
in,444,O
those,444,O
of,444,O
her,444,O
heterozygote,444,O
daughter,444,O
and,444,O
a,444,O
healthy,444,O
subject,444,O
.,444,O
The,445,O
greater,445,O
gene,445,O
expression,445,O
was,445,O
also,445,O
supported,445,O
by,445,O
Western,445,O
blotting,445,O
.,445,O
Inner,446,O
medullar,446,O
collecting,446,O
duct,446,O
(,446,O
IMCD,446,O
),446,O
cells,446,O
transfected,446,O
with,446,O
the,446,O
mutant,446,O
PKD2,446,B-GeneOrGeneProduct
mouse,446,B-OrganismTaxon
gene,446,O
presented,446,O
a,446,O
perinuclear,446,O
and,446,O
diffuse,446,O
cytoplasmic,446,O
localization,446,O
compared,446,O
with,446,O
the,446,O
wild,446,O
type,446,O
ER,446,O
localization,446,O
.,446,O
Patch-clamping,447,O
of,447,O
PBMCs,447,O
from,447,O
the,447,O
p.F482C,447,B-SequenceVariant
homozygous,447,O
and,447,O
heterozygous,447,O
subjects,447,O
revealed,447,O
lower,447,O
polycystin-2,447,B-GeneOrGeneProduct
channel,447,O
function,447,O
than,447,O
in,447,O
controls,447,O
.,447,O
CONCLUSIONS,448,O
:,448,O
We,448,O
report,448,O
for,448,O
the,448,O
first,448,O
time,448,O
a,448,O
patient,448,B-OrganismTaxon
with,448,O
ADPKD,448,B-DiseaseOrPhenotypicFeature
who,448,O
is,448,O
heterozygous,448,O
for,448,O
a,448,O
de,448,O
novo,448,O
PKD1,448,B-GeneOrGeneProduct
variant,448,O
and,448,O
homozygous,448,O
for,448,O
a,448,O
novel,448,O
PKD2,448,B-GeneOrGeneProduct
mutation,448,O
.,448,O
Clinical,449,O
comparison,449,O
of,449,O
cardiorespiratory,449,O
effects,449,O
during,449,O
unilateral,449,O
and,449,O
conventional,449,O
spinal,449,O
anaesthesia,449,O
.,449,O
BACKGROUND,450,O
:,450,O
Spinal,450,O
anaesthesia,450,O
is,450,O
widely,450,O
employed,450,O
in,450,O
clinical,450,O
practice,450,O
but,450,O
has,450,O
the,450,O
main,450,O
drawback,450,O
of,450,O
post-spinal,450,O
block,450,O
hypotension,450,B-DiseaseOrPhenotypicFeature
.,450,O
Efforts,451,O
must,451,O
therefore,451,O
continue,451,O
to,451,O
be,451,O
made,451,O
to,451,O
obviate,451,O
this,451,O
setback,451,O
OBJECTIVE,451,O
:,451,O
To,451,O
evaluate,451,O
the,451,O
cardiovascular,451,O
and,451,O
respiratory,451,O
changes,451,O
during,451,O
unilateral,451,O
and,451,O
conventional,451,O
spinal,451,O
anaesthesia,451,O
.,451,O
METHODS,452,O
:,452,O
With,452,O
ethical,452,O
approval,452,O
",",452,O
we,452,O
studied,452,O
74,452,O
American,452,O
Society,452,O
of,452,O
Anesthesiologists,452,O
(,452,O
ASA,452,O
),452,O
",",452,O
physical,452,O
status,452,O
class,452,O
1,452,O
and,452,O
2,452,O
patients,452,B-OrganismTaxon
scheduled,452,O
for,452,O
elective,452,O
unilateral,452,O
lower,452,O
limb,452,O
surgery,452,O
.,452,O
Patients,453,B-OrganismTaxon
were,453,O
randomly,453,O
allocated,453,O
into,453,O
one,453,O
of,453,O
two,453,O
groups,453,O
:,453,O
lateral,453,O
and,453,O
conventional,453,O
spinal,453,O
anaesthesia,453,O
groups,453,O
.,453,O
In,454,O
the,454,O
lateral,454,O
position,454,O
with,454,O
operative,454,O
side,454,O
down,454,O
",",454,O
patients,454,B-OrganismTaxon
recived,454,O
10,454,O
mg,454,O
(,454,O
2mls,454,O
),454,O
of,454,O
0.5,454,O
%,454,O
hyperbaric,454,O
bupivacaine,454,B-ChemicalEntity
through,454,O
a,454,O
25-gauge,454,O
spinal,454,O
needle,454,O
.,454,O
Patients,455,B-OrganismTaxon
in,455,O
the,455,O
unilateral,455,O
group,455,O
were,455,O
maintained,455,O
in,455,O
the,455,O
lateral,455,O
position,455,O
for,455,O
15,455,O
minutes,455,O
following,455,O
spinal,455,O
injection,455,O
while,455,O
those,455,O
in,455,O
the,455,O
conventional,455,O
group,455,O
were,455,O
turned,455,O
supine,455,O
immediately,455,O
after,455,O
injection,455,O
.,455,O
Blood,456,O
pressure,456,O
",",456,O
heart,456,O
rate,456,O
",",456,O
respiratory,456,O
rate,456,O
and,456,O
oxygen,456,B-ChemicalEntity
saturation,456,O
were,456,O
monitored,456,O
over,456,O
1,456,O
hour,456,O
.,456,O
RESULTS,457,O
:,457,O
Three,457,O
patients,457,B-OrganismTaxon
(,457,O
8.1,457,O
%,457,O
),457,O
in,457,O
the,457,O
unilateral,457,O
group,457,O
and,457,O
5,457,O
(,457,O
13.5,457,O
%,457,O
),457,O
in,457,O
the,457,O
conventional,457,O
group,457,O
developed,457,O
hypotension,457,B-DiseaseOrPhenotypicFeature
",",457,O
P=,457,O
0.71,457,O
.,457,O
Four,458,O
(,458,O
10.8,458,O
%,458,O
),458,O
patients,458,B-OrganismTaxon
in,458,O
the,458,O
conventional,458,O
group,458,O
and,458,O
1,458,O
(,458,O
2.7,458,O
%,458,O
),458,O
in,458,O
the,458,O
unilateral,458,O
group,458,O
",",458,O
P=,458,O
0.17,458,O
required,458,O
epinephrine,458,B-ChemicalEntity
infusion,458,O
to,458,O
treat,458,O
hypotension,458,B-DiseaseOrPhenotypicFeature
.,458,O
Patients,459,B-OrganismTaxon
in,459,O
the,459,O
conventional,459,O
group,459,O
had,459,O
statistically,459,O
significant,459,O
greater,459,O
fall,459,O
in,459,O
the,459,O
systolic,459,O
blood,459,O
pressures,459,O
at,459,O
15,459,O
",",459,O
30,459,O
and,459,O
45,459,O
minutes,459,O
when,459,O
compared,459,O
to,459,O
the,459,O
baseline,459,O
(,459,O
P=,459,O
0.003,459,O
",",459,O
0.001,459,O
and,459,O
0.004,459,O
),459,O
.,459,O
The,460,O
mean,460,O
respiratory,460,O
rate,460,O
and,460,O
oxygen,460,B-ChemicalEntity
saturations,460,O
in,460,O
the,460,O
two,460,O
groups,460,O
were,460,O
similar,460,O
.,460,O
CONCLUSION,461,O
:,461,O
Compared,461,O
to,461,O
conventional,461,O
spinal,461,O
anaesthesia,461,O
",",461,O
unilateral,461,O
spinal,461,O
anaesthesia,461,O
was,461,O
associated,461,O
with,461,O
fewer,461,O
cardiovascular,461,O
perturbations,461,O
.,461,O
Also,462,O
",",462,O
the,462,O
type,462,O
of,462,O
spinal,462,O
block,462,O
instituted,462,O
affected,462,O
neither,462,O
the,462,O
respiratory,462,O
rate,462,O
nor,462,O
the,462,O
arterial,462,O
oxygen,462,B-ChemicalEntity
saturation,462,O
.,462,O
Acute,463,O
effects,463,O
of,463,O
N-,463,B-ChemicalEntity
(,463,I-ChemicalEntity
2-propylpentanoyl,463,I-ChemicalEntity
),463,I-ChemicalEntity
urea,463,I-ChemicalEntity
on,463,O
hippocampal,463,O
amino,463,O
acid,463,O
neurotransmitters,463,O
in,463,O
pilocarpine-induced,463,B-ChemicalEntity
seizure,463,B-DiseaseOrPhenotypicFeature
in,463,O
rats,463,B-OrganismTaxon
.,463,O
The,464,O
present,464,O
study,464,O
aimed,464,O
to,464,O
investigate,464,O
the,464,O
anticonvulsant,464,O
activity,464,O
as,464,O
well,464,O
as,464,O
the,464,O
effects,464,O
on,464,O
the,464,O
level,464,O
of,464,O
hippocampal,464,O
amino,464,O
acid,464,O
neurotransmitters,464,O
(,464,O
glutamate,464,B-ChemicalEntity
",",464,O
aspartate,464,B-ChemicalEntity
",",464,O
glycine,464,B-ChemicalEntity
and,464,O
GABA,464,B-ChemicalEntity
),464,O
of,464,O
N-,464,B-ChemicalEntity
(,464,I-ChemicalEntity
2-propylpentanoyl,464,I-ChemicalEntity
),464,I-ChemicalEntity
urea,464,I-ChemicalEntity
(,464,O
VPU,464,B-ChemicalEntity
),464,O
in,464,O
comparison,464,O
to,464,O
its,464,O
parent,464,O
compound,464,O
",",464,O
valproic,464,B-ChemicalEntity
acid,464,I-ChemicalEntity
(,464,O
VPA,464,B-ChemicalEntity
),464,O
.,464,O
VPU,465,B-ChemicalEntity
was,465,O
more,465,O
potent,465,O
than,465,O
VPA,465,B-ChemicalEntity
",",465,O
exhibiting,465,O
the,465,O
median,465,O
effective,465,O
dose,465,O
(,465,O
ED,465,O
(,465,O
50,465,O
),465,O
),465,O
of,465,O
49,465,O
mg/kg,465,O
in,465,O
protecting,465,O
rats,465,B-OrganismTaxon
against,465,O
pilocarpine-induced,465,B-ChemicalEntity
seizure,465,B-DiseaseOrPhenotypicFeature
whereas,465,O
the,465,O
corresponding,465,O
value,465,O
for,465,O
VPA,465,B-ChemicalEntity
was,465,O
322,465,O
mg/kg,465,O
.,465,O
In,466,O
vivo,466,O
microdialysis,466,O
demonstrated,466,O
that,466,O
an,466,O
intraperitoneal,466,O
administration,466,O
of,466,O
pilocarpine,466,B-ChemicalEntity
induced,466,O
a,466,O
pronounced,466,O
increment,466,O
of,466,O
hippocampal,466,O
glutamate,466,B-ChemicalEntity
and,466,O
aspartate,466,B-ChemicalEntity
whereas,466,O
no,466,O
significant,466,O
change,466,O
was,466,O
observed,466,O
on,466,O
the,466,O
level,466,O
of,466,O
glycine,466,B-ChemicalEntity
and,466,O
GABA,466,B-ChemicalEntity
.,466,O
Pretreatment,467,O
with,467,O
either,467,O
VPU,467,B-ChemicalEntity
(,467,O
50,467,O
and,467,O
100,467,O
mg/kg,467,O
),467,O
or,467,O
VPA,467,B-ChemicalEntity
(,467,O
300,467,O
and,467,O
600,467,O
mg/kg,467,O
),467,O
completely,467,O
abolished,467,O
pilocarpine-evoked,467,B-ChemicalEntity
increases,467,O
in,467,O
extracellular,467,O
glutamate,467,B-ChemicalEntity
and,467,O
aspartate,467,B-ChemicalEntity
.,467,O
In,468,O
addition,468,O
",",468,O
a,468,O
statistically,468,O
significant,468,O
reduction,468,O
was,468,O
also,468,O
observed,468,O
on,468,O
the,468,O
level,468,O
of,468,O
GABA,468,B-ChemicalEntity
and,468,O
glycine,468,B-ChemicalEntity
but,468,O
less,468,O
than,468,O
a,468,O
drastic,468,O
reduction,468,O
of,468,O
glutamate,468,B-ChemicalEntity
and,468,O
aspartate,468,B-ChemicalEntity
level,468,O
.,468,O
Based,469,O
on,469,O
the,469,O
finding,469,O
that,469,O
VPU,469,B-ChemicalEntity
and,469,O
VPA,469,B-ChemicalEntity
could,469,O
protect,469,O
the,469,O
animals,469,O
against,469,O
pilocarpine-induced,469,B-ChemicalEntity
seizure,469,B-DiseaseOrPhenotypicFeature
it,469,O
is,469,O
suggested,469,O
that,469,O
the,469,O
reduction,469,O
of,469,O
inhibitory,469,O
amino,469,O
acid,469,O
neurotransmitters,469,O
was,469,O
comparatively,469,O
minor,469,O
and,469,O
offset,469,O
by,469,O
a,469,O
pronounced,469,O
reduction,469,O
of,469,O
glutamate,469,B-ChemicalEntity
and,469,O
aspartate,469,B-ChemicalEntity
.,469,O
Therefore,470,O
",",470,O
like,470,O
VPA,470,B-ChemicalEntity
",",470,O
the,470,O
finding,470,O
that,470,O
VPU,470,B-ChemicalEntity
could,470,O
drastically,470,O
reduce,470,O
pilocarpine-induced,470,B-ChemicalEntity
increases,470,O
in,470,O
glutamate,470,B-ChemicalEntity
and,470,O
aspartate,470,B-ChemicalEntity
should,470,O
account,470,O
",",470,O
at,470,O
least,470,O
partly,470,O
",",470,O
for,470,O
its,470,O
anticonvulsant,470,O
activity,470,O
observed,470,O
in,470,O
pilocarpine-induced,470,B-ChemicalEntity
seizure,470,B-DiseaseOrPhenotypicFeature
in,470,O
experimental,470,O
animals,470,O
.,470,O
Some,471,O
other,471,O
mechanism,471,O
than,471,O
those,471,O
being,471,O
reported,471,O
herein,471,O
should,471,O
be,471,O
further,471,O
investigated,471,O
.,471,O
Complete,472,B-DiseaseOrPhenotypicFeature
atrioventricular,472,I-DiseaseOrPhenotypicFeature
block,472,I-DiseaseOrPhenotypicFeature
secondary,472,O
to,472,O
lithium,472,B-ChemicalEntity
therapy,472,O
.,472,O
Sinus,473,B-DiseaseOrPhenotypicFeature
node,473,I-DiseaseOrPhenotypicFeature
dysfunction,473,I-DiseaseOrPhenotypicFeature
has,473,O
been,473,O
reported,473,O
most,473,O
frequently,473,O
among,473,O
the,473,O
adverse,473,B-DiseaseOrPhenotypicFeature
cardiovascular,473,I-DiseaseOrPhenotypicFeature
effects,473,I-DiseaseOrPhenotypicFeature
of,473,O
lithium,473,B-ChemicalEntity
.,473,O
In,474,O
the,474,O
present,474,O
case,474,O
",",474,O
complete,474,B-DiseaseOrPhenotypicFeature
atrioventricular,474,I-DiseaseOrPhenotypicFeature
(,474,I-DiseaseOrPhenotypicFeature
AV,474,I-DiseaseOrPhenotypicFeature
),474,I-DiseaseOrPhenotypicFeature
block,474,I-DiseaseOrPhenotypicFeature
with,474,O
syncopal,474,B-DiseaseOrPhenotypicFeature
attacks,474,I-DiseaseOrPhenotypicFeature
developed,474,O
secondary,474,O
to,474,O
lithium,474,B-ChemicalEntity
therapy,474,O
",",474,O
necessitating,474,O
permanent,474,O
pacemaker,474,O
implantation,474,O
.,474,O
Serum,475,O
lithium,475,B-ChemicalEntity
levels,475,O
remained,475,O
under,475,O
or,475,O
within,475,O
the,475,O
therapeutic,475,O
range,475,O
during,475,O
the,475,O
syncopal,475,B-DiseaseOrPhenotypicFeature
attacks,475,I-DiseaseOrPhenotypicFeature
.,475,O
Lithium,476,B-ChemicalEntity
should,476,O
be,476,O
used,476,O
with,476,O
extreme,476,O
caution,476,O
",",476,O
especially,476,O
in,476,O
patients,476,B-OrganismTaxon
with,476,O
mild,476,O
disturbance,476,O
of,476,O
AV,476,O
conduction,476,O
.,476,O
Genetic,477,O
polymorphisms,477,O
in,477,O
the,477,O
carbonyl,477,B-GeneOrGeneProduct
reductase,477,I-GeneOrGeneProduct
3,477,I-GeneOrGeneProduct
gene,477,O
CBR3,477,B-GeneOrGeneProduct
and,477,O
the,477,O
NAD,477,B-GeneOrGeneProduct
(,477,I-GeneOrGeneProduct
P,477,I-GeneOrGeneProduct
),477,I-GeneOrGeneProduct
H,477,I-GeneOrGeneProduct
:,477,I-GeneOrGeneProduct
quinone,477,I-GeneOrGeneProduct
oxidoreductase,477,I-GeneOrGeneProduct
1,477,I-GeneOrGeneProduct
gene,477,O
NQO1,477,B-GeneOrGeneProduct
in,477,O
patients,477,B-OrganismTaxon
who,477,O
developed,477,O
anthracycline-related,477,B-ChemicalEntity
congestive,477,B-DiseaseOrPhenotypicFeature
heart,477,I-DiseaseOrPhenotypicFeature
failure,477,I-DiseaseOrPhenotypicFeature
after,477,O
childhood,477,O
cancer,477,B-DiseaseOrPhenotypicFeature
.,477,O
BACKGROUND,478,O
:,478,O
Exposure,478,O
to,478,O
anthracyclines,478,B-ChemicalEntity
as,478,O
part,478,O
of,478,O
cancer,478,B-DiseaseOrPhenotypicFeature
therapy,478,O
has,478,O
been,478,O
associated,478,O
with,478,O
the,478,O
development,478,O
of,478,O
congestive,478,B-DiseaseOrPhenotypicFeature
heart,478,I-DiseaseOrPhenotypicFeature
failure,478,I-DiseaseOrPhenotypicFeature
(,478,O
CHF,478,B-DiseaseOrPhenotypicFeature
),478,O
.,478,O
The,479,O
potential,479,O
role,479,O
of,479,O
genetic,479,O
risk,479,O
factors,479,O
in,479,O
anthracycline-related,479,B-ChemicalEntity
CHF,479,B-DiseaseOrPhenotypicFeature
remains,479,O
to,479,O
be,479,O
defined,479,O
.,479,O
Thus,480,O
",",480,O
in,480,O
this,480,O
study,480,O
",",480,O
the,480,O
authors,480,O
examined,480,O
whether,480,O
common,480,O
polymorphisms,480,O
in,480,O
candidate,480,O
genes,480,O
involved,480,O
in,480,O
the,480,O
pharmacodynamics,480,O
of,480,O
anthracyclines,480,B-ChemicalEntity
(,480,O
in,480,O
particular,480,O
",",480,O
the,480,O
nicotinamide,480,B-GeneOrGeneProduct
adenine,480,I-GeneOrGeneProduct
dinucleotide,480,I-GeneOrGeneProduct
phosphate,480,I-GeneOrGeneProduct
:,480,I-GeneOrGeneProduct
quinone,480,I-GeneOrGeneProduct
oxidoreductase,480,I-GeneOrGeneProduct
1,480,I-GeneOrGeneProduct
gene,480,O
NQO1,480,B-GeneOrGeneProduct
and,480,O
the,480,O
carbonyl,480,B-GeneOrGeneProduct
reductase,480,I-GeneOrGeneProduct
3,480,I-GeneOrGeneProduct
gene,480,O
CBR3,480,B-GeneOrGeneProduct
),480,O
had,480,O
an,480,O
impact,480,O
on,480,O
the,480,O
risk,480,O
of,480,O
anthracycline-related,480,B-ChemicalEntity
CHF,480,B-DiseaseOrPhenotypicFeature
.,480,O
METHODS,481,O
:,481,O
A,481,O
nested,481,O
case-control,481,O
study,481,O
was,481,O
conducted,481,O
within,481,O
a,481,O
cohort,481,O
of,481,O
1979,481,O
patients,481,B-OrganismTaxon
enrolled,481,O
in,481,O
the,481,O
Childhood,481,O
Cancer,481,O
Survivor,481,O
Study,481,O
who,481,O
received,481,O
treatment,481,O
with,481,O
anthracyclines,481,B-ChemicalEntity
and,481,O
had,481,O
available,481,O
DNA,481,O
.,481,O
Thirty,482,O
patients,482,B-OrganismTaxon
with,482,O
CHF,482,B-DiseaseOrPhenotypicFeature
(,482,O
cases,482,O
),482,O
and,482,O
115,482,O
matched,482,O
controls,482,O
were,482,O
genotyped,482,O
for,482,O
polymorphisms,482,O
in,482,O
NQO1,482,B-GeneOrGeneProduct
(,482,O
NQO1,482,B-GeneOrGeneProduct
*,482,O
2,482,O
),482,O
and,482,O
CBR3,482,B-GeneOrGeneProduct
(,482,O
the,482,O
CBR3,482,B-GeneOrGeneProduct
valine,482,B-SequenceVariant
[,482,I-SequenceVariant
V,482,I-SequenceVariant
],482,I-SequenceVariant
to,482,I-SequenceVariant
methionine,482,I-SequenceVariant
[,482,I-SequenceVariant
M,482,I-SequenceVariant
],482,I-SequenceVariant
substitution,482,I-SequenceVariant
at,482,I-SequenceVariant
position,482,I-SequenceVariant
244,482,I-SequenceVariant
[,482,O
V244M,482,B-SequenceVariant
],482,O
),482,O
.,482,O
Enzyme,483,O
activity,483,O
assays,483,O
with,483,O
recombinant,483,O
CBR3,483,B-GeneOrGeneProduct
isoforms,483,O
(,483,O
CBR3,483,B-GeneOrGeneProduct
V244,483,B-SequenceVariant
and,483,O
CBR3,483,B-GeneOrGeneProduct
M244,483,B-SequenceVariant
),483,O
and,483,O
the,483,O
anthracycline,483,B-ChemicalEntity
substrate,483,O
doxorubicin,483,B-ChemicalEntity
were,483,O
used,483,O
to,483,O
investigate,483,O
the,483,O
functional,483,O
impact,483,O
of,483,O
the,483,O
CBR3,483,B-GeneOrGeneProduct
V244M,483,B-SequenceVariant
polymorphism,483,O
.,483,O
RESULTS,484,O
:,484,O
Multivariate,484,O
analyses,484,O
adjusted,484,O
for,484,O
sex,484,O
and,484,O
primary,484,O
disease,484,O
recurrence,484,O
were,484,O
used,484,O
to,484,O
test,484,O
for,484,O
associations,484,O
between,484,O
the,484,O
candidate,484,O
genetic,484,O
polymorphisms,484,O
(,484,O
NQO1,484,B-GeneOrGeneProduct
*,484,O
2,484,O
and,484,O
CBR3,484,B-GeneOrGeneProduct
V244M,484,B-SequenceVariant
),484,O
and,484,O
the,484,O
risk,484,O
of,484,O
CHF,484,B-DiseaseOrPhenotypicFeature
.,484,O
Analyses,485,O
indicated,485,O
no,485,O
association,485,O
between,485,O
the,485,O
NQO1,485,B-GeneOrGeneProduct
*,485,O
2,485,O
polymorphism,485,O
and,485,O
the,485,O
risk,485,O
of,485,O
anthracycline-related,485,B-ChemicalEntity
CHF,485,B-DiseaseOrPhenotypicFeature
(,485,O
odds,485,O
ratio,485,O
[,485,O
OR,485,O
],485,O
",",485,O
1.04,485,O
;,485,O
P=.97,485,O
),485,O
.,485,O
There,486,O
was,486,O
a,486,O
trend,486,O
toward,486,O
an,486,O
association,486,O
between,486,O
the,486,O
CBR3,486,B-GeneOrGeneProduct
V244M,486,B-SequenceVariant
polymorphism,486,O
and,486,O
the,486,O
risk,486,O
of,486,O
CHF,486,B-DiseaseOrPhenotypicFeature
(,486,O
OR,486,O
",",486,O
8.16,486,O
;,486,O
P=.056,486,O
for,486,O
G/G,486,O
vs,486,O
A/A,486,O
;,486,O
OR,486,O
",",486,O
5.44,486,O
;,486,O
P=.092,486,O
for,486,O
G/A,486,O
vs,486,O
A/A,486,O
),486,O
.,486,O
In,487,O
line,487,O
",",487,O
recombinant,487,O
CBR3,487,B-GeneOrGeneProduct
V244,487,B-SequenceVariant
(,487,O
G,487,O
allele,487,O
),487,O
synthesized,487,O
2.6-fold,487,O
more,487,O
cardiotoxic,487,B-DiseaseOrPhenotypicFeature
doxorubicinol,487,B-ChemicalEntity
per,487,O
unit,487,O
of,487,O
time,487,O
than,487,O
CBR3,487,B-GeneOrGeneProduct
M244,487,B-SequenceVariant
(,487,O
A,487,O
allele,487,O
;,487,O
CBR3,487,B-GeneOrGeneProduct
V244,487,B-SequenceVariant
[,487,O
8.26+/-3.57,487,O
nmol/hour.mg,487,O
],487,O
vs,487,O
CBR3,487,B-GeneOrGeneProduct
M244,487,B-SequenceVariant
[,487,O
3.22+/-0.67,487,O
nmol/hour.mg,487,O
],487,O
;,487,O
P=.01,487,O
),487,O
.,487,O
CONCLUSIONS,488,O
:,488,O
The,488,O
functional,488,O
CBR3,488,B-GeneOrGeneProduct
V244M,488,B-SequenceVariant
polymorphism,488,O
may,488,O
have,488,O
an,488,O
impact,488,O
on,488,O
the,488,O
risk,488,O
of,488,O
anthracycline-related,488,B-ChemicalEntity
CHF,488,B-DiseaseOrPhenotypicFeature
among,488,O
childhood,488,O
cancer,488,B-DiseaseOrPhenotypicFeature
survivors,488,O
by,488,O
modulating,488,O
the,488,O
intracardiac,488,O
formation,488,O
of,488,O
cardiotoxic,488,B-DiseaseOrPhenotypicFeature
anthracycline,488,B-ChemicalEntity
alcohol,488,I-ChemicalEntity
metabolites,488,O
.,488,O
Larger,489,O
confirmatory,489,O
case-control,489,O
studies,489,O
are,489,O
warranted,489,O
.,489,O
Recovery,490,O
of,490,O
tacrolimus-associated,490,B-ChemicalEntity
brachial,490,B-DiseaseOrPhenotypicFeature
neuritis,490,I-DiseaseOrPhenotypicFeature
after,490,O
conversion,490,O
to,490,O
everolimus,490,B-ChemicalEntity
in,490,O
a,490,O
pediatric,490,O
renal,490,O
transplant,490,O
recipient,490,O
--,490,O
case,490,O
report,490,O
and,490,O
review,490,O
of,490,O
the,490,O
literature,490,O
.,490,O
TAC,491,B-ChemicalEntity
has,491,O
been,491,O
shown,491,O
to,491,O
be,491,O
a,491,O
potent,491,O
immunosuppressive,491,O
agent,491,O
for,491,O
solid,491,O
organ,491,O
transplantation,491,O
in,491,O
pediatrics,491,O
.,491,O
Neurotoxicity,492,B-DiseaseOrPhenotypicFeature
is,492,O
a,492,O
potentially,492,O
serious,492,O
toxic,492,O
effect,492,O
.,492,O
It,493,O
is,493,O
characterized,493,O
by,493,O
encephalopathy,493,B-DiseaseOrPhenotypicFeature
",",493,O
headaches,493,B-DiseaseOrPhenotypicFeature
",",493,O
seizures,493,B-DiseaseOrPhenotypicFeature
",",493,O
or,493,O
neurological,493,B-DiseaseOrPhenotypicFeature
deficits,493,I-DiseaseOrPhenotypicFeature
.,493,O
Here,494,O
",",494,O
we,494,O
describe,494,O
an,494,O
eight-and-a-half-yr-old,494,O
male,494,O
renal,494,O
transplant,494,O
recipient,494,O
with,494,O
right,494,O
BN,494,O
.,494,O
MRI,495,O
demonstrated,495,O
hyperintense,495,O
T2,495,O
signals,495,O
in,495,O
the,495,O
cervical,495,O
cord,495,O
and,495,O
right,495,O
brachial,495,O
plexus,495,O
roots,495,O
indicative,495,O
of,495,O
both,495,O
myelitis,495,B-DiseaseOrPhenotypicFeature
and,495,O
right,495,O
brachial,495,B-DiseaseOrPhenotypicFeature
plexitis,495,I-DiseaseOrPhenotypicFeature
.,495,O
Symptoms,496,O
persisted,496,O
for,496,O
three,496,O
months,496,O
despite,496,O
TAC,496,B-ChemicalEntity
dose,496,O
reduction,496,O
",",496,O
administration,496,O
of,496,O
IVIG,496,O
and,496,O
four,496,O
doses,496,O
of,496,O
methylprednisolone,496,B-ChemicalEntity
pulse,496,O
therapy,496,O
.,496,O
Improvement,497,O
and,497,O
eventually,497,O
full,497,O
recovery,497,O
only,497,O
occurred,497,O
after,497,O
TAC,497,B-ChemicalEntity
was,497,O
completely,497,O
discontinued,497,O
and,497,O
successfully,497,O
replaced,497,O
by,497,O
everolimus,497,B-ChemicalEntity
.,497,O
Effects,498,O
of,498,O
common,498,O
germline,498,O
genetic,498,O
variation,498,O
in,498,O
cell,498,O
cycle,498,O
control,498,O
genes,498,O
on,498,O
breast,498,B-DiseaseOrPhenotypicFeature
cancer,498,I-DiseaseOrPhenotypicFeature
survival,498,O
:,498,O
results,498,O
from,498,O
a,498,O
population-based,498,O
cohort,498,O
.,498,O
INTRODUCTION,499,O
:,499,O
Somatic,499,O
alterations,499,O
have,499,O
been,499,O
shown,499,O
to,499,O
correlate,499,O
with,499,O
breast,499,B-DiseaseOrPhenotypicFeature
cancer,499,I-DiseaseOrPhenotypicFeature
prognosis,499,O
and,499,O
survival,499,O
",",499,O
but,499,O
less,499,O
is,499,O
known,499,O
about,499,O
the,499,O
effects,499,O
of,499,O
common,499,O
inherited,499,O
genetic,499,O
variation,499,O
.,499,O
Of,500,O
particular,500,O
interest,500,O
are,500,O
genes,500,O
involved,500,O
in,500,O
cell,500,O
cycle,500,O
pathways,500,O
",",500,O
which,500,O
regulate,500,O
cell,500,O
division,500,O
.,500,O
METHODS,501,O
:,501,O
We,501,O
examined,501,O
associations,501,O
between,501,O
common,501,O
germline,501,O
genetic,501,O
variation,501,O
in,501,O
13,501,O
genes,501,O
involved,501,O
in,501,O
cell,501,O
cycle,501,O
control,501,O
(,501,O
CCND1,501,B-GeneOrGeneProduct
",",501,O
CCND2,501,B-GeneOrGeneProduct
",",501,O
CCND3,501,B-GeneOrGeneProduct
",",501,O
CCNE1,501,B-GeneOrGeneProduct
",",501,O
CDK2,501,B-GeneOrGeneProduct
[,501,I-GeneOrGeneProduct
p33,501,I-GeneOrGeneProduct
],501,I-GeneOrGeneProduct
",",501,O
CDK4,501,B-GeneOrGeneProduct
",",501,O
CDK6,501,B-GeneOrGeneProduct
",",501,O
CDKN1A,501,B-GeneOrGeneProduct
[,501,O
p21,501,B-GeneOrGeneProduct
",",501,O
Cip1,501,B-GeneOrGeneProduct
],501,O
",",501,O
CDKN1B,501,B-GeneOrGeneProduct
[,501,O
p27,501,B-GeneOrGeneProduct
",",501,I-GeneOrGeneProduct
Kip1,501,I-GeneOrGeneProduct
],501,O
",",501,O
CDKN2A,501,B-GeneOrGeneProduct
[,501,O
p16,501,B-GeneOrGeneProduct
],501,O
",",501,O
CDKN2B,501,B-GeneOrGeneProduct
[,501,O
p15,501,B-GeneOrGeneProduct
],501,O
",",501,O
CDKN2C,501,B-GeneOrGeneProduct
[,501,O
p18,501,B-GeneOrGeneProduct
],501,O
",",501,O
and,501,O
CDKN2D,501,B-GeneOrGeneProduct
[,501,O
p19,501,B-GeneOrGeneProduct
],501,O
),501,O
and,501,O
survival,501,O
among,501,O
women,501,B-OrganismTaxon
diagnosed,501,O
with,501,O
invasive,501,B-DiseaseOrPhenotypicFeature
breast,501,I-DiseaseOrPhenotypicFeature
cancer,501,I-DiseaseOrPhenotypicFeature
participating,501,O
in,501,O
the,501,O
SEARCH,501,O
(,501,O
Studies,501,O
of,501,O
Epidemiology,501,O
and,501,O
Risk,501,O
factors,501,O
in,501,O
Cancer,501,O
Heredity,501,O
),501,O
breast,501,B-DiseaseOrPhenotypicFeature
cancer,501,I-DiseaseOrPhenotypicFeature
study,501,O
.,501,O
DNA,502,O
from,502,O
up,502,O
to,502,O
"4,470",502,O
women,502,B-OrganismTaxon
was,502,O
genotyped,502,O
for,502,O
85,502,O
polymorphisms,502,O
that,502,O
tag,502,O
the,502,O
known,502,O
common,502,O
polymorphisms,502,O
(,502,O
minor,502,O
allele,502,O
frequency,502,O
>,502,O
0.05,502,O
),502,O
in,502,O
the,502,O
genes,502,O
.,502,O
The,503,O
genotypes,503,O
of,503,O
each,503,O
polymorphism,503,O
were,503,O
tested,503,O
for,503,O
association,503,O
with,503,O
survival,503,O
using,503,O
Cox,503,O
regression,503,O
analysis,503,O
.,503,O
RESULTS,504,O
:,504,O
The,504,O
rare,504,O
allele,504,O
of,504,O
the,504,O
tagging,504,O
single,504,O
nucleotide,504,O
polymorphism,504,O
(,504,O
SNP,504,O
),504,O
rs2479717,504,B-SequenceVariant
is,504,O
associated,504,O
with,504,O
an,504,O
increased,504,O
risk,504,O
of,504,O
death,504,B-DiseaseOrPhenotypicFeature
(,504,O
hazard,504,O
ratio,504,O
=,504,O
1.26,504,O
per,504,O
rare,504,O
allele,504,O
carried,504,O
",",504,O
95,504,O
%,504,O
confidence,504,O
interval,504,O
:,504,O
1.12,504,O
to,504,O
1.42,504,O
;,504,O
P,504,O
=,504,O
0.0001,504,O
),504,O
",",504,O
which,504,O
was,504,O
not,504,O
attenuated,504,O
after,504,O
adjusting,504,O
for,504,O
tumour,504,B-DiseaseOrPhenotypicFeature
stage,504,O
",",504,O
grade,504,O
",",504,O
and,504,O
treatment,504,O
.,504,O
This,505,O
SNP,505,O
is,505,O
part,505,O
of,505,O
a,505,O
large,505,O
linkage,505,O
disequilibrium,505,O
block,505,O
",",505,O
which,505,O
contains,505,O
CCND3,505,B-GeneOrGeneProduct
",",505,O
BYSL,505,B-GeneOrGeneProduct
",",505,O
TRFP,505,B-GeneOrGeneProduct
",",505,O
USP49,505,B-GeneOrGeneProduct
",",505,O
C6ofr49,505,B-GeneOrGeneProduct
",",505,O
FRS3,505,B-GeneOrGeneProduct
",",505,O
and,505,O
PGC,505,B-GeneOrGeneProduct
.,505,O
We,506,O
evaluated,506,O
the,506,O
association,506,O
of,506,O
survival,506,O
and,506,O
somatic,506,O
expression,506,O
of,506,O
these,506,O
genes,506,O
in,506,O
breast,506,B-DiseaseOrPhenotypicFeature
tumours,506,I-DiseaseOrPhenotypicFeature
using,506,O
expression,506,O
microarray,506,O
data,506,O
from,506,O
seven,506,O
published,506,O
datasets,506,O
.,506,O
Elevated,507,O
expression,507,O
of,507,O
the,507,O
C6orf49,507,B-GeneOrGeneProduct
transcript,507,O
was,507,O
associated,507,O
with,507,O
breast,507,B-DiseaseOrPhenotypicFeature
cancer,507,I-DiseaseOrPhenotypicFeature
survival,507,O
",",507,O
adding,507,O
biological,507,O
interest,507,O
to,507,O
the,507,O
finding,507,O
.,507,O
CONCLUSION,508,O
:,508,O
It,508,O
is,508,O
possible,508,O
that,508,O
CCND3,508,B-GeneOrGeneProduct
rs2479717,508,B-SequenceVariant
",",508,O
or,508,O
another,508,O
variant,508,O
it,508,O
tags,508,O
",",508,O
is,508,O
associated,508,O
with,508,O
prognosis,508,O
after,508,O
a,508,O
diagnosis,508,O
of,508,O
breast,508,B-DiseaseOrPhenotypicFeature
cancer,508,I-DiseaseOrPhenotypicFeature
.,508,O
Further,509,O
study,509,O
is,509,O
required,509,O
to,509,O
validate,509,O
this,509,O
finding,509,O
.,509,O
Association,510,O
between,510,O
polymorphisms,510,O
in,510,O
SLC30A8,510,B-GeneOrGeneProduct
",",510,O
HHEX,510,B-GeneOrGeneProduct
",",510,O
CDKN2A/B,510,B-GeneOrGeneProduct
",",510,O
IGF2BP2,510,B-GeneOrGeneProduct
",",510,O
FTO,510,B-GeneOrGeneProduct
",",510,O
WFS1,510,B-GeneOrGeneProduct
",",510,O
CDKAL1,510,B-GeneOrGeneProduct
",",510,O
KCNQ1,510,B-GeneOrGeneProduct
and,510,O
type,510,B-DiseaseOrPhenotypicFeature
2,510,I-DiseaseOrPhenotypicFeature
diabetes,510,I-DiseaseOrPhenotypicFeature
in,510,O
the,510,O
Korean,510,O
population,510,O
.,510,O
According,511,O
to,511,O
recent,511,O
genome-wide,511,O
association,511,O
studies,511,O
",",511,O
a,511,O
number,511,O
of,511,O
single,511,O
nucleotide,511,O
polymorphisms,511,O
(,511,O
SNPs,511,O
),511,O
are,511,O
reported,511,O
to,511,O
be,511,O
associated,511,O
with,511,O
type,511,B-DiseaseOrPhenotypicFeature
2,511,I-DiseaseOrPhenotypicFeature
diabetes,511,I-DiseaseOrPhenotypicFeature
mellitus,511,I-DiseaseOrPhenotypicFeature
(,511,O
T2DM,511,B-DiseaseOrPhenotypicFeature
),511,O
.,511,O
The,512,O
aim,512,O
of,512,O
the,512,O
present,512,O
study,512,O
was,512,O
to,512,O
investigate,512,O
the,512,O
association,512,O
among,512,O
the,512,O
polymorphisms,512,O
of,512,O
SLC30A8,512,B-GeneOrGeneProduct
",",512,O
HHEX,512,B-GeneOrGeneProduct
",",512,O
CDKN2A/B,512,B-GeneOrGeneProduct
",",512,O
IGF2BP2,512,B-GeneOrGeneProduct
",",512,O
FTO,512,B-GeneOrGeneProduct
",",512,O
WFS1,512,B-GeneOrGeneProduct
",",512,O
CDKAL1,512,B-GeneOrGeneProduct
and,512,O
KCNQ1,512,B-GeneOrGeneProduct
and,512,O
the,512,O
risk,512,O
of,512,O
T2DM,512,B-DiseaseOrPhenotypicFeature
in,512,O
the,512,O
Korean,512,O
population,512,O
.,512,O
This,513,O
study,513,O
was,513,O
based,513,O
on,513,O
a,513,O
multicenter,513,O
case-control,513,O
study,513,O
",",513,O
including,513,O
908,513,O
patients,513,B-OrganismTaxon
with,513,O
T2DM,513,B-DiseaseOrPhenotypicFeature
and,513,O
502,513,O
non-diabetic,513,O
controls,513,O
.,513,O
We,514,O
genotyped,514,O
rs13266634,514,B-SequenceVariant
",",514,O
rs1111875,514,B-SequenceVariant
",",514,O
rs10811661,514,B-SequenceVariant
",",514,O
rs4402960,514,B-SequenceVariant
",",514,O
rs8050136,514,B-SequenceVariant
",",514,O
rs734312,514,B-SequenceVariant
",",514,O
rs7754840,514,B-SequenceVariant
and,514,O
rs2237892,514,B-SequenceVariant
and,514,O
measured,514,O
the,514,O
body,514,O
weight,514,O
",",514,O
body,514,O
mass,514,O
index,514,O
and,514,O
fasting,514,O
plasma,514,O
glucose,514,B-ChemicalEntity
in,514,O
all,514,O
patients,514,B-OrganismTaxon
and,514,O
controls,514,O
.,514,O
The,515,O
strongest,515,O
association,515,O
was,515,O
found,515,O
in,515,O
a,515,O
variant,515,O
of,515,O
CDKAL1,515,B-GeneOrGeneProduct
[,515,O
rs7754840,515,B-SequenceVariant
",",515,O
odds,515,O
ratio,515,O
(,515,O
OR,515,O
),515,O
=,515,O
1.77,515,O
",",515,O
95,515,O
%,515,O
CI,515,O
=,515,O
1.50-2.10,515,O
",",515,O
p,515,O
=,515,O
5.0,515,O
x,515,O
10,515,O
(,515,O
-11,515,O
),515,O
],515,O
.,515,O
The,516,O
G,516,O
allele,516,O
of,516,O
rs1111875,516,B-SequenceVariant
(,516,O
OR,516,O
=,516,O
1.43,516,O
",",516,O
95,516,O
%,516,O
CI,516,O
=,516,O
1.18-1.72,516,O
",",516,O
p,516,O
=,516,O
1.8,516,O
x,516,O
10,516,O
(,516,O
-4,516,O
),516,O
),516,O
in,516,O
HHEX,516,B-GeneOrGeneProduct
),516,O
",",516,O
the,516,O
T,516,O
allele,516,O
of,516,O
rs10811661,516,B-SequenceVariant
(,516,O
OR,516,O
=,516,O
1.47,516,O
",",516,O
95,516,O
%,516,O
CI,516,O
=,516,O
1.23-1.75,516,O
",",516,O
p,516,O
=,516,O
2.1,516,O
x,516,O
10,516,O
(,516,O
-5,516,O
),516,O
),516,O
in,516,O
CDKN2A/B,516,B-GeneOrGeneProduct
),516,O
and,516,O
the,516,O
C,516,O
allele,516,O
of,516,O
rs2237892,516,B-SequenceVariant
(,516,O
OR,516,O
=,516,O
1.31,516,O
",",516,O
95,516,O
%,516,O
CI,516,O
=,516,O
1.10-1.56,516,O
",",516,O
p,516,O
=,516,O
0.003,516,O
),516,O
in,516,O
KCNQ1,516,B-GeneOrGeneProduct
showed,516,O
significant,516,O
associations,516,O
with,516,O
T2DM,516,B-DiseaseOrPhenotypicFeature
.,516,O
Rs13266634,517,B-SequenceVariant
(,517,O
OR,517,O
=,517,O
1.19,517,O
",",517,O
95,517,O
%,517,O
CI,517,O
=,517,O
1.00-1.42,517,O
",",517,O
p,517,O
=,517,O
0.045,517,O
),517,O
in,517,O
SLC30A8,517,B-GeneOrGeneProduct
showed,517,O
a,517,O
nominal,517,O
association,517,O
with,517,O
the,517,O
risk,517,O
of,517,O
T2DM,517,B-DiseaseOrPhenotypicFeature
",",517,O
whereas,517,O
SNPs,517,O
in,517,O
IGF2BP2,517,B-GeneOrGeneProduct
",",517,O
FTO,517,B-GeneOrGeneProduct
and,517,O
WFS1,517,B-GeneOrGeneProduct
were,517,O
not,517,O
associated,517,O
.,517,O
In,518,O
conclusion,518,O
",",518,O
we,518,O
have,518,O
shown,518,O
that,518,O
SNPs,518,O
in,518,O
HHEX,518,B-GeneOrGeneProduct
",",518,O
CDKN2A/B,518,B-GeneOrGeneProduct
",",518,O
CDKAL1,518,B-GeneOrGeneProduct
",",518,O
KCNQ1,518,B-GeneOrGeneProduct
and,518,O
SLC30A8,518,B-GeneOrGeneProduct
confer,518,O
a,518,O
risk,518,O
of,518,O
T2DM,518,B-DiseaseOrPhenotypicFeature
in,518,O
the,518,O
Korean,518,O
population,518,O
.,518,O
Growth,519,B-GeneOrGeneProduct
hormone,519,I-GeneOrGeneProduct
dose,519,O
in,519,O
growth,519,B-DiseaseOrPhenotypicFeature
hormone-deficient,519,I-DiseaseOrPhenotypicFeature
adults,519,O
is,519,O
not,519,O
associated,519,O
with,519,O
IGF-1,519,B-GeneOrGeneProduct
gene,519,O
polymorphisms,519,O
.,519,O
AIMS,520,O
:,520,O
Several,520,O
SNPs,520,O
and,520,O
a,520,O
microsatellite,520,O
cytosine-adenine,520,O
repeat,520,O
promoter,520,O
polymorphism,520,O
of,520,O
the,520,O
IGF-1,520,B-GeneOrGeneProduct
gene,520,O
have,520,O
been,520,O
reported,520,O
to,520,O
be,520,O
associated,520,O
with,520,O
circulating,520,O
IGF-1,520,B-GeneOrGeneProduct
serum,520,O
concentrations,520,O
.,520,O
Variance,521,O
in,521,O
IGF-1,521,B-GeneOrGeneProduct
concentrations,521,O
due,521,O
to,521,O
genetic,521,O
variations,521,O
may,521,O
affect,521,O
different,521,O
response,521,O
to,521,O
growth,521,B-GeneOrGeneProduct
hormone,521,I-GeneOrGeneProduct
(,521,O
GH,521,B-GeneOrGeneProduct
),521,O
treatment,521,O
",",521,O
resulting,521,O
in,521,O
different,521,O
individually,521,O
required,521,O
GH-doses,521,B-GeneOrGeneProduct
in,521,O
GH-deficient,521,B-DiseaseOrPhenotypicFeature
patients,521,B-OrganismTaxon
.,521,O
The,522,O
aim,522,O
of,522,O
this,522,O
study,522,O
was,522,O
to,522,O
test,522,O
if,522,O
the,522,O
IGF-1,522,B-GeneOrGeneProduct
gene,522,O
polymorphisms,522,O
are,522,O
associated,522,O
with,522,O
the,522,O
GH-dose,522,B-GeneOrGeneProduct
of,522,O
GH-deficient,522,B-DiseaseOrPhenotypicFeature
adults,522,O
.,522,O
MATERIALS,523,O
&,523,O
METHODS,523,O
:,523,O
A,523,O
total,523,O
of,523,O
nine,523,O
tagging,523,O
SNPs,523,O
",",523,O
five,523,O
additionally,523,O
selected,523,O
SNPs,523,O
and,523,O
a,523,O
cytosine-adenine,523,O
repeat,523,O
polymorphism,523,O
were,523,O
determined,523,O
in,523,O
133,523,O
German,523,O
adult,523,O
patients,523,B-OrganismTaxon
(,523,O
66,523,O
men,523,B-OrganismTaxon
",",523,O
67,523,O
women,523,B-OrganismTaxon
;,523,O
mean,523,O
age,523,O
45.4,523,O
years,523,O
+/-,523,O
13.1,523,O
standard,523,O
deviation,523,O
;,523,O
majority,523,O
Caucasian,523,O
),523,O
with,523,O
GH-deficiency,523,B-DiseaseOrPhenotypicFeature
(,523,O
GHD,523,B-DiseaseOrPhenotypicFeature
),523,O
of,523,O
different,523,O
origin,523,O
",",523,O
derived,523,O
from,523,O
the,523,O
prospective,523,O
Pfizer,523,O
International,523,O
Metabolic,523,O
Study,523,O
(,523,O
KIMS,523,O
),523,O
Pharmacogenetics,523,O
Study,523,O
.,523,O
Patients,524,B-OrganismTaxon
received,524,O
GH-treatment,524,B-GeneOrGeneProduct
for,524,O
12,524,O
months,524,O
with,524,O
finished,524,O
dose-titration,524,O
of,524,O
GH,524,B-GeneOrGeneProduct
and,524,O
centralized,524,O
IGF-1,524,B-GeneOrGeneProduct
measurements,524,O
.,524,O
GH-dose,525,B-GeneOrGeneProduct
after,525,O
1,525,O
year,525,O
of,525,O
treatment,525,O
",",525,O
IGF-1,525,B-GeneOrGeneProduct
concentrations,525,O
",",525,O
IGF-1-standard,525,B-GeneOrGeneProduct
deviation,525,O
score,525,O
(,525,O
SDS,525,O
),525,O
",",525,O
the,525,O
IGF-1,525,B-GeneOrGeneProduct
:,525,O
GH,525,B-GeneOrGeneProduct
ratio,525,O
and,525,O
anthropometric,525,O
data,525,O
were,525,O
analyzed,525,O
by,525,O
genotype,525,O
.,525,O
RESULTS,526,O
:,526,O
Except,526,O
for,526,O
rs1019731,526,B-SequenceVariant
",",526,O
which,526,O
showed,526,O
a,526,O
significant,526,O
difference,526,O
of,526,O
IGF-1-SDS,526,B-GeneOrGeneProduct
by,526,O
genotypes,526,O
(,526,O
p,526,O
=,526,O
0.02,526,O
),526,O
",",526,O
all,526,O
polymorphisms,526,O
showed,526,O
no,526,O
associations,526,O
with,526,O
the,526,O
GH-doses,526,B-GeneOrGeneProduct
",",526,O
IGF-1,526,B-GeneOrGeneProduct
concentrations,526,O
",",526,O
IGF-1-SDS,526,B-GeneOrGeneProduct
and,526,O
IGF-1,526,B-GeneOrGeneProduct
:,526,O
GH,526,B-GeneOrGeneProduct
ratio,526,O
after,526,O
adjusting,526,O
for,526,O
the,526,O
confounding,526,O
variables,526,O
gender,526,O
",",526,O
age,526,O
and,526,O
BMI,526,O
.,526,O
CONCLUSION,527,O
:,527,O
IGF-1,527,B-GeneOrGeneProduct
gene,527,O
polymorphisms,527,O
were,527,O
not,527,O
associated,527,O
with,527,O
the,527,O
responsiveness,527,O
to,527,O
exogenous,527,O
GH,527,B-GeneOrGeneProduct
in,527,O
GHD,527,B-DiseaseOrPhenotypicFeature
.,527,O
Therefore,528,O
",",528,O
genetic,528,O
variations,528,O
of,528,O
the,528,O
IGF-1,528,B-GeneOrGeneProduct
gene,528,O
seem,528,O
not,528,O
to,528,O
be,528,O
major,528,O
influencing,528,O
factors,528,O
of,528,O
the,528,O
GH-IGF-axis,528,B-GeneOrGeneProduct
causing,528,O
variable,528,O
response,528,O
to,528,O
exogenous,528,O
GH-treatment,528,B-GeneOrGeneProduct
.,528,O
Osteogenesis,529,B-DiseaseOrPhenotypicFeature
imperfecta,529,I-DiseaseOrPhenotypicFeature
type,529,I-DiseaseOrPhenotypicFeature
III,529,I-DiseaseOrPhenotypicFeature
with,529,O
intracranial,529,B-DiseaseOrPhenotypicFeature
hemorrhage,529,I-DiseaseOrPhenotypicFeature
and,529,O
brachydactyly,529,B-DiseaseOrPhenotypicFeature
associated,529,O
with,529,O
mutations,529,O
in,529,O
exon,529,O
49,529,O
of,529,O
COL1A2,529,B-GeneOrGeneProduct
.,529,O
Osteogenesis,530,B-DiseaseOrPhenotypicFeature
imperfecta,530,I-DiseaseOrPhenotypicFeature
(,530,O
OI,530,B-DiseaseOrPhenotypicFeature
),530,O
is,530,O
a,530,O
heritable,530,O
bone,530,B-DiseaseOrPhenotypicFeature
disorder,530,I-DiseaseOrPhenotypicFeature
characterized,530,O
by,530,O
fractures,530,B-DiseaseOrPhenotypicFeature
with,530,O
minimal,530,O
trauma,530,B-DiseaseOrPhenotypicFeature
.,530,O
Intracranial,531,B-DiseaseOrPhenotypicFeature
hemorrhage,531,I-DiseaseOrPhenotypicFeature
has,531,O
been,531,O
reported,531,O
in,531,O
a,531,O
small,531,O
number,531,O
of,531,O
OI,531,B-DiseaseOrPhenotypicFeature
patients,531,B-OrganismTaxon
.,531,O
Here,532,O
we,532,O
describe,532,O
three,532,O
patients,532,B-OrganismTaxon
",",532,O
a,532,O
boy,532,O
(,532,O
aged,532,O
15,532,O
years,532,O
),532,O
and,532,O
two,532,O
girls,532,O
(,532,O
aged,532,O
17,532,O
and,532,O
7,532,O
years,532,O
),532,O
with,532,O
OI,532,B-DiseaseOrPhenotypicFeature
type,532,I-DiseaseOrPhenotypicFeature
III,532,I-DiseaseOrPhenotypicFeature
who,532,O
suffered,532,O
intracranial,532,B-DiseaseOrPhenotypicFeature
hemorrhage,532,I-DiseaseOrPhenotypicFeature
and,532,O
in,532,O
addition,532,O
had,532,O
brachydactyly,532,B-DiseaseOrPhenotypicFeature
and,532,O
nail,532,B-DiseaseOrPhenotypicFeature
hypoplasia,532,I-DiseaseOrPhenotypicFeature
.,532,O
In,533,O
all,533,O
of,533,O
these,533,O
patients,533,B-OrganismTaxon
",",533,O
OI,533,B-DiseaseOrPhenotypicFeature
was,533,O
caused,533,O
by,533,O
glycine,533,O
mutations,533,O
affecting,533,O
exon,533,O
49,533,O
of,533,O
the,533,O
COL1A2,533,B-GeneOrGeneProduct
gene,533,O
",",533,O
which,533,O
codes,533,O
for,533,O
the,533,O
most,533,O
carboxy-terminal,533,O
part,533,O
of,533,O
the,533,O
triple-helical,533,O
domain,533,O
of,533,O
the,533,O
collagen,533,B-GeneOrGeneProduct
type,533,I-GeneOrGeneProduct
I,533,I-GeneOrGeneProduct
alpha,533,I-GeneOrGeneProduct
2,533,I-GeneOrGeneProduct
chain,533,O
.,533,O
These,534,O
observations,534,O
suggest,534,O
that,534,O
mutations,534,O
in,534,O
this,534,O
region,534,O
of,534,O
the,534,O
collagen,534,B-GeneOrGeneProduct
type,534,I-GeneOrGeneProduct
I,534,I-GeneOrGeneProduct
alpha,534,I-GeneOrGeneProduct
2,534,I-GeneOrGeneProduct
chain,534,O
carry,534,O
a,534,O
high,534,O
risk,534,O
of,534,O
abnormal,534,B-DiseaseOrPhenotypicFeature
limb,534,I-DiseaseOrPhenotypicFeature
development,534,I-DiseaseOrPhenotypicFeature
and,534,O
intracranial,534,B-DiseaseOrPhenotypicFeature
bleeding,534,I-DiseaseOrPhenotypicFeature
.,534,O
Mutation,535,O
analysis,535,O
of,535,O
FOXF2,535,B-GeneOrGeneProduct
in,535,O
patients,535,B-OrganismTaxon
with,535,O
disorders,535,B-DiseaseOrPhenotypicFeature
of,535,I-DiseaseOrPhenotypicFeature
sex,535,I-DiseaseOrPhenotypicFeature
development,535,I-DiseaseOrPhenotypicFeature
(,535,O
DSD,535,B-DiseaseOrPhenotypicFeature
),535,O
in,535,O
combination,535,O
with,535,O
cleft,535,B-DiseaseOrPhenotypicFeature
palate,535,I-DiseaseOrPhenotypicFeature
.,535,O
In,536,O
contrast,536,O
to,536,O
disorders,536,B-DiseaseOrPhenotypicFeature
of,536,I-DiseaseOrPhenotypicFeature
sexual,536,I-DiseaseOrPhenotypicFeature
differentiation,536,I-DiseaseOrPhenotypicFeature
caused,536,O
by,536,O
lack,536,O
of,536,O
androgen,536,B-ChemicalEntity
production,536,O
or,536,O
inhibited,536,O
androgen,536,B-ChemicalEntity
action,536,O
",",536,O
defects,536,O
affecting,536,O
development,536,O
of,536,O
the,536,O
bipotent,536,O
genital,536,O
anlagen,536,O
have,536,O
rarely,536,O
been,536,O
investigated,536,O
in,536,O
humans,536,B-OrganismTaxon
.,536,O
We,537,O
have,537,O
previously,537,O
documented,537,O
that,537,O
the,537,O
transcription,537,O
factor,537,O
FOXF2,537,B-GeneOrGeneProduct
is,537,O
highly,537,O
expressed,537,O
in,537,O
human,537,B-OrganismTaxon
foreskin,537,O
.,537,O
Moreover,538,O
",",538,O
Foxf2,538,B-GeneOrGeneProduct
knockout,538,O
mice,538,B-OrganismTaxon
present,538,O
with,538,O
cleft,538,B-DiseaseOrPhenotypicFeature
palate,538,I-DiseaseOrPhenotypicFeature
in,538,O
combination,538,O
with,538,O
hypoplasia,538,B-DiseaseOrPhenotypicFeature
of,538,I-DiseaseOrPhenotypicFeature
the,538,I-DiseaseOrPhenotypicFeature
genital,538,I-DiseaseOrPhenotypicFeature
tubercle,538,I-DiseaseOrPhenotypicFeature
.,538,O
We,539,O
hypothesized,539,O
that,539,O
humans,539,B-OrganismTaxon
with,539,O
disorders,539,B-DiseaseOrPhenotypicFeature
of,539,I-DiseaseOrPhenotypicFeature
sex,539,I-DiseaseOrPhenotypicFeature
development,539,I-DiseaseOrPhenotypicFeature
(,539,O
DSD,539,B-DiseaseOrPhenotypicFeature
),539,O
in,539,O
combination,539,O
with,539,O
cleft,539,B-DiseaseOrPhenotypicFeature
palate,539,I-DiseaseOrPhenotypicFeature
could,539,O
have,539,O
mutations,539,O
in,539,O
the,539,O
FOXF2,539,B-GeneOrGeneProduct
gene,539,O
.,539,O
Eighteen,540,O
children,540,O
with,540,O
DSD,540,B-DiseaseOrPhenotypicFeature
and,540,O
cleft,540,B-DiseaseOrPhenotypicFeature
palate,540,I-DiseaseOrPhenotypicFeature
were,540,O
identified,540,O
in,540,O
the,540,O
L,540,O
beck,540,O
DSD,540,B-DiseaseOrPhenotypicFeature
database,540,O
(,540,O
about,540,O
"1,500",540,O
entries,540,O
),540,O
.,540,O
Genomic,541,O
DNA,541,O
sequence,541,O
analysis,541,O
of,541,O
the,541,O
FOXF2,541,B-GeneOrGeneProduct
gene,541,O
was,541,O
performed,541,O
and,541,O
compared,541,O
with,541,O
10,541,O
normal,541,O
female,541,O
and,541,O
10,541,O
normal,541,O
male,541,O
controls,541,O
",",541,O
respectively,541,O
.,541,O
Two,542,O
heterozygous,542,O
DNA,542,O
sequence,542,O
variations,542,O
were,542,O
solely,542,O
present,542,O
in,542,O
one,542,O
single,542,O
patient,542,B-OrganismTaxon
each,542,O
but,542,O
in,542,O
none,542,O
of,542,O
the,542,O
20,542,O
normal,542,O
controls,542,O
:,542,O
a,542,O
duplication,542,B-SequenceVariant
of,542,I-SequenceVariant
GCC,542,I-SequenceVariant
(,542,O
c.97GCC,542,B-SequenceVariant
[,542,I-SequenceVariant
9,542,I-SequenceVariant
],542,I-SequenceVariant
+,542,I-SequenceVariant
[,542,I-SequenceVariant
10,542,I-SequenceVariant
],542,I-SequenceVariant
),542,O
resulting,542,O
in,542,O
an,542,O
extra,542,O
alanine,542,O
within,542,O
exon,542,O
1,542,O
and,542,O
a,542,O
25,542,B-SequenceVariant
*,542,I-SequenceVariant
G,542,I-SequenceVariant
>,542,I-SequenceVariant
A,542,I-SequenceVariant
substitution,542,O
in,542,O
the,542,O
3'-untranslated,542,O
region,542,O
.,542,O
Two,543,O
patients,543,B-OrganismTaxon
carried,543,O
a,543,O
c.262G,543,B-SequenceVariant
>,543,I-SequenceVariant
A,543,I-SequenceVariant
sequence,543,O
variation,543,O
predicting,543,O
for,543,O
an,543,O
Ala88Thr,543,B-SequenceVariant
exchange,543,O
which,543,O
was,543,O
also,543,O
detected,543,O
in,543,O
2,543,O
normal,543,O
controls,543,O
.,543,O
Two,544,O
silent,544,O
mutations,544,O
",",544,O
c.1272C,544,B-SequenceVariant
>,544,I-SequenceVariant
T,544,I-SequenceVariant
(,544,O
Ser424Ser,544,B-SequenceVariant
),544,O
and,544,O
c.1284T,544,B-SequenceVariant
>,544,I-SequenceVariant
C,544,I-SequenceVariant
(,544,O
Tyr428Tyr,544,B-SequenceVariant
),544,O
",",544,O
respectively,544,O
",",544,O
occurred,544,O
in,544,O
the,544,O
coding,544,O
region,544,O
of,544,O
exon,544,O
2,544,O
",",544,O
again,544,O
in,544,O
both,544,O
patients,544,B-OrganismTaxon
and,544,O
normal,544,O
controls,544,O
.,544,O
In,545,O
conclusion,545,O
",",545,O
the,545,O
majority,545,O
of,545,O
the,545,O
detected,545,O
sequence,545,O
alterations,545,O
were,545,O
polymorphisms,545,O
without,545,O
obvious,545,O
functional,545,O
relevance,545,O
.,545,O
However,546,O
",",546,O
it,546,O
can,546,O
not,546,O
be,546,O
excluded,546,O
that,546,O
the,546,O
2,546,O
unique,546,O
DNA,546,O
sequence,546,O
alterations,546,O
could,546,O
have,546,O
affected,546,O
FOXF2,546,B-GeneOrGeneProduct
on,546,O
the,546,O
mRNA,546,O
or,546,O
protein,546,O
level,546,O
thus,546,O
contributing,546,O
to,546,O
the,546,O
observed,546,O
disturbances,546,O
in,546,O
genital,546,O
and,546,O
palate,546,O
development,546,O
.,546,O
Pure,547,O
monosomy,547,O
and,547,O
pure,547,O
trisomy,547,O
of,547,O
13q21.2-31.1,547,O
consequent,547,O
to,547,O
a,547,O
familial,547,O
insertional,547,O
translocation,547,O
:,547,O
exclusion,547,O
of,547,O
PCDH9,547,B-GeneOrGeneProduct
as,547,O
the,547,O
responsible,547,O
gene,547,O
for,547,O
autosomal,547,B-DiseaseOrPhenotypicFeature
dominant,547,I-DiseaseOrPhenotypicFeature
auditory,547,I-DiseaseOrPhenotypicFeature
neuropathy,547,I-DiseaseOrPhenotypicFeature
(,547,O
AUNA1,547,B-DiseaseOrPhenotypicFeature
),547,O
.,547,O
Insertional,548,O
translocations,548,O
(,548,O
IT,548,O
),548,O
are,548,O
rare,548,O
structural,548,O
rearrangements,548,O
.,548,O
Offspring,549,O
of,549,O
IT,549,O
balanced,549,O
carriers,549,O
are,549,O
at,549,O
high,549,O
risk,549,O
to,549,O
have,549,O
either,549,O
pure,549,O
partial,549,O
trisomy,549,O
or,549,O
monosomy,549,O
for,549,O
the,549,O
inserted,549,O
segment,549,O
as,549,O
manifested,549,O
by,549,O
``,549,O
pure,549,O
'',549,O
phenotypes,549,O
.,549,O
We,550,O
describe,550,O
an,550,O
IT,550,O
between,550,O
chromosomes,550,O
3,550,O
and,550,O
13,550,O
segregating,550,O
in,550,O
a,550,O
three-generation,550,O
pedigree,550,O
.,550,O
Short,551,O
tandem,551,O
repeat,551,O
(,551,O
STR,551,O
),551,O
segregation,551,O
analysis,551,O
and,551,O
array-comparative,551,O
genomic,551,O
hybridization,551,O
were,551,O
used,551,O
to,551,O
define,551,O
the,551,O
IT,551,O
as,551,O
a,551,O
25.1,551,O
Mb,551,O
segment,551,O
spanning,551,O
13q21.2-q31.1,551,O
.,551,O
The,552,O
phenotype,552,O
of,552,O
pure,552,O
monosomy,552,O
included,552,O
deafness,552,B-DiseaseOrPhenotypicFeature
",",552,O
duodenal,552,B-DiseaseOrPhenotypicFeature
stenosis,552,I-DiseaseOrPhenotypicFeature
",",552,O
developmental,552,B-DiseaseOrPhenotypicFeature
and,552,I-DiseaseOrPhenotypicFeature
growth,552,I-DiseaseOrPhenotypicFeature
delay,552,I-DiseaseOrPhenotypicFeature
",",552,O
vertebral,552,B-DiseaseOrPhenotypicFeature
anomalies,552,I-DiseaseOrPhenotypicFeature
",",552,O
and,552,O
facial,552,B-DiseaseOrPhenotypicFeature
dysmorphisms,552,I-DiseaseOrPhenotypicFeature
;,552,O
the,552,O
trisomy,552,O
was,552,O
manifested,552,O
by,552,O
only,552,O
minor,552,O
dysmorphisms,552,B-DiseaseOrPhenotypicFeature
.,552,O
As,553,O
the,553,O
AUNA1,553,B-DiseaseOrPhenotypicFeature
deafness,553,B-DiseaseOrPhenotypicFeature
locus,553,O
on,553,O
13q14-21,553,O
overlaps,553,O
the,553,O
IT,553,O
in,553,O
the,553,O
PCDH9,553,B-GeneOrGeneProduct
(,553,O
protocadherin-9,553,B-GeneOrGeneProduct
),553,O
gene,553,O
region,553,O
",",553,O
PCDH9,553,B-GeneOrGeneProduct
was,553,O
investigated,553,O
as,553,O
a,553,O
candidate,553,O
gene,553,O
for,553,O
deafness,553,B-DiseaseOrPhenotypicFeature
in,553,O
both,553,O
families,553,O
.,553,O
Genotyping,554,O
of,554,O
STRs,554,O
and,554,O
single,554,O
nucleotide,554,O
polymorphisms,554,O
defined,554,O
the,554,O
AUNA1,554,B-DiseaseOrPhenotypicFeature
breakpoint,554,O
as,554,O
35,554,O
kb,554,O
5,554,O
',554,O
to,554,O
PCDH9,554,B-GeneOrGeneProduct
",",554,O
with,554,O
a,554,O
2.4,554,O
Mb,554,O
area,554,O
of,554,O
overlap,554,O
with,554,O
the,554,O
IT,554,O
.,554,O
DNA,555,O
sequencing,555,O
of,555,O
coding,555,O
regions,555,O
in,555,O
the,555,O
AUNA1,555,B-DiseaseOrPhenotypicFeature
family,555,O
and,555,O
in,555,O
the,555,O
retained,555,O
homologue,555,O
chromosome,555,O
in,555,O
the,555,O
monosomic,555,O
patient,555,B-OrganismTaxon
revealed,555,O
no,555,O
mutations,555,O
.,555,O
We,556,O
conclude,556,O
that,556,O
AUNA1,556,B-DiseaseOrPhenotypicFeature
deafness,556,B-DiseaseOrPhenotypicFeature
does,556,O
not,556,O
share,556,O
a,556,O
common,556,O
etiology,556,O
with,556,O
deafness,556,B-DiseaseOrPhenotypicFeature
associated,556,O
with,556,O
monosomy,556,O
13q21.2-q31.3,556,O
;,556,O
deafness,556,B-DiseaseOrPhenotypicFeature
may,556,O
result,556,O
from,556,O
monosomy,556,O
of,556,O
PCHD9,556,B-GeneOrGeneProduct
or,556,O
another,556,O
gene,556,O
in,556,O
the,556,O
IT,556,O
",",556,O
as,556,O
has,556,O
been,556,O
demonstrated,556,O
in,556,O
contiguous,556,O
gene,556,O
deletion,556,O
syndromes,556,O
.,556,O
Precise,557,O
characterization,557,O
of,557,O
the,557,O
breakpoints,557,O
of,557,O
the,557,O
translocated,557,O
region,557,O
is,557,O
useful,557,O
to,557,O
identify,557,O
which,557,O
genes,557,O
may,557,O
be,557,O
contributing,557,O
to,557,O
the,557,O
phenotype,557,O
",",557,O
either,557,O
through,557,O
haploinsufficiency,557,O
or,557,O
extra,557,O
dosage,557,O
effects,557,O
",",557,O
in,557,O
order,557,O
to,557,O
define,557,O
genotype-phenotype,557,O
correlations,557,O
.,557,O
The,558,O
first,558,O
founder,558,O
DGUOK,558,B-GeneOrGeneProduct
mutation,558,O
associated,558,O
with,558,O
hepatocerebral,558,B-DiseaseOrPhenotypicFeature
mitochondrial,558,I-DiseaseOrPhenotypicFeature
DNA,558,I-DiseaseOrPhenotypicFeature
depletion,558,I-DiseaseOrPhenotypicFeature
syndrome,558,I-DiseaseOrPhenotypicFeature
.,558,O
Deoxyguanosine,559,B-DiseaseOrPhenotypicFeature
kinase,559,I-DiseaseOrPhenotypicFeature
(,559,I-DiseaseOrPhenotypicFeature
dGK,559,I-DiseaseOrPhenotypicFeature
),559,I-DiseaseOrPhenotypicFeature
deficiency,559,I-DiseaseOrPhenotypicFeature
is,559,O
a,559,O
frequent,559,O
cause,559,O
of,559,O
mitochondrial,559,B-DiseaseOrPhenotypicFeature
DNA,559,I-DiseaseOrPhenotypicFeature
depletion,559,I-DiseaseOrPhenotypicFeature
associated,559,O
with,559,O
a,559,O
hepatocerebral,559,O
phenotype,559,O
.,559,O
In,560,O
this,560,O
study,560,O
",",560,O
we,560,O
describe,560,O
a,560,O
new,560,O
splice,560,O
site,560,O
mutation,560,O
in,560,O
the,560,O
DGUOK,560,B-GeneOrGeneProduct
gene,560,O
and,560,O
the,560,O
clinical,560,O
",",560,O
radiologic,560,O
",",560,O
and,560,O
genetic,560,O
features,560,O
of,560,O
these,560,O
DGUOK,560,B-GeneOrGeneProduct
patients,560,B-OrganismTaxon
.,560,O
This,561,O
new,561,O
DGUOK,561,B-GeneOrGeneProduct
homozygous,561,O
mutation,561,O
(,561,O
c.444-62C,561,B-SequenceVariant
>,561,I-SequenceVariant
A,561,I-SequenceVariant
),561,O
was,561,O
identified,561,O
in,561,O
three,561,O
patients,561,B-OrganismTaxon
from,561,O
two,561,O
North-African,561,O
consanguineous,561,O
families,561,O
with,561,O
combined,561,O
respiratory,561,B-DiseaseOrPhenotypicFeature
chain,561,I-DiseaseOrPhenotypicFeature
deficiencies,561,I-DiseaseOrPhenotypicFeature
and,561,O
mitochondrial,561,B-DiseaseOrPhenotypicFeature
DNA,561,I-DiseaseOrPhenotypicFeature
depletion,561,I-DiseaseOrPhenotypicFeature
in,561,O
the,561,O
liver,561,O
.,561,O
Brain,562,O
MRIs,562,O
are,562,O
normal,562,O
in,562,O
DGUOK,562,B-GeneOrGeneProduct
patients,562,B-OrganismTaxon
in,562,O
the,562,O
literature,562,O
.,562,O
Interestingly,563,O
",",563,O
we,563,O
found,563,O
subtentorial,563,B-DiseaseOrPhenotypicFeature
abnormal,563,I-DiseaseOrPhenotypicFeature
myelination,563,I-DiseaseOrPhenotypicFeature
and,563,O
moderate,563,B-DiseaseOrPhenotypicFeature
hyperintensity,563,I-DiseaseOrPhenotypicFeature
in,563,O
the,563,O
bilateral,563,O
pallidi,563,O
in,563,O
our,563,O
patients,563,B-OrganismTaxon
.,563,O
This,564,O
new,564,O
mutation,564,O
creates,564,O
a,564,O
cryptic,564,O
splice,564,O
site,564,O
in,564,O
intron,564,O
3,564,O
(,564,O
in,564,O
position,564,O
-62,564,O
),564,O
and,564,O
is,564,O
predicted,564,O
to,564,O
result,564,O
in,564,O
a,564,O
larger,564,O
protein,564,O
with,564,O
an,564,O
in-frame,564,O
insertion,564,O
of,564,O
20,564,O
amino,564,O
acids,564,O
.,564,O
In,565,O
silico,565,O
analysis,565,O
of,565,O
the,565,O
putative,565,O
impact,565,O
of,565,O
the,565,O
insertion,565,O
shows,565,O
serious,565,O
clashes,565,O
in,565,O
protein,565,O
conformation,565,O
:,565,O
this,565,O
insertion,565,O
disrupts,565,O
the,565,O
alpha5,565,O
helix,565,O
of,565,O
the,565,O
dGK,565,B-GeneOrGeneProduct
kinase,565,O
domain,565,O
",",565,O
rendering,565,O
the,565,O
protein,565,O
unable,565,O
to,565,O
bind,565,O
purine,565,O
deoxyribonucleosides,565,B-ChemicalEntity
.,565,O
In,566,O
addition,566,O
",",566,O
a,566,O
common,566,O
haplotype,566,O
that,566,O
segregated,566,O
with,566,O
the,566,O
disease,566,O
in,566,O
both,566,O
families,566,O
was,566,O
detected,566,O
by,566,O
haplotype,566,O
reconstruction,566,O
with,566,O
10,566,O
markers,566,O
(,566,O
microsatellites,566,O
and,566,O
SNPs,566,O
),566,O
",",566,O
which,566,O
span,566,O
4.6,566,O
Mb,566,O
of,566,O
DNA,566,O
covering,566,O
the,566,O
DGUOK,566,B-GeneOrGeneProduct
locus,566,O
.,566,O
In,567,O
conclusion,567,O
",",567,O
we,567,O
report,567,O
a,567,O
new,567,O
DGUOK,567,B-GeneOrGeneProduct
splice,567,O
site,567,O
mutation,567,O
that,567,O
provide,567,O
insight,567,O
into,567,O
a,567,O
critical,567,O
protein,567,O
domain,567,O
(,567,O
dGK,567,B-GeneOrGeneProduct
kinase,567,O
domain,567,O
),567,O
and,567,O
the,567,O
first,567,O
founder,567,O
mutation,567,O
in,567,O
a,567,O
North-African,567,O
population,567,O
.,567,O
Angiotensin,568,B-GeneOrGeneProduct
converting,568,I-GeneOrGeneProduct
enzyme,568,I-GeneOrGeneProduct
gene,568,O
polymorphism,568,O
in,568,O
Turkish,568,O
asthmatic,568,B-DiseaseOrPhenotypicFeature
patients,568,B-OrganismTaxon
.,568,O
Asthma,569,B-DiseaseOrPhenotypicFeature
is,569,O
a,569,O
chronic,569,O
inflammatory,569,B-DiseaseOrPhenotypicFeature
disease,569,I-DiseaseOrPhenotypicFeature
of,569,O
the,569,O
airways,569,O
.,569,O
Several,570,O
candidate,570,O
genes,570,O
have,570,O
been,570,O
identified,570,O
with,570,O
a,570,O
potential,570,O
role,570,O
in,570,O
the,570,O
pathogenesis,570,O
of,570,O
asthma,570,B-DiseaseOrPhenotypicFeature
",",570,O
including,570,O
the,570,O
angiotensin,570,B-GeneOrGeneProduct
converting,570,I-GeneOrGeneProduct
enzyme,570,I-GeneOrGeneProduct
(,570,O
ACE,570,B-GeneOrGeneProduct
),570,O
gene,570,O
.,570,O
We,571,O
aimed,571,O
to,571,O
investigate,571,O
the,571,O
frequency,571,O
of,571,O
an,571,O
ACE,571,B-GeneOrGeneProduct
gene,571,O
polymorphism,571,O
in,571,O
Turkish,571,O
asthmatic,571,B-DiseaseOrPhenotypicFeature
patients,571,B-OrganismTaxon
and,571,O
to,571,O
determine,571,O
its,571,O
impact,571,O
on,571,O
clinical,571,O
parameters,571,O
and,571,O
disease,571,O
severity,571,O
.,571,O
Ninety-seven,572,O
asthmatic,572,B-DiseaseOrPhenotypicFeature
patients,572,B-OrganismTaxon
(,572,O
M/F,572,O
25/72,572,O
",",572,O
mean,572,O
age,572,O
39,572,O
+/-,572,O
13,572,O
years,572,O
),572,O
and,572,O
96,572,O
healthy,572,O
subjects,572,O
(,572,O
M/F,572,O
26/70,572,O
",",572,O
mean,572,O
age,572,O
38,572,O
+/-,572,O
12,572,O
years,572,O
),572,O
were,572,O
included,572,O
.,572,O
At,573,O
baseline,573,O
",",573,O
all,573,O
participants,573,O
completed,573,O
a,573,O
questionnaire,573,O
on,573,O
demographics,573,O
",",573,O
symptoms,573,O
",",573,O
triggering,573,O
factors,573,O
",",573,O
severity,573,O
of,573,O
asthma,573,B-DiseaseOrPhenotypicFeature
",",573,O
and,573,O
the,573,O
presence,573,O
of,573,O
atopism,573,B-DiseaseOrPhenotypicFeature
.,573,O
Blood,574,O
samples,574,O
were,574,O
obtained,574,O
from,574,O
all,574,O
patients,574,B-OrganismTaxon
and,574,O
genomic,574,O
DNA,574,O
was,574,O
isolated,574,O
.,574,O
The,575,O
frequency,575,O
of,575,O
the,575,O
ACE,575,B-GeneOrGeneProduct
genotypes,575,O
(,575,O
I,575,O
=,575,O
insertion,575,O
and,575,O
D,575,O
=,575,O
deletion,575,O
),575,O
among,575,O
asthmatics,575,B-DiseaseOrPhenotypicFeature
and,575,O
controls,575,O
were,575,O
compared,575,O
:,575,O
asthmatics,575,B-DiseaseOrPhenotypicFeature
showed,575,O
a,575,O
40.2,575,O
%,575,O
prevalence,575,O
of,575,O
the,575,O
DD,575,O
genotype,575,O
(,575,O
n,575,O
=,575,O
39,575,O
),575,O
",",575,O
ID,575,O
was,575,O
45.4,575,O
%,575,O
(,575,O
n,575,O
=,575,O
44,575,O
),575,O
",",575,O
and,575,O
II,575,O
was,575,O
14.4,575,O
%,575,O
(,575,O
n,575,O
=,575,O
14.4,575,O
),575,O
.,575,O
In,576,O
the,576,O
control,576,O
subjects,576,O
",",576,O
the,576,O
frequency,576,O
of,576,O
DD,576,O
was,576,O
18.8,576,O
%,576,O
(,576,O
n,576,O
=,576,O
18,576,O
),576,O
",",576,O
ID,576,O
was,576,O
50,576,O
%,576,O
(,576,O
n,576,O
=,576,O
48,576,O
),576,O
and,576,O
II,576,O
was,576,O
31.3,576,O
%,576,O
(,576,O
n,576,O
=,576,O
30,576,O
),576,O
.,576,O
The,577,O
DD,577,O
ACE,577,B-GeneOrGeneProduct
genotype,577,O
was,577,O
significantly,577,O
more,577,O
frequent,577,O
in,577,O
asthmatics,577,B-DiseaseOrPhenotypicFeature
compared,577,O
with,577,O
controls,577,O
(,577,O
p,577,O
<,577,O
0.001,577,O
),577,O
.,577,O
Asthmatics,578,B-DiseaseOrPhenotypicFeature
with,578,O
the,578,O
ID,578,O
ACE,578,B-GeneOrGeneProduct
genotype,578,O
showed,578,O
a,578,O
higher,578,O
frequency,578,O
of,578,O
drug,578,B-DiseaseOrPhenotypicFeature
allergies,578,I-DiseaseOrPhenotypicFeature
",",578,O
although,578,O
this,578,O
was,578,O
not,578,O
statistically,578,O
significant,578,O
(,578,O
p,578,O
=,578,O
0.08,578,O
),578,O
.,578,O
Asthmatics,579,B-DiseaseOrPhenotypicFeature
with,579,O
the,579,O
DD,579,O
genotype,579,O
appeared,579,O
to,579,O
have,579,O
a,579,O
higher,579,O
incidence,579,O
of,579,O
asthmatic,579,B-DiseaseOrPhenotypicFeature
episode,579,O
exacerbations,579,O
due,579,O
to,579,O
viral,579,B-DiseaseOrPhenotypicFeature
infections,579,I-DiseaseOrPhenotypicFeature
",",579,O
but,579,O
again,579,O
this,579,O
was,579,O
not,579,O
statistically,579,O
significant,579,O
(,579,O
p,579,O
=,579,O
0.08,579,O
),579,O
.,579,O
Patients,580,B-OrganismTaxon
with,580,O
mild,580,O
or,580,O
moderate-severe,580,O
asthma,580,B-DiseaseOrPhenotypicFeature
had,580,O
similar,580,O
frequencies,580,O
of,580,O
these,580,O
mutations,580,O
.,580,O
We,581,O
found,581,O
a,581,O
higher,581,O
frequency,581,O
of,581,O
the,581,O
ACE,581,B-GeneOrGeneProduct
DD,581,O
gene,581,O
mutation,581,O
in,581,O
Turkish,581,O
asthmatic,581,B-DiseaseOrPhenotypicFeature
patients,581,B-OrganismTaxon
compared,581,O
with,581,O
non-asthmatics,581,O
",",581,O
suggesting,581,O
that,581,O
this,581,O
ACE,581,B-GeneOrGeneProduct
gene,581,O
polymorphism,581,O
may,581,O
be,581,O
a,581,O
risk,581,O
factor,581,O
for,581,O
asthma,581,B-DiseaseOrPhenotypicFeature
but,581,O
does,581,O
not,581,O
increase,581,O
the,581,O
severity,581,O
of,581,O
the,581,O
disease,581,O
.,581,O
Delirium,582,B-DiseaseOrPhenotypicFeature
in,582,O
a,582,O
patient,582,B-OrganismTaxon
with,582,O
toxic,582,O
flecainide,582,B-ChemicalEntity
plasma,582,O
concentrations,582,O
:,582,O
the,582,O
role,582,O
of,582,O
a,582,O
pharmacokinetic,582,O
drug,582,O
interaction,582,O
with,582,O
paroxetine,582,B-ChemicalEntity
.,582,O
OBJECTIVE,583,O
:,583,O
To,583,O
describe,583,O
a,583,O
case,583,O
of,583,O
flecainide-induced,583,B-ChemicalEntity
delirium,583,B-DiseaseOrPhenotypicFeature
associated,583,O
with,583,O
a,583,O
pharmacokinetic,583,O
drug,583,O
interaction,583,O
with,583,O
paroxetine,583,B-ChemicalEntity
.,583,O
CASE,584,O
SUMMARY,584,O
:,584,O
A,584,O
69-year-old,584,O
white,584,O
female,584,O
presented,584,O
to,584,O
the,584,O
emergency,584,O
department,584,O
with,584,O
a,584,O
history,584,O
of,584,O
confusion,584,B-DiseaseOrPhenotypicFeature
and,584,O
paranoia,584,B-DiseaseOrPhenotypicFeature
over,584,O
the,584,O
past,584,O
several,584,O
days,584,O
.,584,O
On,585,O
admission,585,O
the,585,O
patient,585,B-OrganismTaxon
was,585,O
taking,585,O
carvedilol,585,B-ChemicalEntity
12,585,O
mg,585,O
twice,585,O
daily,585,O
",",585,O
warfarin,585,B-ChemicalEntity
2,585,O
mg/day,585,O
",",585,O
folic,585,B-ChemicalEntity
acid,585,I-ChemicalEntity
1,585,O
mg/day,585,O
",",585,O
levothyroxine,585,B-ChemicalEntity
100,585,O
microg/day,585,O
",",585,O
pantoprazole,585,B-ChemicalEntity
40,585,O
mg/day,585,O
",",585,O
paroxetine,585,B-ChemicalEntity
40,585,O
mg/day,585,O
",",585,O
and,585,O
flecainide,585,B-ChemicalEntity
100,585,O
mg,585,O
twice,585,O
daily,585,O
.,585,O
Flecainide,586,B-ChemicalEntity
had,586,O
been,586,O
started,586,O
2,586,O
weeks,586,O
prior,586,O
for,586,O
atrial,586,B-DiseaseOrPhenotypicFeature
fibrillation,586,I-DiseaseOrPhenotypicFeature
.,586,O
Laboratory,587,O
test,587,O
findings,587,O
on,587,O
admission,587,O
were,587,O
notable,587,O
only,587,O
for,587,O
a,587,O
flecainide,587,B-ChemicalEntity
plasma,587,O
concentration,587,O
of,587,O
1360,587,O
microg/L,587,O
(,587,O
reference,587,O
range,587,O
200-1000,587,O
),587,O
.,587,O
A,588,O
metabolic,588,O
drug,588,O
interaction,588,O
between,588,O
flecainide,588,B-ChemicalEntity
and,588,O
paroxetine,588,B-ChemicalEntity
",",588,O
which,588,O
the,588,O
patient,588,B-OrganismTaxon
had,588,O
been,588,O
taking,588,O
for,588,O
more,588,O
than,588,O
5,588,O
years,588,O
",",588,O
was,588,O
considered,588,O
.,588,O
Paroxetine,589,B-ChemicalEntity
was,589,O
discontinued,589,O
and,589,O
the,589,O
dose,589,O
of,589,O
flecainide,589,B-ChemicalEntity
was,589,O
reduced,589,O
to,589,O
50,589,O
mg,589,O
twice,589,O
daily,589,O
.,589,O
Her,590,O
delirium,590,B-DiseaseOrPhenotypicFeature
resolved,590,O
3,590,O
days,590,O
later,590,O
.,590,O
DISCUSSION,591,O
:,591,O
Flecainide,591,B-ChemicalEntity
and,591,O
pharmacologically,591,O
similar,591,O
agents,591,O
that,591,O
interact,591,O
with,591,O
sodium,591,B-ChemicalEntity
channels,591,O
may,591,O
cause,591,O
delirium,591,B-DiseaseOrPhenotypicFeature
in,591,O
susceptible,591,O
patients,591,B-OrganismTaxon
.,591,O
A,592,O
MEDLINE,592,O
search,592,O
(,592,O
1966-January,592,O
2009,592,O
),592,O
revealed,592,O
one,592,O
in,592,O
vivo,592,O
pharmacokinetic,592,O
study,592,O
on,592,O
the,592,O
interaction,592,O
between,592,O
flecainide,592,B-ChemicalEntity
",",592,O
a,592,O
CYP2D6,592,B-GeneOrGeneProduct
substrate,592,O
",",592,O
and,592,O
paroxetine,592,B-ChemicalEntity
",",592,O
a,592,O
CYP2D6,592,B-GeneOrGeneProduct
inhibitor,592,O
",",592,O
as,592,O
well,592,O
as,592,O
3,592,O
case,592,O
reports,592,O
of,592,O
flecainide-induced,592,B-ChemicalEntity
delirium,592,B-DiseaseOrPhenotypicFeature
.,592,O
According,593,O
to,593,O
the,593,O
Naranjo,593,O
probability,593,O
scale,593,O
",",593,O
flecainide,593,B-ChemicalEntity
was,593,O
the,593,O
probable,593,O
cause,593,O
of,593,O
the,593,O
patient,593,B-OrganismTaxon
's,593,O
delirium,593,B-DiseaseOrPhenotypicFeature
;,593,O
the,593,O
Horn,593,O
Drug,593,O
Interaction,593,O
Probability,593,O
Scale,593,O
indicates,593,O
a,593,O
possible,593,O
pharmacokinetic,593,O
drug,593,O
interaction,593,O
between,593,O
flecainide,593,B-ChemicalEntity
and,593,O
paroxetine,593,B-ChemicalEntity
.,593,O
CONCLUSIONS,594,O
:,594,O
Supratherapeutic,594,O
flecainide,594,B-ChemicalEntity
plasma,594,O
concentrations,594,O
may,594,O
cause,594,O
delirium,594,B-DiseaseOrPhenotypicFeature
.,594,O
Because,595,O
toxicity,595,B-DiseaseOrPhenotypicFeature
may,595,O
occur,595,O
when,595,O
flecainide,595,B-ChemicalEntity
is,595,O
prescribed,595,O
with,595,O
paroxetine,595,B-ChemicalEntity
and,595,O
other,595,O
potent,595,O
CYP2D6,595,B-GeneOrGeneProduct
inhibitors,595,O
",",595,O
flecainide,595,B-ChemicalEntity
plasma,595,O
concentrations,595,O
should,595,O
be,595,O
monitored,595,O
closely,595,O
with,595,O
commencement,595,O
of,595,O
CYP2D6,595,B-GeneOrGeneProduct
inhibitors,595,O
.,595,O
Adenosine,596,B-GeneOrGeneProduct
A,596,I-GeneOrGeneProduct
(,596,I-GeneOrGeneProduct
2A,596,I-GeneOrGeneProduct
),596,I-GeneOrGeneProduct
receptor,596,I-GeneOrGeneProduct
gene,596,O
(,596,O
ADORA2A,596,B-GeneOrGeneProduct
),596,O
variants,596,O
may,596,O
increase,596,O
autistic,596,B-DiseaseOrPhenotypicFeature
symptoms,596,I-DiseaseOrPhenotypicFeature
and,596,O
anxiety,596,B-DiseaseOrPhenotypicFeature
in,596,O
autism,596,B-DiseaseOrPhenotypicFeature
spectrum,596,I-DiseaseOrPhenotypicFeature
disorder,596,I-DiseaseOrPhenotypicFeature
.,596,O
Autism,597,B-DiseaseOrPhenotypicFeature
spectrum,597,I-DiseaseOrPhenotypicFeature
disorders,597,I-DiseaseOrPhenotypicFeature
(,597,O
ASDs,597,B-DiseaseOrPhenotypicFeature
),597,O
are,597,O
heterogeneous,597,O
disorders,597,O
presenting,597,O
with,597,O
increased,597,O
rates,597,O
of,597,O
anxiety,597,B-DiseaseOrPhenotypicFeature
.,597,O
The,598,O
adenosine,598,B-GeneOrGeneProduct
A,598,I-GeneOrGeneProduct
(,598,I-GeneOrGeneProduct
2A,598,I-GeneOrGeneProduct
),598,I-GeneOrGeneProduct
receptor,598,I-GeneOrGeneProduct
gene,598,O
(,598,O
ADORA2A,598,B-GeneOrGeneProduct
),598,O
is,598,O
associated,598,O
with,598,O
panic,598,B-DiseaseOrPhenotypicFeature
disorder,598,I-DiseaseOrPhenotypicFeature
and,598,O
is,598,O
located,598,O
on,598,O
chromosome,598,O
22q11.23,598,O
.,598,O
Its,599,O
gene,599,O
product,599,O
",",599,O
the,599,O
adenosine,599,B-GeneOrGeneProduct
A,599,I-GeneOrGeneProduct
(,599,I-GeneOrGeneProduct
2A,599,I-GeneOrGeneProduct
),599,I-GeneOrGeneProduct
receptor,599,I-GeneOrGeneProduct
",",599,O
is,599,O
strongly,599,O
expressed,599,O
in,599,O
the,599,O
caudate,599,O
nucleus,599,O
",",599,O
which,599,O
also,599,O
is,599,O
involved,599,O
in,599,O
ASD,599,B-DiseaseOrPhenotypicFeature
.,599,O
As,600,O
autistic,600,B-DiseaseOrPhenotypicFeature
symptoms,600,I-DiseaseOrPhenotypicFeature
are,600,O
increased,600,O
in,600,O
individuals,600,O
with,600,O
22q11.2,600,B-DiseaseOrPhenotypicFeature
deletion,600,I-DiseaseOrPhenotypicFeature
syndrome,600,I-DiseaseOrPhenotypicFeature
",",600,O
and,600,O
large,600,O
22q11.2,600,B-DiseaseOrPhenotypicFeature
deletions,600,I-DiseaseOrPhenotypicFeature
and,600,O
duplications,600,O
have,600,O
been,600,O
observed,600,O
in,600,O
ASD,600,B-DiseaseOrPhenotypicFeature
individuals,600,O
",",600,O
in,600,O
this,600,O
study,600,O
",",600,O
98,600,O
individuals,600,O
with,600,O
ASD,600,B-DiseaseOrPhenotypicFeature
and,600,O
234,600,O
control,600,O
individuals,600,O
were,600,O
genotyped,600,O
for,600,O
eight,600,O
single-nucleotide,600,O
polymorphisms,600,O
in,600,O
ADORA2A,600,B-GeneOrGeneProduct
.,600,O
Nominal,601,O
association,601,O
with,601,O
the,601,O
disorder,601,O
was,601,O
observed,601,O
for,601,O
rs2236624-CC,601,B-SequenceVariant
",",601,O
and,601,O
phenotypic,601,O
variability,601,O
in,601,O
ASD,601,B-DiseaseOrPhenotypicFeature
symptoms,601,O
was,601,O
influenced,601,O
by,601,O
rs3761422,601,B-SequenceVariant
",",601,O
rs5751876,601,B-SequenceVariant
and,601,O
rs35320474,601,B-SequenceVariant
.,601,O
In,602,O
addition,602,O
",",602,O
association,602,O
of,602,O
ADORA2A,602,B-GeneOrGeneProduct
variants,602,O
with,602,O
anxiety,602,B-DiseaseOrPhenotypicFeature
was,602,O
replicated,602,O
for,602,O
individuals,602,O
with,602,O
ASD,602,B-DiseaseOrPhenotypicFeature
.,602,O
Findings,603,O
point,603,O
toward,603,O
a,603,O
possible,603,O
mediating,603,O
role,603,O
of,603,O
ADORA2A,603,B-GeneOrGeneProduct
variants,603,O
on,603,O
phenotypic,603,O
expression,603,O
in,603,O
ASD,603,B-DiseaseOrPhenotypicFeature
that,603,O
need,603,O
to,603,O
be,603,O
replicated,603,O
in,603,O
a,603,O
larger,603,O
sample,603,O
.,603,O
Bilateral,604,O
haemorrhagic,604,B-DiseaseOrPhenotypicFeature
infarction,604,I-DiseaseOrPhenotypicFeature
of,604,I-DiseaseOrPhenotypicFeature
the,604,I-DiseaseOrPhenotypicFeature
globus,604,I-DiseaseOrPhenotypicFeature
pallidus,604,I-DiseaseOrPhenotypicFeature
after,604,O
cocaine,604,B-ChemicalEntity
and,604,O
alcohol,604,B-ChemicalEntity
intoxication,604,O
.,604,O
Cocaine,605,B-ChemicalEntity
is,605,O
a,605,O
risk,605,O
factor,605,O
for,605,O
both,605,O
ischemic,605,B-DiseaseOrPhenotypicFeature
and,605,I-DiseaseOrPhenotypicFeature
haemorrhagic,605,I-DiseaseOrPhenotypicFeature
stroke,605,I-DiseaseOrPhenotypicFeature
.,605,O
We,606,O
present,606,O
the,606,O
case,606,O
of,606,O
a,606,O
31-year-old,606,O
man,606,B-OrganismTaxon
with,606,O
bilateral,606,O
ischemia,606,B-DiseaseOrPhenotypicFeature
of,606,I-DiseaseOrPhenotypicFeature
the,606,I-DiseaseOrPhenotypicFeature
globus,606,I-DiseaseOrPhenotypicFeature
pallidus,606,I-DiseaseOrPhenotypicFeature
after,606,O
excessive,606,O
alcohol,606,B-ChemicalEntity
and,606,O
intranasal,606,O
cocaine,606,B-ChemicalEntity
use,606,O
.,606,O
Drug-related,607,O
globus,607,B-DiseaseOrPhenotypicFeature
pallidus,607,I-DiseaseOrPhenotypicFeature
infarctions,607,I-DiseaseOrPhenotypicFeature
are,607,O
most,607,O
often,607,O
associated,607,O
with,607,O
heroin,607,B-ChemicalEntity
.,607,O
Bilateral,608,O
basal,608,B-DiseaseOrPhenotypicFeature
ganglia,608,I-DiseaseOrPhenotypicFeature
infarcts,608,I-DiseaseOrPhenotypicFeature
after,608,O
the,608,O
use,608,O
of,608,O
cocaine,608,B-ChemicalEntity
",",608,O
without,608,O
concurrent,608,O
heroin,608,B-ChemicalEntity
use,608,O
",",608,O
have,608,O
never,608,O
been,608,O
reported,608,O
.,608,O
In,609,O
our,609,O
patient,609,B-OrganismTaxon
",",609,O
transient,609,O
cardiac,609,B-DiseaseOrPhenotypicFeature
arrhythmia,609,I-DiseaseOrPhenotypicFeature
or,609,O
respiratory,609,B-DiseaseOrPhenotypicFeature
dysfunction,609,I-DiseaseOrPhenotypicFeature
related,609,O
to,609,O
cocaine,609,B-ChemicalEntity
and/or,609,O
ethanol,609,B-ChemicalEntity
use,609,O
were,609,O
the,609,O
most,609,O
likely,609,O
causes,609,O
of,609,O
cerebral,609,B-DiseaseOrPhenotypicFeature
hypoperfusion,609,I-DiseaseOrPhenotypicFeature
.,609,O
Vitamin,610,B-GeneOrGeneProduct
D,610,I-GeneOrGeneProduct
receptor,610,I-GeneOrGeneProduct
expression,610,O
is,610,O
associated,610,O
with,610,O
PIK3CA,610,B-GeneOrGeneProduct
and,610,O
KRAS,610,B-GeneOrGeneProduct
mutations,610,O
in,610,O
colorectal,610,B-DiseaseOrPhenotypicFeature
cancer,610,I-DiseaseOrPhenotypicFeature
.,610,O
Vitamin,611,B-ChemicalEntity
D,611,I-ChemicalEntity
is,611,O
associated,611,O
with,611,O
decreased,611,O
risks,611,O
of,611,O
various,611,O
cancers,611,B-DiseaseOrPhenotypicFeature
",",611,O
including,611,O
colon,611,B-DiseaseOrPhenotypicFeature
cancer,611,I-DiseaseOrPhenotypicFeature
.,611,O
The,612,O
vitamin,612,B-GeneOrGeneProduct
D,612,I-GeneOrGeneProduct
receptor,612,I-GeneOrGeneProduct
(,612,O
VDR,612,B-GeneOrGeneProduct
),612,O
is,612,O
a,612,O
transcription,612,O
factor,612,O
",",612,O
which,612,O
plays,612,O
an,612,O
important,612,O
role,612,O
in,612,O
cellular,612,O
differentiation,612,O
and,612,O
inhibition,612,O
of,612,O
proliferation,612,O
.,612,O
A,613,O
link,613,O
between,613,O
VDR,613,B-GeneOrGeneProduct
and,613,O
the,613,O
RAS-mitogen-activated,613,B-GeneOrGeneProduct
protein,613,I-GeneOrGeneProduct
kinase,613,I-GeneOrGeneProduct
(,613,O
MAPK,613,B-GeneOrGeneProduct
),613,O
or,613,O
phosphatidylinositol,613,B-GeneOrGeneProduct
3-kinase,613,I-GeneOrGeneProduct
(,613,O
PI3K,613,B-GeneOrGeneProduct
),613,O
-AKT,613,O
pathway,613,O
has,613,O
been,613,O
suggested,613,O
.,613,O
However,614,O
",",614,O
the,614,O
prognostic,614,O
role,614,O
of,614,O
VDR,614,B-GeneOrGeneProduct
expression,614,O
or,614,O
its,614,O
relationship,614,O
with,614,O
PIK3CA,614,B-GeneOrGeneProduct
or,614,O
KRAS,614,B-GeneOrGeneProduct
mutation,614,O
remains,614,O
uncertain,614,O
.,614,O
Among,615,O
619,615,O
colorectal,615,B-DiseaseOrPhenotypicFeature
cancers,615,I-DiseaseOrPhenotypicFeature
in,615,O
two,615,O
prospective,615,O
cohort,615,O
studies,615,O
",",615,O
233,615,O
(,615,O
38,615,O
%,615,O
),615,O
tumors,615,B-DiseaseOrPhenotypicFeature
showed,615,O
VDR,615,B-GeneOrGeneProduct
overexpression,615,O
by,615,O
immunohistochemistry,615,O
.,615,O
We,616,O
analyzed,616,O
for,616,O
PIK3CA,616,B-GeneOrGeneProduct
and,616,O
KRAS,616,B-GeneOrGeneProduct
mutations,616,O
and,616,O
LINE-1,616,O
methylation,616,O
by,616,O
Pyrosequencing,616,O
",",616,O
microsatellite,616,O
instability,616,O
(,616,O
MSI,616,O
),616,O
",",616,O
and,616,O
DNA,616,O
methylation,616,O
(,616,O
epigenetic,616,O
changes,616,O
),616,O
in,616,O
eight,616,O
CpG,616,O
island,616,O
methylator,616,O
phenotype,616,O
(,616,O
CIMP,616,O
),616,O
-specific,616,O
promoters,616,O
[,616,O
CACNA1G,616,B-GeneOrGeneProduct
",",616,O
CDKN2A,616,B-GeneOrGeneProduct
(,616,O
p16,616,B-GeneOrGeneProduct
),616,O
",",616,O
CRABP1,616,B-GeneOrGeneProduct
",",616,O
IGF2,616,B-GeneOrGeneProduct
",",616,O
MLH1,616,B-GeneOrGeneProduct
",",616,O
NEUROG1,616,B-GeneOrGeneProduct
",",616,O
RUNX3,616,B-GeneOrGeneProduct
",",616,O
and,616,O
SOCS1,616,B-GeneOrGeneProduct
],616,O
by,616,O
MethyLight,616,O
(,616,O
real-time,616,O
PCR,616,O
),616,O
.,616,O
VDR,617,B-GeneOrGeneProduct
overexpression,617,O
was,617,O
significantly,617,O
associated,617,O
with,617,O
KRAS,617,B-GeneOrGeneProduct
mutation,617,O
(,617,O
odds,617,O
ratio,617,O
",",617,O
1.55,617,O
;,617,O
95,617,O
%,617,O
confidence,617,O
interval,617,O
",",617,O
1.11-2.16,617,O
),617,O
and,617,O
PIK3CA,617,B-GeneOrGeneProduct
mutation,617,O
(,617,O
odds,617,O
ratio,617,O
",",617,O
2.17,617,O
;,617,O
95,617,O
%,617,O
confidence,617,O
interval,617,O
",",617,O
1.36-3.47,617,O
),617,O
",",617,O
both,617,O
of,617,O
which,617,O
persisted,617,O
in,617,O
multivariate,617,O
logistic,617,O
regression,617,O
analysis,617,O
.,617,O
VDR,618,B-GeneOrGeneProduct
was,618,O
not,618,O
independently,618,O
associated,618,O
with,618,O
body,618,O
mass,618,O
index,618,O
",",618,O
family,618,O
history,618,O
of,618,O
colorectal,618,B-DiseaseOrPhenotypicFeature
cancer,618,I-DiseaseOrPhenotypicFeature
",",618,O
tumor,618,B-DiseaseOrPhenotypicFeature
location,618,O
(,618,O
colon,618,O
versus,618,O
rectum,618,O
),618,O
",",618,O
stage,618,O
",",618,O
tumor,618,B-DiseaseOrPhenotypicFeature
grade,618,O
",",618,O
signet,618,O
ring,618,O
cells,618,O
",",618,O
CIMP,618,O
",",618,O
MSI,618,O
",",618,O
LINE-1,618,O
hypomethylation,618,O
",",618,O
BRAF,618,B-GeneOrGeneProduct
",",618,O
p53,618,B-GeneOrGeneProduct
",",618,O
p21,618,B-GeneOrGeneProduct
",",618,O
beta-catenin,618,B-GeneOrGeneProduct
",",618,O
or,618,O
cyclooxygenase-2,618,B-GeneOrGeneProduct
.,618,O
VDR,619,B-GeneOrGeneProduct
expression,619,O
was,619,O
not,619,O
significantly,619,O
related,619,O
with,619,O
patient,619,B-OrganismTaxon
survival,619,O
",",619,O
prognosis,619,O
",",619,O
or,619,O
clinical,619,O
outcome,619,O
.,619,O
In,620,O
conclusion,620,O
",",620,O
VDR,620,B-GeneOrGeneProduct
overexpression,620,O
in,620,O
colorectal,620,B-DiseaseOrPhenotypicFeature
cancer,620,I-DiseaseOrPhenotypicFeature
is,620,O
independently,620,O
associated,620,O
with,620,O
PIK3CA,620,B-GeneOrGeneProduct
and,620,O
KRAS,620,B-GeneOrGeneProduct
mutations,620,O
.,620,O
Our,621,O
data,621,O
support,621,O
potential,621,O
interactions,621,O
between,621,O
the,621,O
VDR,621,B-GeneOrGeneProduct
",",621,O
RAS-MAPK,621,B-GeneOrGeneProduct
and,621,O
PI3K-AKT,621,B-GeneOrGeneProduct
pathways,621,O
",",621,O
and,621,O
possible,621,O
influence,621,O
by,621,O
KRAS,621,B-GeneOrGeneProduct
or,621,O
PIK3CA,621,B-GeneOrGeneProduct
mutation,621,O
on,621,O
therapy,621,O
or,621,O
chemoprevention,621,O
targeting,621,O
VDR,621,B-GeneOrGeneProduct
.,621,O
Phenylephrine,622,B-ChemicalEntity
but,622,O
not,622,O
ephedrine,622,B-ChemicalEntity
reduces,622,O
frontal,622,O
lobe,622,O
oxygenation,622,O
following,622,O
anesthesia-induced,622,O
hypotension,622,B-DiseaseOrPhenotypicFeature
.,622,O
BACKGROUND,623,O
:,623,O
Vasopressor,623,O
agents,623,O
are,623,O
used,623,O
to,623,O
correct,623,O
anesthesia-induced,623,O
hypotension,623,B-DiseaseOrPhenotypicFeature
.,623,O
We,624,O
describe,624,O
the,624,O
effect,624,O
of,624,O
phenylephrine,624,B-ChemicalEntity
and,624,O
ephedrine,624,B-ChemicalEntity
on,624,O
frontal,624,O
lobe,624,O
oxygenation,624,O
(,624,O
S,624,O
(,624,O
c,624,O
),624,O
O,624,O
(,624,O
2,624,O
),624,O
),624,O
following,624,O
anesthesia-induced,624,O
hypotension,624,B-DiseaseOrPhenotypicFeature
.,624,O
METHODS,625,O
:,625,O
Following,625,O
induction,625,O
of,625,O
anesthesia,625,O
by,625,O
fentanyl,625,B-ChemicalEntity
(,625,O
0.15,625,O
mg,625,O
kg,625,O
(,625,O
-1,625,O
),625,O
),625,O
and,625,O
propofol,625,B-ChemicalEntity
(,625,O
2.0,625,O
mg,625,O
kg,625,O
(,625,O
-1,625,O
),625,O
),625,O
",",625,O
13,625,O
patients,625,B-OrganismTaxon
received,625,O
phenylephrine,625,B-ChemicalEntity
(,625,O
0.1,625,O
mg,625,O
iv,625,O
),625,O
and,625,O
12,625,O
patients,625,B-OrganismTaxon
received,625,O
ephedrine,625,B-ChemicalEntity
(,625,O
10,625,O
mg,625,O
iv,625,O
),625,O
to,625,O
restore,625,O
mean,625,O
arterial,625,O
pressure,625,O
(,625,O
MAP,625,O
),625,O
.,625,O
Heart,626,O
rate,626,O
(,626,O
HR,626,O
),626,O
",",626,O
MAP,626,O
",",626,O
stroke,626,B-DiseaseOrPhenotypicFeature
volume,626,O
(,626,O
SV,626,O
),626,O
",",626,O
cardiac,626,O
output,626,O
(,626,O
CO,626,O
),626,O
",",626,O
and,626,O
frontal,626,O
lobe,626,O
oxygenation,626,O
(,626,O
S,626,O
(,626,O
c,626,O
),626,O
O,626,O
(,626,O
2,626,O
),626,O
),626,O
were,626,O
registered,626,O
.,626,O
RESULTS,627,O
:,627,O
Induction,627,O
of,627,O
anesthesia,627,O
was,627,O
followed,627,O
by,627,O
a,627,O
decrease,627,O
in,627,O
MAP,627,O
",",627,O
HR,627,O
",",627,O
SV,627,O
",",627,O
and,627,O
CO,627,O
concomitant,627,O
with,627,O
an,627,O
elevation,627,O
in,627,O
S,627,O
(,627,O
c,627,O
),627,O
O,627,O
(,627,O
2,627,O
),627,O
.,627,O
After,628,O
administration,628,O
of,628,O
phenylephrine,628,B-ChemicalEntity
",",628,O
MAP,628,O
increased,628,O
(,628,O
51,628,O
+/-,628,O
12,628,O
to,628,O
81,628,O
+/-,628,O
13,628,O
mmHg,628,O
;,628,O
P,628,O
<,628,O
0.001,628,O
;,628,O
mean,628,O
+/-,628,O
SD,628,O
),628,O
.,628,O
However,629,O
",",629,O
a,629,O
14,629,O
%,629,O
(,629,O
from,629,O
70,629,O
+/-,629,O
8,629,O
%,629,O
to,629,O
60,629,O
+/-,629,O
7,629,O
%,629,O
),629,O
reduction,629,O
in,629,O
S,629,O
(,629,O
c,629,O
),629,O
O,629,O
(,629,O
2,629,O
),629,O
(,629,O
P,629,O
<,629,O
0.05,629,O
),629,O
followed,629,O
with,629,O
no,629,O
change,629,O
in,629,O
CO,629,O
(,629,O
3.7,629,O
+/-,629,O
1.1,629,O
to,629,O
3.4,629,O
+/-,629,O
0.9,629,O
l,629,O
min,629,O
(,629,O
-1,629,O
),629,O
),629,O
.,629,O
The,630,O
administration,630,O
of,630,O
ephedrine,630,B-ChemicalEntity
led,630,O
to,630,O
a,630,O
similar,630,O
increase,630,O
in,630,O
MAP,630,O
(,630,O
53,630,O
+/-,630,O
9,630,O
to,630,O
79,630,O
+/-,630,O
8,630,O
mmHg,630,O
;,630,O
P,630,O
<,630,O
0.001,630,O
),630,O
",",630,O
restored,630,O
CO,630,O
(,630,O
3.2,630,O
+/-,630,O
1.2,630,O
to,630,O
5.0,630,O
+/-,630,O
1.3,630,O
l,630,O
min,630,O
(,630,O
-1,630,O
),630,O
),630,O
",",630,O
and,630,O
preserved,630,O
S,630,O
(,630,O
c,630,O
),630,O
O,630,O
(,630,O
2,630,O
),630,O
.,630,O
CONCLUSIONS,631,O
:,631,O
The,631,O
utilization,631,O
of,631,O
phenylephrine,631,B-ChemicalEntity
to,631,O
correct,631,O
hypotension,631,B-DiseaseOrPhenotypicFeature
induced,631,O
by,631,O
anesthesia,631,O
has,631,O
a,631,O
negative,631,O
impact,631,O
on,631,O
S,631,O
(,631,O
c,631,O
),631,O
O,631,O
(,631,O
2,631,O
),631,O
while,631,O
ephedrine,631,B-ChemicalEntity
maintains,631,O
frontal,631,O
lobe,631,O
oxygenation,631,O
potentially,631,O
related,631,O
to,631,O
an,631,O
increase,631,O
in,631,O
CO,631,O
.,631,O
Two,632,O
novel,632,O
mutations,632,O
of,632,O
the,632,O
TSH-beta,632,B-GeneOrGeneProduct
subunit,632,O
gene,632,O
underlying,632,O
congenital,632,B-DiseaseOrPhenotypicFeature
central,632,I-DiseaseOrPhenotypicFeature
hypothyroidism,632,I-DiseaseOrPhenotypicFeature
undetectable,632,O
in,632,O
neonatal,632,O
TSH,632,B-GeneOrGeneProduct
screening,632,O
.,632,O
CONTEXT,633,O
:,633,O
Patients,633,B-OrganismTaxon
with,633,O
TSH-beta,633,B-GeneOrGeneProduct
subunit,633,O
defects,633,O
and,633,O
congenital,633,B-DiseaseOrPhenotypicFeature
hypothyroidism,633,I-DiseaseOrPhenotypicFeature
are,633,O
missed,633,O
by,633,O
TSH-based,633,B-GeneOrGeneProduct
neonatal,633,O
screening,633,O
.,633,O
OBJECTIVE,634,O
:,634,O
Our,634,O
objective,634,O
was,634,O
to,634,O
report,634,O
the,634,O
molecular,634,O
consequences,634,O
of,634,O
a,634,O
novel,634,O
splice-junction,634,O
mutation,634,O
and,634,O
a,634,O
novel,634,O
missense,634,O
mutation,634,O
in,634,O
the,634,O
TSH-beta,634,B-GeneOrGeneProduct
subunit,634,O
gene,634,O
found,634,O
in,634,O
two,634,O
patients,634,B-OrganismTaxon
with,634,O
congenital,634,B-DiseaseOrPhenotypicFeature
central,634,I-DiseaseOrPhenotypicFeature
hypothyroidism,634,I-DiseaseOrPhenotypicFeature
and,634,O
conventional,634,O
treatment-resistant,634,O
anemia,634,B-DiseaseOrPhenotypicFeature
.,634,O
RESULTS,635,O
:,635,O
Patient,635,B-OrganismTaxon
1,635,O
had,635,O
a,635,O
homozygous,635,O
G,635,B-SequenceVariant
to,635,I-SequenceVariant
A,635,I-SequenceVariant
nucleotide,635,O
change,635,O
at,635,O
the,635,O
5,635,O
',635,O
donor,635,O
splice,635,O
site,635,O
of,635,O
exon/intron,635,O
2,635,O
.,635,O
This,636,O
resulted,636,O
in,636,O
a,636,O
silent,636,O
change,636,O
at,636,O
codon,636,O
34,636,O
of,636,O
the,636,O
mature,636,O
protein,636,O
.,636,O
In,637,O
vitro,637,O
splicing,637,O
assays,637,O
showed,637,O
that,637,O
the,637,O
mutant,637,O
minigene,637,O
dramatically,637,O
affected,637,O
pre-mRNA,637,O
processing,637,O
",",637,O
causing,637,O
exon,637,O
2,637,O
to,637,O
be,637,O
completely,637,O
skipped,637,O
.,637,O
The,638,O
putative,638,O
product,638,O
from,638,O
a,638,O
new,638,O
out-of-frame,638,O
translational,638,O
start,638,O
point,638,O
in,638,O
exon,638,O
3,638,O
is,638,O
expected,638,O
to,638,O
yield,638,O
a,638,O
nonsense,638,O
25-amino-acid,638,O
peptide,638,O
.,638,O
In,639,O
patient,639,B-OrganismTaxon
2,639,O
",",639,O
sequence,639,O
analysis,639,O
revealed,639,O
a,639,O
compound,639,O
heterozygosis,639,O
for,639,O
the,639,O
already,639,O
reported,639,O
313delT,639,B-SequenceVariant
(,639,O
C105Vfs114X,639,B-SequenceVariant
),639,O
mutation,639,O
and,639,O
for,639,O
a,639,O
second,639,O
novel,639,O
mutation,639,O
in,639,O
exon,639,O
3,639,O
",",639,O
substituting,639,O
G,639,B-SequenceVariant
for,639,I-SequenceVariant
A,639,I-SequenceVariant
at,639,I-SequenceVariant
cDNA,639,I-SequenceVariant
nucleotide,639,I-SequenceVariant
position,639,I-SequenceVariant
323,639,I-SequenceVariant
",",639,O
resulting,639,O
in,639,O
a,639,O
C88Y,639,B-SequenceVariant
change,639,O
.,639,O
This,640,O
cysteine,640,O
residue,640,O
is,640,O
conserved,640,O
among,640,O
all,640,O
dimeric,640,O
pituitary,640,O
and,640,O
placental,640,O
glycoprotein,640,B-GeneOrGeneProduct
hormone-beta,640,I-GeneOrGeneProduct
subunits,640,I-GeneOrGeneProduct
.,640,O
Data,641,O
from,641,O
in,641,O
silico,641,O
analysis,641,O
confirmed,641,O
that,641,O
the,641,O
C88Y,641,B-SequenceVariant
mutation,641,O
would,641,O
affect,641,O
subunit,641,O
conformation,641,O
.,641,O
Indeed,642,O
",",642,O
two,642,O
different,642,O
bioinformatics,642,O
approaches,642,O
",",642,O
PolyPhen,642,O
and,642,O
SIFT,642,O
analysis,642,O
",",642,O
predicted,642,O
C88Y,642,B-SequenceVariant
to,642,O
be,642,O
a,642,O
damaging,642,O
substitution,642,O
.,642,O
CONCLUSIONS,643,O
:,643,O
In,643,O
isolated,643,O
TSH,643,B-DiseaseOrPhenotypicFeature
deficiency,643,I-DiseaseOrPhenotypicFeature
",",643,O
the,643,O
exact,643,O
molecular,643,O
diagnosis,643,O
is,643,O
mandatory,643,O
for,643,O
diagnosis,643,O
of,643,O
isolated,643,B-DiseaseOrPhenotypicFeature
pituitary,643,I-DiseaseOrPhenotypicFeature
deficiency,643,I-DiseaseOrPhenotypicFeature
",",643,O
delineation,643,O
of,643,O
prognosis,643,O
",",643,O
and,643,O
genetic,643,O
counseling,643,O
.,643,O
Moreover,644,O
",",644,O
diagnosis,644,O
of,644,O
central,644,B-DiseaseOrPhenotypicFeature
hypothyroidism,644,I-DiseaseOrPhenotypicFeature
should,644,O
be,644,O
considered,644,O
in,644,O
the,644,O
face,644,O
of,644,O
severe,644,O
infant,644,O
anemia,644,B-DiseaseOrPhenotypicFeature
of,644,O
uncertain,644,O
etiology,644,O
.,644,O
High,645,O
frequency,645,O
of,645,O
lamivudine,645,B-ChemicalEntity
resistance,645,O
mutations,645,O
in,645,O
Brazilian,645,O
patients,645,B-OrganismTaxon
co-infected,645,B-DiseaseOrPhenotypicFeature
with,645,I-DiseaseOrPhenotypicFeature
HIV,645,I-DiseaseOrPhenotypicFeature
and,645,I-DiseaseOrPhenotypicFeature
hepatitis,645,I-DiseaseOrPhenotypicFeature
B,645,I-DiseaseOrPhenotypicFeature
.,645,O
This,646,O
study,646,O
analyzed,646,O
the,646,O
genotype,646,O
distribution,646,O
and,646,O
frequency,646,O
of,646,O
lamivudine,646,B-ChemicalEntity
(,646,O
LAM,646,B-ChemicalEntity
),646,O
and,646,O
tenofovir,646,B-ChemicalEntity
(,646,O
TDF,646,B-ChemicalEntity
),646,O
resistance,646,O
mutations,646,O
in,646,O
a,646,O
group,646,O
of,646,O
patients,646,B-OrganismTaxon
co-infected,646,B-DiseaseOrPhenotypicFeature
with,646,I-DiseaseOrPhenotypicFeature
HIV,646,I-DiseaseOrPhenotypicFeature
and,646,I-DiseaseOrPhenotypicFeature
hepatitis,646,I-DiseaseOrPhenotypicFeature
B,646,I-DiseaseOrPhenotypicFeature
virus,646,I-DiseaseOrPhenotypicFeature
(,646,O
HBV,646,B-OrganismTaxon
),646,O
.,646,O
A,647,O
cross-sectional,647,O
study,647,O
of,647,O
847,647,O
patients,647,B-OrganismTaxon
with,647,O
HIV,647,B-OrganismTaxon
was,647,O
conducted,647,O
.,647,O
Patients,648,B-OrganismTaxon
provided,648,O
blood,648,O
samples,648,O
for,648,O
HBsAg,648,B-ChemicalEntity
detection,648,O
.,648,O
The,649,O
load,649,O
of,649,O
HBV,649,B-OrganismTaxon
was,649,O
determined,649,O
using,649,O
an,649,O
``,649,O
in-house,649,O
'',649,O
real-time,649,O
polymerase,649,O
chain,649,O
reaction,649,O
.,649,O
HBV,650,B-OrganismTaxon
genotypes/subgenotypes,650,O
",",650,O
antiviral,650,O
resistance,650,O
",",650,O
basal,650,O
core,650,O
promoter,650,O
(,650,O
BCP,650,O
),650,O
",",650,O
and,650,O
precore,650,B-GeneOrGeneProduct
mutations,650,O
were,650,O
detected,650,O
by,650,O
DNA,650,O
sequencing,650,O
.,650,O
Twenty-eight,651,O
patients,651,B-OrganismTaxon
with,651,O
co-infection,651,O
were,651,O
identified,651,O
.,651,O
The,652,O
distribution,652,O
of,652,O
HBV,652,B-OrganismTaxon
genotypes,652,O
among,652,O
these,652,O
patients,652,B-OrganismTaxon
was,652,O
A,652,O
(,652,O
n,652,O
=,652,O
9,652,O
;,652,O
50,652,O
%,652,O
),652,O
",",652,O
D,652,O
(,652,O
n,652,O
=,652,O
4,652,O
;,652,O
22.2,652,O
%,652,O
),652,O
",",652,O
G,652,O
(,652,O
n,652,O
=,652,O
3,652,O
;,652,O
16.7,652,O
%,652,O
),652,O
",",652,O
and,652,O
F,652,O
(,652,O
n,652,O
=,652,O
2,652,O
;,652,O
11.1,652,O
%,652,O
),652,O
.,652,O
Eighteen,653,O
patients,653,B-OrganismTaxon
were,653,O
treated,653,O
with,653,O
LAM,653,B-ChemicalEntity
and,653,O
six,653,O
patients,653,B-OrganismTaxon
were,653,O
treated,653,O
with,653,O
LAM,653,B-ChemicalEntity
plus,653,O
TDF,653,B-ChemicalEntity
.,653,O
The,654,O
length,654,O
of,654,O
exposure,654,O
to,654,O
LAM,654,B-ChemicalEntity
and,654,O
TDF,654,B-ChemicalEntity
varied,654,O
from,654,O
4,654,O
to,654,O
216,654,O
months,654,O
.,654,O
LAM,655,B-ChemicalEntity
resistance,655,O
substitutions,655,O
(,655,O
rtL180M,655,O
+,655,O
rtM204V,655,O
),655,O
were,655,O
detected,655,O
in,655,O
10,655,O
(,655,O
50,655,O
%,655,O
),655,O
of,655,O
the,655,O
20,655,O
patients,655,B-OrganismTaxon
with,655,O
viremia,655,B-DiseaseOrPhenotypicFeature
.,655,O
This,656,O
pattern,656,O
and,656,O
an,656,O
accompanying,656,O
rtV173L,656,O
mutation,656,O
was,656,O
found,656,O
in,656,O
four,656,O
patients,656,B-OrganismTaxon
.,656,O
Three,657,O
patients,657,B-OrganismTaxon
with,657,O
the,657,O
triple,657,O
polymerase,657,B-GeneOrGeneProduct
substitution,657,O
pattern,657,O
(,657,O
rtV173L,657,O
+,657,O
rtL180M,657,O
+,657,O
rtM204V,657,O
),657,O
had,657,O
associated,657,O
changes,657,O
in,657,O
the,657,O
envelope,657,B-GeneOrGeneProduct
gene,657,O
(,657,O
sE164D,657,O
+,657,O
sI195M,657,O
),657,O
.,657,O
Mutations,658,O
in,658,O
the,658,O
BCP,658,O
region,658,O
(,658,O
A1762T,658,B-SequenceVariant
",",658,O
G1764A,658,B-SequenceVariant
),658,O
and,658,O
in,658,O
the,658,O
precore,658,B-GeneOrGeneProduct
region,658,O
(,658,O
G1896A,658,B-SequenceVariant
",",658,O
G1899A,658,B-SequenceVariant
),658,O
were,658,O
also,658,O
found,658,O
.,658,O
No,659,O
putative,659,O
TDF,659,B-ChemicalEntity
resistance,659,O
substitution,659,O
was,659,O
detected,659,O
.,659,O
The,660,O
data,660,O
suggest,660,O
that,660,O
prolonged,660,O
LAM,660,B-ChemicalEntity
use,660,O
is,660,O
associated,660,O
with,660,O
the,660,O
emergence,660,O
of,660,O
particular,660,O
changes,660,O
in,660,O
the,660,O
HBV,660,B-OrganismTaxon
genome,660,O
",",660,O
including,660,O
substitutions,660,O
that,660,O
may,660,O
elicit,660,O
a,660,O
vaccine,660,O
escape,660,O
phenotype,660,O
.,660,O
No,661,O
putative,661,O
TDF,661,B-ChemicalEntity
resistance,661,O
change,661,O
was,661,O
detected,661,O
after,661,O
prolonged,661,O
use,661,O
of,661,O
TDF,661,B-ChemicalEntity
.,661,O
Serotonin,662,B-GeneOrGeneProduct
6,662,I-GeneOrGeneProduct
receptor,662,I-GeneOrGeneProduct
gene,662,O
is,662,O
associated,662,O
with,662,O
methamphetamine-induced,662,B-ChemicalEntity
psychosis,662,B-DiseaseOrPhenotypicFeature
in,662,O
a,662,O
Japanese,662,O
population,662,O
.,662,O
BACKGROUND,663,O
:,663,O
Altered,663,O
serotonergic,663,O
neural,663,O
transmission,663,O
is,663,O
hypothesized,663,O
to,663,O
be,663,O
a,663,O
susceptibility,663,O
factor,663,O
for,663,O
psychotic,663,B-DiseaseOrPhenotypicFeature
disorders,663,I-DiseaseOrPhenotypicFeature
such,663,O
as,663,O
schizophrenia,663,B-DiseaseOrPhenotypicFeature
.,663,O
The,664,O
serotonin,664,B-GeneOrGeneProduct
6,664,I-GeneOrGeneProduct
(,664,I-GeneOrGeneProduct
5-HT6,664,I-GeneOrGeneProduct
),664,I-GeneOrGeneProduct
receptor,664,I-GeneOrGeneProduct
is,664,O
therapeutically,664,O
targeted,664,O
by,664,O
several,664,O
second,664,O
generation,664,O
antipsychotics,664,B-ChemicalEntity
",",664,O
such,664,O
as,664,O
clozapine,664,B-ChemicalEntity
and,664,O
olanzapine,664,B-ChemicalEntity
",",664,O
and,664,O
d-amphetamine-induced,664,B-ChemicalEntity
hyperactivity,664,B-DiseaseOrPhenotypicFeature
in,664,O
rats,664,B-OrganismTaxon
is,664,O
corrected,664,O
with,664,O
the,664,O
use,664,O
of,664,O
a,664,O
selective,664,O
5-HT6,664,B-ChemicalEntity
receptor,664,I-ChemicalEntity
antagonist,664,I-ChemicalEntity
.,664,O
In,665,O
addition,665,O
",",665,O
the,665,O
disrupted,665,O
prepulse,665,O
inhibition,665,O
induced,665,O
by,665,O
d-amphetamine,665,B-ChemicalEntity
or,665,O
phencyclidine,665,B-ChemicalEntity
was,665,O
restored,665,O
by,665,O
5-HT6,665,B-ChemicalEntity
receptor,665,I-ChemicalEntity
antagonist,665,I-ChemicalEntity
in,665,O
an,665,O
animal,665,O
study,665,O
using,665,O
rats,665,B-OrganismTaxon
.,665,O
These,666,O
animal,666,O
models,666,O
were,666,O
considered,666,O
to,666,O
reflect,666,O
the,666,O
positive,666,O
symptoms,666,O
of,666,O
schizophrenia,666,B-DiseaseOrPhenotypicFeature
",",666,O
and,666,O
the,666,O
above,666,O
evidence,666,O
suggests,666,O
that,666,O
altered,666,O
5-HT6,666,B-GeneOrGeneProduct
receptors,666,I-GeneOrGeneProduct
are,666,O
involved,666,O
in,666,O
the,666,O
pathophysiology,666,O
of,666,O
psychotic,666,B-DiseaseOrPhenotypicFeature
disorders,666,I-DiseaseOrPhenotypicFeature
.,666,O
The,667,O
symptoms,667,O
of,667,O
methamphetamine,667,B-ChemicalEntity
(,667,O
METH,667,B-ChemicalEntity
),667,O
-induced,667,O
psychosis,667,B-DiseaseOrPhenotypicFeature
are,667,O
similar,667,O
to,667,O
those,667,O
of,667,O
paranoid,667,B-DiseaseOrPhenotypicFeature
type,667,I-DiseaseOrPhenotypicFeature
schizophrenia,667,I-DiseaseOrPhenotypicFeature
.,667,O
Therefore,668,O
",",668,O
we,668,O
conducted,668,O
an,668,O
analysis,668,O
of,668,O
the,668,O
association,668,O
of,668,O
the,668,O
5-HT6,668,B-GeneOrGeneProduct
gene,668,O
(,668,O
HTR6,668,B-GeneOrGeneProduct
),668,O
with,668,O
METH-induced,668,B-ChemicalEntity
psychosis,668,B-DiseaseOrPhenotypicFeature
.,668,O
METHOD,669,O
:,669,O
Using,669,O
five,669,O
tagging,669,O
SNPs,669,O
(,669,O
rs6693503,669,B-SequenceVariant
",",669,O
rs1805054,669,B-SequenceVariant
",",669,O
rs4912138,669,B-SequenceVariant
",",669,O
rs3790757,669,B-SequenceVariant
and,669,O
rs9659997,669,B-SequenceVariant
),669,O
",",669,O
we,669,O
conducted,669,O
a,669,O
genetic,669,O
association,669,O
analysis,669,O
of,669,O
case-control,669,O
samples,669,O
(,669,O
197,669,O
METH-induced,669,B-ChemicalEntity
psychosis,669,B-DiseaseOrPhenotypicFeature
patients,669,B-OrganismTaxon
and,669,O
337,669,O
controls,669,O
),669,O
in,669,O
the,669,O
Japanese,669,O
population,669,O
.,669,O
The,670,O
age,670,O
and,670,O
sex,670,O
of,670,O
the,670,O
control,670,O
subjects,670,O
did,670,O
not,670,O
differ,670,O
from,670,O
those,670,O
of,670,O
the,670,O
methamphetamine,670,B-ChemicalEntity
dependence,670,O
patients,670,B-OrganismTaxon
.,670,O
RESULTS,671,O
:,671,O
rs6693503,671,B-SequenceVariant
was,671,O
associated,671,O
with,671,O
METH-induced,671,B-ChemicalEntity
psychosis,671,B-DiseaseOrPhenotypicFeature
patients,671,B-OrganismTaxon
in,671,O
the,671,O
allele/genotype-wise,671,O
analysis,671,O
.,671,O
Moreover,672,O
",",672,O
this,672,O
association,672,O
remained,672,O
significant,672,O
after,672,O
Bonferroni,672,O
correction,672,O
.,672,O
In,673,O
the,673,O
haplotype-wise,673,O
analysis,673,O
",",673,O
we,673,O
detected,673,O
an,673,O
association,673,O
between,673,O
two,673,O
markers,673,O
(,673,O
rs6693503,673,B-SequenceVariant
and,673,O
rs1805054,673,B-SequenceVariant
),673,O
and,673,O
three,673,O
markers,673,O
(,673,O
rs6693503,673,B-SequenceVariant
",",673,O
rs1805054,673,B-SequenceVariant
and,673,O
rs4912138,673,B-SequenceVariant
),673,O
in,673,O
HTR6,673,B-GeneOrGeneProduct
and,673,O
METH-induced,673,B-ChemicalEntity
psychosis,673,B-DiseaseOrPhenotypicFeature
patients,673,B-OrganismTaxon
",",673,O
respectively,673,O
.,673,O
CONCLUSION,674,O
:,674,O
HTR6,674,B-GeneOrGeneProduct
may,674,O
play,674,O
an,674,O
important,674,O
role,674,O
in,674,O
the,674,O
pathophysiology,674,O
of,674,O
METH-induced,674,B-ChemicalEntity
psychosis,674,B-DiseaseOrPhenotypicFeature
in,674,O
the,674,O
Japanese,674,O
population,674,O
.,674,O
The,675,O
fibrinogen,675,B-GeneOrGeneProduct
gamma,675,I-GeneOrGeneProduct
10034C,675,B-SequenceVariant
>,675,I-SequenceVariant
T,675,I-SequenceVariant
polymorphism,675,O
is,675,O
not,675,O
associated,675,O
with,675,O
Peripheral,675,B-DiseaseOrPhenotypicFeature
Arterial,675,I-DiseaseOrPhenotypicFeature
Disease,675,I-DiseaseOrPhenotypicFeature
.,675,O
Conversion,676,O
of,676,O
fibrinogen,676,B-GeneOrGeneProduct
to,676,O
fibrin,676,B-GeneOrGeneProduct
plays,676,O
an,676,O
essential,676,O
role,676,O
in,676,O
hemostasis,676,O
and,676,O
results,676,O
in,676,O
stabilization,676,O
of,676,O
the,676,O
fibrin,676,B-GeneOrGeneProduct
clot,676,O
.,676,O
Fibrinogen,677,B-GeneOrGeneProduct
consists,677,O
of,677,O
three,677,O
pairs,677,O
of,677,O
non-identical,677,O
polypeptide,677,O
chains,677,O
",",677,O
encoded,677,O
by,677,O
different,677,O
genes,677,O
(,677,O
fibrinogen,677,B-GeneOrGeneProduct
alpha,677,I-GeneOrGeneProduct
[,677,O
FGA,677,B-GeneOrGeneProduct
],677,O
",",677,O
fibrinogen,677,B-GeneOrGeneProduct
beta,677,I-GeneOrGeneProduct
[,677,O
FGB,677,B-GeneOrGeneProduct
],677,O
and,677,O
fibrinogen,677,B-GeneOrGeneProduct
gamma,677,I-GeneOrGeneProduct
[,677,O
FGG,677,B-GeneOrGeneProduct
],677,O
),677,O
.,677,O
A,678,O
functional,678,O
single,678,O
nucleotide,678,O
polymorphism,678,O
(,678,O
SNP,678,O
),678,O
in,678,O
the,678,O
3,678,O
',678,O
untranslated,678,O
region,678,O
of,678,O
the,678,O
FGG,678,B-GeneOrGeneProduct
gene,678,O
(,678,O
FGG,678,B-GeneOrGeneProduct
10034C,678,B-SequenceVariant
>,678,I-SequenceVariant
T,678,I-SequenceVariant
",",678,O
rs2066865,678,B-SequenceVariant
),678,O
has,678,O
been,678,O
associated,678,O
with,678,O
deep,678,B-DiseaseOrPhenotypicFeature
venous,678,I-DiseaseOrPhenotypicFeature
thrombosis,678,I-DiseaseOrPhenotypicFeature
and,678,O
myocardial,678,B-DiseaseOrPhenotypicFeature
infarction,678,I-DiseaseOrPhenotypicFeature
.,678,O
Aim,679,O
of,679,O
the,679,O
present,679,O
study,679,O
was,679,O
to,679,O
analyze,679,O
the,679,O
role,679,O
of,679,O
this,679,O
polymorphism,679,O
in,679,O
peripheral,679,B-DiseaseOrPhenotypicFeature
arterial,679,I-DiseaseOrPhenotypicFeature
disease,679,I-DiseaseOrPhenotypicFeature
(,679,O
PAD,679,B-DiseaseOrPhenotypicFeature
),679,O
.,679,O
The,680,O
study,680,O
was,680,O
designed,680,O
as,680,O
case-control,680,O
study,680,O
including,680,O
891,680,O
patients,680,B-OrganismTaxon
with,680,O
documented,680,O
PAD,680,B-DiseaseOrPhenotypicFeature
and,680,O
777,680,O
control,680,O
subjects,680,O
.,680,O
FGG,681,B-GeneOrGeneProduct
genotypes,681,O
were,681,O
determined,681,O
by,681,O
exonuclease,681,O
(,681,O
TaqMan,681,O
),681,O
assays,681,O
.,681,O
FGG,682,B-GeneOrGeneProduct
genotype,682,O
frequencies,682,O
were,682,O
not,682,O
significantly,682,O
different,682,O
between,682,O
PAD,682,B-DiseaseOrPhenotypicFeature
patients,682,B-OrganismTaxon
(,682,O
CC,682,O
:,682,O
57.3,682,O
%,682,O
",",682,O
CT,682,O
:,682,O
36.7,682,O
%,682,O
",",682,O
TT,682,O
:,682,O
5.8,682,O
%,682,O
),682,O
and,682,O
control,682,O
subjects,682,O
(,682,O
CC,682,O
:,682,O
60.9,682,O
%,682,O
",",682,O
CT,682,O
:,682,O
33.5,682,O
%,682,O
",",682,O
TT,682,O
5.6,682,O
%,682,O
;,682,O
p=0.35,682,O
),682,O
.,682,O
In,683,O
a,683,O
multivariate,683,O
logistic,683,O
regression,683,O
analysis,683,O
including,683,O
age,683,O
",",683,O
sex,683,O
",",683,O
smoking,683,O
",",683,O
diabetes,683,B-DiseaseOrPhenotypicFeature
",",683,O
arterial,683,O
hypertension,683,B-DiseaseOrPhenotypicFeature
and,683,O
hypercholesterolemia,683,B-DiseaseOrPhenotypicFeature
",",683,O
the,683,O
FGG,683,B-GeneOrGeneProduct
10034,683,B-SequenceVariant
T,683,I-SequenceVariant
variant,683,O
was,683,O
not,683,O
significantly,683,O
associated,683,O
with,683,O
the,683,O
presence,683,O
of,683,O
PAD,683,B-DiseaseOrPhenotypicFeature
(,683,O
Odds,683,O
ratio,683,O
1.07,683,O
",",683,O
95,683,O
%,683,O
confidence,683,O
interval,683,O
0.84,683,O
-,683,O
1.37,683,O
;,683,O
p,683,O
=,683,O
0.60,683,O
),683,O
.,683,O
The,684,O
FGG,684,B-GeneOrGeneProduct
10034C,684,B-SequenceVariant
>,684,I-SequenceVariant
T,684,I-SequenceVariant
polymorphism,684,O
was,684,O
furthermore,684,O
not,684,O
associated,684,O
with,684,O
age,684,O
at,684,O
onset,684,O
of,684,O
PAD,684,B-DiseaseOrPhenotypicFeature
.,684,O
We,685,O
conclude,685,O
that,685,O
the,685,O
thrombophilic,685,O
FGG,685,B-GeneOrGeneProduct
10034,685,B-SequenceVariant
T,685,I-SequenceVariant
gene,685,O
variant,685,O
does,685,O
not,685,O
contribute,685,O
to,685,O
the,685,O
genetic,685,O
susceptibility,685,O
to,685,O
PAD,685,B-DiseaseOrPhenotypicFeature
.,685,O
A,686,O
Taiwanese,686,O
boy,686,O
with,686,O
congenital,686,B-DiseaseOrPhenotypicFeature
generalized,686,I-DiseaseOrPhenotypicFeature
lipodystrophy,686,I-DiseaseOrPhenotypicFeature
caused,686,O
by,686,O
homozygous,686,O
Ile262fs,686,B-SequenceVariant
mutation,686,O
in,686,O
the,686,O
BSCL2,686,B-GeneOrGeneProduct
gene,686,O
.,686,O
Congenital,687,B-DiseaseOrPhenotypicFeature
generalized,687,I-DiseaseOrPhenotypicFeature
lipodystrophy,687,I-DiseaseOrPhenotypicFeature
(,687,O
CGL,687,B-DiseaseOrPhenotypicFeature
),687,O
is,687,O
a,687,O
rare,687,O
autosomal,687,B-DiseaseOrPhenotypicFeature
recessive,687,I-DiseaseOrPhenotypicFeature
disease,687,I-DiseaseOrPhenotypicFeature
that,687,O
is,687,O
characterized,687,O
by,687,O
a,687,O
near-complete,687,O
absence,687,O
of,687,O
adipose,687,O
tissue,687,O
from,687,O
birth,687,O
or,687,O
early,687,O
infancy,687,O
.,687,O
Mutations,688,O
in,688,O
the,688,O
BSCL2,688,B-GeneOrGeneProduct
gene,688,O
are,688,O
known,688,O
to,688,O
result,688,O
in,688,O
CGL2,688,B-DiseaseOrPhenotypicFeature
",",688,O
a,688,O
more,688,O
severe,688,O
phenotype,688,O
than,688,O
CGL1,688,B-DiseaseOrPhenotypicFeature
",",688,O
with,688,O
earlier,688,O
onset,688,O
",",688,O
more,688,O
extensive,688,O
fat,688,O
loss,688,O
and,688,O
biochemical,688,O
changes,688,O
",",688,O
more,688,O
severe,688,O
intellectual,688,B-DiseaseOrPhenotypicFeature
impairment,688,I-DiseaseOrPhenotypicFeature
",",688,O
and,688,O
more,688,O
severe,688,O
cardiomyopathy,688,B-DiseaseOrPhenotypicFeature
.,688,O
We,689,O
report,689,O
a,689,O
3-month-old,689,O
Taiwanese,689,O
boy,689,O
with,689,O
initial,689,O
presentation,689,O
of,689,O
a,689,O
lack,689,O
of,689,O
subcutaneous,689,O
fat,689,O
",",689,O
prominent,689,O
musculature,689,O
",",689,O
generalized,689,O
eruptive,689,B-DiseaseOrPhenotypicFeature
xanthomas,689,I-DiseaseOrPhenotypicFeature
",",689,O
and,689,O
extreme,689,O
hypertriglyceridemia,689,B-DiseaseOrPhenotypicFeature
.,689,O
Absence,690,O
of,690,O
mechanical,690,O
adipose,690,O
tissue,690,O
in,690,O
the,690,O
orbits,690,O
and,690,O
scalp,690,O
was,690,O
revealed,690,O
by,690,O
head,690,O
magnetic,690,O
resonance,690,O
imaging,690,O
.,690,O
Hepatomegaly,691,B-DiseaseOrPhenotypicFeature
was,691,O
noticed,691,O
",",691,O
and,691,O
histological,691,O
examination,691,O
of,691,O
a,691,O
liver,691,O
biopsy,691,O
specimen,691,O
suggested,691,O
severe,691,O
hepatic,691,B-DiseaseOrPhenotypicFeature
steatosis,691,I-DiseaseOrPhenotypicFeature
and,691,O
periportal,691,O
necrosis,691,B-DiseaseOrPhenotypicFeature
.,691,O
However,692,O
",",692,O
echocardiography,692,O
indicated,692,O
no,692,O
sign,692,O
of,692,O
cardiomyopathy,692,B-DiseaseOrPhenotypicFeature
and,692,O
he,692,O
showed,692,O
no,692,O
distinct,692,O
intellectual,692,B-DiseaseOrPhenotypicFeature
impairment,692,I-DiseaseOrPhenotypicFeature
that,692,O
interfered,692,O
with,692,O
daily,692,O
life,692,O
.,692,O
About,693,O
1,693,O
year,693,O
later,693,O
",",693,O
abdominal,693,O
computed,693,O
tomography,693,O
revealed,693,O
enlargement,693,B-DiseaseOrPhenotypicFeature
of,693,I-DiseaseOrPhenotypicFeature
kidneys,693,I-DiseaseOrPhenotypicFeature
.,693,O
He,694,O
had,694,O
a,694,O
homozygous,694,O
insertion,694,O
of,694,O
a,694,O
nucleotide,694,O
",",694,O
783insG,694,B-SequenceVariant
(,694,O
Ile262fs,694,B-SequenceVariant
mutation,694,O
),694,O
",",694,O
in,694,O
exon,694,O
7,694,O
of,694,O
the,694,O
BSCL2,694,B-GeneOrGeneProduct
gene,694,O
.,694,O
We,695,O
reviewed,695,O
the,695,O
genotype,695,O
of,695,O
CGL,695,B-DiseaseOrPhenotypicFeature
cases,695,O
from,695,O
Japan,695,O
",",695,O
India,695,O
",",695,O
China,695,O
and,695,O
Taiwan,695,O
",",695,O
and,695,O
found,695,O
that,695,O
BSCL2,695,B-GeneOrGeneProduct
is,695,O
a,695,O
major,695,O
causative,695,O
gene,695,O
for,695,O
CGL,695,B-DiseaseOrPhenotypicFeature
in,695,O
Asian,695,O
.,695,O
A,696,O
novel,696,O
mutation,696,O
screening,696,O
system,696,O
for,696,O
Ehlers-Danlos,696,B-DiseaseOrPhenotypicFeature
Syndrome,696,I-DiseaseOrPhenotypicFeature
",",696,I-DiseaseOrPhenotypicFeature
vascular,696,I-DiseaseOrPhenotypicFeature
type,696,I-DiseaseOrPhenotypicFeature
by,696,O
high-resolution,696,O
melting,696,O
curve,696,O
analysis,696,O
in,696,O
combination,696,O
with,696,O
small,696,O
amplicon,696,O
genotyping,696,O
using,696,O
genomic,696,O
DNA,696,O
.,696,O
Ehlers-Danlos,697,B-DiseaseOrPhenotypicFeature
syndrome,697,I-DiseaseOrPhenotypicFeature
",",697,I-DiseaseOrPhenotypicFeature
vascular,697,I-DiseaseOrPhenotypicFeature
type,697,I-DiseaseOrPhenotypicFeature
(,697,O
vEDS,697,B-DiseaseOrPhenotypicFeature
),697,O
(,697,O
MIM,697,B-DiseaseOrPhenotypicFeature
#,697,I-DiseaseOrPhenotypicFeature
130050,697,I-DiseaseOrPhenotypicFeature
),697,O
is,697,O
an,697,O
autosomal,697,B-DiseaseOrPhenotypicFeature
dominant,697,I-DiseaseOrPhenotypicFeature
disorder,697,I-DiseaseOrPhenotypicFeature
caused,697,O
by,697,O
type,697,B-GeneOrGeneProduct
III,697,I-GeneOrGeneProduct
procollagen,697,I-GeneOrGeneProduct
gene,697,O
(,697,O
COL3A1,697,B-GeneOrGeneProduct
),697,O
mutations,697,O
.,697,O
Most,698,O
COL3A1,698,B-GeneOrGeneProduct
mutations,698,O
are,698,O
detected,698,O
by,698,O
using,698,O
total,698,O
RNA,698,O
from,698,O
patient-derived,698,B-OrganismTaxon
fibroblasts,698,O
",",698,O
which,698,O
requires,698,O
an,698,O
invasive,698,O
skin,698,O
biopsy,698,O
.,698,O
High-resolution,699,O
melting,699,O
curve,699,O
analysis,699,O
(,699,O
hrMCA,699,O
),699,O
has,699,O
recently,699,O
been,699,O
developed,699,O
as,699,O
a,699,O
post-PCR,699,O
mutation,699,O
scanning,699,O
method,699,O
which,699,O
enables,699,O
simple,699,O
",",699,O
rapid,699,O
",",699,O
cost-effective,699,O
",",699,O
and,699,O
highly,699,O
sensitive,699,O
mutation,699,O
screening,699,O
of,699,O
large,699,O
genes,699,O
.,699,O
We,700,O
established,700,O
a,700,O
hrMCA,700,O
method,700,O
to,700,O
screen,700,O
for,700,O
COL3A1,700,B-GeneOrGeneProduct
mutations,700,O
using,700,O
genomic,700,O
DNA,700,O
.,700,O
PCR,701,O
primers,701,O
pairs,701,O
for,701,O
COL3A1,701,B-GeneOrGeneProduct
(,701,O
52,701,O
amplicons,701,O
),701,O
were,701,O
designed,701,O
to,701,O
cover,701,O
all,701,O
coding,701,O
regions,701,O
of,701,O
the,701,O
52,701,O
exons,701,O
",",701,O
including,701,O
the,701,O
splicing,701,O
sites,701,O
.,701,O
We,702,O
used,702,O
15,702,O
DNA,702,O
samples,702,O
(,702,O
8,702,O
validation,702,O
samples,702,O
and,702,O
7,702,O
samples,702,O
of,702,O
clinically,702,O
suspected,702,O
vEDS,702,B-DiseaseOrPhenotypicFeature
patients,702,B-OrganismTaxon
),702,O
in,702,O
this,702,O
study,702,O
.,702,O
The,703,O
eight,703,O
known,703,O
COL3A1,703,B-GeneOrGeneProduct
mutations,703,O
in,703,O
validation,703,O
samples,703,O
were,703,O
all,703,O
successfully,703,O
detected,703,O
by,703,O
the,703,O
hrMCA,703,O
.,703,O
In,704,O
addition,704,O
",",704,O
we,704,O
identified,704,O
five,704,O
novel,704,O
COL3A1,704,B-GeneOrGeneProduct
mutations,704,O
",",704,O
including,704,O
one,704,O
deletion,704,O
(,704,O
c.2187delA,704,B-SequenceVariant
),704,O
and,704,O
one,704,O
nonsense,704,O
mutation,704,O
(,704,O
c.2992C,704,B-SequenceVariant
>,704,I-SequenceVariant
T,704,I-SequenceVariant
),704,O
that,704,O
could,704,O
not,704,O
be,704,O
determined,704,O
by,704,O
the,704,O
conventional,704,O
total,704,O
RNA,704,O
method,704,O
.,704,O
Furthermore,705,O
",",705,O
we,705,O
established,705,O
a,705,O
small,705,O
amplicon,705,O
genotyping,705,O
(,705,O
SAG,705,O
),705,O
method,705,O
for,705,O
detecting,705,O
three,705,O
high,705,O
frequency,705,O
coding-region,705,O
SNPs,705,O
(,705,O
rs1800255,705,B-SequenceVariant
:,705,O
G,705,B-SequenceVariant
>,705,I-SequenceVariant
A,705,I-SequenceVariant
",",705,O
rs1801184,705,B-SequenceVariant
:,705,O
T,705,B-SequenceVariant
>,705,I-SequenceVariant
C,705,I-SequenceVariant
",",705,O
and,705,O
rs2271683,705,B-SequenceVariant
:,705,O
A,705,B-SequenceVariant
>,705,I-SequenceVariant
G,705,I-SequenceVariant
),705,O
in,705,O
COL3A1,705,B-GeneOrGeneProduct
to,705,O
differentiate,705,O
mutations,705,O
before,705,O
sequencing,705,O
.,705,O
The,706,O
use,706,O
of,706,O
hrMCA,706,O
in,706,O
combination,706,O
with,706,O
SAG,706,O
from,706,O
genomic,706,O
DNA,706,O
enables,706,O
rapid,706,O
detection,706,O
of,706,O
COL3A1,706,B-GeneOrGeneProduct
mutations,706,O
with,706,O
high,706,O
efficiency,706,O
and,706,O
specificity,706,O
.,706,O
A,707,O
better,707,O
understanding,707,O
of,707,O
the,707,O
genotype-phenotype,707,O
correlation,707,O
in,707,O
COL3A1,707,B-GeneOrGeneProduct
using,707,O
this,707,O
method,707,O
will,707,O
lead,707,O
to,707,O
improve,707,O
in,707,O
diagnosis,707,O
and,707,O
treatment,707,O
.,707,O
Mutation,708,O
screening,708,O
of,708,O
the,708,O
GUCA1B,708,B-GeneOrGeneProduct
gene,708,O
in,708,O
patients,708,B-OrganismTaxon
with,708,O
autosomal,708,O
dominant,708,O
cone,708,B-DiseaseOrPhenotypicFeature
and,708,I-DiseaseOrPhenotypicFeature
cone,708,I-DiseaseOrPhenotypicFeature
rod,708,I-DiseaseOrPhenotypicFeature
dystrophy,708,I-DiseaseOrPhenotypicFeature
.,708,O
Background,709,O
:,709,O
Heterozygous,709,O
mutations,709,O
in,709,O
GUCA1A,709,B-GeneOrGeneProduct
(,709,O
MIM,709,O
#,709,O
600364,709,O
),709,O
have,709,O
been,709,O
identified,709,O
to,709,O
cause,709,O
autosomal,709,O
dominantly,709,O
inherited,709,O
cone,709,B-DiseaseOrPhenotypicFeature
dystrophy,709,I-DiseaseOrPhenotypicFeature
",",709,O
cone,709,B-DiseaseOrPhenotypicFeature
rod,709,I-DiseaseOrPhenotypicFeature
dystrophy,709,I-DiseaseOrPhenotypicFeature
and,709,O
macular,709,B-DiseaseOrPhenotypicFeature
dystrophy,709,I-DiseaseOrPhenotypicFeature
.,709,O
However,710,O
",",710,O
the,710,O
role,710,O
of,710,O
GUCA1B,710,B-GeneOrGeneProduct
gene,710,O
mutations,710,O
in,710,O
inherited,710,O
retinal,710,B-DiseaseOrPhenotypicFeature
disease,710,I-DiseaseOrPhenotypicFeature
has,710,O
been,710,O
controversial,710,O
.,710,O
We,711,O
therefore,711,O
performed,711,O
a,711,O
mutation,711,O
analysis,711,O
of,711,O
the,711,O
GUCA1B,711,B-GeneOrGeneProduct
gene,711,O
in,711,O
a,711,O
clinically,711,O
well,711,O
characterized,711,O
group,711,O
of,711,O
patients,711,B-OrganismTaxon
of,711,O
European,711,O
and,711,O
North-American,711,O
geographical,711,O
origin,711,O
with,711,O
autosomal,711,O
dominantly,711,O
inherited,711,O
cone,711,B-DiseaseOrPhenotypicFeature
dystrophy,711,I-DiseaseOrPhenotypicFeature
and,711,O
cone,711,B-DiseaseOrPhenotypicFeature
rod,711,I-DiseaseOrPhenotypicFeature
dystrophy,711,I-DiseaseOrPhenotypicFeature
.,711,O
Material,712,O
and,712,O
Methods,712,O
:,712,O
Twenty-four,712,O
unrelated,712,O
patients,712,B-OrganismTaxon
diagnosed,712,O
with,712,O
cone,712,B-DiseaseOrPhenotypicFeature
dystrophy,712,I-DiseaseOrPhenotypicFeature
or,712,O
cone,712,B-DiseaseOrPhenotypicFeature
rod,712,I-DiseaseOrPhenotypicFeature
dystrophy,712,I-DiseaseOrPhenotypicFeature
according,712,O
to,712,O
standard,712,O
diagnostic,712,O
criteria,712,O
and,712,O
a,712,O
family,712,O
history,712,O
consistent,712,O
with,712,O
an,712,O
autosomal,712,O
dominant,712,O
mode,712,O
of,712,O
inheritance,712,O
were,712,O
included,712,O
in,712,O
the,712,O
study,712,O
.,712,O
Mutation,713,O
analysis,713,O
of,713,O
all,713,O
coding,713,O
exons,713,O
of,713,O
the,713,O
GUCA1B,713,B-GeneOrGeneProduct
gene,713,O
was,713,O
performed,713,O
by,713,O
polymerase,713,O
chain,713,O
reaction,713,O
amplification,713,O
of,713,O
genomic,713,O
DNA,713,O
and,713,O
subsequent,713,O
DNA,713,O
sequencing,713,O
.,713,O
Results,714,O
:,714,O
Three,714,O
different,714,O
sequence,714,O
variants,714,O
",",714,O
c.-17T,714,B-SequenceVariant
>,714,I-SequenceVariant
C,714,I-SequenceVariant
",",714,O
c.171T,714,B-SequenceVariant
>,714,I-SequenceVariant
C,714,I-SequenceVariant
",",714,O
c.465G,714,B-SequenceVariant
>,714,I-SequenceVariant
T,714,I-SequenceVariant
were,714,O
identified,714,O
.,714,O
The,715,O
sequence,715,O
variant,715,O
c.465G,715,B-SequenceVariant
>,715,I-SequenceVariant
T,715,I-SequenceVariant
encodes,715,O
a,715,O
conservative,715,O
amino,715,O
acid,715,O
substitution,715,O
",",715,O
p.Glu155Asp,715,B-SequenceVariant
",",715,O
located,715,O
in,715,O
EF-hand,715,O
4,715,O
",",715,O
the,715,O
calcium,715,B-ChemicalEntity
binding,715,O
site,715,O
of,715,O
GCAP2,715,B-GeneOrGeneProduct
protein,715,O
.,715,O
All,716,O
sequence,716,O
variants,716,O
were,716,O
previously,716,O
reported,716,O
in,716,O
healthy,716,O
subjects,716,O
.,716,O
Conclusion,717,O
:,717,O
The,717,O
absence,717,O
of,717,O
clearly,717,O
pathogenic,717,O
mutations,717,O
in,717,O
the,717,O
selected,717,O
patient,717,B-OrganismTaxon
group,717,O
suggests,717,O
that,717,O
the,717,O
GUCA1B,717,B-GeneOrGeneProduct
gene,717,O
is,717,O
a,717,O
minor,717,O
cause,717,O
for,717,O
retinal,717,B-DiseaseOrPhenotypicFeature
degenerations,717,I-DiseaseOrPhenotypicFeature
in,717,O
Europeans,717,O
or,717,O
North-Americans,717,O
.,717,O
Large,718,O
contiguous,718,O
gene,718,O
deletions,718,O
in,718,O
Sjogren-Larsson,718,B-DiseaseOrPhenotypicFeature
syndrome,718,I-DiseaseOrPhenotypicFeature
.,718,O
Sjogren-Larsson,719,B-DiseaseOrPhenotypicFeature
syndrome,719,I-DiseaseOrPhenotypicFeature
(,719,O
SLS,719,B-DiseaseOrPhenotypicFeature
),719,O
is,719,O
an,719,O
autosomal,719,B-DiseaseOrPhenotypicFeature
recessive,719,I-DiseaseOrPhenotypicFeature
disorder,719,I-DiseaseOrPhenotypicFeature
characterized,719,O
by,719,O
ichthyosis,719,B-DiseaseOrPhenotypicFeature
",",719,O
mental,719,B-DiseaseOrPhenotypicFeature
retardation,719,I-DiseaseOrPhenotypicFeature
",",719,O
spasticity,719,B-DiseaseOrPhenotypicFeature
and,719,O
mutations,719,O
in,719,O
the,719,O
ALDH3A2,719,B-GeneOrGeneProduct
gene,719,O
for,719,O
fatty,719,B-GeneOrGeneProduct
aldehyde,719,I-GeneOrGeneProduct
dehydrogenase,719,I-GeneOrGeneProduct
",",719,O
an,719,O
enzyme,719,O
that,719,O
catalyzes,719,O
the,719,O
oxidation,719,O
of,719,O
fatty,719,B-ChemicalEntity
aldehyde,719,I-ChemicalEntity
to,719,O
fatty,719,B-ChemicalEntity
acid,719,I-ChemicalEntity
.,719,O
More,720,O
than,720,O
70,720,O
mutations,720,O
have,720,O
been,720,O
identified,720,O
in,720,O
SLS,720,B-DiseaseOrPhenotypicFeature
patients,720,B-OrganismTaxon
",",720,O
including,720,O
small,720,O
deletions,720,O
or,720,O
insertions,720,O
",",720,O
missense,720,O
mutations,720,O
",",720,O
splicing,720,O
defects,720,O
and,720,O
complex,720,O
nucleotide,720,O
changes,720,O
.,720,O
We,721,O
now,721,O
describe,721,O
2,721,O
SLS,721,B-DiseaseOrPhenotypicFeature
patients,721,B-OrganismTaxon
whose,721,O
disease,721,O
is,721,O
caused,721,O
by,721,O
large,721,O
contiguous,721,O
gene,721,O
deletions,721,O
of,721,O
the,721,O
ALDH3A2,721,B-GeneOrGeneProduct
locus,721,O
on,721,O
17p11.2,721,O
.,721,O
The,722,O
deletions,722,O
were,722,O
defined,722,O
using,722,O
long,722,O
distance,722,O
inverse,722,O
PCR,722,O
and,722,O
microarray-based,722,O
comparative,722,O
genomic,722,O
hybridization,722,O
.,722,O
A,723,O
24-year-old,723,O
SLS,723,B-DiseaseOrPhenotypicFeature
female,723,O
was,723,O
homozygous,723,O
for,723,O
a,723,O
352-kb,723,B-SequenceVariant
deletion,723,I-SequenceVariant
involving,723,O
ALDH3A2,723,B-GeneOrGeneProduct
and,723,I-GeneOrGeneProduct
4,723,I-GeneOrGeneProduct
contiguous,723,O
genes,723,O
including,723,O
ALDH3A1,723,B-GeneOrGeneProduct
",",723,O
which,723,O
codes,723,O
for,723,O
the,723,O
major,723,O
soluble,723,O
protein,723,O
in,723,O
cornea,723,O
.,723,O
Although,724,O
lacking,724,O
corneal,724,B-DiseaseOrPhenotypicFeature
disease,724,I-DiseaseOrPhenotypicFeature
",",724,O
she,724,O
showed,724,O
severe,724,O
symptoms,724,O
of,724,O
SLS,724,B-DiseaseOrPhenotypicFeature
with,724,O
uncommon,724,O
deterioration,724,O
in,724,O
oral,724,O
motor,724,O
function,724,O
and,724,O
loss,724,O
of,724,O
ambulation,724,O
.,724,O
The,725,O
other,725,O
19-month-old,725,O
female,725,O
patient,725,B-OrganismTaxon
was,725,O
a,725,O
compound,725,O
heterozygote,725,O
for,725,O
a,725,O
1.44-Mb,725,B-SequenceVariant
contiguous,725,I-SequenceVariant
gene,725,I-SequenceVariant
deletion,725,I-SequenceVariant
and,725,O
a,725,O
missense,725,O
mutation,725,O
(,725,O
c.407C,725,B-SequenceVariant
>,725,I-SequenceVariant
T,725,I-SequenceVariant
",",725,O
P136L,725,B-SequenceVariant
),725,O
in,725,O
ALDH3A2,725,B-GeneOrGeneProduct
.,725,O
These,726,O
studies,726,O
suggest,726,O
that,726,O
large,726,O
gene,726,O
deletions,726,O
may,726,O
account,726,O
for,726,O
up,726,O
to,726,O
5,726,O
%,726,O
of,726,O
the,726,O
mutant,726,O
alleles,726,O
in,726,O
SLS,726,B-DiseaseOrPhenotypicFeature
.,726,O
Geneticists,727,O
should,727,O
consider,727,O
the,727,O
possibility,727,O
of,727,O
compound,727,O
heterozygosity,727,O
for,727,O
large,727,O
deletions,727,O
in,727,O
patients,727,B-OrganismTaxon
with,727,O
SLS,727,B-DiseaseOrPhenotypicFeature
and,727,O
other,727,O
inborn,727,B-DiseaseOrPhenotypicFeature
errors,727,I-DiseaseOrPhenotypicFeature
of,727,I-DiseaseOrPhenotypicFeature
metabolism,727,I-DiseaseOrPhenotypicFeature
",",727,O
which,727,O
has,727,O
implications,727,O
for,727,O
carrier,727,O
testing,727,O
and,727,O
prenatal,727,O
diagnosis,727,O
.,727,O
Homozygously,728,O
deleted,728,O
gene,728,O
DACH1,728,B-GeneOrGeneProduct
regulates,728,O
tumor-initiating,728,B-DiseaseOrPhenotypicFeature
activity,728,O
of,728,O
glioma,728,B-DiseaseOrPhenotypicFeature
cells,728,O
.,728,O
Loss,729,O
or,729,O
reduction,729,O
in,729,O
function,729,O
of,729,O
tumor,729,B-DiseaseOrPhenotypicFeature
suppressor,729,O
genes,729,O
contributes,729,O
to,729,O
tumorigenesis,729,B-DiseaseOrPhenotypicFeature
.,729,O
Here,730,O
",",730,O
by,730,O
allelic,730,O
DNA,730,O
copy,730,O
number,730,O
analysis,730,O
using,730,O
single-nucleotide,730,O
polymorphism,730,O
genotyping,730,O
array,730,O
and,730,O
mass,730,O
spectrometry,730,O
",",730,O
we,730,O
report,730,O
homozygous,730,O
deletion,730,O
in,730,O
glioblastoma,730,B-DiseaseOrPhenotypicFeature
multiformes,730,O
at,730,O
chromosome,730,O
13q21,730,O
",",730,O
where,730,O
DACH1,730,B-GeneOrGeneProduct
gene,730,O
is,730,O
located,730,O
.,730,O
We,731,O
found,731,O
decreased,731,O
cell,731,O
proliferation,731,O
of,731,O
a,731,O
series,731,O
of,731,O
glioma,731,B-DiseaseOrPhenotypicFeature
cell,731,O
lines,731,O
by,731,O
forced,731,O
expression,731,O
of,731,O
DACH1,731,B-GeneOrGeneProduct
.,731,O
We,732,O
then,732,O
generated,732,O
U87TR-Da,732,B-CellLine
glioma,732,B-DiseaseOrPhenotypicFeature
cells,732,O
",",732,O
where,732,O
DACH1,732,B-GeneOrGeneProduct
expression,732,O
could,732,O
be,732,O
activated,732,O
by,732,O
exposure,732,O
of,732,O
the,732,O
cells,732,O
to,732,O
doxycycline,732,B-ChemicalEntity
.,732,O
Both,733,O
ex,733,O
vivo,733,O
cellular,733,O
proliferation,733,O
and,733,O
in,733,O
vivo,733,O
growth,733,O
of,733,O
s.c.,733,O
transplanted,733,O
tumors,733,B-DiseaseOrPhenotypicFeature
in,733,O
mice,733,B-OrganismTaxon
are,733,O
reduced,733,O
in,733,O
U87TR-Da,733,B-CellLine
cells,733,O
with,733,O
DACH1,733,B-GeneOrGeneProduct
expression,733,O
(,733,O
U87-DACH1-high,733,B-CellLine
),733,O
",",733,O
compared,733,O
with,733,O
DACH1-nonexpressing,733,B-GeneOrGeneProduct
U87TR-Da,733,B-CellLine
cells,733,O
(,733,O
U87-DACH1-low,733,B-CellLine
),733,O
.,733,O
U87-DACH1-low,734,B-CellLine
cells,734,O
form,734,O
spheroids,734,O
with,734,O
CD133,734,B-GeneOrGeneProduct
and,734,O
Nestin,734,B-GeneOrGeneProduct
expression,734,O
in,734,O
serum-free,734,O
medium,734,O
but,734,O
U87-DACH1-high,734,B-CellLine
cells,734,O
do,734,O
not,734,O
.,734,O
Compared,735,O
with,735,O
spheroid-forming,735,O
U87-DACH1-low,735,B-CellLine
cells,735,O
",",735,O
adherent,735,O
U87-DACH1-high,735,B-CellLine
cells,735,O
display,735,O
lower,735,O
tumorigenicity,735,O
",",735,O
indicating,735,O
DACH1,735,B-GeneOrGeneProduct
decreases,735,O
the,735,O
number,735,O
of,735,O
tumor-initiating,735,B-DiseaseOrPhenotypicFeature
cells,735,O
.,735,O
Gene,736,O
expression,736,O
analysis,736,O
and,736,O
chromatin,736,O
immunoprecipitation,736,O
assay,736,O
reveal,736,O
that,736,O
fibroblast,736,B-GeneOrGeneProduct
growth,736,I-GeneOrGeneProduct
factor,736,I-GeneOrGeneProduct
2,736,I-GeneOrGeneProduct
(,736,O
FGF2/bFGF,736,B-GeneOrGeneProduct
),736,O
is,736,O
transcriptionally,736,O
repressed,736,O
by,736,O
DACH1,736,B-GeneOrGeneProduct
",",736,O
especially,736,O
in,736,O
cells,736,O
cultured,736,O
in,736,O
serum-free,736,O
medium,736,O
.,736,O
Exogenous,737,O
bFGF,737,B-GeneOrGeneProduct
rescues,737,O
spheroid-forming,737,O
activity,737,O
and,737,O
tumorigenicity,737,O
of,737,O
the,737,O
U87-DACH1-high,737,B-CellLine
cells,737,O
",",737,O
suggesting,737,O
that,737,O
loss,737,O
of,737,O
DACH1,737,B-GeneOrGeneProduct
increases,737,O
the,737,O
number,737,O
of,737,O
tumor-initiating,737,B-DiseaseOrPhenotypicFeature
cells,737,O
through,737,O
transcriptional,737,O
activation,737,O
of,737,O
bFGF,737,B-GeneOrGeneProduct
.,737,O
These,738,O
results,738,O
illustrate,738,O
that,738,O
DACH1,738,B-GeneOrGeneProduct
is,738,O
a,738,O
distinctive,738,O
tumor,738,B-DiseaseOrPhenotypicFeature
suppressor,738,O
",",738,O
which,738,O
does,738,O
not,738,O
only,738,O
suppress,738,O
growth,738,O
of,738,O
tumor,738,B-DiseaseOrPhenotypicFeature
cells,738,O
but,738,O
also,738,O
regulates,738,O
bFGF-mediated,738,B-GeneOrGeneProduct
tumor-initiating,738,B-DiseaseOrPhenotypicFeature
activity,738,O
of,738,O
glioma,738,B-DiseaseOrPhenotypicFeature
cells,738,O
.,738,O
Genotype,739,O
rs8099917,739,B-SequenceVariant
near,739,O
the,739,O
IL28B,739,B-GeneOrGeneProduct
gene,739,O
and,739,O
amino,739,O
acid,739,O
substitution,739,O
at,739,O
position,739,O
70,739,O
in,739,O
the,739,O
core,739,O
region,739,O
of,739,O
the,739,O
hepatitis,739,B-OrganismTaxon
C,739,I-OrganismTaxon
virus,739,I-OrganismTaxon
are,739,O
determinants,739,O
of,739,O
serum,739,O
apolipoprotein,739,B-GeneOrGeneProduct
B-100,739,I-GeneOrGeneProduct
concentration,739,O
in,739,O
chronic,739,B-DiseaseOrPhenotypicFeature
hepatitis,739,I-DiseaseOrPhenotypicFeature
C.,739,O
The,739,O
life,739,O
cycle,739,O
of,739,O
the,739,O
hepatitis,739,B-OrganismTaxon
C,739,I-OrganismTaxon
virus,739,I-OrganismTaxon
(,739,O
HCV,739,B-OrganismTaxon
),739,O
is,739,O
closely,739,O
related,739,O
to,739,O
host,739,O
lipoprotein,739,O
metabolism,739,O
.,739,O
Serum,740,O
levels,740,O
of,740,O
lipid,740,B-ChemicalEntity
are,740,O
associated,740,O
with,740,O
the,740,O
response,740,O
to,740,O
pegylated,740,B-GeneOrGeneProduct
interferon,740,I-GeneOrGeneProduct
plus,740,O
ribavirin,740,B-ChemicalEntity
(,740,O
PEG-IFN/RBV,740,B-GeneOrGeneProduct
),740,O
therapy,740,O
",",740,O
while,740,O
single,740,O
nucleotide,740,O
polymorphisms,740,O
(,740,O
SNPs,740,O
),740,O
around,740,O
the,740,O
human,740,B-OrganismTaxon
interleukin,740,B-GeneOrGeneProduct
28B,740,I-GeneOrGeneProduct
(,740,O
IL28B,740,B-GeneOrGeneProduct
),740,O
gene,740,O
locus,740,O
and,740,O
amino,740,O
acid,740,O
substitutions,740,O
in,740,O
the,740,O
core,740,O
region,740,O
of,740,O
the,740,O
HCV,740,B-OrganismTaxon
have,740,O
been,740,O
reported,740,O
to,740,O
affect,740,O
the,740,O
efficacy,740,O
of,740,O
PEG-IFN/RBV,740,B-GeneOrGeneProduct
therapy,740,O
in,740,O
chronic,740,B-DiseaseOrPhenotypicFeature
hepatitis,740,I-DiseaseOrPhenotypicFeature
with,740,O
HCV,740,B-DiseaseOrPhenotypicFeature
genotype,740,I-DiseaseOrPhenotypicFeature
1b,740,I-DiseaseOrPhenotypicFeature
infection,740,I-DiseaseOrPhenotypicFeature
.,740,O
The,741,O
aim,741,O
of,741,O
this,741,O
study,741,O
was,741,O
to,741,O
elucidate,741,O
the,741,O
relationship,741,O
between,741,O
serum,741,O
lipid,741,B-ChemicalEntity
and,741,O
factors,741,O
that,741,O
are,741,O
able,741,O
to,741,O
predict,741,O
the,741,O
efficacy,741,O
of,741,O
PEG-IFN/RB,741,B-GeneOrGeneProduct
therapy,741,O
",",741,O
with,741,O
specific,741,O
focus,741,O
on,741,O
apolipoprotein,741,B-GeneOrGeneProduct
B-100,741,I-GeneOrGeneProduct
(,741,O
apoB-100,741,B-GeneOrGeneProduct
),741,O
in,741,O
148,741,O
subjects,741,O
with,741,O
chronic,741,O
HCV,741,B-DiseaseOrPhenotypicFeature
G1b,741,I-DiseaseOrPhenotypicFeature
infection,741,I-DiseaseOrPhenotypicFeature
.,741,O
Our,742,O
results,742,O
demonstrated,742,O
that,742,O
both,742,O
the,742,O
aa,742,O
70,742,O
substitution,742,O
in,742,O
the,742,O
core,742,O
region,742,O
of,742,O
the,742,O
HCV,742,B-OrganismTaxon
and,742,O
the,742,O
rs8099917,742,B-SequenceVariant
SNP,742,O
located,742,O
proximal,742,O
to,742,O
the,742,O
IL28B,742,B-GeneOrGeneProduct
were,742,O
independent,742,O
factors,742,O
in,742,O
determining,742,O
serum,742,O
apoB-100,742,B-GeneOrGeneProduct
and,742,O
low-density,742,B-ChemicalEntity
lipoprotein,742,I-ChemicalEntity
(,742,I-ChemicalEntity
LDL,742,I-ChemicalEntity
),742,I-ChemicalEntity
cholesterol,742,I-ChemicalEntity
levels,742,O
.,742,O
A,743,O
significant,743,O
association,743,O
was,743,O
noted,743,O
between,743,O
higher,743,O
levels,743,O
of,743,O
apoB-100,743,B-GeneOrGeneProduct
(,743,O
P,743,O
=,743,O
1.1,743,O
10,743,O
(,743,O
-3,743,O
),743,O
),743,O
and,743,O
LDL,743,B-ChemicalEntity
cholesterol,743,I-ChemicalEntity
(,743,O
P,743,O
=,743,O
0.02,743,O
),743,O
and,743,O
the,743,O
subjects,743,O
having,743,O
Arg70,743,B-SequenceVariant
.,743,O
A,744,O
significant,744,O
association,744,O
was,744,O
also,744,O
observed,744,O
between,744,O
subjects,744,O
carrying,744,O
the,744,O
rs8099917,744,B-SequenceVariant
TT,744,O
responder,744,O
genotype,744,O
and,744,O
higher,744,O
levels,744,O
of,744,O
apoB-100,744,B-GeneOrGeneProduct
(,744,O
P,744,O
=,744,O
6.4,744,O
10,744,O
(,744,O
-3,744,O
),744,O
),744,O
and,744,O
LDL,744,B-ChemicalEntity
cholesterol,744,I-ChemicalEntity
(,744,O
P,744,O
=,744,O
4.2,744,O
10,744,O
(,744,O
-3,744,O
),744,O
),744,O
.,744,O
Our,745,O
results,745,O
suggest,745,O
that,745,O
apoB-100,745,B-GeneOrGeneProduct
and,745,O
LDL,745,B-ChemicalEntity
cholesterol,745,I-ChemicalEntity
are,745,O
markers,745,O
of,745,O
impaired,745,O
cellular,745,O
lipoprotein,745,O
pathways,745,O
and/or,745,O
host,745,O
endogenous,745,O
interferon,745,O
response,745,O
to,745,O
HCV,745,B-OrganismTaxon
in,745,O
chronic,745,O
HCV,745,B-DiseaseOrPhenotypicFeature
infection,745,I-DiseaseOrPhenotypicFeature
.,745,O
In,746,O
particular,746,O
",",746,O
serum,746,O
apoB-100,746,B-GeneOrGeneProduct
concentration,746,O
might,746,O
be,746,O
an,746,O
informative,746,O
marker,746,O
for,746,O
judging,746,O
changes,746,O
in,746,O
HCV-associated,746,B-OrganismTaxon
intracellular,746,O
lipoprotein,746,O
metabolism,746,O
in,746,O
patients,746,B-OrganismTaxon
carrying,746,O
the,746,O
rs8099917,746,B-SequenceVariant
responder,746,O
genotype,746,O
.,746,O
Identification,747,O
of,747,O
a,747,O
novel,747,O
FBN1,747,B-GeneOrGeneProduct
gene,747,O
mutation,747,O
in,747,O
a,747,O
Chinese,747,O
family,747,O
with,747,O
Marfan,747,B-DiseaseOrPhenotypicFeature
syndrome,747,I-DiseaseOrPhenotypicFeature
.,747,O
PURPOSE,748,O
:,748,O
To,748,O
identify,748,O
the,748,O
mutation,748,O
in,748,O
the,748,O
fibrillin-1,748,B-GeneOrGeneProduct
gene,748,O
(,748,O
FBN1,748,B-GeneOrGeneProduct
),748,O
in,748,O
a,748,O
Chinese,748,O
family,748,O
with,748,O
Marfan,748,B-DiseaseOrPhenotypicFeature
syndrome,748,I-DiseaseOrPhenotypicFeature
(,748,O
MFS,748,B-DiseaseOrPhenotypicFeature
),748,O
.,748,O
METHODS,749,O
:,749,O
Patients,749,B-OrganismTaxon
and,749,O
family,749,O
members,749,O
were,749,O
given,749,O
complete,749,O
physical,749,O
",",749,O
ophthalmic,749,O
",",749,O
and,749,O
cardiovascular,749,O
examinations,749,O
.,749,O
Genomic,750,O
DNA,750,O
was,750,O
extracted,750,O
from,750,O
leukocytes,750,O
of,750,O
venous,750,O
blood,750,O
of,750,O
six,750,O
individuals,750,O
in,750,O
the,750,O
family,750,O
and,750,O
170,750,O
healthy,750,O
Chinese,750,O
individuals,750,O
.,750,O
All,751,O
of,751,O
the,751,O
65,751,O
coding,751,O
exons,751,O
and,751,O
their,751,O
flanking,751,O
intronic,751,O
boundaries,751,O
of,751,O
FBN1,751,B-GeneOrGeneProduct
were,751,O
amplified,751,O
in,751,O
the,751,O
proband,751,O
by,751,O
polymerase,751,O
chain,751,O
reaction,751,O
and,751,O
followed,751,O
by,751,O
direct,751,O
sequencing,751,O
.,751,O
The,752,O
mutation,752,O
identified,752,O
in,752,O
the,752,O
proband,752,O
was,752,O
screened,752,O
in,752,O
the,752,O
other,752,O
family,752,O
members,752,O
and,752,O
the,752,O
170,752,O
healthy,752,O
Chinese,752,O
individuals,752,O
by,752,O
direct,752,O
sequencing,752,O
.,752,O
Protein,753,O
conservation,753,O
analysis,753,O
was,753,O
performed,753,O
in,753,O
six,753,O
species,753,O
using,753,O
an,753,O
online,753,O
ClustalW,753,O
tool,753,O
.,753,O
Protein,754,O
structure,754,O
was,754,O
modeled,754,O
based,754,O
on,754,O
the,754,O
Protein,754,O
data,754,O
bank,754,O
and,754,O
mutated,754,O
in,754,O
DeepView,754,O
v4.0.1,754,O
to,754,O
predict,754,O
the,754,O
functional,754,O
consequences,754,O
of,754,O
the,754,O
mutation,754,O
.,754,O
RESULTS,755,O
:,755,O
A,755,O
novel,755,O
heterozygous,755,O
c.3703T,755,B-SequenceVariant
>,755,I-SequenceVariant
C,755,I-SequenceVariant
change,755,O
in,755,O
exon,755,O
29,755,O
of,755,O
FBN1,755,B-GeneOrGeneProduct
was,755,O
detected,755,O
in,755,O
the,755,O
proband,755,O
",",755,O
which,755,O
resulted,755,O
in,755,O
the,755,O
substitution,755,O
of,755,O
serine,755,B-SequenceVariant
by,755,I-SequenceVariant
proline,755,I-SequenceVariant
at,755,I-SequenceVariant
codon,755,I-SequenceVariant
1235,755,I-SequenceVariant
(,755,O
p.S1235P,755,B-SequenceVariant
),755,O
.,755,O
This,756,O
mutation,756,O
was,756,O
also,756,O
present,756,O
in,756,O
two,756,O
family,756,O
members,756,O
but,756,O
absent,756,O
in,756,O
the,756,O
other,756,O
",",756,O
unaffected,756,O
family,756,O
members,756,O
and,756,O
the,756,O
170,756,O
healthy,756,O
Chinese,756,O
individuals,756,O
.,756,O
The,757,O
mutant,757,O
residue,757,O
located,757,O
in,757,O
the,757,O
calcium,757,B-ChemicalEntity
binding,757,O
epidermal,757,B-GeneOrGeneProduct
growth,757,I-GeneOrGeneProduct
factor-like,757,O
#,757,O
15,757,O
domain,757,O
is,757,O
highly,757,O
conserved,757,O
among,757,O
mammalian,757,O
species,757,O
and,757,O
could,757,O
probably,757,O
induce,757,O
conformation,757,O
change,757,O
of,757,O
the,757,O
domain,757,O
.,757,O
CONCLUSIONS,758,O
:,758,O
We,758,O
indentified,758,O
a,758,O
novel,758,O
p.S1235P,758,B-SequenceVariant
mutation,758,O
in,758,O
FBN1,758,B-GeneOrGeneProduct
",",758,O
which,758,O
is,758,O
the,758,O
causative,758,O
mutation,758,O
for,758,O
MFS,758,B-DiseaseOrPhenotypicFeature
in,758,O
this,758,O
family,758,O
.,758,O
Our,759,O
result,759,O
expands,759,O
the,759,O
mutation,759,O
spectrum,759,O
of,759,O
FBN1,759,B-GeneOrGeneProduct
and,759,O
contributes,759,O
to,759,O
the,759,O
study,759,O
of,759,O
the,759,O
molecular,759,O
pathogenesis,759,O
of,759,O
Marfan,759,B-DiseaseOrPhenotypicFeature
syndrome,759,I-DiseaseOrPhenotypicFeature
.,759,O
Reciprocal,760,O
effects,760,O
of,760,O
NNK,760,B-ChemicalEntity
and,760,O
SLURP-1,760,B-GeneOrGeneProduct
on,760,O
oncogene,760,O
expression,760,O
in,760,O
target,760,O
epithelial,760,O
cells,760,O
.,760,O
AIMS,761,O
:,761,O
To,761,O
elucidate,761,O
how,761,O
the,761,O
nicotinic,761,B-GeneOrGeneProduct
acetylcholine,761,I-GeneOrGeneProduct
receptors,761,I-GeneOrGeneProduct
expressed,761,O
on,761,O
bronchial,761,O
and,761,O
oral,761,O
epithelial,761,O
cells,761,O
targeted,761,O
by,761,O
the,761,O
tobacco,761,B-OrganismTaxon
nitrosamine,761,B-ChemicalEntity
(,761,O
4-,761,B-ChemicalEntity
(,761,I-ChemicalEntity
methylnitrosamino,761,I-ChemicalEntity
),761,I-ChemicalEntity
-1-,761,I-ChemicalEntity
(,761,I-ChemicalEntity
3-pyridyl,761,I-ChemicalEntity
),761,I-ChemicalEntity
-1-butanone,761,I-ChemicalEntity
),761,O
(,761,O
NNK,761,B-ChemicalEntity
),761,O
facilitate,761,O
carcinogenic,761,B-DiseaseOrPhenotypicFeature
transformation,761,O
.,761,O
MAIN,762,O
METHODS,762,O
:,762,O
Since,762,O
NNK-dependent,762,B-ChemicalEntity
transformation,762,O
can,762,O
be,762,O
abolished,762,O
by,762,O
the,762,O
nicotinergic,762,O
secreted,762,O
mammalian,762,O
Ly-6/urokinase,762,B-GeneOrGeneProduct
plasminogen,762,I-GeneOrGeneProduct
activator,762,I-GeneOrGeneProduct
receptor,762,I-GeneOrGeneProduct
related,762,I-GeneOrGeneProduct
protein-1,762,I-GeneOrGeneProduct
(,762,O
SLURP-1,762,B-GeneOrGeneProduct
),762,O
",",762,O
we,762,O
compared,762,O
effects,762,O
of,762,O
NNK,762,B-ChemicalEntity
and,762,O
recombinant,762,O
(,762,O
r,762,O
),762,O
SLURP-1,762,B-GeneOrGeneProduct
on,762,O
the,762,O
expression,762,O
of,762,O
genes,762,O
related,762,O
to,762,O
tumorigenesis,762,B-DiseaseOrPhenotypicFeature
in,762,O
human,762,B-OrganismTaxon
immortalized,762,O
bronchial,762,O
and,762,O
oral,762,O
epithelial,762,O
cell,762,O
lines,762,O
BEP2D,762,B-CellLine
and,762,O
Het-1A,762,B-CellLine
",",762,O
respectively,762,O
.,762,O
KEY,763,O
FINDINGS,763,O
:,763,O
NNK,763,B-ChemicalEntity
stimulated,763,O
expression,763,O
of,763,O
oncogenic,763,O
genes,763,O
",",763,O
including,763,O
MYB,763,B-GeneOrGeneProduct
and,763,O
PIK3CA,763,B-GeneOrGeneProduct
in,763,O
BEP2D,763,B-CellLine
",",763,O
ETS1,763,B-GeneOrGeneProduct
",",763,O
NRAS,763,B-GeneOrGeneProduct
and,763,O
SRC,763,B-GeneOrGeneProduct
in,763,O
Het-1A,763,B-CellLine
",",763,O
and,763,O
AKT1,763,B-GeneOrGeneProduct
",",763,O
KIT,763,B-GeneOrGeneProduct
and,763,O
RB1,763,B-GeneOrGeneProduct
in,763,O
both,763,O
cell,763,O
types,763,O
",",763,O
which,763,O
could,763,O
be,763,O
abolished,763,O
in,763,O
the,763,O
presence,763,O
of,763,O
rSLURP-1,763,B-GeneOrGeneProduct
.,763,O
Other,764,O
cancer-related,764,B-DiseaseOrPhenotypicFeature
genes,764,O
whose,764,O
upregulation,764,O
by,764,O
NNK,764,B-ChemicalEntity
was,764,O
abolishable,764,O
by,764,O
rSLURP-1,764,B-GeneOrGeneProduct
were,764,O
the,764,O
growth,764,O
factors,764,O
EGF,764,B-GeneOrGeneProduct
in,764,O
BEP2D,764,B-CellLine
cells,764,O
and,764,O
HGF,764,B-GeneOrGeneProduct
in,764,O
Het-1A,764,B-CellLine
cells,764,O
",",764,O
and,764,O
the,764,O
transcription,764,O
factors,764,O
CDKN2A,764,B-GeneOrGeneProduct
and,764,O
STAT3,764,B-GeneOrGeneProduct
(,764,O
Het-1A,764,B-CellLine
only,764,O
),764,O
.,764,O
NNK,765,B-ChemicalEntity
also,765,O
upregulated,765,O
the,765,O
anti-apoptotic,765,O
BCL2,765,B-GeneOrGeneProduct
(,765,O
Het-1A,765,B-CellLine
),765,O
and,765,O
downregulated,765,O
the,765,O
pro-apoptotic,765,O
TNF,765,B-GeneOrGeneProduct
(,765,O
Het-1A,765,B-CellLine
),765,O
",",765,O
BAX,765,B-GeneOrGeneProduct
and,765,O
CASP8,765,B-GeneOrGeneProduct
(,765,O
BEP2D,765,B-CellLine
),765,O
",",765,O
all,765,O
of,765,O
which,765,O
could,765,O
be,765,O
abolished,765,O
",",765,O
in,765,O
part,765,O
",",765,O
by,765,O
rSLURP-1,765,B-GeneOrGeneProduct
.,765,O
NNK,766,B-ChemicalEntity
decreased,766,O
expression,766,O
of,766,O
the,766,O
CTNNB1,766,B-GeneOrGeneProduct
gene,766,O
encoding,766,O
the,766,O
intercellular,766,O
adhesion,766,O
molecule,766,O
beta-catenin,766,B-GeneOrGeneProduct
(,766,O
BEP2D,766,B-CellLine
),766,O
",",766,O
as,766,O
well,766,O
as,766,O
tumor,766,B-DiseaseOrPhenotypicFeature
suppressors,766,O
CDKN3,766,B-GeneOrGeneProduct
and,766,O
FOXD3,766,B-GeneOrGeneProduct
in,766,O
BEP2D,766,B-CellLine
cells,766,O
and,766,O
SERPINB5,766,B-GeneOrGeneProduct
in,766,O
Het-1A,766,B-CellLine
cells,766,O
.,766,O
These,767,O
pro-oncogenic,767,O
effects,767,O
of,767,O
NNK,767,B-ChemicalEntity
were,767,O
abolished,767,O
by,767,O
rSLURP-1,767,B-GeneOrGeneProduct
that,767,O
also,767,O
upregulated,767,O
RUNX3,767,B-GeneOrGeneProduct
.,767,O
SIGNIFICANCE,768,O
:,768,O
The,768,O
obtained,768,O
results,768,O
identified,768,O
target,768,O
genes,768,O
for,768,O
both,768,O
NNK,768,B-ChemicalEntity
and,768,O
SLURP-1,768,B-GeneOrGeneProduct
and,768,O
shed,768,O
light,768,O
on,768,O
the,768,O
molecular,768,O
mechanism,768,O
of,768,O
their,768,O
reciprocal,768,O
effects,768,O
on,768,O
tumorigenic,768,B-DiseaseOrPhenotypicFeature
transformation,768,O
of,768,O
bronchial,768,O
and,768,O
oral,768,O
epithelial,768,O
cells,768,O
.,768,O
Contribution,769,O
of,769,O
STAT4,769,B-GeneOrGeneProduct
gene,769,O
single-nucleotide,769,O
polymorphism,769,O
to,769,O
systemic,769,B-DiseaseOrPhenotypicFeature
lupus,769,I-DiseaseOrPhenotypicFeature
erythematosus,769,I-DiseaseOrPhenotypicFeature
in,769,O
the,769,O
Polish,769,O
population,769,O
.,769,O
The,770,O
STAT4,770,B-GeneOrGeneProduct
has,770,O
been,770,O
found,770,O
to,770,O
be,770,O
a,770,O
susceptible,770,O
gene,770,O
in,770,O
the,770,O
development,770,O
of,770,O
systemic,770,B-DiseaseOrPhenotypicFeature
lupus,770,I-DiseaseOrPhenotypicFeature
erythematosus,770,I-DiseaseOrPhenotypicFeature
(,770,O
SLE,770,B-DiseaseOrPhenotypicFeature
),770,O
in,770,O
various,770,O
populations,770,O
.,770,O
There,771,O
are,771,O
evident,771,O
population,771,O
differences,771,O
in,771,O
the,771,O
context,771,O
of,771,O
clinical,771,O
manifestations,771,O
of,771,O
SLE,771,B-DiseaseOrPhenotypicFeature
",",771,O
therefore,771,O
we,771,O
investigated,771,O
the,771,O
prevalence,771,O
of,771,O
the,771,O
STAT4,771,B-GeneOrGeneProduct
G,771,B-SequenceVariant
>,771,I-SequenceVariant
C,771,I-SequenceVariant
(,771,O
rs7582694,771,B-SequenceVariant
),771,O
polymorphism,771,O
in,771,O
patients,771,B-OrganismTaxon
with,771,O
SLE,771,B-DiseaseOrPhenotypicFeature
(,771,O
n,771,O
=,771,O
253,771,O
),771,O
and,771,O
controls,771,O
(,771,O
n,771,O
=,771,O
521,771,O
),771,O
in,771,O
a,771,O
sample,771,O
of,771,O
the,771,O
Polish,771,O
population,771,O
.,771,O
We,772,O
found,772,O
that,772,O
patients,772,B-OrganismTaxon
with,772,O
the,772,O
STAT4,772,B-GeneOrGeneProduct
C/G,772,O
and,772,O
CC,772,O
genotypes,772,O
exhibited,772,O
a,772,O
1.583-fold,772,O
increased,772,O
risk,772,O
of,772,O
SLE,772,B-DiseaseOrPhenotypicFeature
incidence,772,O
(,772,O
95,772,O
%,772,O
CI,772,O
=,772,O
1.168-2.145,772,O
",",772,O
p,772,O
=,772,O
0.003,772,O
),772,O
",",772,O
with,772,O
OR,772,O
for,772,O
the,772,O
C/C,772,O
versus,772,O
C/G,772,O
and,772,O
G/G,772,O
genotypes,772,O
was,772,O
1.967,772,O
(,772,O
95,772,O
%,772,O
CI,772,O
=,772,O
1.152-3.358,772,O
",",772,O
p,772,O
=,772,O
0.0119,772,O
),772,O
.,772,O
The,773,O
OR,773,O
for,773,O
the,773,O
STAT4,773,B-GeneOrGeneProduct
C,773,O
allele,773,O
frequency,773,O
showed,773,O
a,773,O
1.539-fold,773,O
increased,773,O
risk,773,O
of,773,O
SLE,773,B-DiseaseOrPhenotypicFeature
(,773,O
95,773,O
%,773,O
CI,773,O
=,773,O
1.209-1.959,773,O
",",773,O
p,773,O
=,773,O
0.0004,773,O
),773,O
.,773,O
We,774,O
also,774,O
observed,774,O
an,774,O
increased,774,O
frequency,774,O
of,774,O
STAT4,774,B-GeneOrGeneProduct
C/C,774,O
and,774,O
C/G,774,O
genotypes,774,O
in,774,O
SLE,774,B-DiseaseOrPhenotypicFeature
patients,774,B-OrganismTaxon
with,774,O
renal,774,B-DiseaseOrPhenotypicFeature
symptoms,774,I-DiseaseOrPhenotypicFeature
OR,774,O
=,774,O
2.259,774,O
(,774,O
1.365-3.738,774,O
",",774,O
p,774,O
=,774,O
0.0014,774,O
),774,O
",",774,O
(,774,O
p,774,O
(,774,O
corr,774,O
),774,O
=,774,O
0.0238,774,O
),774,O
and,774,O
in,774,O
SLE,774,B-DiseaseOrPhenotypicFeature
patients,774,B-OrganismTaxon
with,774,O
neurologic,774,O
manifestations,774,O
OR,774,O
=,774,O
2.867,774,O
(,774,O
1.467-5.604,774,O
",",774,O
p,774,O
=,774,O
0.0016,774,O
),774,O
",",774,O
(,774,O
p,774,O
(,774,O
corr,774,O
),774,O
=,774,O
0.0272,774,O
),774,O
.,774,O
Moreover,775,O
",",775,O
we,775,O
found,775,O
a,775,O
contribution,775,O
of,775,O
STAT4,775,B-GeneOrGeneProduct
C/C,775,O
and,775,O
C/G,775,O
genotypes,775,O
to,775,O
the,775,O
presence,775,O
of,775,O
the,775,O
anti-snRNP,775,O
Ab,775,O
OR,775,O
=,775,O
3.237,775,O
(,775,O
1.667-6.288,775,O
",",775,O
p,775,O
=,775,O
0.0003,775,O
),775,O
",",775,O
(,775,O
p,775,O
(,775,O
corr,775,O
),775,O
=,775,O
0.0051,775,O
),775,O
and,775,O
the,775,O
presence,775,O
of,775,O
the,775,O
anti-Scl-70,775,O
Ab,775,O
OR,775,O
=,775,O
2.665,775,O
(,775,O
1.380-5.147,775,O
",",775,O
p,775,O
=,775,O
0.0028,775,O
),775,O
",",775,O
(,775,O
p,775,O
(,775,O
corr,775,O
),775,O
=,775,O
0.0476,775,O
),775,O
.,775,O
Our,776,O
studies,776,O
confirmed,776,O
an,776,O
association,776,O
of,776,O
the,776,O
STAT4,776,B-GeneOrGeneProduct
C,776,O
(,776,O
rs7582694,776,B-SequenceVariant
),776,O
variant,776,O
with,776,O
the,776,O
development,776,O
of,776,O
SLE,776,B-DiseaseOrPhenotypicFeature
and,776,O
occurrence,776,O
of,776,O
some,776,O
clinical,776,O
manifestations,776,O
of,776,O
the,776,O
disease,776,O
.,776,O
Critical,777,O
role,777,O
of,777,O
neuronal,777,B-GeneOrGeneProduct
pentraxin,777,I-GeneOrGeneProduct
1,777,I-GeneOrGeneProduct
in,777,O
mitochondria-mediated,777,O
hypoxic-ischemic,777,B-DiseaseOrPhenotypicFeature
neuronal,777,I-DiseaseOrPhenotypicFeature
injury,777,I-DiseaseOrPhenotypicFeature
.,777,O
Developing,778,O
brain,778,O
is,778,O
highly,778,O
susceptible,778,O
to,778,O
hypoxic-ischemic,778,B-DiseaseOrPhenotypicFeature
(,778,I-DiseaseOrPhenotypicFeature
HI,778,I-DiseaseOrPhenotypicFeature
),778,I-DiseaseOrPhenotypicFeature
injury,778,I-DiseaseOrPhenotypicFeature
leading,778,O
to,778,O
severe,778,O
neurological,778,B-DiseaseOrPhenotypicFeature
disabilities,778,I-DiseaseOrPhenotypicFeature
in,778,O
surviving,778,O
infants,778,O
and,778,O
children,778,O
.,778,O
Previously,779,O
",",779,O
we,779,O
have,779,O
reported,779,O
induction,779,O
of,779,O
neuronal,779,B-GeneOrGeneProduct
pentraxin,779,I-GeneOrGeneProduct
1,779,I-GeneOrGeneProduct
(,779,O
NP1,779,B-GeneOrGeneProduct
),779,O
",",779,O
a,779,O
novel,779,O
neuronal,779,O
protein,779,O
of,779,O
long-pentraxin,779,O
family,779,O
",",779,O
following,779,O
HI,779,B-DiseaseOrPhenotypicFeature
neuronal,779,I-DiseaseOrPhenotypicFeature
injury,779,I-DiseaseOrPhenotypicFeature
.,779,O
Here,780,O
",",780,O
we,780,O
investigated,780,O
how,780,O
this,780,O
specific,780,O
signal,780,O
is,780,O
propagated,780,O
to,780,O
cause,780,O
the,780,O
HI,780,B-DiseaseOrPhenotypicFeature
neuronal,780,I-DiseaseOrPhenotypicFeature
death,780,I-DiseaseOrPhenotypicFeature
.,780,O
We,781,O
used,781,O
wild-type,781,O
(,781,O
WT,781,O
),781,O
and,781,O
NP1,781,B-GeneOrGeneProduct
knockout,781,O
(,781,O
NP1-KO,781,B-GeneOrGeneProduct
),781,O
mouse,781,B-OrganismTaxon
hippocampal,781,O
cultures,781,O
",",781,O
modeled,781,O
in,781,O
vitro,781,O
following,781,O
exposure,781,O
to,781,O
oxygen,781,B-ChemicalEntity
glucose,781,B-ChemicalEntity
deprivation,781,O
(,781,O
OGD,781,O
),781,O
",",781,O
and,781,O
in,781,O
vivo,781,O
neonatal,781,O
(,781,O
P9-10,781,O
),781,O
mouse,781,B-OrganismTaxon
model,781,O
of,781,O
HI,781,B-DiseaseOrPhenotypicFeature
brain,781,I-DiseaseOrPhenotypicFeature
injury,781,I-DiseaseOrPhenotypicFeature
.,781,O
Our,782,O
results,782,O
show,782,O
induction,782,O
of,782,O
NP1,782,B-GeneOrGeneProduct
in,782,O
primary,782,O
hippocampal,782,O
neurons,782,O
following,782,O
OGD,782,O
exposure,782,O
(,782,O
4-8,782,O
h,782,O
),782,O
and,782,O
in,782,O
the,782,O
ipsilateral,782,O
hippocampal,782,O
CA1,782,B-GeneOrGeneProduct
and,782,O
CA3,782,B-GeneOrGeneProduct
regions,782,O
at,782,O
24-48,782,O
h,782,O
post-HI,782,O
compared,782,O
to,782,O
the,782,O
contralateral,782,O
side,782,O
.,782,O
We,783,O
also,783,O
found,783,O
increased,783,O
PTEN,783,B-GeneOrGeneProduct
activity,783,O
concurrent,783,O
with,783,O
OGD,783,O
time-dependent,783,O
(,783,O
4-8,783,O
h,783,O
),783,O
dephosphorylation,783,O
of,783,O
Akt,783,B-GeneOrGeneProduct
(,783,O
Ser473,783,B-SequenceVariant
),783,O
and,783,O
GSK-3b,783,B-GeneOrGeneProduct
(,783,O
Ser9,783,B-SequenceVariant
),783,O
.,783,O
OGD,784,O
also,784,O
caused,784,O
a,784,O
time-dependent,784,O
decrease,784,O
in,784,O
the,784,O
phosphorylation,784,O
of,784,O
Bad,784,B-GeneOrGeneProduct
(,784,O
Ser136,784,B-SequenceVariant
),784,O
",",784,O
and,784,O
Bax,784,B-GeneOrGeneProduct
protein,784,O
levels,784,O
.,784,O
Immunofluorescence,785,O
staining,785,O
and,785,O
subcellular,785,O
fractionation,785,O
analyses,785,O
revealed,785,O
increased,785,O
mitochondrial,785,O
translocation,785,O
of,785,O
Bad,785,B-GeneOrGeneProduct
and,785,O
Bax,785,B-GeneOrGeneProduct
proteins,785,O
from,785,O
cytoplasm,785,O
following,785,O
OGD,785,O
(,785,O
4,785,O
h,785,O
),785,O
and,785,O
simultaneously,785,O
increased,785,O
release,785,O
of,785,O
Cyt,785,B-GeneOrGeneProduct
C,785,I-GeneOrGeneProduct
from,785,O
mitochondria,785,O
followed,785,O
by,785,O
activation,785,O
of,785,O
caspase-3,785,B-GeneOrGeneProduct
.,785,O
NP1,786,B-GeneOrGeneProduct
protein,786,O
was,786,O
immunoprecipitated,786,O
with,786,O
Bad,786,B-GeneOrGeneProduct
and,786,O
Bax,786,B-GeneOrGeneProduct
proteins,786,O
;,786,O
OGD,786,O
caused,786,O
increased,786,O
interactions,786,O
of,786,O
NP1,786,B-GeneOrGeneProduct
with,786,O
Bad,786,B-GeneOrGeneProduct
and,786,O
Bax,786,B-GeneOrGeneProduct
",",786,O
thereby,786,O
",",786,O
facilitating,786,O
their,786,O
mitochondrial,786,O
translocation,786,O
and,786,O
dissipation,786,O
of,786,O
mitochondrial,786,O
membrane,786,O
potential,786,O
(,786,O
D,786,O
(,786,O
m,786,O
),786,O
),786,O
.,786,O
This,787,O
NP1,787,B-GeneOrGeneProduct
induction,787,O
preceded,787,O
the,787,O
increased,787,O
mitochondrial,787,O
release,787,O
of,787,O
cytochrome,787,B-GeneOrGeneProduct
C,787,I-GeneOrGeneProduct
(,787,O
Cyt,787,B-GeneOrGeneProduct
C,787,I-GeneOrGeneProduct
),787,O
into,787,O
the,787,O
cytosol,787,O
",",787,O
activation,787,O
of,787,O
caspase-3,787,B-GeneOrGeneProduct
and,787,O
OGD,787,O
time-dependent,787,O
cell,787,O
death,787,O
in,787,O
WT,787,O
primary,787,O
hippocampal,787,O
neurons,787,O
.,787,O
In,788,O
contrast,788,O
",",788,O
in,788,O
NP1-KO,788,B-GeneOrGeneProduct
neurons,788,O
there,788,O
was,788,O
no,788,O
translocation,788,O
of,788,O
Bad,788,B-GeneOrGeneProduct
and,788,O
Bax,788,B-GeneOrGeneProduct
from,788,O
cytosol,788,O
to,788,O
the,788,O
mitochondria,788,O
",",788,O
and,788,O
no,788,O
evidence,788,O
of,788,O
D,788,O
(,788,O
m,788,O
),788,O
loss,788,O
",",788,O
increased,788,O
Cyt,788,B-GeneOrGeneProduct
C,788,I-GeneOrGeneProduct
release,788,O
and,788,O
caspase-3,788,B-GeneOrGeneProduct
activation,788,O
following,788,O
OGD,788,O
;,788,O
which,788,O
resulted,788,O
in,788,O
significantly,788,O
reduced,788,O
neuronal,788,B-DiseaseOrPhenotypicFeature
death,788,I-DiseaseOrPhenotypicFeature
.,788,O
Our,789,O
results,789,O
indicate,789,O
a,789,O
regulatory,789,O
role,789,O
of,789,O
NP1,789,B-GeneOrGeneProduct
in,789,O
Bad/Bax-dependent,789,B-GeneOrGeneProduct
mitochondrial,789,O
release,789,O
of,789,O
Cyt,789,B-GeneOrGeneProduct
C,789,I-GeneOrGeneProduct
and,789,O
caspase-3,789,B-GeneOrGeneProduct
activation,789,O
.,789,O
Together,790,O
our,790,O
findings,790,O
demonstrate,790,O
a,790,O
novel,790,O
mechanism,790,O
by,790,O
which,790,O
NP1,790,B-GeneOrGeneProduct
regulates,790,O
mitochondria-driven,790,O
hippocampal,790,O
cell,790,O
death,790,O
;,790,O
suggesting,790,O
NP1,790,B-GeneOrGeneProduct
as,790,O
a,790,O
potential,790,O
therapeutic,790,O
target,790,O
against,790,O
HI,790,B-DiseaseOrPhenotypicFeature
brain,790,I-DiseaseOrPhenotypicFeature
injury,790,I-DiseaseOrPhenotypicFeature
in,790,O
neonates,790,O
.,790,O
Depression,791,B-DiseaseOrPhenotypicFeature
",",791,O
impulsiveness,791,B-DiseaseOrPhenotypicFeature
",",791,O
sleep,791,O
",",791,O
and,791,O
memory,791,O
in,791,O
past,791,O
and,791,O
present,791,O
polydrug,791,O
users,791,O
of,791,O
"3,4-methylenedioxymethamphetamine",791,B-ChemicalEntity
(,791,O
MDMA,791,B-ChemicalEntity
",",791,O
ecstasy,791,B-ChemicalEntity
),791,O
.,791,O
RATIONALE,792,O
:,792,O
Ecstasy,792,B-ChemicalEntity
(,792,O
"3,4-methylenedioxymethamphetamine",792,B-ChemicalEntity
",",792,O
MDMA,792,B-ChemicalEntity
),792,O
is,792,O
a,792,O
worldwide,792,O
recreational,792,O
drug,792,O
of,792,O
abuse,792,O
.,792,O
Unfortunately,793,O
",",793,O
the,793,O
results,793,O
from,793,O
human,793,B-OrganismTaxon
research,793,O
investigating,793,O
its,793,O
psychological,793,O
effects,793,O
have,793,O
been,793,O
inconsistent,793,O
.,793,O
OBJECTIVES,794,O
:,794,O
The,794,O
present,794,O
study,794,O
aimed,794,O
to,794,O
be,794,O
the,794,O
largest,794,O
to,794,O
date,794,O
in,794,O
sample,794,O
size,794,O
and,794,O
5HT-related,794,B-ChemicalEntity
behaviors,794,O
;,794,O
the,794,O
first,794,O
to,794,O
compare,794,O
present,794,O
ecstasy,794,B-ChemicalEntity
users,794,O
with,794,O
past,794,O
users,794,O
after,794,O
an,794,O
abstinence,794,O
of,794,O
4,794,O
or,794,O
more,794,O
years,794,O
",",794,O
and,794,O
the,794,O
first,794,O
to,794,O
include,794,O
robust,794,O
controls,794,O
for,794,O
other,794,O
recreational,794,O
substances,794,O
.,794,O
METHODS,795,O
:,795,O
A,795,O
sample,795,O
of,795,O
997,795,O
participants,795,O
(,795,O
52,795,O
%,795,O
male,795,O
),795,O
was,795,O
recruited,795,O
to,795,O
four,795,O
control,795,O
groups,795,O
(,795,O
non-drug,795,O
(,795,O
ND,795,O
),795,O
",",795,O
alcohol/nicotine,795,B-ChemicalEntity
(,795,O
AN,795,B-ChemicalEntity
),795,O
",",795,O
cannabis/alcohol/nicotine,795,B-ChemicalEntity
(,795,O
CAN,795,B-ChemicalEntity
),795,O
",",795,O
non-ecstasy,795,O
polydrug,795,O
(,795,O
PD,795,O
),795,O
),795,O
",",795,O
and,795,O
two,795,O
ecstasy,795,B-ChemicalEntity
polydrug,795,O
groups,795,O
(,795,O
present,795,O
(,795,O
MDMA,795,B-ChemicalEntity
),795,O
and,795,O
past,795,O
users,795,O
(,795,O
EX-MDMA,795,O
),795,O
.,795,O
Participants,796,O
completed,796,O
a,796,O
drug,796,O
history,796,O
questionnaire,796,O
",",796,O
Beck,796,O
Depression,796,O
Inventory,796,O
",",796,O
Barratt,796,O
Impulsiveness,796,O
Scale,796,O
",",796,O
Pittsburgh,796,O
Sleep,796,O
Quality,796,O
Index,796,O
",",796,O
and,796,O
Wechsler,796,O
Memory,796,O
Scale-Revised,796,O
which,796,O
",",796,O
in,796,O
total,796,O
",",796,O
provided,796,O
13,796,O
psychometric,796,O
measures,796,O
.,796,O
RESULTS,797,O
:,797,O
While,797,O
the,797,O
CAN,797,B-ChemicalEntity
and,797,O
PD,797,O
groups,797,O
tended,797,O
to,797,O
record,797,O
greater,797,O
deficits,797,O
than,797,O
the,797,O
non-drug,797,O
controls,797,O
",",797,O
the,797,O
MDMA,797,B-ChemicalEntity
and,797,O
EX-MDMA,797,O
groups,797,O
recorded,797,O
greater,797,O
deficits,797,O
than,797,O
all,797,O
the,797,O
control,797,O
groups,797,O
on,797,O
ten,797,O
of,797,O
the,797,O
13,797,O
psychometric,797,O
measures,797,O
.,797,O
Strikingly,798,O
",",798,O
despite,798,O
prolonged,798,O
abstinence,798,O
(,798,O
mean,798,O
",",798,O
4.98,798,O
;,798,O
range,798,O
",",798,O
4-9,798,O
years,798,O
),798,O
",",798,O
past,798,O
ecstasy,798,B-ChemicalEntity
users,798,O
showed,798,O
few,798,O
signs,798,O
of,798,O
recovery,798,O
.,798,O
Compared,799,O
with,799,O
present,799,O
ecstasy,799,B-ChemicalEntity
users,799,O
",",799,O
the,799,O
past,799,O
users,799,O
showed,799,O
no,799,O
change,799,O
for,799,O
ten,799,O
measures,799,O
",",799,O
increased,799,O
impairment,799,O
for,799,O
two,799,O
measures,799,O
",",799,O
and,799,O
improvement,799,O
on,799,O
just,799,O
one,799,O
measure,799,O
.,799,O
CONCLUSIONS,800,O
:,800,O
Given,800,O
this,800,O
record,800,O
of,800,O
impaired,800,B-DiseaseOrPhenotypicFeature
memory,800,I-DiseaseOrPhenotypicFeature
and,800,O
clinically,800,O
significant,800,O
levels,800,O
of,800,O
depression,800,B-DiseaseOrPhenotypicFeature
",",800,O
impulsiveness,800,B-DiseaseOrPhenotypicFeature
",",800,O
and,800,O
sleep,800,B-DiseaseOrPhenotypicFeature
disturbance,800,I-DiseaseOrPhenotypicFeature
",",800,O
the,800,O
prognosis,800,O
for,800,O
the,800,O
current,800,O
generation,800,O
of,800,O
ecstasy,800,B-ChemicalEntity
users,800,O
is,800,O
a,800,O
major,800,O
cause,800,O
for,800,O
concern,800,O
.,800,O
Cultured,801,B-ChemicalEntity
mycelium,801,I-ChemicalEntity
Cordyceps,801,I-ChemicalEntity
sinensis,801,I-ChemicalEntity
protects,801,O
liver,801,O
sinusoidal,801,O
endothelial,801,O
cells,801,O
in,801,O
acute,801,O
liver,801,B-DiseaseOrPhenotypicFeature
injured,801,I-DiseaseOrPhenotypicFeature
mice,801,B-OrganismTaxon
.,801,O
Cultured,802,B-ChemicalEntity
mycelium,802,I-ChemicalEntity
Cordyceps,802,I-ChemicalEntity
sinensis,802,I-ChemicalEntity
(,802,O
CMCS,802,B-ChemicalEntity
),802,O
was,802,O
widely,802,O
used,802,O
for,802,O
a,802,O
variety,802,O
of,802,O
diseases,802,O
including,802,O
liver,802,B-DiseaseOrPhenotypicFeature
injury,802,I-DiseaseOrPhenotypicFeature
",",802,O
the,802,O
current,802,O
study,802,O
aims,802,O
to,802,O
investigate,802,O
the,802,O
protective,802,O
effects,802,O
of,802,O
CMCS,802,B-ChemicalEntity
on,802,O
liver,802,O
sinusoidal,802,O
endothelial,802,O
cells,802,O
(,802,O
LSECs,802,O
),802,O
in,802,O
acute,802,O
injury,802,B-DiseaseOrPhenotypicFeature
liver,802,I-DiseaseOrPhenotypicFeature
and,802,O
related,802,O
action,802,O
mechanisms,802,O
.,802,O
The,803,O
mice,803,B-OrganismTaxon
were,803,O
injected,803,O
intraperitoneally,803,O
with,803,O
lipopolysaccharide,803,B-ChemicalEntity
(,803,O
LPS,803,B-ChemicalEntity
),803,O
and,803,O
D-galactosamine,803,B-ChemicalEntity
(,803,O
D-GalN,803,B-ChemicalEntity
),803,O
.,803,O
39,804,O
male,804,O
BABL/c,804,B-CellLine
mice,804,B-OrganismTaxon
were,804,O
randomly,804,O
divided,804,O
into,804,O
four,804,O
groups,804,O
:,804,O
normal,804,O
control,804,O
",",804,O
model,804,O
control,804,O
",",804,O
CMCS,804,B-ChemicalEntity
treatment,804,O
and,804,O
"1,10-phenanthroline",804,B-ChemicalEntity
treatment,804,O
groups,804,O
.,804,O
The,805,O
Serum,805,O
liver,805,O
function,805,O
parameters,805,O
including,805,O
alanine,805,B-GeneOrGeneProduct
aminotransferase,805,I-GeneOrGeneProduct
(,805,O
ALT,805,B-GeneOrGeneProduct
),805,O
and,805,O
aspartate,805,B-GeneOrGeneProduct
aminotransferase,805,I-GeneOrGeneProduct
(,805,O
AST,805,B-GeneOrGeneProduct
),805,O
levels,805,O
were,805,O
assayed,805,O
with,805,O
the,805,O
commercial,805,O
kit,805,O
.,805,O
The,806,O
inflammation,806,B-DiseaseOrPhenotypicFeature
and,806,O
scaffold,806,O
structure,806,O
in,806,O
liver,806,O
were,806,O
stained,806,O
with,806,O
hematoxylin,806,O
and,806,O
eosin,806,O
and,806,O
silver,806,O
staining,806,O
respectively,806,O
.,806,O
The,807,O
LSECs,807,O
and,807,O
sub-endothelial,807,O
basement,807,O
membrane,807,O
were,807,O
observed,807,O
with,807,O
the,807,O
scanning,807,O
and,807,O
transmission,807,O
electronic,807,O
microscope,807,O
.,807,O
The,808,O
protein,808,O
expressions,808,O
of,808,O
intercellular,808,B-GeneOrGeneProduct
adhesion,808,I-GeneOrGeneProduct
molecule-1,808,I-GeneOrGeneProduct
(,808,O
ICAM-1,808,B-GeneOrGeneProduct
),808,O
and,808,O
vascular,808,B-GeneOrGeneProduct
cell,808,I-GeneOrGeneProduct
adhesion,808,I-GeneOrGeneProduct
molecule-1,808,I-GeneOrGeneProduct
(,808,O
VCAM-1,808,B-GeneOrGeneProduct
),808,O
in,808,O
liver,808,O
were,808,O
analyzed,808,O
with,808,O
Western,808,O
blotting,808,O
.,808,O
Expression,809,O
of,809,O
von,809,B-GeneOrGeneProduct
Willebrand,809,I-GeneOrGeneProduct
factor,809,I-GeneOrGeneProduct
(,809,O
vWF,809,B-GeneOrGeneProduct
),809,O
was,809,O
investigated,809,O
with,809,O
immunofluorescence,809,O
staining,809,O
.,809,O
The,810,O
lipid,810,B-ChemicalEntity
peroxidation,810,O
indicators,810,O
including,810,O
antisuperoxideanion,810,O
(,810,O
ASAFR,810,O
),810,O
",",810,O
hydroxyl,810,B-ChemicalEntity
free,810,I-ChemicalEntity
radical,810,I-ChemicalEntity
(,810,O
.OH,810,B-ChemicalEntity
),810,O
",",810,O
superoxide,810,B-GeneOrGeneProduct
dismutase,810,I-GeneOrGeneProduct
(,810,O
SOD,810,B-GeneOrGeneProduct
),810,O
",",810,O
malondialdehyde,810,B-ChemicalEntity
and,810,O
glutathione,810,B-GeneOrGeneProduct
S-transferase,810,I-GeneOrGeneProduct
(,810,O
GST,810,B-GeneOrGeneProduct
),810,O
were,810,O
determined,810,O
with,810,O
kits,810,O
",",810,O
and,810,O
matrix,810,B-GeneOrGeneProduct
metalloproteinase-2,810,I-GeneOrGeneProduct
and,810,I-GeneOrGeneProduct
9,810,I-GeneOrGeneProduct
(,810,O
MMP-2/9,810,B-GeneOrGeneProduct
),810,O
activities,810,O
in,810,O
liver,810,O
were,810,O
analyzed,810,O
with,810,O
gelatin,810,O
zymography,810,O
and,810,O
in,810,O
situ,810,O
fluorescent,810,O
zymography,810,O
respectively,810,O
.,810,O
The,811,O
model,811,O
mice,811,B-OrganismTaxon
had,811,O
much,811,O
higher,811,O
serum,811,O
levels,811,O
of,811,O
ALT,811,B-GeneOrGeneProduct
and,811,O
AST,811,B-GeneOrGeneProduct
than,811,O
the,811,O
normal,811,O
mice,811,B-OrganismTaxon
.,811,O
Compared,812,O
to,812,O
that,812,O
in,812,O
the,812,O
normal,812,O
control,812,O
",",812,O
more,812,O
severe,812,O
liver,812,B-DiseaseOrPhenotypicFeature
inflammation,812,I-DiseaseOrPhenotypicFeature
and,812,O
hepatocyte,812,O
apoptosis,812,O
",",812,O
worse,812,O
hepatic,812,O
lipid,812,B-ChemicalEntity
peroxidation,812,O
demonstrated,812,O
by,812,O
the,812,O
increased,812,O
ASAFR,812,O
",",812,O
.OH,812,B-ChemicalEntity
and,812,O
MDA,812,B-ChemicalEntity
",",812,O
but,812,O
decreased,812,O
SOD,812,B-GeneOrGeneProduct
and,812,O
GST,812,B-GeneOrGeneProduct
",",812,O
increased,812,O
MMP-2/9,812,B-GeneOrGeneProduct
activities,812,O
and,812,O
VCAM-1,812,B-GeneOrGeneProduct
",",812,O
ICAM-1,812,B-GeneOrGeneProduct
and,812,O
vWF,812,B-GeneOrGeneProduct
expressions,812,O
",",812,O
which,812,O
revealed,812,O
obvious,812,O
LSEC,812,B-DiseaseOrPhenotypicFeature
injury,812,I-DiseaseOrPhenotypicFeature
and,812,O
scaffold,812,O
structure,812,O
broken,812,O
",",812,O
were,812,O
shown,812,O
in,812,O
the,812,O
model,812,O
control,812,O
.,812,O
Compared,813,O
with,813,O
the,813,O
model,813,O
group,813,O
",",813,O
CMCS,813,B-ChemicalEntity
and,813,O
"1,10-phenanthroline",813,B-ChemicalEntity
significantly,813,O
improved,813,O
serum,813,O
ALT/AST,813,B-GeneOrGeneProduct
",",813,O
attenuated,813,O
hepatic,813,B-DiseaseOrPhenotypicFeature
inflammation,813,I-DiseaseOrPhenotypicFeature
and,813,O
improved,813,O
peroxidative,813,O
injury,813,B-DiseaseOrPhenotypicFeature
in,813,I-DiseaseOrPhenotypicFeature
liver,813,I-DiseaseOrPhenotypicFeature
",",813,O
decreased,813,O
MMP-2/9,813,B-GeneOrGeneProduct
activities,813,O
in,813,O
liver,813,O
tissue,813,O
",",813,O
improved,813,O
integration,813,O
of,813,O
scaffold,813,O
structure,813,O
",",813,O
and,813,O
decreased,813,O
protein,813,O
expression,813,O
of,813,O
VCAM-1,813,B-GeneOrGeneProduct
and,813,O
ICAM-1,813,B-GeneOrGeneProduct
.,813,O
CMCS,814,B-ChemicalEntity
could,814,O
protect,814,O
LSECs,814,B-DiseaseOrPhenotypicFeature
from,814,I-DiseaseOrPhenotypicFeature
injury,814,I-DiseaseOrPhenotypicFeature
and,814,O
maintain,814,O
the,814,O
microvasculature,814,O
integration,814,O
in,814,O
acute,814,O
injured,814,B-DiseaseOrPhenotypicFeature
liver,814,I-DiseaseOrPhenotypicFeature
of,814,O
mice,814,B-OrganismTaxon
induced,814,O
by,814,O
LPS/D-GalN,814,B-ChemicalEntity
.,814,O
Its,815,O
action,815,O
mechanism,815,O
was,815,O
associated,815,O
with,815,O
the,815,O
down-regulation,815,O
of,815,O
MMP-2/9,815,B-GeneOrGeneProduct
activities,815,O
and,815,O
inhibition,815,O
of,815,O
peroxidation,815,O
in,815,O
injured,815,B-DiseaseOrPhenotypicFeature
liver,815,I-DiseaseOrPhenotypicFeature
.,815,O
Necrotising,816,B-DiseaseOrPhenotypicFeature
fasciitis,816,I-DiseaseOrPhenotypicFeature
after,816,O
bortezomib,816,B-ChemicalEntity
and,816,O
dexamethasone-containing,816,B-ChemicalEntity
regimen,816,O
in,816,O
an,816,O
elderly,816,O
patient,816,B-OrganismTaxon
of,816,O
Waldenstrom,816,B-DiseaseOrPhenotypicFeature
macroglobulinaemia,816,I-DiseaseOrPhenotypicFeature
.,816,O
Bortezomib,817,B-ChemicalEntity
and,817,O
high-dose,817,O
dexamethasone-containing,817,B-ChemicalEntity
regimens,817,O
are,817,O
considered,817,O
to,817,O
be,817,O
generally,817,O
tolerable,817,O
with,817,O
few,817,O
severe,817,O
bacterial,817,B-DiseaseOrPhenotypicFeature
infections,817,I-DiseaseOrPhenotypicFeature
in,817,O
patients,817,B-OrganismTaxon
with,817,O
B-cell,817,O
malignancies,817,B-DiseaseOrPhenotypicFeature
.,817,O
However,818,O
",",818,O
information,818,O
is,818,O
limited,818,O
concerning,818,O
the,818,O
safety,818,O
of,818,O
the,818,O
regimen,818,O
in,818,O
elderly,818,O
patients,818,B-OrganismTaxon
.,818,O
We,819,O
report,819,O
a,819,O
case,819,O
of,819,O
a,819,O
76-year-old,819,O
man,819,B-OrganismTaxon
with,819,O
Waldenstrom,819,B-DiseaseOrPhenotypicFeature
macroglobulinaemia,819,I-DiseaseOrPhenotypicFeature
who,819,O
suffered,819,O
necrotising,819,B-DiseaseOrPhenotypicFeature
fasciitis,819,I-DiseaseOrPhenotypicFeature
without,819,O
neutropenia,819,B-DiseaseOrPhenotypicFeature
after,819,O
the,819,O
combination,819,O
treatment,819,O
with,819,O
bortezomib,819,B-ChemicalEntity
",",819,O
high-dose,819,O
dexamethasone,819,B-ChemicalEntity
and,819,O
rituximab,819,B-ChemicalEntity
.,819,O
Despite,820,O
immediate,820,O
intravenous,820,O
antimicrobial,820,O
therapy,820,O
",",820,O
he,820,O
succumbed,820,O
23,820,O
h,820,O
after,820,O
the,820,O
onset,820,O
.,820,O
Physicians,821,O
should,821,O
recognise,821,O
the,821,O
possibility,821,O
of,821,O
fatal,821,O
bacterial,821,B-DiseaseOrPhenotypicFeature
infections,821,I-DiseaseOrPhenotypicFeature
related,821,O
to,821,O
bortezomib,821,B-ChemicalEntity
plus,821,O
high-dose,821,O
dexamethasone,821,B-ChemicalEntity
in,821,O
elderly,821,O
patients,821,B-OrganismTaxon
",",821,O
and,821,O
we,821,O
believe,821,O
this,821,O
case,821,O
warrants,821,O
further,821,O
investigation,821,O
.,821,O
A,822,O
comparison,822,O
of,822,O
severe,822,O
hemodynamic,822,O
disturbances,822,O
between,822,O
dexmedetomidine,822,B-ChemicalEntity
and,822,O
propofol,822,B-ChemicalEntity
for,822,O
sedation,822,O
in,822,O
neurocritical,822,O
care,822,O
patients,822,B-OrganismTaxon
.,822,O
OBJECTIVE,823,O
:,823,O
Dexmedetomidine,823,B-ChemicalEntity
and,823,O
propofol,823,B-ChemicalEntity
are,823,O
commonly,823,O
used,823,O
sedatives,823,O
in,823,O
neurocritical,823,O
care,823,O
as,823,O
they,823,O
allow,823,O
for,823,O
frequent,823,O
neurologic,823,O
examinations,823,O
.,823,O
However,824,O
",",824,O
both,824,O
agents,824,O
are,824,O
associated,824,O
with,824,O
significant,824,O
hemodynamic,824,O
side,824,O
effects,824,O
.,824,O
The,825,O
primary,825,O
objective,825,O
of,825,O
this,825,O
study,825,O
is,825,O
to,825,O
compare,825,O
the,825,O
prevalence,825,O
of,825,O
severe,825,O
hemodynamic,825,O
effects,825,O
in,825,O
neurocritical,825,O
care,825,O
patients,825,B-OrganismTaxon
receiving,825,O
dexmedetomidine,825,B-ChemicalEntity
and,825,O
propofol,825,B-ChemicalEntity
.,825,O
DESIGN,826,O
:,826,O
Multicenter,826,O
",",826,O
retrospective,826,O
",",826,O
propensity-matched,826,O
cohort,826,O
study,826,O
.,826,O
SETTING,827,O
:,827,O
Neurocritical,827,O
care,827,O
units,827,O
at,827,O
two,827,O
academic,827,O
medical,827,O
centers,827,O
with,827,O
dedicated,827,O
neurocritical,827,O
care,827,O
teams,827,O
and,827,O
board-certified,827,O
neurointensivists,827,O
.,827,O
PATIENTS,828,B-OrganismTaxon
:,828,O
Neurocritical,828,O
care,828,O
patients,828,B-OrganismTaxon
admitted,828,O
between,828,O
July,828,O
2009,828,O
and,828,O
September,828,O
2012,828,O
were,828,O
evaluated,828,O
and,828,O
then,828,O
matched,828,O
1:1,828,O
based,828,O
on,828,O
propensity,828,O
scoring,828,O
of,828,O
baseline,828,O
characteristics,828,O
.,828,O
INTERVENTIONS,829,O
:,829,O
Continuous,829,O
sedation,829,O
with,829,O
dexmedetomidine,829,B-ChemicalEntity
or,829,O
propofol,829,B-ChemicalEntity
.,829,O
MEASUREMENTS,830,O
AND,830,O
MAIN,830,O
RESULTS,830,O
:,830,O
A,830,O
total,830,O
of,830,O
342,830,O
patients,830,B-OrganismTaxon
(,830,O
105,830,O
dexmedetomidine,830,B-ChemicalEntity
and,830,O
237,830,O
propofol,830,B-ChemicalEntity
),830,O
were,830,O
included,830,O
in,830,O
the,830,O
analysis,830,O
",",830,O
with,830,O
190,830,O
matched,830,O
(,830,O
95,830,O
in,830,O
each,830,O
group,830,O
),830,O
by,830,O
propensity,830,O
score,830,O
.,830,O
The,831,O
primary,831,O
outcome,831,O
of,831,O
this,831,O
study,831,O
was,831,O
a,831,O
composite,831,O
of,831,O
severe,831,O
hypotension,831,B-DiseaseOrPhenotypicFeature
(,831,O
mean,831,O
arterial,831,O
pressure,831,O
<,831,O
60,831,O
mm,831,O
Hg,831,O
),831,O
and,831,O
bradycardia,831,B-DiseaseOrPhenotypicFeature
(,831,O
heart,831,O
rate,831,O
<,831,O
50,831,O
beats/min,831,O
),831,O
during,831,O
sedative,831,O
infusion,831,O
.,831,O
No,832,O
difference,832,O
in,832,O
the,832,O
primary,832,O
composite,832,O
outcome,832,O
in,832,O
both,832,O
the,832,O
unmatched,832,O
(,832,O
30,832,O
%,832,O
vs,832,O
30,832,O
%,832,O
",",832,O
p,832,O
=,832,O
0.94,832,O
),832,O
or,832,O
matched,832,O
cohorts,832,O
(,832,O
28,832,O
%,832,O
vs,832,O
34,832,O
%,832,O
",",832,O
p,832,O
=,832,O
0.35,832,O
),832,O
could,832,O
be,832,O
found,832,O
.,832,O
When,833,O
analyzed,833,O
separately,833,O
",",833,O
no,833,O
differences,833,O
could,833,O
be,833,O
found,833,O
in,833,O
the,833,O
prevalence,833,O
of,833,O
severe,833,O
hypotension,833,B-DiseaseOrPhenotypicFeature
or,833,O
bradycardia,833,B-DiseaseOrPhenotypicFeature
in,833,O
either,833,O
the,833,O
unmatched,833,O
or,833,O
matched,833,O
cohorts,833,O
.,833,O
CONCLUSIONS,834,O
:,834,O
Severe,834,O
hypotension,834,B-DiseaseOrPhenotypicFeature
and,834,O
bradycardia,834,B-DiseaseOrPhenotypicFeature
occur,834,O
at,834,O
similar,834,O
prevalence,834,O
in,834,O
neurocritical,834,O
care,834,O
patients,834,B-OrganismTaxon
who,834,O
receive,834,O
dexmedetomidine,834,B-ChemicalEntity
or,834,O
propofol,834,B-ChemicalEntity
.,834,O
Providers,835,O
should,835,O
similarly,835,O
consider,835,O
the,835,O
likelihood,835,O
of,835,O
hypotension,835,B-DiseaseOrPhenotypicFeature
or,835,O
bradycardia,835,B-DiseaseOrPhenotypicFeature
before,835,O
starting,835,O
either,835,O
sedative,835,O
.,835,O
Effects,836,O
of,836,O
dehydroepiandrosterone,836,B-ChemicalEntity
in,836,O
amphetamine-induced,836,B-ChemicalEntity
schizophrenia,836,B-DiseaseOrPhenotypicFeature
models,836,O
in,836,O
mice,836,B-OrganismTaxon
.,836,O
OBJECTIVE,837,O
:,837,O
To,837,O
examine,837,O
the,837,O
effects,837,O
of,837,O
dehydroepiandrosterone,837,B-ChemicalEntity
(,837,O
DHEA,837,B-ChemicalEntity
),837,O
on,837,O
animal,837,O
models,837,O
of,837,O
schizophrenia,837,B-DiseaseOrPhenotypicFeature
.,837,O
METHODS,838,O
:,838,O
Seventy,838,O
Swiss,838,O
albino,838,O
female,838,O
mice,838,B-OrganismTaxon
(,838,O
25-35,838,O
g,838,O
),838,O
were,838,O
divided,838,O
into,838,O
4,838,O
groups,838,O
:,838,O
amphetamine-free,838,B-ChemicalEntity
(,838,O
control,838,O
),838,O
",",838,O
amphetamine,838,B-ChemicalEntity
",",838,O
50,838,O
",",838,O
and,838,O
100,838,O
mg/kg,838,O
DHEA,838,B-ChemicalEntity
.,838,O
The,839,O
DHEA,839,B-ChemicalEntity
was,839,O
administered,839,O
intraperitoneally,839,O
(,839,O
ip,839,O
),839,O
for,839,O
5,839,O
days,839,O
.,839,O
Amphetamine,840,B-ChemicalEntity
(,840,O
3,840,O
mg/kg,840,O
ip,840,O
),840,O
induced,840,O
hyper,840,B-DiseaseOrPhenotypicFeature
locomotion,840,I-DiseaseOrPhenotypicFeature
",",840,O
apomorphine,840,B-ChemicalEntity
(,840,O
1.5,840,O
mg/kg,840,O
subcutaneously,840,O
[,840,O
sc,840,O
],840,O
),840,O
induced,840,O
climbing,840,O
",",840,O
and,840,O
haloperidol,840,B-ChemicalEntity
(,840,O
1.5,840,O
mg/kg,840,O
sc,840,O
),840,O
induced,840,O
catalepsy,840,B-DiseaseOrPhenotypicFeature
tests,840,O
were,840,O
used,840,O
as,840,O
animal,840,O
models,840,O
of,840,O
schizophrenia,840,B-DiseaseOrPhenotypicFeature
.,840,O
The,841,O
study,841,O
was,841,O
conducted,841,O
at,841,O
the,841,O
Animal,841,O
Experiment,841,O
Laboratories,841,O
",",841,O
Department,841,O
of,841,O
Pharmacology,841,O
",",841,O
Medical,841,O
School,841,O
",",841,O
Eskisehir,841,O
Osmangazi,841,O
University,841,O
",",841,O
Eskisehir,841,O
",",841,O
Turkey,841,O
between,841,O
March,841,O
and,841,O
May,841,O
2012,841,O
.,841,O
Statistical,842,O
analysis,842,O
was,842,O
carried,842,O
out,842,O
using,842,O
Kruskal-Wallis,842,O
test,842,O
for,842,O
hyper,842,B-DiseaseOrPhenotypicFeature
locomotion,842,I-DiseaseOrPhenotypicFeature
",",842,O
and,842,O
one-way,842,O
ANOVA,842,O
for,842,O
climbing,842,O
and,842,O
catalepsy,842,B-DiseaseOrPhenotypicFeature
tests,842,O
.,842,O
RESULTS,843,O
:,843,O
In,843,O
the,843,O
amphetamine-induced,843,B-ChemicalEntity
locomotion,843,O
test,843,O
",",843,O
there,843,O
were,843,O
significant,843,O
increases,843,O
in,843,O
all,843,O
movements,843,O
compared,843,O
with,843,O
the,843,O
amphetamine-free,843,B-ChemicalEntity
group,843,O
.,843,O
Both,844,O
DHEA,844,B-ChemicalEntity
50,844,O
mg/kg,844,O
(,844,O
p,844,O
<,844,O
0.05,844,O
),844,O
",",844,O
and,844,O
100,844,O
mg/kg,844,O
(,844,O
p,844,O
<,844,O
0.01,844,O
),844,O
significantly,844,O
decreased,844,O
all,844,O
movements,844,O
compared,844,O
with,844,O
the,844,O
amphetamine-induced,844,B-ChemicalEntity
locomotion,844,O
group,844,O
.,844,O
There,845,O
was,845,O
a,845,O
significant,845,O
difference,845,O
between,845,O
groups,845,O
in,845,O
the,845,O
haloperidol-induced,845,B-ChemicalEntity
catalepsy,845,B-DiseaseOrPhenotypicFeature
test,845,O
(,845,O
p,845,O
<,845,O
0.05,845,O
),845,O
.,845,O
There,846,O
was,846,O
no,846,O
significant,846,O
difference,846,O
between,846,O
groups,846,O
in,846,O
terms,846,O
of,846,O
total,846,O
climbing,846,O
time,846,O
in,846,O
the,846,O
apomorphine-induced,846,B-ChemicalEntity
climbing,846,O
test,846,O
(,846,O
p,846,O
>,846,O
0.05,846,O
),846,O
.,846,O
CONCLUSION,847,O
:,847,O
We,847,O
observed,847,O
that,847,O
DHEA,847,B-ChemicalEntity
reduced,847,O
locomotor,847,O
activity,847,O
and,847,O
increased,847,O
catalepsy,847,B-DiseaseOrPhenotypicFeature
at,847,O
both,847,O
doses,847,O
",",847,O
while,847,O
it,847,O
had,847,O
no,847,O
effect,847,O
on,847,O
climbing,847,O
behavior,847,O
.,847,O
We,848,O
suggest,848,O
that,848,O
DHEA,848,B-ChemicalEntity
displays,848,O
typical,848,O
neuroleptic-like,848,O
effects,848,O
",",848,O
and,848,O
may,848,O
be,848,O
used,848,O
in,848,O
the,848,O
treatment,848,O
of,848,O
schizophrenia,848,B-DiseaseOrPhenotypicFeature
.,848,O
Aconitine-induced,849,B-ChemicalEntity
Ca2+,849,B-ChemicalEntity
overload,849,O
causes,849,O
arrhythmia,849,B-DiseaseOrPhenotypicFeature
and,849,O
triggers,849,O
apoptosis,849,O
through,849,O
p38,849,B-GeneOrGeneProduct
MAPK,849,I-GeneOrGeneProduct
signaling,849,O
pathway,849,O
in,849,O
rats,849,B-OrganismTaxon
.,849,O
Aconitine,850,B-ChemicalEntity
is,850,O
a,850,O
major,850,O
bioactive,850,O
diterpenoid,850,B-ChemicalEntity
alkaloid,850,I-ChemicalEntity
with,850,O
high,850,O
content,850,O
derived,850,O
from,850,O
herbal,850,O
aconitum,850,O
plants,850,O
.,850,O
Emerging,851,O
evidence,851,O
indicates,851,O
that,851,O
voltage-dependent,851,O
Na,851,B-ChemicalEntity
(,851,I-ChemicalEntity
+,851,I-ChemicalEntity
),851,I-ChemicalEntity
channels,851,O
have,851,O
pivotal,851,O
roles,851,O
in,851,O
the,851,O
cardiotoxicity,851,B-DiseaseOrPhenotypicFeature
of,851,O
aconitine,851,B-ChemicalEntity
.,851,O
However,852,O
",",852,O
no,852,O
reports,852,O
are,852,O
available,852,O
on,852,O
the,852,O
role,852,O
of,852,O
Ca,852,B-ChemicalEntity
(,852,I-ChemicalEntity
2+,852,I-ChemicalEntity
),852,I-ChemicalEntity
in,852,O
aconitine,852,B-ChemicalEntity
poisoning,852,B-DiseaseOrPhenotypicFeature
.,852,O
In,853,O
this,853,O
study,853,O
",",853,O
we,853,O
explored,853,O
the,853,O
importance,853,O
of,853,O
pathological,853,O
Ca,853,B-ChemicalEntity
(,853,I-ChemicalEntity
2+,853,I-ChemicalEntity
),853,I-ChemicalEntity
signaling,853,O
in,853,O
aconitine,853,B-ChemicalEntity
poisoning,853,B-DiseaseOrPhenotypicFeature
in,853,O
vitro,853,O
and,853,O
in,853,O
vivo,853,O
.,853,O
We,854,O
found,854,O
that,854,O
Ca,854,B-ChemicalEntity
(,854,I-ChemicalEntity
2+,854,I-ChemicalEntity
),854,I-ChemicalEntity
overload,854,O
lead,854,O
to,854,O
accelerated,854,O
beating,854,O
rhythm,854,O
in,854,O
adult,854,O
rat,854,B-OrganismTaxon
ventricular,854,O
myocytes,854,O
and,854,O
caused,854,O
arrhythmia,854,B-DiseaseOrPhenotypicFeature
in,854,O
conscious,854,O
freely,854,O
moving,854,O
rats,854,B-OrganismTaxon
.,854,O
To,855,O
investigate,855,O
effects,855,O
of,855,O
aconitine,855,B-ChemicalEntity
on,855,O
myocardial,855,B-DiseaseOrPhenotypicFeature
injury,855,I-DiseaseOrPhenotypicFeature
",",855,O
we,855,O
performed,855,O
cytotoxicity,855,B-DiseaseOrPhenotypicFeature
assay,855,O
in,855,O
neonatal,855,O
rat,855,B-OrganismTaxon
ventricular,855,O
myocytes,855,O
(,855,O
NRVMs,855,O
),855,O
",",855,O
as,855,O
well,855,O
as,855,O
measured,855,O
lactate,855,B-GeneOrGeneProduct
dehydrogenase,855,I-GeneOrGeneProduct
level,855,O
in,855,O
the,855,O
culture,855,O
medium,855,O
of,855,O
NRVMs,855,O
and,855,O
activities,855,O
of,855,O
serum,855,O
cardiac,855,O
enzymes,855,O
in,855,O
rats,855,B-OrganismTaxon
.,855,O
The,856,O
results,856,O
showed,856,O
that,856,O
aconitine,856,B-ChemicalEntity
resulted,856,O
in,856,O
myocardial,856,B-DiseaseOrPhenotypicFeature
injury,856,I-DiseaseOrPhenotypicFeature
and,856,O
reduced,856,O
NRVMs,856,O
viability,856,O
dose-dependently,856,O
.,856,O
To,857,O
confirm,857,O
the,857,O
pro-apoptotic,857,O
effects,857,O
",",857,O
we,857,O
performed,857,O
flow,857,O
cytometric,857,O
detection,857,O
",",857,O
cardiac,857,O
histology,857,O
",",857,O
transmission,857,O
electron,857,O
microscopy,857,O
and,857,O
terminal,857,O
deoxynucleotidyl,857,O
transferase-mediated,857,O
dUTP-biotin,857,B-ChemicalEntity
nick,857,O
end,857,O
labeling,857,O
assay,857,O
.,857,O
The,858,O
results,858,O
showed,858,O
that,858,O
aconitine,858,B-ChemicalEntity
stimulated,858,O
apoptosis,858,O
time-dependently,858,O
.,858,O
The,859,O
expression,859,O
analysis,859,O
of,859,O
Ca,859,B-ChemicalEntity
(,859,I-ChemicalEntity
2+,859,I-ChemicalEntity
),859,I-ChemicalEntity
handling,859,O
proteins,859,O
demonstrated,859,O
that,859,O
aconitine,859,B-ChemicalEntity
promoted,859,O
Ca,859,B-ChemicalEntity
(,859,I-ChemicalEntity
2+,859,I-ChemicalEntity
),859,I-ChemicalEntity
overload,859,O
through,859,O
the,859,O
expression,859,O
regulation,859,O
of,859,O
Ca,859,B-ChemicalEntity
(,859,I-ChemicalEntity
2+,859,I-ChemicalEntity
),859,I-ChemicalEntity
handling,859,O
proteins,859,O
.,859,O
The,860,O
expression,860,O
analysis,860,O
of,860,O
apoptosis-related,860,O
proteins,860,O
revealed,860,O
that,860,O
pro-apoptotic,860,O
protein,860,O
expression,860,O
was,860,O
upregulated,860,O
",",860,O
and,860,O
anti-apoptotic,860,O
protein,860,O
BCL-2,860,B-GeneOrGeneProduct
expression,860,O
was,860,O
downregulated,860,O
.,860,O
Furthermore,861,O
",",861,O
increased,861,O
phosphorylation,861,O
of,861,O
MAPK,861,B-GeneOrGeneProduct
family,861,O
members,861,O
",",861,O
especially,861,O
the,861,O
P-P38/P38,861,O
ratio,861,O
was,861,O
found,861,O
in,861,O
cardiac,861,O
tissues,861,O
.,861,O
Hence,862,O
",",862,O
our,862,O
results,862,O
suggest,862,O
that,862,O
aconitine,862,B-ChemicalEntity
significantly,862,O
aggravates,862,O
Ca,862,B-ChemicalEntity
(,862,I-ChemicalEntity
2+,862,I-ChemicalEntity
),862,I-ChemicalEntity
overload,862,O
and,862,O
causes,862,O
arrhythmia,862,B-DiseaseOrPhenotypicFeature
and,862,O
finally,862,O
promotes,862,O
apoptotic,862,O
development,862,O
via,862,O
phosphorylation,862,O
of,862,O
P38,862,B-GeneOrGeneProduct
mitogen-activated,862,I-GeneOrGeneProduct
protein,862,I-GeneOrGeneProduct
kinase,862,I-GeneOrGeneProduct
.,862,O
Absence,863,O
of,863,O
PKC-alpha,863,B-GeneOrGeneProduct
attenuates,863,O
lithium-induced,863,B-ChemicalEntity
nephrogenic,863,B-DiseaseOrPhenotypicFeature
diabetes,863,I-DiseaseOrPhenotypicFeature
insipidus,863,I-DiseaseOrPhenotypicFeature
.,863,O
Lithium,864,B-ChemicalEntity
",",864,O
an,864,O
effective,864,O
antipsychotic,864,O
",",864,O
induces,864,O
nephrogenic,864,B-DiseaseOrPhenotypicFeature
diabetes,864,I-DiseaseOrPhenotypicFeature
insipidus,864,I-DiseaseOrPhenotypicFeature
(,864,O
NDI,864,B-DiseaseOrPhenotypicFeature
),864,O
in,864,O
40,864,O
%,864,O
of,864,O
patients,864,B-OrganismTaxon
.,864,O
The,865,O
decreased,865,O
capacity,865,O
to,865,O
concentrate,865,O
urine,865,O
is,865,O
likely,865,O
due,865,O
to,865,O
lithium,865,B-ChemicalEntity
acutely,865,O
disrupting,865,O
the,865,O
cAMP,865,B-ChemicalEntity
pathway,865,O
and,865,O
chronically,865,O
reducing,865,O
urea,865,B-GeneOrGeneProduct
transporter,865,I-GeneOrGeneProduct
(,865,O
UT-A1,865,B-GeneOrGeneProduct
),865,O
and,865,O
water,865,O
channel,865,O
(,865,O
AQP2,865,B-GeneOrGeneProduct
),865,O
expression,865,O
in,865,O
the,865,O
inner,865,O
medulla,865,O
.,865,O
Targeting,866,O
an,866,O
alternative,866,O
signaling,866,O
pathway,866,O
",",866,O
such,866,O
as,866,O
PKC-mediated,866,B-GeneOrGeneProduct
signaling,866,O
",",866,O
may,866,O
be,866,O
an,866,O
effective,866,O
method,866,O
of,866,O
treating,866,O
lithium-induced,866,B-ChemicalEntity
polyuria,866,B-DiseaseOrPhenotypicFeature
.,866,O
PKC-alpha,867,B-GeneOrGeneProduct
null,867,O
mice,867,B-OrganismTaxon
(,867,O
PKCa,867,B-GeneOrGeneProduct
KO,867,O
),867,O
and,867,O
strain-matched,867,O
wild,867,O
type,867,O
(,867,O
WT,867,O
),867,O
controls,867,O
were,867,O
treated,867,O
with,867,O
lithium,867,B-ChemicalEntity
for,867,O
0,867,O
",",867,O
3,867,O
or,867,O
5,867,O
days,867,O
.,867,O
WT,868,O
mice,868,B-OrganismTaxon
had,868,O
increased,868,O
urine,868,O
output,868,O
and,868,O
lowered,868,O
urine,868,O
osmolality,868,O
after,868,O
3,868,O
and,868,O
5,868,O
days,868,O
of,868,O
treatment,868,O
whereas,868,O
PKCa,868,B-GeneOrGeneProduct
KO,868,O
mice,868,B-OrganismTaxon
had,868,O
no,868,O
change,868,O
in,868,O
urine,868,O
output,868,O
or,868,O
concentration,868,O
.,868,O
Western,869,O
blot,869,O
analysis,869,O
revealed,869,O
that,869,O
AQP2,869,B-GeneOrGeneProduct
expression,869,O
in,869,O
medullary,869,O
tissues,869,O
was,869,O
lowered,869,O
after,869,O
3,869,O
and,869,O
5,869,O
days,869,O
in,869,O
WT,869,O
mice,869,B-OrganismTaxon
;,869,O
however,869,O
",",869,O
AQP2,869,B-GeneOrGeneProduct
was,869,O
unchanged,869,O
in,869,O
PKCa,869,B-GeneOrGeneProduct
KO,869,O
.,869,O
Similar,870,O
results,870,O
were,870,O
observed,870,O
with,870,O
UT-A1,870,B-GeneOrGeneProduct
expression,870,O
.,870,O
Animals,871,O
were,871,O
also,871,O
treated,871,O
with,871,O
lithium,871,B-ChemicalEntity
for,871,O
6,871,O
weeks,871,O
.,871,O
Lithium-treated,872,B-ChemicalEntity
WT,872,O
mice,872,B-OrganismTaxon
had,872,O
19-fold,872,O
increased,872,O
urine,872,O
output,872,O
whereas,872,O
treated,872,O
PKCa,872,B-GeneOrGeneProduct
KO,872,O
animals,872,O
had,872,O
a,872,O
4-fold,872,O
increase,872,O
in,872,O
output,872,O
.,872,O
AQP2,873,B-GeneOrGeneProduct
and,873,O
UT-A1,873,B-GeneOrGeneProduct
expression,873,O
was,873,O
lowered,873,O
in,873,O
6,873,O
week,873,O
lithium-treated,873,B-ChemicalEntity
WT,873,O
animals,873,O
whereas,873,O
in,873,O
treated,873,O
PKCa,873,B-GeneOrGeneProduct
KO,873,O
mice,873,B-OrganismTaxon
",",873,O
AQP2,873,B-GeneOrGeneProduct
was,873,O
only,873,O
reduced,873,O
by,873,O
2-fold,873,O
and,873,O
UT-A1,873,B-GeneOrGeneProduct
expression,873,O
was,873,O
unaffected,873,O
.,873,O
Urinary,874,O
sodium,874,B-ChemicalEntity
",",874,O
potassium,874,B-ChemicalEntity
and,874,O
calcium,874,B-ChemicalEntity
were,874,O
elevated,874,O
in,874,O
lithium-fed,874,B-ChemicalEntity
WT,874,O
but,874,O
not,874,O
in,874,O
lithium-fed,874,B-ChemicalEntity
PKCa,874,B-GeneOrGeneProduct
KO,874,O
mice,874,B-OrganismTaxon
.,874,O
Our,875,O
data,875,O
show,875,O
that,875,O
ablation,875,O
of,875,O
PKCa,875,B-GeneOrGeneProduct
preserves,875,O
AQP2,875,B-GeneOrGeneProduct
and,875,O
UT-A1,875,B-GeneOrGeneProduct
protein,875,O
expression,875,O
and,875,O
localization,875,O
in,875,O
lithium-induced,875,B-ChemicalEntity
NDI,875,B-DiseaseOrPhenotypicFeature
",",875,O
and,875,O
prevents,875,O
the,875,O
development,875,O
of,875,O
the,875,O
severe,875,O
polyuria,875,B-DiseaseOrPhenotypicFeature
associated,875,O
with,875,O
lithium,875,B-ChemicalEntity
therapy,875,O
.,875,O
Leukemia,876,B-GeneOrGeneProduct
inhibitory,876,I-GeneOrGeneProduct
factor,876,I-GeneOrGeneProduct
protects,876,O
the,876,O
lung,876,O
during,876,O
respiratory,876,B-DiseaseOrPhenotypicFeature
syncytial,876,I-DiseaseOrPhenotypicFeature
viral,876,I-DiseaseOrPhenotypicFeature
infection,876,I-DiseaseOrPhenotypicFeature
.,876,O
BACKGROUND,877,O
:,877,O
Respiratory,877,B-OrganismTaxon
syncytial,877,I-OrganismTaxon
virus,877,I-OrganismTaxon
(,877,O
RSV,877,B-OrganismTaxon
),877,O
infects,877,O
the,877,O
lung,877,O
epithelium,877,O
where,877,O
it,877,O
stimulates,877,O
the,877,O
production,877,O
of,877,O
numerous,877,O
host,877,O
cytokines,877,O
that,877,O
are,877,O
associated,877,O
with,877,O
disease,877,O
burden,877,O
and,877,O
acute,877,B-DiseaseOrPhenotypicFeature
lung,877,I-DiseaseOrPhenotypicFeature
injury,877,I-DiseaseOrPhenotypicFeature
.,877,O
Characterizing,878,O
the,878,O
host,878,O
cytokine,878,O
response,878,O
to,878,O
RSV,878,B-DiseaseOrPhenotypicFeature
infection,878,I-DiseaseOrPhenotypicFeature
",",878,O
the,878,O
regulation,878,O
of,878,O
host,878,O
cytokines,878,O
and,878,O
the,878,O
impact,878,O
of,878,O
neutralizing,878,O
an,878,O
RSV-inducible,878,B-OrganismTaxon
cytokine,878,O
during,878,O
infection,878,B-DiseaseOrPhenotypicFeature
were,878,O
undertaken,878,O
in,878,O
this,878,O
study,878,O
.,878,O
METHODS,879,O
:,879,O
A549,879,B-CellLine
",",879,O
primary,879,O
human,879,B-OrganismTaxon
small,879,O
airway,879,O
epithelial,879,O
(,879,O
SAE,879,B-CellLine
),879,O
cells,879,O
and,879,O
wild-type,879,O
",",879,O
TIR-domain-containing,879,B-GeneOrGeneProduct
adapter-inducing,879,I-GeneOrGeneProduct
interferon-b,879,I-GeneOrGeneProduct
(,879,O
Trif,879,B-GeneOrGeneProduct
),879,O
and,879,O
mitochondrial,879,B-GeneOrGeneProduct
antiviral-signaling,879,I-GeneOrGeneProduct
protein,879,I-GeneOrGeneProduct
(,879,O
Mavs,879,B-GeneOrGeneProduct
),879,O
knockout,879,O
(,879,O
KO,879,O
),879,O
mice,879,B-OrganismTaxon
were,879,O
infected,879,O
with,879,O
RSV,879,B-OrganismTaxon
and,879,O
cytokine,879,O
responses,879,O
were,879,O
investigated,879,O
by,879,O
ELISA,879,O
",",879,O
multiplex,879,O
analysis,879,O
and,879,O
qPCR,879,O
.,879,O
Neutralizing,880,O
anti-leukemia,880,O
inhibitory,880,I-GeneOrGeneProduct
factor,880,I-GeneOrGeneProduct
(,880,O
LIF,880,B-GeneOrGeneProduct
),880,O
IgG,880,O
or,880,O
control,880,O
IgG,880,O
was,880,O
administered,880,O
to,880,O
a,880,O
group,880,O
of,880,O
wild-type,880,O
animals,880,O
prior,880,O
to,880,O
RSV,880,B-DiseaseOrPhenotypicFeature
infection,880,I-DiseaseOrPhenotypicFeature
.,880,O
RESULTS,881,O
AND,881,O
DISCUSSION,881,O
:,881,O
RSV-infected,881,B-DiseaseOrPhenotypicFeature
A549,881,B-CellLine
and,881,O
SAE,881,B-CellLine
cells,881,O
release,881,O
a,881,O
network,881,O
of,881,O
cytokines,881,O
",",881,O
including,881,O
newly,881,O
identified,881,O
RSV-inducible,881,B-OrganismTaxon
cytokines,881,O
LIF,881,B-GeneOrGeneProduct
",",881,O
migration,881,B-GeneOrGeneProduct
inhibitory,881,I-GeneOrGeneProduct
factor,881,I-GeneOrGeneProduct
(,881,O
MIF,881,B-GeneOrGeneProduct
),881,O
",",881,O
stem,881,B-GeneOrGeneProduct
cell,881,I-GeneOrGeneProduct
factor,881,I-GeneOrGeneProduct
(,881,O
SCF,881,B-GeneOrGeneProduct
),881,O
",",881,O
CCL27,881,B-GeneOrGeneProduct
",",881,O
CXCL12,881,B-GeneOrGeneProduct
and,881,O
stem,881,B-GeneOrGeneProduct
cell,881,I-GeneOrGeneProduct
growth,881,I-GeneOrGeneProduct
factor,881,I-GeneOrGeneProduct
beta,881,I-GeneOrGeneProduct
(,881,O
SCGF-b,881,B-GeneOrGeneProduct
),881,O
.,881,O
These,882,O
RSV-inducible,882,B-OrganismTaxon
cytokines,882,O
were,882,O
also,882,O
observed,882,O
in,882,O
the,882,O
airways,882,O
of,882,O
mice,882,B-OrganismTaxon
during,882,O
an,882,O
infection,882,B-DiseaseOrPhenotypicFeature
.,882,O
To,883,O
identify,883,O
the,883,O
regulation,883,O
of,883,O
RSV,883,B-OrganismTaxon
inducible,883,O
cytokines,883,O
",",883,O
Mavs,883,B-GeneOrGeneProduct
and,883,O
Trif,883,B-GeneOrGeneProduct
deficient,883,O
animals,883,O
were,883,O
infected,883,O
with,883,O
RSV,883,B-OrganismTaxon
.,883,O
In,884,O
vivo,884,O
induction,884,O
of,884,O
airway,884,O
IL-1b,884,B-GeneOrGeneProduct
",",884,O
IL-4,884,B-GeneOrGeneProduct
",",884,O
IL-5,884,B-GeneOrGeneProduct
",",884,O
IL-6,884,B-GeneOrGeneProduct
",",884,O
IL-12,884,B-GeneOrGeneProduct
(,884,O
p40,884,B-GeneOrGeneProduct
),884,O
",",884,O
IFN-g,884,B-GeneOrGeneProduct
",",884,O
CCL2,884,B-GeneOrGeneProduct
",",884,O
CCL5,884,B-GeneOrGeneProduct
",",884,O
CCL3,884,B-GeneOrGeneProduct
",",884,O
CXCL1,884,B-GeneOrGeneProduct
",",884,O
IP-10/CXCL10,884,B-GeneOrGeneProduct
",",884,O
IL-22,884,B-GeneOrGeneProduct
",",884,O
MIG/CXCL9,884,B-GeneOrGeneProduct
and,884,O
MIF,884,B-GeneOrGeneProduct
were,884,O
dependent,884,O
on,884,O
Mavs,884,B-GeneOrGeneProduct
expression,884,O
in,884,O
mice,884,B-OrganismTaxon
.,884,O
Loss,885,O
of,885,O
Trif,885,B-GeneOrGeneProduct
expression,885,O
in,885,O
mice,885,B-OrganismTaxon
altered,885,O
the,885,O
RSV,885,B-OrganismTaxon
induction,885,O
of,885,O
IL-1b,885,B-GeneOrGeneProduct
",",885,O
IL-5,885,B-GeneOrGeneProduct
",",885,O
CXCL12,885,B-GeneOrGeneProduct
",",885,O
MIF,885,B-GeneOrGeneProduct
",",885,O
LIF,885,B-GeneOrGeneProduct
",",885,O
CXCL12,885,B-GeneOrGeneProduct
and,885,O
IFN-g.,885,B-GeneOrGeneProduct
Silencing,885,O
of,885,O
retinoic,885,B-GeneOrGeneProduct
acid-inducible,885,I-GeneOrGeneProduct
gene-1,885,I-GeneOrGeneProduct
(,885,O
RIG-I,885,B-GeneOrGeneProduct
),885,O
expression,885,O
in,885,O
A549,885,B-CellLine
cells,885,O
had,885,O
a,885,O
greater,885,O
impact,885,O
on,885,O
RSV-inducible,885,B-OrganismTaxon
cytokines,885,O
than,885,O
melanoma,885,B-GeneOrGeneProduct
differentiation-associated,885,I-GeneOrGeneProduct
protein,885,I-GeneOrGeneProduct
5,885,I-GeneOrGeneProduct
(,885,O
MDA5,885,B-GeneOrGeneProduct
),885,O
and,885,O
laboratory,885,B-GeneOrGeneProduct
of,885,I-GeneOrGeneProduct
genetics,885,I-GeneOrGeneProduct
and,885,I-GeneOrGeneProduct
physiology,885,I-GeneOrGeneProduct
2,885,I-GeneOrGeneProduct
(,885,O
LGP2,885,B-GeneOrGeneProduct
),885,O
",",885,O
and,885,O
Trif,885,B-GeneOrGeneProduct
expression,885,O
.,885,O
To,886,O
evaluate,886,O
the,886,O
role,886,O
of,886,O
LIF,886,B-GeneOrGeneProduct
in,886,O
the,886,O
airways,886,O
during,886,O
RSV,886,B-DiseaseOrPhenotypicFeature
infection,886,I-DiseaseOrPhenotypicFeature
",",886,O
animals,886,O
were,886,O
treated,886,O
with,886,O
neutralizing,886,O
anti-LIF,886,O
IgG,886,O
",",886,O
which,886,O
enhanced,886,O
RSV,886,B-OrganismTaxon
pathology,886,O
observed,886,O
with,886,O
increased,886,O
airspace,886,O
protein,886,O
content,886,O
",",886,O
apoptosis,886,O
and,886,O
airway,886,O
hyperresponsiveness,886,O
compared,886,O
to,886,O
control,886,O
IgG,886,O
treatment,886,O
.,886,O
CONCLUSIONS,887,O
:,887,O
RSV,887,B-DiseaseOrPhenotypicFeature
infection,887,I-DiseaseOrPhenotypicFeature
in,887,O
the,887,O
epithelium,887,O
induces,887,O
a,887,O
network,887,O
of,887,O
immune,887,O
factors,887,O
to,887,O
counter,887,O
infection,887,B-DiseaseOrPhenotypicFeature
",",887,O
primarily,887,O
in,887,O
a,887,O
RIG-I,887,B-GeneOrGeneProduct
dependent,887,O
manner,887,O
.,887,O
Expression,888,O
of,888,O
LIF,888,B-GeneOrGeneProduct
protects,888,O
the,888,O
lung,888,O
from,888,O
lung,888,B-DiseaseOrPhenotypicFeature
injury,888,I-DiseaseOrPhenotypicFeature
and,888,O
enhanced,888,O
pathology,888,O
during,888,O
RSV,888,B-DiseaseOrPhenotypicFeature
infection,888,I-DiseaseOrPhenotypicFeature
.,888,O
Neuroprotective,889,O
effect,889,O
of,889,O
neuroserpin,889,B-GeneOrGeneProduct
in,889,O
oxygen-glucose,889,B-ChemicalEntity
deprivation-,889,O
and,889,O
reoxygenation-treated,889,O
rat,889,B-OrganismTaxon
astrocytes,889,O
in,889,O
vitro,889,O
.,889,O
Neuroserpin,890,B-GeneOrGeneProduct
(,890,O
NSP,890,B-GeneOrGeneProduct
),890,O
reportedly,890,O
exerts,890,O
neuroprotective,890,O
effects,890,O
in,890,O
cerebral,890,B-DiseaseOrPhenotypicFeature
ischemic,890,I-DiseaseOrPhenotypicFeature
animal,890,O
models,890,O
and,890,O
patients,890,B-OrganismTaxon
;,890,O
however,890,O
",",890,O
the,890,O
mechanism,890,O
of,890,O
protection,890,O
is,890,O
poorly,890,O
understood,890,O
.,890,O
We,891,O
thus,891,O
attempted,891,O
to,891,O
confirm,891,O
neuroprotective,891,O
effects,891,O
of,891,O
NSP,891,B-GeneOrGeneProduct
on,891,O
astrocytes,891,O
in,891,O
the,891,O
ischemic,891,B-DiseaseOrPhenotypicFeature
state,891,O
and,891,O
then,891,O
explored,891,O
the,891,O
relative,891,O
mechanisms,891,O
.,891,O
Astrocytes,892,O
from,892,O
neonatal,892,O
rats,892,B-OrganismTaxon
were,892,O
treated,892,O
with,892,O
oxygen-glucose,892,B-ChemicalEntity
deprivation,892,O
(,892,O
OGD,892,O
),892,O
followed,892,O
by,892,O
reoxygenation,892,O
(,892,O
OGD/R,892,O
),892,O
.,892,O
To,893,O
confirm,893,O
the,893,O
neuroprotective,893,O
effects,893,O
of,893,O
NSP,893,B-GeneOrGeneProduct
",",893,O
we,893,O
measured,893,O
the,893,O
cell,893,O
survival,893,O
rate,893,O
",",893,O
relative,893,O
lactate,893,B-GeneOrGeneProduct
dehydrogenase,893,I-GeneOrGeneProduct
(,893,O
LDH,893,B-GeneOrGeneProduct
),893,O
release,893,O
;,893,O
we,893,O
also,893,O
performed,893,O
morphological,893,O
methods,893,O
",",893,O
namely,893,O
Hoechst,893,O
33342,893,O
staining,893,O
and,893,O
Annexin,893,B-GeneOrGeneProduct
V,893,I-GeneOrGeneProduct
assay,893,O
.,893,O
To,894,O
explore,894,O
the,894,O
potential,894,O
mechanisms,894,O
of,894,O
NSP,894,B-GeneOrGeneProduct
",",894,O
the,894,O
release,894,O
of,894,O
nitric,894,B-ChemicalEntity
oxide,894,I-ChemicalEntity
(,894,O
NO,894,B-ChemicalEntity
),894,O
and,894,O
TNF-alpha,894,B-GeneOrGeneProduct
related,894,O
to,894,O
NSP,894,B-GeneOrGeneProduct
administration,894,O
were,894,O
measured,894,O
by,894,O
enzyme-linked,894,O
immunosorbent,894,O
assay,894,O
.,894,O
The,895,O
proteins,895,O
related,895,O
to,895,O
the,895,O
NF-kappaB,895,B-GeneOrGeneProduct
",",895,O
ERK1/2,895,B-GeneOrGeneProduct
",",895,O
and,895,O
PI3K/Akt,895,B-GeneOrGeneProduct
pathways,895,O
were,895,O
investigated,895,O
by,895,O
Western,895,O
blotting,895,O
.,895,O
To,896,O
verify,896,O
the,896,O
cause-and-effect,896,O
relationship,896,O
between,896,O
neuroprotection,896,O
and,896,O
the,896,O
NF-kappaB,896,B-GeneOrGeneProduct
pathway,896,O
",",896,O
a,896,O
NF-kappaB,896,B-GeneOrGeneProduct
pathway,896,O
inhibitor,896,O
sc3060,896,B-ChemicalEntity
was,896,O
employed,896,O
to,896,O
observe,896,O
the,896,O
effects,896,O
of,896,O
NSP-induced,896,B-GeneOrGeneProduct
neuroprotection,896,O
.,896,O
We,897,O
found,897,O
that,897,O
NSP,897,B-GeneOrGeneProduct
significantly,897,O
increased,897,O
the,897,O
cell,897,O
survival,897,O
rate,897,O
and,897,O
reduced,897,O
LDH,897,B-GeneOrGeneProduct
release,897,O
in,897,O
OGD/R-treated,897,O
astrocytes,897,O
.,897,O
It,898,O
also,898,O
reduced,898,O
NO/TNF-alpha,898,B-ChemicalEntity
release,898,O
.,898,O
Western,899,O
blotting,899,O
showed,899,O
that,899,O
the,899,O
protein,899,O
levels,899,O
of,899,O
p-IKKBalpha/beta,899,O
and,899,O
P65,899,B-GeneOrGeneProduct
were,899,O
upregulated,899,O
by,899,O
the,899,O
OGD/R,899,O
treatment,899,O
and,899,O
such,899,O
effects,899,O
were,899,O
significantly,899,O
inhibited,899,O
by,899,O
NSP,899,B-GeneOrGeneProduct
administration,899,O
.,899,O
The,900,O
NSP-induced,900,B-GeneOrGeneProduct
inhibition,900,O
could,900,O
be,900,O
significantly,900,O
reversed,900,O
by,900,O
administration,900,O
of,900,O
the,900,O
NF-kappaB,900,B-GeneOrGeneProduct
pathway,900,O
inhibitor,900,O
sc3060,900,B-ChemicalEntity
",",900,O
whereas,900,O
",",900,O
expressions,900,O
of,900,O
p-ERK1,900,O
",",900,O
p-ERK2,900,O
",",900,O
and,900,O
p-AKT,900,O
were,900,O
upregulated,900,O
by,900,O
the,900,O
OGD/R,900,O
treatment,900,O
;,900,O
however,900,O
",",900,O
their,900,O
levels,900,O
were,900,O
unchanged,900,O
by,900,O
NSP,900,B-GeneOrGeneProduct
administration,900,O
.,900,O
Our,901,O
results,901,O
thus,901,O
verified,901,O
the,901,O
neuroprotective,901,O
effects,901,O
of,901,O
NSP,901,B-GeneOrGeneProduct
in,901,O
ischemic,901,B-DiseaseOrPhenotypicFeature
astrocytes,901,O
.,901,O
The,902,O
potential,902,O
mechanisms,902,O
include,902,O
inhibition,902,O
of,902,O
the,902,O
release,902,O
of,902,O
NO/TNF-alpha,902,B-ChemicalEntity
and,902,O
repression,902,O
of,902,O
the,902,O
NF-kappaB,902,B-GeneOrGeneProduct
signaling,902,O
pathways,902,O
.,902,O
Our,903,O
data,903,O
also,903,O
indicated,903,O
that,903,O
NSP,903,B-GeneOrGeneProduct
has,903,O
little,903,O
influence,903,O
on,903,O
the,903,O
MAPK,903,B-GeneOrGeneProduct
and,903,O
PI3K/Akt,903,B-GeneOrGeneProduct
pathways,903,O
.,903,O
Protein-Trap,904,O
Insertional,904,O
Mutagenesis,904,O
Uncovers,904,O
New,904,O
Genes,904,O
Involved,904,O
in,904,O
Zebrafish,904,B-OrganismTaxon
Skin,904,O
Development,904,O
",",904,O
Including,904,O
a,904,O
Neuregulin,904,B-GeneOrGeneProduct
2a-Based,904,O
ErbB,904,B-GeneOrGeneProduct
Signaling,904,O
Pathway,904,O
Required,904,O
during,904,O
Median,904,O
Fin,904,O
Fold,904,O
Morphogenesis,904,O
.,904,O
Skin,905,B-DiseaseOrPhenotypicFeature
disorders,905,I-DiseaseOrPhenotypicFeature
are,905,O
widespread,905,O
",",905,O
but,905,O
available,905,O
treatments,905,O
are,905,O
limited,905,O
.,905,O
A,906,O
more,906,O
comprehensive,906,O
understanding,906,O
of,906,O
skin,906,O
development,906,O
mechanisms,906,O
will,906,O
drive,906,O
identification,906,O
of,906,O
new,906,O
treatment,906,O
targets,906,O
and,906,O
modalities,906,O
.,906,O
Here,907,O
we,907,O
report,907,O
the,907,O
Zebrafish,907,B-OrganismTaxon
Integument,907,O
Project,907,O
(,907,O
ZIP,907,O
),907,O
",",907,O
an,907,O
expression-driven,907,O
platform,907,O
for,907,O
identifying,907,O
new,907,O
skin,907,O
genes,907,O
and,907,O
phenotypes,907,O
in,907,O
the,907,O
vertebrate,907,O
model,907,O
Danio,907,B-OrganismTaxon
rerio,907,I-OrganismTaxon
(,907,O
zebrafish,907,B-OrganismTaxon
),907,O
.,907,O
In,908,O
vivo,908,O
selection,908,O
for,908,O
skin-specific,908,O
expression,908,O
of,908,O
gene-break,908,O
transposon,908,O
(,908,O
GBT,908,O
),908,O
mutant,908,O
lines,908,O
identified,908,O
eleven,908,O
new,908,O
",",908,O
revertible,908,O
GBT,908,O
alleles,908,O
of,908,O
genes,908,O
involved,908,O
in,908,O
skin,908,O
development,908,O
.,908,O
Eight,909,O
genes,909,O
--,909,O
fras1,909,B-GeneOrGeneProduct
",",909,O
grip1,909,B-GeneOrGeneProduct
",",909,O
hmcn1,909,B-GeneOrGeneProduct
",",909,O
msxc,909,B-GeneOrGeneProduct
",",909,O
col4a4,909,B-GeneOrGeneProduct
",",909,O
ahnak,909,B-GeneOrGeneProduct
",",909,O
capn12,909,B-GeneOrGeneProduct
",",909,O
and,909,O
nrg2a,909,B-GeneOrGeneProduct
--,909,O
had,909,O
been,909,O
described,909,O
in,909,O
an,909,O
integumentary,909,O
context,909,O
to,909,O
varying,909,O
degrees,909,O
",",909,O
while,909,O
arhgef25b,909,B-GeneOrGeneProduct
",",909,O
fkbp10b,909,B-GeneOrGeneProduct
",",909,O
and,909,O
megf6a,909,B-GeneOrGeneProduct
emerged,909,O
as,909,O
novel,909,O
skin,909,O
genes,909,O
.,909,O
Embryos,910,O
homozygous,910,O
for,910,O
a,910,O
GBT,910,O
insertion,910,O
within,910,O
neuregulin,910,B-GeneOrGeneProduct
2a,910,I-GeneOrGeneProduct
(,910,O
nrg2a,910,B-GeneOrGeneProduct
),910,O
revealed,910,O
a,910,O
novel,910,O
requirement,910,O
for,910,O
a,910,O
Neuregulin,910,B-GeneOrGeneProduct
2a,910,I-GeneOrGeneProduct
(,910,O
Nrg2a,910,B-GeneOrGeneProduct
),910,O
-ErbB2/3-AKT,910,O
signaling,910,O
pathway,910,O
governing,910,O
the,910,O
apicobasal,910,O
organization,910,O
of,910,O
a,910,O
subset,910,O
of,910,O
epidermal,910,O
cells,910,O
during,910,O
median,910,O
fin,910,O
fold,910,O
(,910,O
MFF,910,O
),910,O
morphogenesis,910,O
.,910,O
In,911,O
nrg2a,911,B-GeneOrGeneProduct
mutant,911,O
larvae,911,O
",",911,O
the,911,O
basal,911,O
keratinocytes,911,O
within,911,O
the,911,O
apical,911,O
MFF,911,O
",",911,O
known,911,O
as,911,O
ridge,911,O
cells,911,O
",",911,O
displayed,911,O
reduced,911,O
pAKT,911,O
levels,911,O
as,911,O
well,911,O
as,911,O
reduced,911,O
apical,911,O
domains,911,O
and,911,O
exaggerated,911,O
basolateral,911,O
domains,911,O
.,911,O
Those,912,O
defects,912,O
compromised,912,O
proper,912,O
ridge,912,O
cell,912,O
elongation,912,O
into,912,O
a,912,O
flattened,912,O
epithelial,912,O
morphology,912,O
",",912,O
resulting,912,O
in,912,O
thickened,912,O
MFF,912,O
edges,912,O
.,912,O
Pharmacological,913,O
inhibition,913,O
verified,913,O
that,913,O
Nrg2a,913,B-GeneOrGeneProduct
signals,913,O
through,913,O
the,913,O
ErbB,913,B-GeneOrGeneProduct
receptor,913,I-GeneOrGeneProduct
tyrosine,913,I-GeneOrGeneProduct
kinase,913,I-GeneOrGeneProduct
network,913,O
.,913,O
Moreover,914,O
",",914,O
knockdown,914,O
of,914,O
the,914,O
epithelial,914,O
polarity,914,O
regulator,914,O
and,914,O
tumor,914,B-DiseaseOrPhenotypicFeature
suppressor,914,O
lgl2,914,B-GeneOrGeneProduct
ameliorated,914,O
the,914,O
nrg2a,914,B-GeneOrGeneProduct
mutant,914,O
phenotype,914,O
.,914,O
Identifying,915,O
Lgl2,915,B-GeneOrGeneProduct
as,915,O
an,915,O
antagonist,915,O
of,915,O
Nrg2a-ErbB,915,B-GeneOrGeneProduct
signaling,915,O
revealed,915,O
a,915,O
significantly,915,O
earlier,915,O
role,915,O
for,915,O
Lgl2,915,B-GeneOrGeneProduct
during,915,O
epidermal,915,O
morphogenesis,915,O
than,915,O
has,915,O
been,915,O
described,915,O
to,915,O
date,915,O
.,915,O
Furthermore,916,O
",",916,O
our,916,O
findings,916,O
demonstrated,916,O
that,916,O
successive,916,O
",",916,O
coordinated,916,O
ridge,916,O
cell,916,O
shape,916,O
changes,916,O
drive,916,O
apical,916,O
MFF,916,O
development,916,O
",",916,O
making,916,O
MFF,916,O
ridge,916,O
cells,916,O
a,916,O
valuable,916,O
model,916,O
for,916,O
investigating,916,O
how,916,O
the,916,O
coordinated,916,O
regulation,916,O
of,916,O
cell,916,O
polarity,916,O
and,916,O
cell,916,O
shape,916,O
changes,916,O
serves,916,O
as,916,O
a,916,O
crucial,916,O
mechanism,916,O
of,916,O
epithelial,916,O
morphogenesis,916,O
.,916,O
The,917,O
impact,917,O
of,917,O
PPARa,917,B-GeneOrGeneProduct
activation,917,O
on,917,O
whole,917,O
genome,917,O
gene,917,O
expression,917,O
in,917,O
human,917,B-OrganismTaxon
precision,917,O
cut,917,O
liver,917,O
slices,917,O
.,917,O
BACKGROUND,918,O
:,918,O
Studies,918,O
in,918,O
mice,918,B-OrganismTaxon
have,918,O
shown,918,O
that,918,O
PPARa,918,B-GeneOrGeneProduct
is,918,O
an,918,O
important,918,O
regulator,918,O
of,918,O
lipid,918,B-ChemicalEntity
metabolism,918,O
in,918,O
liver,918,O
and,918,O
key,918,O
transcription,918,O
factor,918,O
involved,918,O
in,918,O
the,918,O
adaptive,918,O
response,918,O
to,918,O
fasting,918,O
.,918,O
However,919,O
",",919,O
much,919,O
less,919,O
is,919,O
known,919,O
about,919,O
the,919,O
role,919,O
of,919,O
PPARa,919,B-GeneOrGeneProduct
in,919,O
human,919,B-OrganismTaxon
liver,919,O
.,919,O
METHODS,920,O
:,920,O
Here,920,O
we,920,O
set,920,O
out,920,O
to,920,O
study,920,O
the,920,O
function,920,O
of,920,O
PPARa,920,B-GeneOrGeneProduct
in,920,O
human,920,B-OrganismTaxon
liver,920,O
via,920,O
analysis,920,O
of,920,O
whole,920,O
genome,920,O
gene,920,O
regulation,920,O
in,920,O
human,920,B-OrganismTaxon
liver,920,O
slices,920,O
treated,920,O
with,920,O
the,920,O
PPARa,920,B-GeneOrGeneProduct
agonist,920,O
Wy14643,920,B-ChemicalEntity
.,920,O
RESULTS,921,O
:,921,O
Quantitative,921,O
PCR,921,O
indicated,921,O
that,921,O
PPARa,921,B-GeneOrGeneProduct
is,921,O
well,921,O
expressed,921,O
in,921,O
human,921,B-OrganismTaxon
liver,921,O
and,921,O
human,921,B-OrganismTaxon
liver,921,O
slices,921,O
and,921,O
that,921,O
the,921,O
classical,921,O
PPARa,921,B-GeneOrGeneProduct
targets,921,O
PLIN2,921,B-GeneOrGeneProduct
",",921,O
VLDLR,921,B-GeneOrGeneProduct
",",921,O
ANGPTL4,921,B-GeneOrGeneProduct
",",921,O
CPT1A,921,B-GeneOrGeneProduct
and,921,O
PDK4,921,B-GeneOrGeneProduct
are,921,O
robustly,921,O
induced,921,O
by,921,O
PPARa,921,B-GeneOrGeneProduct
activation,921,O
.,921,O
Transcriptomics,922,O
analysis,922,O
indicated,922,O
that,922,O
617,922,O
genes,922,O
were,922,O
upregulated,922,O
and,922,O
665,922,O
genes,922,O
were,922,O
downregulated,922,O
by,922,O
PPARa,922,B-GeneOrGeneProduct
activation,922,O
(,922,O
q,922,O
value,922,O
<,922,O
0.05,922,O
),922,O
.,922,O
Many,923,O
genes,923,O
induced,923,O
by,923,O
PPARa,923,B-GeneOrGeneProduct
activation,923,O
were,923,O
involved,923,O
in,923,O
lipid,923,B-ChemicalEntity
metabolism,923,O
(,923,O
ACSL5,923,B-GeneOrGeneProduct
",",923,O
AGPAT9,923,B-GeneOrGeneProduct
",",923,O
FADS1,923,B-GeneOrGeneProduct
",",923,O
SLC27A4,923,B-GeneOrGeneProduct
),923,O
",",923,O
xenobiotic,923,O
metabolism,923,O
(,923,O
POR,923,B-GeneOrGeneProduct
",",923,O
ABCC2,923,B-GeneOrGeneProduct
",",923,O
CYP3A5,923,B-GeneOrGeneProduct
),923,O
or,923,O
the,923,O
unfolded,923,O
protein,923,O
response,923,O
",",923,O
whereas,923,O
most,923,O
of,923,O
the,923,O
downregulated,923,O
genes,923,O
were,923,O
involved,923,O
in,923,O
immune-related,923,O
pathways,923,O
.,923,O
Among,924,O
the,924,O
most,924,O
highly,924,O
repressed,924,O
genes,924,O
upon,924,O
PPARa,924,B-GeneOrGeneProduct
activation,924,O
were,924,O
several,924,O
chemokines,924,B-GeneOrGeneProduct
(,924,O
e.g,924,O
.,924,O
CXCL9-11,925,B-GeneOrGeneProduct
",",925,O
CCL8,925,B-GeneOrGeneProduct
",",925,O
CX3CL1,925,B-GeneOrGeneProduct
",",925,O
CXCL6,925,B-GeneOrGeneProduct
),925,O
",",925,O
interferon,925,B-GeneOrGeneProduct
g-induced,925,O
genes,925,O
(,925,O
e.g,925,O
.,925,O
IFITM1,926,B-GeneOrGeneProduct
",",926,O
IFIT1,926,B-GeneOrGeneProduct
",",926,O
IFIT2,926,B-GeneOrGeneProduct
",",926,O
IFIT3,926,B-GeneOrGeneProduct
),926,O
and,926,O
numerous,926,O
other,926,O
immune-related,926,O
genes,926,O
(,926,O
e.g,926,O
.,926,O
TLR3,927,B-GeneOrGeneProduct
",",927,O
NOS2,927,B-GeneOrGeneProduct
",",927,O
and,927,O
LCN2,927,B-GeneOrGeneProduct
),927,O
.,927,O
Comparative,928,O
analysis,928,O
of,928,O
gene,928,O
regulation,928,O
by,928,O
Wy14643,928,B-ChemicalEntity
between,928,O
human,928,B-OrganismTaxon
liver,928,O
slices,928,O
and,928,O
primary,928,O
human,928,B-OrganismTaxon
hepatocytes,928,O
showed,928,O
that,928,O
down-regulation,928,O
of,928,O
gene,928,O
expression,928,O
by,928,O
PPARa,928,B-GeneOrGeneProduct
is,928,O
much,928,O
better,928,O
captured,928,O
by,928,O
liver,928,O
slices,928,O
as,928,O
compared,928,O
to,928,O
primary,928,O
hepatocytes,928,O
.,928,O
In,929,O
particular,929,O
",",929,O
PPARa,929,B-GeneOrGeneProduct
activation,929,O
markedly,929,O
suppressed,929,O
immunity/inflammation-related,929,O
genes,929,O
in,929,O
human,929,B-OrganismTaxon
liver,929,O
slices,929,O
but,929,O
not,929,O
in,929,O
primary,929,O
hepatocytes,929,O
.,929,O
Finally,930,O
",",930,O
several,930,O
putative,930,O
new,930,O
target,930,O
genes,930,O
of,930,O
PPARa,930,B-GeneOrGeneProduct
were,930,O
identified,930,O
that,930,O
were,930,O
commonly,930,O
induced,930,O
by,930,O
PPARa,930,B-GeneOrGeneProduct
activation,930,O
in,930,O
the,930,O
two,930,O
human,930,B-OrganismTaxon
liver,930,O
model,930,O
systems,930,O
",",930,O
including,930,O
TSKU,930,B-GeneOrGeneProduct
",",930,O
RHOF,930,B-GeneOrGeneProduct
",",930,O
CA12,930,B-GeneOrGeneProduct
and,930,O
VSIG10L,930,B-GeneOrGeneProduct
.,930,O
CONCLUSION,931,O
:,931,O
Our,931,O
paper,931,O
demonstrates,931,O
the,931,O
suitability,931,O
and,931,O
superiority,931,O
of,931,O
human,931,B-OrganismTaxon
liver,931,O
slices,931,O
over,931,O
primary,931,O
hepatocytes,931,O
for,931,O
studying,931,O
the,931,O
functional,931,O
role,931,O
of,931,O
PPARa,931,B-GeneOrGeneProduct
in,931,O
human,931,B-OrganismTaxon
liver,931,O
.,931,O
Our,932,O
data,932,O
underscore,932,O
the,932,O
major,932,O
role,932,O
of,932,O
PPARa,932,B-GeneOrGeneProduct
in,932,O
regulation,932,O
of,932,O
hepatic,932,O
lipid,932,B-ChemicalEntity
and,932,O
xenobiotic,932,O
metabolism,932,O
in,932,O
human,932,B-OrganismTaxon
liver,932,O
and,932,O
reveal,932,O
a,932,O
marked,932,O
immuno-suppressive/anti-inflammatory,932,O
effect,932,O
of,932,O
PPARa,932,B-GeneOrGeneProduct
in,932,O
human,932,B-OrganismTaxon
liver,932,O
slices,932,O
that,932,O
may,932,O
be,932,O
therapeutically,932,O
relevant,932,O
for,932,O
non-alcoholic,932,B-DiseaseOrPhenotypicFeature
fatty,932,I-DiseaseOrPhenotypicFeature
liver,932,I-DiseaseOrPhenotypicFeature
disease,932,I-DiseaseOrPhenotypicFeature
.,932,O
Upregulation,933,O
of,933,O
centrosomal,933,B-GeneOrGeneProduct
protein,933,I-GeneOrGeneProduct
55,933,I-GeneOrGeneProduct
is,933,O
associated,933,O
with,933,O
unfavorable,933,O
prognosis,933,O
and,933,O
tumor,933,B-DiseaseOrPhenotypicFeature
invasion,933,O
in,933,O
epithelial,933,B-DiseaseOrPhenotypicFeature
ovarian,933,I-DiseaseOrPhenotypicFeature
carcinoma,933,I-DiseaseOrPhenotypicFeature
.,933,O
Centrosomal,934,B-GeneOrGeneProduct
protein,934,I-GeneOrGeneProduct
55,934,I-GeneOrGeneProduct
(,934,O
CEP55,934,B-GeneOrGeneProduct
),934,O
is,934,O
a,934,O
cell,934,O
cycle,934,O
regulator,934,O
implicated,934,O
in,934,O
development,934,O
of,934,O
certain,934,O
cancers,934,B-DiseaseOrPhenotypicFeature
.,934,O
However,935,O
",",935,O
characteristics,935,O
of,935,O
CEP55,935,B-GeneOrGeneProduct
expression,935,O
and,935,O
its,935,O
clinical/prognostic,935,O
significance,935,O
are,935,O
unclear,935,O
in,935,O
human,935,B-OrganismTaxon
epithelial,935,B-DiseaseOrPhenotypicFeature
ovarian,935,I-DiseaseOrPhenotypicFeature
carcinoma,935,I-DiseaseOrPhenotypicFeature
(,935,O
EOC,935,B-DiseaseOrPhenotypicFeature
),935,O
.,935,O
Therefore,936,O
",",936,O
we,936,O
investigated,936,O
the,936,O
expression,936,O
and,936,O
clinicopathological,936,O
significance,936,O
of,936,O
CEP55,936,B-GeneOrGeneProduct
in,936,O
patients,936,B-OrganismTaxon
with,936,O
EOC,936,B-DiseaseOrPhenotypicFeature
and,936,O
its,936,O
role,936,O
in,936,O
regulating,936,O
invasion,936,O
and,936,O
metastasis,936,B-DiseaseOrPhenotypicFeature
of,936,I-DiseaseOrPhenotypicFeature
ovarian,936,I-DiseaseOrPhenotypicFeature
cell,936,O
lines,936,O
.,936,O
CEP55,937,B-GeneOrGeneProduct
mRNA,937,O
and,937,O
protein,937,O
expression,937,O
levels,937,O
were,937,O
detected,937,O
by,937,O
quantitative,937,O
real-time,937,O
PCR,937,O
(,937,O
qRT-PCR,937,O
),937,O
",",937,O
Western,937,O
blotting,937,O
",",937,O
and,937,O
immunohistochemistry,937,O
(,937,O
IHC,937,O
),937,O
.,937,O
Potential,938,O
associations,938,O
of,938,O
CEP55,938,B-GeneOrGeneProduct
expression,938,O
scores,938,O
with,938,O
clinical,938,O
parameters,938,O
and,938,O
patient,938,B-OrganismTaxon
survival,938,O
were,938,O
evaluated,938,O
.,938,O
CEP55,939,B-GeneOrGeneProduct
function,939,O
was,939,O
investigated,939,O
further,939,O
using,939,O
RNA,939,O
interference,939,O
",",939,O
wound,939,O
healing,939,O
assay,939,O
",",939,O
transwell,939,O
assay,939,O
",",939,O
immunofluorescence,939,O
analysis,939,O
",",939,O
qRT-PCR,939,O
",",939,O
and,939,O
Western,939,O
blotting,939,O
.,939,O
CEP55,940,B-GeneOrGeneProduct
was,940,O
significantly,940,O
upregulated,940,O
in,940,O
ovarian,940,B-DiseaseOrPhenotypicFeature
cancer,940,I-DiseaseOrPhenotypicFeature
cell,940,O
lines,940,O
and,940,O
lesions,940,O
compared,940,O
with,940,O
normal,940,O
cells,940,O
and,940,O
adjacent,940,O
noncancerous,940,O
ovarian,940,O
tissues,940,O
.,940,O
In,941,O
the,941,O
213,941,O
EOC,941,B-DiseaseOrPhenotypicFeature
samples,941,O
",",941,O
CEP55,941,B-GeneOrGeneProduct
protein,941,O
levels,941,O
were,941,O
positively,941,O
correlated,941,O
with,941,O
clinical,941,O
stage,941,O
(,941,O
P,941,O
<,941,O
0.001,941,O
),941,O
",",941,O
lymph,941,B-DiseaseOrPhenotypicFeature
node,941,I-DiseaseOrPhenotypicFeature
metastasis,941,I-DiseaseOrPhenotypicFeature
(,941,O
P,941,O
<,941,O
0.001,941,O
),941,O
",",941,O
intraperitoneal,941,B-DiseaseOrPhenotypicFeature
metastasis,941,I-DiseaseOrPhenotypicFeature
(,941,O
P,941,O
<,941,O
0.001,941,O
),941,O
",",941,O
tumor,941,B-DiseaseOrPhenotypicFeature
recurrence,941,O
(,941,O
P,941,O
<,941,O
0.001,941,O
),941,O
",",941,O
differentiation,941,O
grade,941,O
(,941,O
P,941,O
<,941,O
0.001,941,O
),941,O
",",941,O
residual,941,O
tumor,941,B-DiseaseOrPhenotypicFeature
size,941,O
(,941,O
P,941,O
<,941,O
0.001,941,O
),941,O
",",941,O
ascites,941,B-DiseaseOrPhenotypicFeature
see,941,O
tumor,941,B-DiseaseOrPhenotypicFeature
cells,941,O
(,941,O
P,941,O
=,941,O
0.020,941,O
),941,O
",",941,O
and,941,O
serum,941,O
CA153,941,B-GeneOrGeneProduct
level,941,O
(,941,O
P,941,O
<,941,O
0.001,941,O
),941,O
.,941,O
Moreover,942,O
",",942,O
patients,942,B-OrganismTaxon
with,942,O
aberrant,942,O
CEP55,942,B-GeneOrGeneProduct
protein,942,O
expression,942,O
showed,942,O
tendencies,942,O
to,942,O
receive,942,O
neoadjuvant,942,O
chemotherapy,942,O
(,942,O
P,942,O
<,942,O
0.001,942,O
),942,O
and,942,O
cytoreductive,942,O
surgery,942,O
(,942,O
P,942,O
=,942,O
0.020,942,O
),942,O
.,942,O
By,943,O
contrast,943,O
",",943,O
no,943,O
significant,943,O
correlation,943,O
was,943,O
detected,943,O
between,943,O
the,943,O
protein,943,O
levels,943,O
and,943,O
patient,943,B-OrganismTaxon
age,943,O
",",943,O
histological,943,O
type,943,O
",",943,O
or,943,O
serum,943,O
CA125,943,B-GeneOrGeneProduct
",",943,O
CA199,943,B-GeneOrGeneProduct
",",943,O
CA724,943,B-GeneOrGeneProduct
",",943,O
NSE,943,B-GeneOrGeneProduct
",",943,O
CEA,943,B-GeneOrGeneProduct
",",943,O
and,943,O
b-HCG,943,B-GeneOrGeneProduct
levels,943,O
.,943,O
Patients,944,B-OrganismTaxon
with,944,O
high,944,O
CEP55,944,B-GeneOrGeneProduct
protein,944,O
expression,944,O
had,944,O
shorter,944,O
overall,944,O
survival,944,O
and,944,O
disease-free,944,O
survival,944,O
compared,944,O
with,944,O
those,944,O
with,944,O
low,944,O
CEP55,944,B-GeneOrGeneProduct
expression,944,O
.,944,O
Multivariate,945,O
analysis,945,O
implicated,945,O
CEP55,945,B-GeneOrGeneProduct
as,945,O
an,945,O
independent,945,O
prognostic,945,O
indicator,945,O
for,945,O
EOC,945,B-DiseaseOrPhenotypicFeature
patients,945,B-OrganismTaxon
.,945,O
Additionally,946,O
",",946,O
downregulation,946,O
of,946,O
CEP55,946,B-GeneOrGeneProduct
in,946,O
ovarian,946,B-DiseaseOrPhenotypicFeature
cancer,946,I-DiseaseOrPhenotypicFeature
cells,946,O
remarkably,946,O
inhibited,946,O
cellular,946,O
motility,946,O
and,946,O
invasion,946,O
.,946,O
Aberrant,947,O
CEP55,947,B-GeneOrGeneProduct
expression,947,O
may,947,O
predict,947,O
unfavorable,947,O
clinical,947,O
outcomes,947,O
in,947,O
EOC,947,B-DiseaseOrPhenotypicFeature
patients,947,B-OrganismTaxon
and,947,O
play,947,O
an,947,O
important,947,O
role,947,O
in,947,O
regulating,947,O
invasion,947,O
in,947,O
ovarian,947,B-DiseaseOrPhenotypicFeature
cancer,947,I-DiseaseOrPhenotypicFeature
cells,947,O
.,947,O
Thus,948,O
",",948,O
CEP55,948,B-GeneOrGeneProduct
may,948,O
serve,948,O
as,948,O
a,948,O
prognostic,948,O
marker,948,O
and,948,O
therapeutic,948,O
target,948,O
for,948,O
EOC,948,B-DiseaseOrPhenotypicFeature
.,948,O
Transgelin,949,B-GeneOrGeneProduct
increases,949,O
metastatic,949,O
potential,949,O
of,949,O
colorectal,949,B-DiseaseOrPhenotypicFeature
cancer,949,I-DiseaseOrPhenotypicFeature
cells,949,O
in,949,O
vivo,949,O
and,949,O
alters,949,O
expression,949,O
of,949,O
genes,949,O
involved,949,O
in,949,O
cell,949,O
motility,949,O
.,949,O
BACKGROUND,950,O
:,950,O
Transgelin,950,B-GeneOrGeneProduct
is,950,O
an,950,O
actin-binding,950,B-GeneOrGeneProduct
protein,950,I-GeneOrGeneProduct
that,950,O
promotes,950,O
motility,950,O
in,950,O
normal,950,O
cells,950,O
.,950,O
Although,951,O
the,951,O
role,951,O
of,951,O
transgelin,951,B-GeneOrGeneProduct
in,951,O
cancer,951,B-DiseaseOrPhenotypicFeature
is,951,O
controversial,951,O
",",951,O
a,951,O
number,951,O
of,951,O
studies,951,O
have,951,O
shown,951,O
that,951,O
elevated,951,O
levels,951,O
correlate,951,O
with,951,O
aggressive,951,O
tumor,951,B-DiseaseOrPhenotypicFeature
behavior,951,O
",",951,O
advanced,951,O
stage,951,O
",",951,O
and,951,O
poor,951,O
prognosis,951,O
.,951,O
Here,952,O
we,952,O
sought,952,O
to,952,O
determine,952,O
the,952,O
role,952,O
of,952,O
transgelin,952,B-GeneOrGeneProduct
more,952,O
directly,952,O
by,952,O
determining,952,O
whether,952,O
experimental,952,O
manipulation,952,O
of,952,O
transgelin,952,B-GeneOrGeneProduct
levels,952,O
in,952,O
colorectal,952,B-DiseaseOrPhenotypicFeature
cancer,952,I-DiseaseOrPhenotypicFeature
(,952,O
CRC,952,B-DiseaseOrPhenotypicFeature
),952,O
cells,952,O
led,952,O
to,952,O
changes,952,O
in,952,O
metastatic,952,O
potential,952,O
in,952,O
vivo,952,O
.,952,O
METHODS,953,O
:,953,O
Isogenic,953,O
CRC,953,B-DiseaseOrPhenotypicFeature
cell,953,O
lines,953,O
that,953,O
differ,953,O
in,953,O
transgelin,953,B-GeneOrGeneProduct
expression,953,O
were,953,O
characterized,953,O
using,953,O
in,953,O
vitro,953,O
assays,953,O
of,953,O
growth,953,O
and,953,O
invasiveness,953,O
and,953,O
a,953,O
mouse,953,B-OrganismTaxon
tail,953,O
vein,953,O
assay,953,O
of,953,O
experimental,953,O
metastasis,953,O
.,953,O
Downstream,954,O
effects,954,O
of,954,O
transgelin,954,B-GeneOrGeneProduct
overexpression,954,O
were,954,O
investigated,954,O
by,954,O
gene,954,O
expression,954,O
profiling,954,O
and,954,O
quantitative,954,O
PCR,954,O
.,954,O
RESULTS,955,O
:,955,O
Stable,955,O
overexpression,955,O
of,955,O
transgelin,955,B-GeneOrGeneProduct
in,955,O
RKO,955,B-CellLine
cells,955,O
",",955,O
which,955,O
have,955,O
low,955,O
endogenous,955,O
levels,955,O
",",955,O
led,955,O
to,955,O
increased,955,O
invasiveness,955,O
",",955,O
growth,955,O
at,955,O
low,955,O
density,955,O
",",955,O
and,955,O
growth,955,O
in,955,O
soft,955,O
agar,955,O
.,955,O
Overexpression,956,O
also,956,O
led,956,O
to,956,O
an,956,O
increase,956,O
in,956,O
the,956,O
number,956,O
and,956,O
size,956,O
of,956,O
lung,956,B-DiseaseOrPhenotypicFeature
metastases,956,I-DiseaseOrPhenotypicFeature
in,956,O
the,956,O
mouse,956,B-OrganismTaxon
tail,956,O
vein,956,O
injection,956,O
model,956,O
.,956,O
Similarly,957,O
",",957,O
attenuation,957,O
of,957,O
transgelin,957,B-GeneOrGeneProduct
expression,957,O
in,957,O
HCT116,957,B-CellLine
cells,957,O
",",957,O
which,957,O
have,957,O
high,957,O
endogenous,957,O
levels,957,O
",",957,O
decreased,957,O
metastases,957,B-DiseaseOrPhenotypicFeature
in,957,O
the,957,O
same,957,O
model,957,O
.,957,O
Investigation,958,O
of,958,O
mRNA,958,O
expression,958,O
patterns,958,O
showed,958,O
that,958,O
transgelin,958,B-GeneOrGeneProduct
overexpression,958,O
altered,958,O
the,958,O
levels,958,O
of,958,O
approximately,958,O
250,958,O
other,958,O
transcripts,958,O
",",958,O
with,958,O
over-representation,958,O
of,958,O
genes,958,O
that,958,O
affect,958,O
function,958,O
of,958,O
actin,958,B-GeneOrGeneProduct
or,958,O
other,958,O
cytoskeletal,958,B-GeneOrGeneProduct
proteins,958,I-GeneOrGeneProduct
.,958,O
Changes,959,O
included,959,O
increases,959,O
in,959,O
HOOK1,959,B-GeneOrGeneProduct
",",959,O
SDCCAG8,959,B-GeneOrGeneProduct
",",959,O
ENAH/Mena,959,B-GeneOrGeneProduct
",",959,O
and,959,O
TNS1,959,B-GeneOrGeneProduct
and,959,O
decreases,959,O
in,959,O
EMB,959,B-GeneOrGeneProduct
",",959,O
BCL11B,959,B-GeneOrGeneProduct
",",959,O
and,959,O
PTPRD,959,B-GeneOrGeneProduct
.,959,O
CONCLUSIONS,960,O
:,960,O
Increases,960,O
or,960,O
decreases,960,O
in,960,O
transgelin,960,B-GeneOrGeneProduct
levels,960,O
have,960,O
reciprocal,960,O
effects,960,O
on,960,O
tumor,960,B-DiseaseOrPhenotypicFeature
cell,960,O
behavior,960,O
",",960,O
with,960,O
higher,960,O
expression,960,O
promoting,960,O
metastasis,960,O
.,960,O
Chronic,961,O
overexpression,961,O
influences,961,O
steady-state,961,O
levels,961,O
of,961,O
mRNAs,961,O
for,961,O
metastasis-related,961,O
genes,961,O
.,961,O
CFI-rs7356506,962,B-GeneOrGeneProduct
polymorphisms,962,O
associated,962,O
with,962,O
Vogt-Koyanagi-Harada,962,B-DiseaseOrPhenotypicFeature
syndrome,962,I-DiseaseOrPhenotypicFeature
.,962,O
PURPOSE,963,O
:,963,O
Complement,963,B-GeneOrGeneProduct
factor,963,I-GeneOrGeneProduct
I,963,I-GeneOrGeneProduct
(,963,O
CFI,963,B-GeneOrGeneProduct
),963,O
plays,963,O
an,963,O
important,963,O
role,963,O
in,963,O
complement,963,O
activation,963,O
pathways,963,O
and,963,O
is,963,O
known,963,O
to,963,O
affect,963,O
the,963,O
development,963,O
of,963,O
uveitis,963,B-DiseaseOrPhenotypicFeature
.,963,O
The,964,O
present,964,O
study,964,O
was,964,O
performed,964,O
to,964,O
investigate,964,O
the,964,O
existence,964,O
of,964,O
an,964,O
association,964,O
between,964,O
CFI,964,B-GeneOrGeneProduct
genetic,964,O
polymorphisms,964,O
and,964,O
Vogt-Koyanagi-Harada,964,B-DiseaseOrPhenotypicFeature
(,964,I-DiseaseOrPhenotypicFeature
VKH,964,I-DiseaseOrPhenotypicFeature
),964,I-DiseaseOrPhenotypicFeature
syndrome,964,I-DiseaseOrPhenotypicFeature
.,964,O
METHODS,965,O
:,965,O
A,965,O
total,965,O
of,965,O
100,965,O
patients,965,B-OrganismTaxon
diagnosed,965,O
with,965,O
VKH,965,B-DiseaseOrPhenotypicFeature
syndrome,965,I-DiseaseOrPhenotypicFeature
and,965,O
300,965,O
healthy,965,O
controls,965,O
were,965,O
recruited,965,O
for,965,O
the,965,O
study,965,O
.,965,O
Two,966,O
milliliters,966,O
of,966,O
peripheral,966,O
blood,966,O
were,966,O
collected,966,O
in,966,O
a,966,O
sterile,966,O
anticoagulative,966,O
tube,966,O
.,966,O
CFI-rs7356506,967,B-GeneOrGeneProduct
polymorphisms,967,O
were,967,O
genotyped,967,O
using,967,O
Sequenom,967,O
MassARRAY,967,O
technology,967,O
.,967,O
Allele,968,O
and,968,O
genotype,968,O
frequencies,968,O
were,968,O
compared,968,O
between,968,O
patients,968,B-OrganismTaxon
and,968,O
controls,968,O
using,968,O
a,968,O
X,968,O
(,968,O
2,968,O
),968,O
test,968,O
.,968,O
The,969,O
analyses,969,O
were,969,O
stratified,969,O
for,969,O
recurrent,969,O
status,969,O
",",969,O
complicated,969,O
cataract,969,B-DiseaseOrPhenotypicFeature
status,969,O
",",969,O
and,969,O
steroid-sensitive,969,B-ChemicalEntity
status,969,O
.,969,O
RESULTS,970,O
:,970,O
No,970,O
significant,970,O
association,970,O
was,970,O
found,970,O
between,970,O
CFI-rs7356506,970,B-GeneOrGeneProduct
polymorphisms,970,O
and,970,O
VKH,970,B-DiseaseOrPhenotypicFeature
syndrome,970,I-DiseaseOrPhenotypicFeature
.,970,O
However,971,O
",",971,O
patients,971,B-OrganismTaxon
with,971,O
recurrent,971,O
VKH,971,B-DiseaseOrPhenotypicFeature
syndrome,971,I-DiseaseOrPhenotypicFeature
had,971,O
lower,971,O
frequencies,971,O
of,971,O
the,971,O
G,971,O
allele,971,O
and,971,O
GG,971,O
homozygosity,971,O
in,971,O
CFI-rs7356506,971,B-GeneOrGeneProduct
when,971,O
compared,971,O
to,971,O
the,971,O
controls,971,O
(,971,O
p=0.016,971,O
",",971,O
odds,971,O
ratio,971,O
[,971,O
OR,971,O
],971,O
=0.429,971,O
",",971,O
95,971,O
%,971,O
confidence,971,O
interval,971,O
[,971,O
CI,971,O
],971,O
=0.212-0.871,971,O
;,971,O
p=0.014,971,O
",",971,O
OR=0.364,971,O
",",971,O
95,971,O
%,971,O
CI=0.158-0.837,971,O
",",971,O
respectively,971,O
),971,O
.,971,O
Furthermore,972,O
",",972,O
there,972,O
were,972,O
significant,972,O
decreases,972,O
in,972,O
the,972,O
frequencies,972,O
of,972,O
the,972,O
G,972,O
allele,972,O
and,972,O
GG,972,O
homozygosity,972,O
in,972,O
CFI-rs7356506,972,B-GeneOrGeneProduct
in,972,O
patients,972,B-OrganismTaxon
with,972,O
VKH,972,B-DiseaseOrPhenotypicFeature
syndrome,972,I-DiseaseOrPhenotypicFeature
with,972,O
complicated,972,O
cataract,972,B-DiseaseOrPhenotypicFeature
compared,972,O
to,972,O
the,972,O
controls,972,O
(,972,O
p,972,O
<,972,O
0.001,972,O
",",972,O
OR=0.357,972,O
",",972,O
95,972,O
%,972,O
CI=0.197-0.648,972,O
;,972,O
p,972,O
<,972,O
0.001,972,O
",",972,O
OR=0.273,972,O
",",972,O
95,972,O
%,972,O
CI=0.135-0.551,972,O
",",972,O
respectively,972,O
),972,O
.,972,O
Nevertheless,973,O
",",973,O
no,973,O
significant,973,O
association,973,O
with,973,O
patients,973,B-OrganismTaxon
with,973,O
VKH,973,B-DiseaseOrPhenotypicFeature
syndrome,973,I-DiseaseOrPhenotypicFeature
in,973,O
steroid-sensitive,973,B-ChemicalEntity
statuses,973,O
was,973,O
detected,973,O
for,973,O
CFI-rs7356506,973,B-GeneOrGeneProduct
polymorphisms,973,O
.,973,O
CONCLUSIONS,974,O
:,974,O
Our,974,O
results,974,O
indicate,974,O
that,974,O
CFI,974,B-GeneOrGeneProduct
polymorphisms,974,O
are,974,O
not,974,O
significantly,974,O
associated,974,O
with,974,O
VKH,974,B-DiseaseOrPhenotypicFeature
syndrome,974,I-DiseaseOrPhenotypicFeature
;,974,O
nevertheless,974,O
",",974,O
we,974,O
identified,974,O
a,974,O
trend,974,O
for,974,O
the,974,O
association,974,O
of,974,O
CFI-7356506,974,B-GeneOrGeneProduct
with,974,O
VKH,974,B-DiseaseOrPhenotypicFeature
syndrome,974,I-DiseaseOrPhenotypicFeature
that,974,O
depends,974,O
on,974,O
the,974,O
recurrent,974,O
status,974,O
and,974,O
the,974,O
complicated,974,O
cataract,974,B-DiseaseOrPhenotypicFeature
status,974,O
but,974,O
not,974,O
on,974,O
the,974,O
steroid-sensitive,974,B-ChemicalEntity
status,974,O
.,974,O
Serum,975,B-GeneOrGeneProduct
Amyloid,975,I-GeneOrGeneProduct
A,975,I-GeneOrGeneProduct
Induces,975,O
Inflammation,975,O
",",975,O
Proliferation,975,O
and,975,O
Cell,975,O
Death,975,O
in,975,O
Activated,975,O
Hepatic,975,O
Stellate,975,O
Cells,975,O
.,975,O
Serum,976,B-GeneOrGeneProduct
amyloid,976,I-GeneOrGeneProduct
A,976,I-GeneOrGeneProduct
(,976,O
SAA,976,B-GeneOrGeneProduct
),976,O
is,976,O
an,976,O
evolutionary,976,O
highly,976,O
conserved,976,O
acute,976,O
phase,976,O
protein,976,O
that,976,O
is,976,O
predominantly,976,O
secreted,976,O
by,976,O
hepatocytes,976,O
.,976,O
However,977,O
",",977,O
its,977,O
role,977,O
in,977,O
liver,977,B-DiseaseOrPhenotypicFeature
injury,977,I-DiseaseOrPhenotypicFeature
and,977,I-DiseaseOrPhenotypicFeature
fibrogenesis,977,I-DiseaseOrPhenotypicFeature
has,977,O
not,977,O
been,977,O
elucidated,977,O
so,977,O
far,977,O
.,977,O
In,978,O
this,978,O
study,978,O
",",978,O
we,978,O
determined,978,O
the,978,O
effects,978,O
of,978,O
SAA,978,B-GeneOrGeneProduct
on,978,O
hepatic,978,O
stellate,978,O
cells,978,O
(,978,O
HSCs,978,O
),978,O
",",978,O
the,978,O
main,978,O
fibrogenic,978,O
cell,978,O
type,978,O
of,978,O
the,978,O
liver,978,O
.,978,O
Serum,979,B-GeneOrGeneProduct
amyloid,979,I-GeneOrGeneProduct
A,979,I-GeneOrGeneProduct
potently,979,O
activated,979,O
IkappaB,979,B-GeneOrGeneProduct
kinase,979,I-GeneOrGeneProduct
",",979,O
c-Jun,979,B-GeneOrGeneProduct
N-terminal,979,I-GeneOrGeneProduct
kinase,979,I-GeneOrGeneProduct
(,979,O
JNK,979,B-GeneOrGeneProduct
),979,O
",",979,O
Erk,979,B-GeneOrGeneProduct
and,979,O
Akt,979,B-GeneOrGeneProduct
and,979,O
enhanced,979,O
NF-kappaB-dependent,979,B-GeneOrGeneProduct
luciferase,979,O
activity,979,O
in,979,O
primary,979,O
human,979,B-OrganismTaxon
and,979,O
rat,979,B-OrganismTaxon
HSCs,979,O
.,979,O
Serum,980,B-GeneOrGeneProduct
amyloid,980,I-GeneOrGeneProduct
A,980,I-GeneOrGeneProduct
induced,980,O
the,980,O
transcription,980,O
of,980,O
MCP-1,980,B-GeneOrGeneProduct
",",980,O
RANTES,980,B-GeneOrGeneProduct
and,980,O
MMP9,980,B-GeneOrGeneProduct
in,980,O
an,980,O
NF-kappaB-,980,B-GeneOrGeneProduct
and,980,O
JNK-dependent,980,B-GeneOrGeneProduct
manner,980,O
.,980,O
Blockade,981,O
of,981,O
NF-kappaB,981,B-GeneOrGeneProduct
revealed,981,O
cytotoxic,981,B-DiseaseOrPhenotypicFeature
effects,981,O
of,981,O
SAA,981,B-GeneOrGeneProduct
in,981,O
primary,981,O
HSCs,981,O
with,981,O
signs,981,O
of,981,O
apoptosis,981,O
such,981,O
as,981,O
caspase,981,B-GeneOrGeneProduct
3,981,I-GeneOrGeneProduct
and,981,O
PARP,981,B-GeneOrGeneProduct
cleavage,981,O
and,981,O
Annexin,981,B-GeneOrGeneProduct
V,981,I-GeneOrGeneProduct
staining,981,O
.,981,O
Serum,982,B-GeneOrGeneProduct
amyloid,982,I-GeneOrGeneProduct
A,982,I-GeneOrGeneProduct
induced,982,O
HSC,982,O
proliferation,982,O
",",982,O
which,982,O
depended,982,O
on,982,O
JNK,982,B-GeneOrGeneProduct
",",982,O
Erk,982,B-GeneOrGeneProduct
and,982,O
Akt,982,B-GeneOrGeneProduct
activity,982,O
.,982,O
In,983,O
primary,983,O
hepatocytes,983,O
",",983,O
SAA,983,B-GeneOrGeneProduct
also,983,O
activated,983,O
MAP,983,B-GeneOrGeneProduct
kinases,983,I-GeneOrGeneProduct
",",983,O
but,983,O
did,983,O
not,983,O
induce,983,O
relevant,983,O
cell,983,O
death,983,O
after,983,O
NF-kappaB,983,B-GeneOrGeneProduct
inhibition,983,O
.,983,O
In,984,O
two,984,O
models,984,O
of,984,O
hepatic,984,B-DiseaseOrPhenotypicFeature
fibrogenesis,984,I-DiseaseOrPhenotypicFeature
",",984,O
CCl4,984,B-GeneOrGeneProduct
treatment,984,O
and,984,O
bile,984,O
duct,984,O
ligation,984,O
",",984,O
hepatic,984,O
mRNA,984,O
levels,984,O
of,984,O
SAA1,984,B-GeneOrGeneProduct
and,984,O
SAA3,984,B-GeneOrGeneProduct
were,984,O
strongly,984,O
increased,984,O
.,984,O
In,985,O
conclusion,985,O
",",985,O
SAA,985,B-GeneOrGeneProduct
may,985,O
modulate,985,O
fibrogenic,985,O
responses,985,O
in,985,O
the,985,O
liver,985,O
in,985,O
a,985,O
positive,985,O
and,985,O
negative,985,O
fashion,985,O
by,985,O
inducing,985,O
inflammation,985,O
",",985,O
proliferation,985,O
and,985,O
cell,985,O
death,985,O
in,985,O
HSCs,985,O
.,985,O
MOL1,986,B-GeneOrGeneProduct
is,986,O
required,986,O
for,986,O
cambium,986,O
homeostasis,986,O
in,986,O
Arabidopsis,986,B-OrganismTaxon
.,986,O
Plants,987,O
maintain,987,O
pools,987,O
of,987,O
pluripotent,987,O
stem,987,O
cells,987,O
which,987,O
allow,987,O
them,987,O
to,987,O
constantly,987,O
produce,987,O
new,987,O
tissues,987,O
and,987,O
organs,987,O
.,987,O
Stem,988,O
cell,988,O
homeostasis,988,O
in,988,O
shoot,988,O
and,988,O
root,988,O
tips,988,O
depends,988,O
on,988,O
negative,988,O
regulation,988,O
by,988,O
ligand-receptor,988,O
pairs,988,O
of,988,O
the,988,O
CLE,988,B-GeneOrGeneProduct
peptide,988,I-GeneOrGeneProduct
and,988,O
leucine-rich,988,B-GeneOrGeneProduct
repeat,988,I-GeneOrGeneProduct
receptor-like,988,I-GeneOrGeneProduct
kinase,988,I-GeneOrGeneProduct
(,988,O
LRR-RLK,988,B-GeneOrGeneProduct
),988,O
families,988,O
.,988,O
However,989,O
",",989,O
regulation,989,O
of,989,O
the,989,O
cambium,989,O
",",989,O
the,989,O
stem,989,O
cell,989,O
niche,989,O
required,989,O
for,989,O
lateral,989,O
growth,989,O
of,989,O
shoots,989,O
and,989,O
roots,989,O
",",989,O
is,989,O
poorly,989,O
characterized,989,O
.,989,O
Here,990,O
we,990,O
show,990,O
that,990,O
the,990,O
LRR-RLK,990,B-GeneOrGeneProduct
MOL1,990,B-GeneOrGeneProduct
is,990,O
necessary,990,O
for,990,O
cambium,990,O
homeostasis,990,O
in,990,O
Arabidopsis,990,B-OrganismTaxon
thaliana,990,I-OrganismTaxon
.,990,O
By,991,O
employing,991,O
promoter,991,O
reporter,991,O
lines,991,O
",",991,O
we,991,O
reveal,991,O
that,991,O
MOL1,991,B-GeneOrGeneProduct
is,991,O
active,991,O
in,991,O
a,991,O
domain,991,O
that,991,O
is,991,O
distinct,991,O
from,991,O
the,991,O
domain,991,O
of,991,O
the,991,O
positively,991,O
acting,991,O
CLE41/PXY,991,B-GeneOrGeneProduct
signaling,991,O
module,991,O
.,991,O
In,992,O
particular,992,O
",",992,O
we,992,O
show,992,O
that,992,O
MOL1,992,B-GeneOrGeneProduct
acts,992,O
in,992,O
an,992,O
opposing,992,O
manner,992,O
to,992,O
the,992,O
CLE41/PXY,992,B-GeneOrGeneProduct
module,992,O
and,992,O
that,992,O
changing,992,O
the,992,O
domain,992,O
or,992,O
level,992,O
of,992,O
MOL1,992,B-GeneOrGeneProduct
expression,992,O
both,992,O
result,992,O
in,992,O
disturbed,992,O
cambium,992,O
organization,992,O
.,992,O
Underlining,993,O
discrete,993,O
roles,993,O
of,993,O
MOL1,993,B-GeneOrGeneProduct
and,993,O
PXY,993,B-GeneOrGeneProduct
",",993,O
both,993,O
LRR-RLKs,993,B-GeneOrGeneProduct
are,993,O
not,993,O
able,993,O
to,993,O
replace,993,O
each,993,O
other,993,O
when,993,O
their,993,O
expression,993,O
domains,993,O
are,993,O
interchanged,993,O
.,993,O
Furthermore,994,O
",",994,O
MOL1,994,B-GeneOrGeneProduct
but,994,O
not,994,O
PXY,994,B-GeneOrGeneProduct
is,994,O
able,994,O
to,994,O
rescue,994,O
CLV1,994,B-GeneOrGeneProduct
deficiency,994,O
in,994,O
the,994,O
shoot,994,O
apical,994,O
meristem,994,O
.,994,O
By,995,O
identifying,995,O
genes,995,O
mis-expressed,995,O
in,995,O
mol1,995,B-GeneOrGeneProduct
mutants,995,O
",",995,O
we,995,O
demonstrate,995,O
that,995,O
MOL1,995,B-GeneOrGeneProduct
represses,995,O
genes,995,O
associated,995,O
with,995,O
stress-related,995,O
ethylene,995,B-ChemicalEntity
and,995,O
jasmonic,995,B-ChemicalEntity
acid,995,I-ChemicalEntity
hormone,995,O
signaling,995,O
pathways,995,O
which,995,O
have,995,O
known,995,O
roles,995,O
in,995,O
coordinating,995,O
lateral,995,O
growth,995,O
of,995,O
the,995,O
Arabidopsis,995,B-OrganismTaxon
stem,995,O
.,995,O
Our,996,O
findings,996,O
provide,996,O
evidence,996,O
that,996,O
common,996,O
regulatory,996,O
mechanisms,996,O
in,996,O
different,996,O
plant,996,O
stem,996,O
cell,996,O
niches,996,O
are,996,O
adapted,996,O
to,996,O
specific,996,O
niche,996,O
anatomies,996,O
and,996,O
emphasize,996,O
the,996,O
importance,996,O
of,996,O
a,996,O
complex,996,O
spatial,996,O
organization,996,O
of,996,O
intercellular,996,O
signaling,996,O
cascades,996,O
for,996,O
a,996,O
strictly,996,O
bidirectional,996,O
tissue,996,O
production,996,O
.,996,O
Male,997,O
11b-HSD1,997,B-GeneOrGeneProduct
Knockout,997,O
Mice,997,B-OrganismTaxon
Fed,997,O
Trans-Fats,997,B-ChemicalEntity
and,997,O
Fructose,997,B-ChemicalEntity
Are,997,O
Not,997,O
Protected,997,O
From,997,O
Metabolic,997,B-DiseaseOrPhenotypicFeature
Syndrome,997,I-DiseaseOrPhenotypicFeature
or,997,O
Nonalcoholic,997,B-DiseaseOrPhenotypicFeature
Fatty,997,I-DiseaseOrPhenotypicFeature
Liver,997,I-DiseaseOrPhenotypicFeature
Disease,997,I-DiseaseOrPhenotypicFeature
.,997,O
Nonalcoholic,998,B-DiseaseOrPhenotypicFeature
fatty,998,I-DiseaseOrPhenotypicFeature
liver,998,I-DiseaseOrPhenotypicFeature
disease,998,I-DiseaseOrPhenotypicFeature
(,998,O
NAFLD,998,B-DiseaseOrPhenotypicFeature
),998,O
defines,998,O
a,998,O
spectrum,998,O
of,998,O
conditions,998,O
from,998,O
simple,998,O
steatosis,998,B-DiseaseOrPhenotypicFeature
to,998,O
nonalcoholic,998,B-DiseaseOrPhenotypicFeature
steatohepatitis,998,I-DiseaseOrPhenotypicFeature
(,998,O
NASH,998,B-DiseaseOrPhenotypicFeature
),998,O
and,998,O
cirrhosis,998,B-DiseaseOrPhenotypicFeature
and,998,O
is,998,O
regarded,998,O
as,998,O
the,998,O
hepatic,998,O
manifestation,998,O
of,998,O
the,998,O
metabolic,998,B-DiseaseOrPhenotypicFeature
syndrome,998,I-DiseaseOrPhenotypicFeature
.,998,O
Glucocorticoids,999,B-ChemicalEntity
can,999,O
promote,999,O
steatosis,999,B-DiseaseOrPhenotypicFeature
by,999,O
stimulating,999,O
lipolysis,999,O
within,999,O
adipose,999,O
tissue,999,O
",",999,O
free,999,B-ChemicalEntity
fatty,999,I-ChemicalEntity
acid,999,I-ChemicalEntity
delivery,999,O
to,999,O
liver,999,O
and,999,O
hepatic,999,O
de,999,O
novo,999,O
lipogenesis,999,O
.,999,O
Glucocorticoids,1000,B-ChemicalEntity
can,1000,O
be,1000,O
reactivated,1000,O
in,1000,O
liver,1000,O
through,1000,O
11b-hydroxysteroid,1000,B-GeneOrGeneProduct
dehydrogenase,1000,I-GeneOrGeneProduct
type,1000,I-GeneOrGeneProduct
1,1000,I-GeneOrGeneProduct
(,1000,O
11b-HSD1,1000,B-GeneOrGeneProduct
),1000,O
enzyme,1000,O
activity,1000,O
.,1000,O
Inhibition,1001,O
of,1001,O
11b-HSD1,1001,B-GeneOrGeneProduct
has,1001,O
been,1001,O
suggested,1001,O
as,1001,O
a,1001,O
potential,1001,O
treatment,1001,O
for,1001,O
NAFLD,1001,B-DiseaseOrPhenotypicFeature
.,1001,O
To,1002,O
test,1002,O
this,1002,O
",",1002,O
male,1002,O
mice,1002,B-OrganismTaxon
with,1002,O
global,1002,O
(,1002,O
11b-HSD1,1002,B-GeneOrGeneProduct
knockout,1002,O
[,1002,O
KO,1002,O
],1002,O
),1002,O
and,1002,O
liver-specific,1002,O
(,1002,O
LKO,1002,O
),1002,O
11b-HSD1,1002,B-GeneOrGeneProduct
loss,1002,O
of,1002,O
function,1002,O
were,1002,O
fed,1002,O
the,1002,O
American,1002,O
Lifestyle,1002,O
Induced,1002,O
Obesity,1002,O
Syndrome,1002,O
(,1002,O
ALIOS,1002,O
),1002,O
diet,1002,O
",",1002,O
known,1002,O
to,1002,O
recapitulate,1002,O
the,1002,O
spectrum,1002,O
of,1002,O
NAFLD,1002,B-DiseaseOrPhenotypicFeature
",",1002,O
and,1002,O
metabolic,1002,O
and,1002,O
liver,1002,O
phenotypes,1002,O
assessed,1002,O
.,1002,O
Body,1003,O
weight,1003,O
",",1003,O
muscle,1003,O
and,1003,O
adipose,1003,O
tissue,1003,O
masses,1003,O
",",1003,O
and,1003,O
parameters,1003,O
of,1003,O
glucose,1003,B-ChemicalEntity
homeostasis,1003,O
showed,1003,O
that,1003,O
11b-HSD1KO,1003,B-GeneOrGeneProduct
and,1003,O
LKO,1003,O
mice,1003,B-OrganismTaxon
were,1003,O
not,1003,O
protected,1003,O
from,1003,O
systemic,1003,O
metabolic,1003,B-DiseaseOrPhenotypicFeature
disease,1003,I-DiseaseOrPhenotypicFeature
.,1003,O
Evaluation,1004,O
of,1004,O
hepatic,1004,O
histology,1004,O
",",1004,O
triglyceride,1004,B-ChemicalEntity
content,1004,O
",",1004,O
and,1004,O
blinded,1004,O
NAFLD,1004,B-DiseaseOrPhenotypicFeature
activity,1004,O
score,1004,O
assessment,1004,O
indicated,1004,O
that,1004,O
levels,1004,O
of,1004,O
steatosis,1004,B-DiseaseOrPhenotypicFeature
were,1004,O
similar,1004,O
between,1004,O
11b-HSD1KO,1004,B-GeneOrGeneProduct
",",1004,O
LKO,1004,O
",",1004,O
and,1004,O
control,1004,O
mice,1004,B-OrganismTaxon
.,1004,O
Unexpectedly,1005,O
",",1005,O
histological,1005,O
analysis,1005,O
revealed,1005,O
significantly,1005,O
increased,1005,O
levels,1005,O
of,1005,O
immune,1005,O
foci,1005,O
present,1005,O
in,1005,O
livers,1005,O
of,1005,O
11b-HSD1KO,1005,B-GeneOrGeneProduct
but,1005,O
not,1005,O
LKO,1005,O
or,1005,O
control,1005,O
mice,1005,B-OrganismTaxon
",",1005,O
suggestive,1005,O
of,1005,O
a,1005,O
transition,1005,O
to,1005,O
NASH,1005,B-DiseaseOrPhenotypicFeature
.,1005,O
This,1006,O
was,1006,O
endorsed,1006,O
by,1006,O
elevated,1006,O
hepatic,1006,O
expression,1006,O
of,1006,O
key,1006,O
immune,1006,O
cell,1006,O
and,1006,O
inflammatory,1006,B-DiseaseOrPhenotypicFeature
markers,1006,O
.,1006,O
These,1007,O
data,1007,O
indicate,1007,O
that,1007,O
11b-HSD1-deficient,1007,B-GeneOrGeneProduct
mice,1007,B-OrganismTaxon
are,1007,O
not,1007,O
protected,1007,O
from,1007,O
metabolic,1007,B-DiseaseOrPhenotypicFeature
disease,1007,I-DiseaseOrPhenotypicFeature
or,1007,O
hepatosteatosis,1007,B-DiseaseOrPhenotypicFeature
in,1007,O
the,1007,O
face,1007,O
of,1007,O
a,1007,O
NAFLD-inducing,1007,B-DiseaseOrPhenotypicFeature
diet,1007,O
.,1007,O
However,1008,O
",",1008,O
global,1008,O
deficiency,1008,O
of,1008,O
11b-HSD1,1008,B-GeneOrGeneProduct
did,1008,O
increase,1008,O
markers,1008,O
of,1008,O
hepatic,1008,B-DiseaseOrPhenotypicFeature
inflammation,1008,I-DiseaseOrPhenotypicFeature
and,1008,O
suggests,1008,O
a,1008,O
critical,1008,O
role,1008,O
for,1008,O
11b-HSD1,1008,B-GeneOrGeneProduct
in,1008,O
restraining,1008,O
the,1008,O
transition,1008,O
to,1008,O
NASH,1008,B-DiseaseOrPhenotypicFeature
.,1008,O
Decreased,1009,O
Whole-Body,1009,O
Fat,1009,O
Mass,1009,O
Produced,1009,O
by,1009,O
Chronic,1009,O
Alcohol,1009,B-ChemicalEntity
Consumption,1009,O
is,1009,O
Associated,1009,O
with,1009,O
Activation,1009,O
of,1009,O
S6K1-Mediated,1009,B-GeneOrGeneProduct
Protein,1009,O
Synthesis,1009,O
and,1009,O
Increased,1009,O
Autophagy,1009,O
in,1009,O
Epididymal,1009,O
White,1009,O
Adipose,1009,O
Tissue,1009,O
.,1009,O
BACKGROUND,1010,O
:,1010,O
Chronic,1010,O
alcohol,1010,B-ChemicalEntity
consumption,1010,O
leads,1010,O
to,1010,O
a,1010,O
loss,1010,O
of,1010,O
white,1010,O
adipose,1010,O
tissue,1010,O
(,1010,O
WAT,1010,O
),1010,O
but,1010,O
the,1010,O
underlying,1010,O
mechanisms,1010,O
for,1010,O
this,1010,O
lipodystrophy,1010,B-DiseaseOrPhenotypicFeature
are,1010,O
not,1010,O
fully,1010,O
elucidated,1010,O
.,1010,O
This,1011,O
study,1011,O
tested,1011,O
the,1011,O
hypothesis,1011,O
that,1011,O
the,1011,O
reduction,1011,O
in,1011,O
WAT,1011,O
mass,1011,O
in,1011,O
chronic,1011,O
alcohol-fed,1011,B-ChemicalEntity
mice,1011,B-OrganismTaxon
is,1011,O
associated,1011,O
with,1011,O
a,1011,O
decreased,1011,O
protein,1011,O
synthesis,1011,O
specifically,1011,O
related,1011,O
to,1011,O
impaired,1011,O
function,1011,O
of,1011,O
mammalian,1011,B-GeneOrGeneProduct
target,1011,I-GeneOrGeneProduct
of,1011,I-GeneOrGeneProduct
rapamycin,1011,I-GeneOrGeneProduct
(,1011,O
mTOR,1011,B-GeneOrGeneProduct
),1011,O
.,1011,O
METHODS,1012,O
:,1012,O
Adult,1012,O
male,1012,O
mice,1012,B-OrganismTaxon
were,1012,O
provided,1012,O
an,1012,O
alcohol-containing,1012,B-ChemicalEntity
liquid,1012,O
diet,1012,O
for,1012,O
24,1012,O
weeks,1012,O
or,1012,O
an,1012,O
isonitrogenous,1012,O
isocaloric,1012,O
control,1012,O
diet,1012,O
.,1012,O
In,1013,O
vivo,1013,O
protein,1013,O
synthesis,1013,O
was,1013,O
determined,1013,O
at,1013,O
this,1013,O
time,1013,O
and,1013,O
thereafter,1013,O
epididymal,1013,O
WAT,1013,O
(,1013,O
eWAT,1013,O
),1013,O
was,1013,O
excised,1013,O
for,1013,O
analysis,1013,O
of,1013,O
signal,1013,O
transduction,1013,O
pathways,1013,O
central,1013,O
to,1013,O
controling,1013,O
protein,1013,O
synthesis,1013,O
and,1013,O
degradation,1013,O
.,1013,O
RESULTS,1014,O
:,1014,O
While,1014,O
chronic,1014,O
alcohol,1014,B-ChemicalEntity
feeding,1014,O
decreased,1014,O
whole-body,1014,O
and,1014,O
eWAT,1014,O
mass,1014,O
",",1014,O
this,1014,O
was,1014,O
associated,1014,O
with,1014,O
a,1014,O
discordant,1014,O
increase,1014,O
in,1014,O
protein,1014,O
synthesis,1014,O
in,1014,O
eWAT,1014,O
.,1014,O
This,1015,O
increase,1015,O
was,1015,O
not,1015,O
associated,1015,O
with,1015,O
a,1015,O
change,1015,O
in,1015,O
mTOR,1015,B-GeneOrGeneProduct
",",1015,O
4E-BP1,1015,B-GeneOrGeneProduct
",",1015,O
Akt,1015,B-GeneOrGeneProduct
",",1015,O
or,1015,O
PRAS40,1015,B-GeneOrGeneProduct
phosphorylation,1015,O
.,1015,O
Instead,1016,O
",",1016,O
a,1016,O
selective,1016,O
increase,1016,O
in,1016,O
phosphorylation,1016,O
of,1016,O
S6K1,1016,B-GeneOrGeneProduct
and,1016,O
its,1016,O
downstream,1016,O
substrates,1016,O
",",1016,O
S6,1016,B-GeneOrGeneProduct
and,1016,O
eIF4B,1016,B-GeneOrGeneProduct
was,1016,O
detected,1016,O
in,1016,O
alcohol-fed,1016,B-ChemicalEntity
mice,1016,B-OrganismTaxon
.,1016,O
Alcohol,1017,B-ChemicalEntity
also,1017,O
increased,1017,O
eEF2K,1017,B-GeneOrGeneProduct
phosphorylation,1017,O
and,1017,O
decreased,1017,O
eEF2,1017,B-GeneOrGeneProduct
phosphorylation,1017,O
consistent,1017,O
with,1017,O
increased,1017,O
translation,1017,O
elongation,1017,O
.,1017,O
Alcohol,1018,B-ChemicalEntity
increased,1018,O
Atg12-5,1018,B-GeneOrGeneProduct
",",1018,O
LC3B-I,1018,B-GeneOrGeneProduct
and,1018,I-GeneOrGeneProduct
-II,1018,I-GeneOrGeneProduct
",",1018,O
and,1018,O
ULK1,1018,B-GeneOrGeneProduct
S555,1018,B-SequenceVariant
phosphorylation,1018,O
",",1018,O
suggesting,1018,O
increased,1018,O
autophagy,1018,O
",",1018,O
while,1018,O
markers,1018,O
of,1018,O
apoptosis,1018,O
(,1018,O
cleaved,1018,O
caspase-3,1018,B-GeneOrGeneProduct
and,1018,I-GeneOrGeneProduct
-9,1018,I-GeneOrGeneProduct
",",1018,O
and,1018,O
PARP,1018,B-GeneOrGeneProduct
),1018,O
were,1018,O
unchanged,1018,O
.,1018,O
Lipolytic,1019,O
enzymes,1019,O
(,1019,O
ATGL,1019,B-GeneOrGeneProduct
and,1019,O
HSL,1019,B-GeneOrGeneProduct
phosphorylation,1019,O
),1019,O
were,1019,O
increased,1019,O
and,1019,O
lipogenic,1019,O
regulators,1019,O
(,1019,O
PPARgamma,1019,B-GeneOrGeneProduct
and,1019,O
C/EBPalpha,1019,B-GeneOrGeneProduct
),1019,O
were,1019,O
decreased,1019,O
in,1019,O
eWAT,1019,O
by,1019,O
alcohol,1019,B-ChemicalEntity
.,1019,O
Although,1020,O
alcohol,1020,B-ChemicalEntity
increased,1020,O
TNF-alpha,1020,B-GeneOrGeneProduct
",",1020,O
IL-6,1020,B-GeneOrGeneProduct
",",1020,O
and,1020,O
IL-1beta,1020,B-GeneOrGeneProduct
mRNA,1020,O
",",1020,O
no,1020,O
change,1020,O
in,1020,O
key,1020,O
components,1020,O
of,1020,O
the,1020,O
NLRP3,1020,B-GeneOrGeneProduct
inflammasome,1020,O
(,1020,O
NLRP3,1020,B-GeneOrGeneProduct
",",1020,O
ACS,1020,B-GeneOrGeneProduct
",",1020,O
and,1020,O
cleaved,1020,O
caspase-1,1020,B-GeneOrGeneProduct
),1020,O
was,1020,O
detected,1020,O
suggesting,1020,O
alcohol,1020,B-ChemicalEntity
did,1020,O
not,1020,O
increase,1020,O
pyroptosis,1020,O
.,1020,O
Plasma,1021,O
insulin,1021,B-GeneOrGeneProduct
did,1021,O
not,1021,O
differ,1021,O
between,1021,O
groups,1021,O
.,1021,O
CONCLUSIONS,1022,O
:,1022,O
These,1022,O
results,1022,O
demonstrate,1022,O
that,1022,O
the,1022,O
alcohol-induced,1022,B-ChemicalEntity
decrease,1022,O
in,1022,O
whole-body,1022,O
fat,1022,O
mass,1022,O
resulted,1022,O
in,1022,O
part,1022,O
from,1022,O
activation,1022,O
of,1022,O
autophagy,1022,O
in,1022,O
eWAT,1022,O
as,1022,O
protein,1022,O
synthesis,1022,O
was,1022,O
increased,1022,O
and,1022,O
mediated,1022,O
by,1022,O
the,1022,O
specific,1022,O
increase,1022,O
in,1022,O
the,1022,O
activity,1022,O
of,1022,O
S6K1,1022,B-GeneOrGeneProduct
.,1022,O
Phosphatidylinositol,1023,B-GeneOrGeneProduct
4-kinase,1023,I-GeneOrGeneProduct
IIb,1023,I-GeneOrGeneProduct
negatively,1023,O
regulates,1023,O
invadopodia,1023,O
formation,1023,O
and,1023,O
suppresses,1023,O
an,1023,O
invasive,1023,O
cellular,1023,O
phenotype,1023,O
.,1023,O
The,1024,O
type,1024,B-GeneOrGeneProduct
II,1024,I-GeneOrGeneProduct
phosphatidylinositol,1024,I-GeneOrGeneProduct
4-kinase,1024,I-GeneOrGeneProduct
(,1024,O
PI4KII,1024,B-GeneOrGeneProduct
),1024,O
enzymes,1024,O
synthesize,1024,O
the,1024,O
lipid,1024,B-ChemicalEntity
phosphatidylinositol,1024,B-ChemicalEntity
4-phosphate,1024,I-ChemicalEntity
(,1024,O
PI,1024,B-ChemicalEntity
(,1024,I-ChemicalEntity
4,1024,I-ChemicalEntity
),1024,I-ChemicalEntity
P,1024,I-ChemicalEntity
),1024,O
",",1024,O
which,1024,O
has,1024,O
been,1024,O
detected,1024,O
at,1024,O
the,1024,O
Golgi,1024,O
complex,1024,O
and,1024,O
endosomal,1024,O
compartments,1024,O
and,1024,O
recruits,1024,O
clathrin,1024,B-GeneOrGeneProduct
adaptors,1024,O
.,1024,O
Despite,1025,O
common,1025,O
mechanistic,1025,O
similarities,1025,O
between,1025,O
the,1025,O
isoforms,1025,O
",",1025,O
the,1025,O
extent,1025,O
of,1025,O
their,1025,O
redundancy,1025,O
is,1025,O
unclear,1025,O
.,1025,O
We,1026,O
found,1026,O
that,1026,O
depletion,1026,O
of,1026,O
PI4KIIa,1026,B-GeneOrGeneProduct
and,1026,O
PI4KIIb,1026,B-GeneOrGeneProduct
using,1026,O
small,1026,O
interfering,1026,O
RNA,1026,O
led,1026,O
to,1026,O
actin,1026,B-GeneOrGeneProduct
remodeling,1026,O
.,1026,O
Depletion,1027,O
of,1027,O
PI4KIIb,1027,B-GeneOrGeneProduct
also,1027,O
induced,1027,O
the,1027,O
formation,1027,O
of,1027,O
invadopodia,1027,O
containing,1027,O
membrane,1027,B-GeneOrGeneProduct
type,1027,I-GeneOrGeneProduct
I,1027,I-GeneOrGeneProduct
matrix,1027,I-GeneOrGeneProduct
metalloproteinase,1027,I-GeneOrGeneProduct
(,1027,O
MT1-MMP,1027,B-GeneOrGeneProduct
),1027,O
.,1027,O
Depletion,1028,O
of,1028,O
PI4KII,1028,B-GeneOrGeneProduct
isoforms,1028,O
also,1028,O
differentially,1028,O
affected,1028,O
trans-Golgi,1028,O
network,1028,O
(,1028,O
TGN,1028,O
),1028,O
pools,1028,O
of,1028,O
PI,1028,B-ChemicalEntity
(,1028,I-ChemicalEntity
4,1028,I-ChemicalEntity
),1028,I-ChemicalEntity
P,1028,I-ChemicalEntity
and,1028,O
post-TGN,1028,O
traffic,1028,O
.,1028,O
PI4KIIb,1029,B-GeneOrGeneProduct
depletion,1029,O
caused,1029,O
increased,1029,O
MT1-MMP,1029,B-GeneOrGeneProduct
trafficking,1029,O
to,1029,O
invasive,1029,O
structures,1029,O
at,1029,O
the,1029,O
plasma,1029,O
membrane,1029,O
and,1029,O
was,1029,O
accompanied,1029,O
by,1029,O
reduced,1029,O
colocalization,1029,O
of,1029,O
MT1-MMP,1029,B-GeneOrGeneProduct
with,1029,O
membranes,1029,O
containing,1029,O
the,1029,O
endosomal,1029,O
markers,1029,O
Rab5,1029,B-GeneOrGeneProduct
and,1029,O
Rab7,1029,B-GeneOrGeneProduct
but,1029,O
increased,1029,O
localization,1029,O
with,1029,O
the,1029,O
exocytic,1029,O
Rab8,1029,B-GeneOrGeneProduct
.,1029,O
Depletion,1030,O
of,1030,O
PI4KIIb,1030,B-GeneOrGeneProduct
was,1030,O
sufficient,1030,O
to,1030,O
confer,1030,O
an,1030,O
aggressive,1030,O
invasive,1030,O
phenotype,1030,O
on,1030,O
minimally,1030,O
invasive,1030,O
HeLa,1030,B-CellLine
and,1030,O
MCF-7,1030,B-CellLine
cell,1030,O
lines,1030,O
.,1030,O
Mining,1031,O
oncogenomic,1031,O
databases,1031,O
revealed,1031,O
that,1031,O
loss,1031,O
of,1031,O
the,1031,O
PI4K2B,1031,B-GeneOrGeneProduct
allele,1031,O
and,1031,O
underexpression,1031,O
of,1031,O
PI4KIIb,1031,B-GeneOrGeneProduct
mRNA,1031,O
are,1031,O
associated,1031,O
with,1031,O
human,1031,B-OrganismTaxon
cancers,1031,B-DiseaseOrPhenotypicFeature
.,1031,O
This,1032,O
finding,1032,O
supports,1032,O
the,1032,O
cell,1032,O
data,1032,O
and,1032,O
suggests,1032,O
that,1032,O
PI4KIIb,1032,B-GeneOrGeneProduct
may,1032,O
be,1032,O
a,1032,O
clinically,1032,O
significant,1032,O
suppressor,1032,O
of,1032,O
invasion,1032,O
.,1032,O
We,1033,O
propose,1033,O
that,1033,O
PI4KIIb,1033,B-GeneOrGeneProduct
synthesizes,1033,O
a,1033,O
pool,1033,O
of,1033,O
PI,1033,B-ChemicalEntity
(,1033,I-ChemicalEntity
4,1033,I-ChemicalEntity
),1033,I-ChemicalEntity
P,1033,I-ChemicalEntity
that,1033,O
maintains,1033,O
MT1-MMP,1033,B-GeneOrGeneProduct
traffic,1033,O
in,1033,O
the,1033,O
degradative,1033,O
pathway,1033,O
and,1033,O
suppresses,1033,O
the,1033,O
formation,1033,O
of,1033,O
invadopodia,1033,O
.,1033,O
Long-term,1034,O
exposure,1034,O
of,1034,O
MCF-7,1034,B-CellLine
breast,1034,B-DiseaseOrPhenotypicFeature
cancer,1034,I-DiseaseOrPhenotypicFeature
cells,1034,O
to,1034,O
ethanol,1034,B-ChemicalEntity
stimulates,1034,O
oncogenic,1034,O
features,1034,O
.,1034,O
Alcohol,1035,B-ChemicalEntity
consumption,1035,O
is,1035,O
a,1035,O
risk,1035,O
factor,1035,O
for,1035,O
breast,1035,B-DiseaseOrPhenotypicFeature
cancer,1035,I-DiseaseOrPhenotypicFeature
.,1035,O
Little,1036,O
is,1036,O
known,1036,O
regarding,1036,O
the,1036,O
mechanism,1036,O
",",1036,O
although,1036,O
it,1036,O
is,1036,O
assumed,1036,O
that,1036,O
acetaldehyde,1036,B-ChemicalEntity
or,1036,O
estrogen,1036,B-ChemicalEntity
mediated,1036,O
pathways,1036,O
play,1036,O
a,1036,O
role,1036,O
.,1036,O
We,1037,O
previously,1037,O
showed,1037,O
that,1037,O
long-term,1037,O
exposure,1037,O
to,1037,O
2.5,1037,O
mM,1037,O
ethanol,1037,B-ChemicalEntity
(,1037,O
blood,1037,O
alcohol,1037,B-ChemicalEntity
~0.012,1037,O
%,1037,O
),1037,O
of,1037,O
MCF-12A,1037,B-CellLine
",",1037,O
a,1037,O
human,1037,B-OrganismTaxon
normal,1037,O
epithelial,1037,O
breast,1037,O
cell,1037,O
line,1037,O
",",1037,O
induced,1037,O
epithelial,1037,O
mesenchymal,1037,O
transition,1037,O
(,1037,O
EMT,1037,O
),1037,O
and,1037,O
oncogenic,1037,O
transformation,1037,O
.,1037,O
In,1038,O
this,1038,O
study,1038,O
",",1038,O
we,1038,O
investigated,1038,O
in,1038,O
the,1038,O
human,1038,B-OrganismTaxon
breast,1038,B-DiseaseOrPhenotypicFeature
cancer,1038,I-DiseaseOrPhenotypicFeature
cell,1038,O
line,1038,O
MCF-7,1038,B-CellLine
",",1038,O
whether,1038,O
a,1038,O
similar,1038,O
exposure,1038,O
to,1038,O
ethanol,1038,B-ChemicalEntity
at,1038,O
concentrations,1038,O
ranging,1038,O
up,1038,O
to,1038,O
peak,1038,O
blood,1038,O
levels,1038,O
in,1038,O
heavy,1038,O
drinkers,1038,O
would,1038,O
increase,1038,O
malignant,1038,O
progression,1038,O
.,1038,O
Short-term,1039,O
(,1039,O
1-week,1039,O
),1039,O
incubation,1039,O
to,1039,O
ethanol,1039,B-ChemicalEntity
at,1039,O
as,1039,O
low,1039,O
as,1039,O
1-5,1039,O
mM,1039,O
(,1039,O
corresponding,1039,O
to,1039,O
blood,1039,O
alcohol,1039,B-ChemicalEntity
concentration,1039,O
of,1039,O
~0.0048-0.024,1039,O
%,1039,O
),1039,O
upregulated,1039,O
the,1039,O
stem,1039,O
cell,1039,O
related,1039,O
proteins,1039,O
Oct4,1039,B-GeneOrGeneProduct
and,1039,O
Nanog,1039,B-GeneOrGeneProduct
",",1039,O
but,1039,O
they,1039,O
were,1039,O
reduced,1039,O
after,1039,O
exposure,1039,O
at,1039,O
25,1039,O
mM,1039,O
.,1039,O
Long-term,1040,O
(,1040,O
4-week,1040,O
),1040,O
exposure,1040,O
to,1040,O
25,1040,O
mM,1040,O
ethanol,1040,B-ChemicalEntity
upregulated,1040,O
the,1040,O
Oct4,1040,B-GeneOrGeneProduct
and,1040,O
Nanog,1040,B-GeneOrGeneProduct
proteins,1040,O
",",1040,O
as,1040,O
well,1040,O
as,1040,O
the,1040,O
malignancy,1040,B-DiseaseOrPhenotypicFeature
marker,1040,O
Ceacam6,1040,B-GeneOrGeneProduct
.,1040,O
DNA,1041,O
microarray,1041,O
analysis,1041,O
in,1041,O
cells,1041,O
exposed,1041,O
for,1041,O
1,1041,O
week,1041,O
showed,1041,O
upregulated,1041,O
expression,1041,O
of,1041,O
metallothionein,1041,B-GeneOrGeneProduct
genes,1041,O
",",1041,O
particularly,1041,O
MT1X,1041,B-GeneOrGeneProduct
.,1041,O
Long-term,1042,O
exposure,1042,O
upregulated,1042,O
expression,1042,O
of,1042,O
some,1042,O
malignancy,1042,B-DiseaseOrPhenotypicFeature
related,1042,O
genes,1042,O
(,1042,O
STEAP4,1042,B-GeneOrGeneProduct
",",1042,O
SERPINA3,1042,B-GeneOrGeneProduct
",",1042,O
SAMD9,1042,B-GeneOrGeneProduct
",",1042,O
GDF15,1042,B-GeneOrGeneProduct
",",1042,O
KRT15,1042,B-GeneOrGeneProduct
",",1042,O
ITGB6,1042,B-GeneOrGeneProduct
",",1042,O
TP63,1042,B-GeneOrGeneProduct
",",1042,O
and,1042,O
PGR,1042,B-GeneOrGeneProduct
",",1042,O
as,1042,O
well,1042,O
as,1042,O
the,1042,O
CEACAM,1042,B-GeneOrGeneProduct
",",1042,O
interferon,1042,B-GeneOrGeneProduct
related,1042,O
",",1042,O
and,1042,O
HLA,1042,B-GeneOrGeneProduct
gene,1042,O
families,1042,O
),1042,O
.,1042,O
Some,1043,O
of,1043,O
these,1043,O
findings,1043,O
were,1043,O
validated,1043,O
by,1043,O
RT-PCR,1043,O
.,1043,O
A,1044,O
similar,1044,O
treatment,1044,O
also,1044,O
modulated,1044,O
numerous,1044,O
microRNAs,1044,O
(,1044,O
miRs,1044,O
),1044,O
including,1044,O
one,1044,O
regulator,1044,O
of,1044,O
Oct4,1044,B-GeneOrGeneProduct
as,1044,O
well,1044,O
as,1044,O
miRs,1044,O
involved,1044,O
in,1044,O
oncogenesis,1044,O
and/or,1044,O
malignancy,1044,B-DiseaseOrPhenotypicFeature
",",1044,O
with,1044,O
only,1044,O
a,1044,O
few,1044,O
estrogen-induced,1044,B-ChemicalEntity
miRs,1044,O
.,1044,O
Long-term,1045,O
25,1045,O
mM,1045,O
ethanol,1045,B-ChemicalEntity
also,1045,O
induced,1045,O
a,1045,O
5.6-fold,1045,O
upregulation,1045,O
of,1045,O
anchorage-independent,1045,O
growth,1045,O
",",1045,O
an,1045,O
indicator,1045,O
of,1045,O
malignant-like,1045,O
features,1045,O
.,1045,O
Exposure,1046,O
to,1046,O
acetaldehyde,1046,B-ChemicalEntity
resulted,1046,O
in,1046,O
little,1046,O
or,1046,O
no,1046,O
effect,1046,O
comparable,1046,O
to,1046,O
that,1046,O
of,1046,O
ethanol,1046,B-ChemicalEntity
.,1046,O
The,1047,O
previously,1047,O
shown,1047,O
alcohol,1047,B-ChemicalEntity
induction,1047,O
of,1047,O
oncogenic,1047,O
transformation,1047,O
of,1047,O
normal,1047,O
breast,1047,O
cells,1047,O
is,1047,O
now,1047,O
complemented,1047,O
by,1047,O
the,1047,O
current,1047,O
results,1047,O
suggesting,1047,O
alcohol,1047,B-ChemicalEntity
's,1047,O
potential,1047,O
involvement,1047,O
in,1047,O
malignant,1047,O
progression,1047,O
of,1047,O
breast,1047,B-DiseaseOrPhenotypicFeature
cancer,1047,I-DiseaseOrPhenotypicFeature
.,1047,O
CenpH,1048,B-GeneOrGeneProduct
regulates,1048,O
meiotic,1048,O
G2/M,1048,O
transition,1048,O
by,1048,O
modulating,1048,O
the,1048,O
APC/CCdh1-cyclin,1048,B-GeneOrGeneProduct
B1,1048,I-GeneOrGeneProduct
pathway,1048,O
in,1048,O
oocytes,1048,O
.,1048,O
Meiotic,1049,O
resumption,1049,O
(,1049,O
G2/M,1049,O
transition,1049,O
),1049,O
and,1049,O
progression,1049,O
through,1049,O
meiosis,1049,O
I,1049,O
(,1049,O
MI,1049,O
),1049,O
are,1049,O
two,1049,O
key,1049,O
stages,1049,O
for,1049,O
producing,1049,O
fertilization-competent,1049,O
eggs,1049,O
.,1049,O
Here,1050,O
",",1050,O
we,1050,O
report,1050,O
that,1050,O
CenpH,1050,B-GeneOrGeneProduct
",",1050,O
a,1050,O
component,1050,O
of,1050,O
the,1050,O
kinetochore,1050,O
inner,1050,O
plate,1050,O
",",1050,O
is,1050,O
responsible,1050,O
for,1050,O
G2/M,1050,O
transition,1050,O
in,1050,O
meiotic,1050,O
mouse,1050,B-OrganismTaxon
oocytes,1050,O
.,1050,O
Depletion,1051,O
of,1051,O
CenpH,1051,B-GeneOrGeneProduct
by,1051,O
morpholino,1051,B-ChemicalEntity
injection,1051,O
decreased,1051,O
cyclin,1051,B-GeneOrGeneProduct
B1,1051,I-GeneOrGeneProduct
levels,1051,O
",",1051,O
resulting,1051,O
in,1051,O
attenuation,1051,O
of,1051,O
maturation-promoting,1051,B-GeneOrGeneProduct
factor,1051,I-GeneOrGeneProduct
(,1051,O
MPF,1051,B-GeneOrGeneProduct
),1051,O
activation,1051,O
",",1051,O
and,1051,O
severely,1051,O
compromised,1051,O
meiotic,1051,O
resumption,1051,O
.,1051,O
CenpH,1052,B-GeneOrGeneProduct
protects,1052,O
cyclin,1052,B-GeneOrGeneProduct
B1,1052,I-GeneOrGeneProduct
from,1052,O
destruction,1052,O
by,1052,O
competing,1052,O
with,1052,O
the,1052,O
action,1052,O
of,1052,O
APC/C,1052,B-GeneOrGeneProduct
(,1052,O
Cdh1,1052,B-GeneOrGeneProduct
),1052,O
Impaired,1052,O
G2/M,1052,O
transition,1052,O
after,1052,O
CenpH,1052,B-GeneOrGeneProduct
depletion,1052,O
could,1052,O
be,1052,O
rescued,1052,O
by,1052,O
expression,1052,O
of,1052,O
exogenous,1052,O
cyclin,1052,B-GeneOrGeneProduct
B1,1052,I-GeneOrGeneProduct
.,1052,O
Unexpectedly,1053,O
",",1053,O
blocking,1053,O
CenpH,1053,B-GeneOrGeneProduct
did,1053,O
not,1053,O
affect,1053,O
spindle,1053,O
organization,1053,O
and,1053,O
meiotic,1053,O
cell,1053,O
cycle,1053,O
progression,1053,O
after,1053,O
germinal,1053,O
vesicle,1053,O
breakdown,1053,O
.,1053,O
Our,1054,O
findings,1054,O
reveal,1054,O
a,1054,O
novel,1054,O
role,1054,O
of,1054,O
CenpH,1054,B-GeneOrGeneProduct
in,1054,O
regulating,1054,O
meiotic,1054,O
G2/M,1054,O
transition,1054,O
by,1054,O
acting,1054,O
via,1054,O
the,1054,O
APC/C,1054,B-GeneOrGeneProduct
(,1054,O
Cdh1,1054,B-GeneOrGeneProduct
),1054,O
-cyclin,1054,O
B1,1054,I-GeneOrGeneProduct
pathway,1054,O
.,1054,O
Concordance,1055,O
between,1055,O
PIK3CA,1055,B-GeneOrGeneProduct
mutations,1055,O
in,1055,O
endoscopic,1055,O
biopsy,1055,O
and,1055,O
surgically,1055,O
resected,1055,O
specimens,1055,O
of,1055,O
esophageal,1055,B-DiseaseOrPhenotypicFeature
squamous,1055,I-DiseaseOrPhenotypicFeature
cell,1055,I-DiseaseOrPhenotypicFeature
carcinoma,1055,I-DiseaseOrPhenotypicFeature
.,1055,O
BACKGROUND,1056,O
:,1056,O
PIK3CA,1056,B-GeneOrGeneProduct
mutations,1056,O
are,1056,O
expected,1056,O
to,1056,O
be,1056,O
potential,1056,O
therapeutic,1056,O
targets,1056,O
for,1056,O
esophageal,1056,B-DiseaseOrPhenotypicFeature
squamous,1056,I-DiseaseOrPhenotypicFeature
cell,1056,I-DiseaseOrPhenotypicFeature
carcinoma,1056,I-DiseaseOrPhenotypicFeature
(,1056,O
ESCC,1056,B-DiseaseOrPhenotypicFeature
),1056,O
.,1056,O
We,1057,O
aimed,1057,O
to,1057,O
clarify,1057,O
the,1057,O
concordance,1057,O
between,1057,O
PIK3CA,1057,B-GeneOrGeneProduct
mutations,1057,O
detected,1057,O
in,1057,O
endoscopic,1057,O
biopsy,1057,O
specimens,1057,O
and,1057,O
corresponding,1057,O
surgically,1057,O
resected,1057,O
specimens,1057,O
.,1057,O
METHODS,1058,O
:,1058,O
We,1058,O
examined,1058,O
five,1058,O
hotspot,1058,O
mutations,1058,O
in,1058,O
the,1058,O
PIK3CA,1058,B-GeneOrGeneProduct
gene,1058,O
(,1058,O
E542K,1058,B-SequenceVariant
",",1058,O
E545K,1058,B-SequenceVariant
",",1058,O
E546K,1058,B-SequenceVariant
",",1058,O
H1047R,1058,B-SequenceVariant
",",1058,O
and,1058,O
H1047L,1058,B-SequenceVariant
),1058,O
in,1058,O
formalin-fixed,1058,B-ChemicalEntity
and,1058,O
paraffin-embedded,1058,B-ChemicalEntity
tissue,1058,O
sections,1058,O
of,1058,O
paired,1058,O
endoscopic,1058,O
biopsy,1058,O
and,1058,O
surgically,1058,O
resected,1058,O
specimens,1058,O
from,1058,O
181,1058,O
patients,1058,B-OrganismTaxon
undergoing,1058,O
curative,1058,O
resection,1058,O
for,1058,O
ESCC,1058,B-DiseaseOrPhenotypicFeature
between,1058,O
2000,1058,O
and,1058,O
2011,1058,O
using,1058,O
a,1058,O
Luminex,1058,O
technology-based,1058,O
multiplex,1058,O
gene,1058,O
mutation,1058,O
detection,1058,O
kit,1058,O
.,1058,O
RESULTS,1059,O
:,1059,O
Mutation,1059,O
analyses,1059,O
were,1059,O
successfully,1059,O
performed,1059,O
for,1059,O
both,1059,O
endoscopic,1059,O
biopsy,1059,O
and,1059,O
surgically,1059,O
resected,1059,O
specimens,1059,O
in,1059,O
all,1059,O
the,1059,O
cases,1059,O
.,1059,O
A,1060,O
PIK3CA,1060,B-GeneOrGeneProduct
mutation,1060,O
was,1060,O
detected,1060,O
in,1060,O
either,1060,O
type,1060,O
of,1060,O
specimen,1060,O
in,1060,O
13,1060,O
cases,1060,O
(,1060,O
7.2,1060,O
%,1060,O
",",1060,O
95,1060,O
%,1060,O
confidence,1060,O
interval,1060,O
:,1060,O
3.9-12.0,1060,O
),1060,O
.,1060,O
The,1061,O
overall,1061,O
concordance,1061,O
rate,1061,O
",",1061,O
positive,1061,O
predictive,1061,O
value,1061,O
",",1061,O
and,1061,O
negative,1061,O
predictive,1061,O
value,1061,O
were,1061,O
98.3,1061,O
%,1061,O
(,1061,O
178/181,1061,O
),1061,O
",",1061,O
90.9,1061,O
%,1061,O
(,1061,O
10/11,1061,O
),1061,O
",",1061,O
and,1061,O
98.8,1061,O
%,1061,O
(,1061,O
168/170,1061,O
),1061,O
",",1061,O
respectively,1061,O
.,1061,O
Among,1062,O
patients,1062,B-OrganismTaxon
with,1062,O
a,1062,O
PIK3CA,1062,B-GeneOrGeneProduct
mutation,1062,O
detected,1062,O
in,1062,O
both,1062,O
types,1062,O
of,1062,O
specimens,1062,O
",",1062,O
the,1062,O
concordance,1062,O
between,1062,O
PIK3CA,1062,B-GeneOrGeneProduct
mutation,1062,O
genotypes,1062,O
was,1062,O
100,1062,O
%,1062,O
.,1062,O
There,1063,O
were,1063,O
three,1063,O
cases,1063,O
with,1063,O
a,1063,O
discordant,1063,O
mutation,1063,O
status,1063,O
between,1063,O
the,1063,O
types,1063,O
of,1063,O
specimens,1063,O
(,1063,O
PIK3CA,1063,B-GeneOrGeneProduct
mutation,1063,O
in,1063,O
surgically,1063,O
resected,1063,O
specimen,1063,O
and,1063,O
wild-type,1063,O
in,1063,O
biopsy,1063,O
specimen,1063,O
in,1063,O
two,1063,O
cases,1063,O
",",1063,O
and,1063,O
the,1063,O
opposite,1063,O
pattern,1063,O
in,1063,O
one,1063,O
case,1063,O
),1063,O
",",1063,O
suggesting,1063,O
possible,1063,O
intratumoral,1063,O
heterogeneity,1063,O
in,1063,O
the,1063,O
PIK3CA,1063,B-GeneOrGeneProduct
mutation,1063,O
status,1063,O
.,1063,O
CONCLUSIONS,1064,O
:,1064,O
The,1064,O
PIK3CA,1064,B-GeneOrGeneProduct
mutation,1064,O
status,1064,O
was,1064,O
highly,1064,O
concordant,1064,O
between,1064,O
endoscopic,1064,O
biopsy,1064,O
and,1064,O
surgically,1064,O
resected,1064,O
specimens,1064,O
from,1064,O
the,1064,O
same,1064,O
patient,1064,B-OrganismTaxon
",",1064,O
suggesting,1064,O
that,1064,O
endoscopic,1064,O
biopsy,1064,O
specimens,1064,O
can,1064,O
be,1064,O
clinically,1064,O
used,1064,O
to,1064,O
detect,1064,O
PIK3CA,1064,B-GeneOrGeneProduct
mutations,1064,O
in,1064,O
patients,1064,B-OrganismTaxon
with,1064,O
ESCC,1064,B-DiseaseOrPhenotypicFeature
.,1064,O
Oncogenic,1065,O
activity,1065,O
of,1065,O
amplified,1065,O
miniature,1065,B-GeneOrGeneProduct
chromosome,1065,I-GeneOrGeneProduct
maintenance,1065,I-GeneOrGeneProduct
8,1065,I-GeneOrGeneProduct
in,1065,O
human,1065,B-OrganismTaxon
malignancies,1065,B-DiseaseOrPhenotypicFeature
.,1065,O
Miniature,1066,B-GeneOrGeneProduct
chromosome,1066,I-GeneOrGeneProduct
maintenance,1066,I-GeneOrGeneProduct
(,1066,O
MCM,1066,B-GeneOrGeneProduct
),1066,O
proteins,1066,O
play,1066,O
critical,1066,O
roles,1066,O
in,1066,O
DNA,1066,O
replication,1066,O
licensing,1066,O
",",1066,O
initiation,1066,O
and,1066,O
elongation,1066,O
.,1066,O
MCM8,1067,B-GeneOrGeneProduct
",",1067,O
one,1067,O
of,1067,O
the,1067,O
MCM,1067,B-GeneOrGeneProduct
proteins,1067,O
playing,1067,O
a,1067,O
critical,1067,O
role,1067,O
in,1067,O
DNA,1067,O
repairing,1067,O
and,1067,O
recombination,1067,O
",",1067,O
was,1067,O
found,1067,O
to,1067,O
have,1067,O
overexpression,1067,O
and,1067,O
increased,1067,O
DNA,1067,O
copy,1067,O
number,1067,O
in,1067,O
a,1067,O
variety,1067,O
of,1067,O
human,1067,B-OrganismTaxon
malignancies,1067,B-DiseaseOrPhenotypicFeature
.,1067,O
The,1068,O
gain,1068,O
of,1068,O
MCM8,1068,B-GeneOrGeneProduct
is,1068,O
associated,1068,O
with,1068,O
aggressive,1068,O
clinical,1068,O
features,1068,O
of,1068,O
several,1068,O
human,1068,B-OrganismTaxon
cancers,1068,B-DiseaseOrPhenotypicFeature
.,1068,O
Increased,1069,O
expression,1069,O
of,1069,O
MCM8,1069,B-GeneOrGeneProduct
in,1069,O
prostate,1069,B-DiseaseOrPhenotypicFeature
cancer,1069,I-DiseaseOrPhenotypicFeature
is,1069,O
associated,1069,O
with,1069,O
cancer,1069,B-DiseaseOrPhenotypicFeature
recurrence,1069,O
.,1069,O
Forced,1070,O
expression,1070,O
of,1070,O
MCM8,1070,B-GeneOrGeneProduct
in,1070,O
RWPE1,1070,B-CellLine
cells,1070,O
",",1070,O
the,1070,O
immortalized,1070,O
but,1070,O
non-transformed,1070,O
prostate,1070,O
epithelial,1070,O
cell,1070,O
line,1070,O
",",1070,O
exhibited,1070,O
fast,1070,O
cell,1070,O
growth,1070,O
and,1070,O
transformation,1070,O
",",1070,O
while,1070,O
knock,1070,O
down,1070,O
of,1070,O
MCM8,1070,B-GeneOrGeneProduct
in,1070,O
PC3,1070,B-CellLine
",",1070,O
DU145,1070,B-CellLine
and,1070,O
LNCaP,1070,B-CellLine
cells,1070,O
induced,1070,O
cell,1070,O
growth,1070,O
arrest,1070,O
",",1070,O
and,1070,O
decreased,1070,O
tumour,1070,B-DiseaseOrPhenotypicFeature
volumes,1070,O
and,1070,O
mortality,1070,O
of,1070,O
severe,1070,O
combined,1070,O
immunodeficiency,1070,B-DiseaseOrPhenotypicFeature
mice,1070,B-OrganismTaxon
xenografted,1070,O
with,1070,O
PC3,1070,B-CellLine
and,1070,O
DU145,1070,B-CellLine
cells,1070,O
.,1070,O
MCM8,1071,B-GeneOrGeneProduct
bound,1071,O
cyclin,1071,B-GeneOrGeneProduct
D1,1071,I-GeneOrGeneProduct
and,1071,O
activated,1071,O
Rb,1071,B-GeneOrGeneProduct
protein,1071,O
phosphorylation,1071,O
by,1071,O
cyclin-dependent,1071,B-GeneOrGeneProduct
kinase,1071,I-GeneOrGeneProduct
4,1071,I-GeneOrGeneProduct
in,1071,O
vitro,1071,O
and,1071,O
in,1071,O
vivo,1071,O
.,1071,O
The,1072,O
cyclin,1072,B-GeneOrGeneProduct
D1/MCM8,1072,O
interaction,1072,O
is,1072,O
required,1072,O
for,1072,O
Rb,1072,B-GeneOrGeneProduct
phosphorylation,1072,O
and,1072,O
S-phase,1072,O
entry,1072,O
in,1072,O
cancer,1072,B-DiseaseOrPhenotypicFeature
cells,1072,O
.,1072,O
As,1073,O
a,1073,O
result,1073,O
",",1073,O
our,1073,O
study,1073,O
showed,1073,O
that,1073,O
copy,1073,O
number,1073,O
increase,1073,O
and,1073,O
overexpression,1073,O
of,1073,O
MCM8,1073,B-GeneOrGeneProduct
may,1073,O
play,1073,O
critical,1073,O
roles,1073,O
in,1073,O
human,1073,B-OrganismTaxon
cancer,1073,B-DiseaseOrPhenotypicFeature
development,1073,O
.,1073,O
A,1074,O
Type,1074,B-DiseaseOrPhenotypicFeature
2,1074,I-DiseaseOrPhenotypicFeature
Diabetes-Associated,1074,O
Functional,1074,O
Regulatory,1074,O
Variant,1074,O
in,1074,O
a,1074,O
Pancreatic,1074,O
Islet,1074,O
Enhancer,1074,O
at,1074,O
the,1074,O
ADCY5,1074,B-GeneOrGeneProduct
Locus,1074,O
.,1074,O
Molecular,1075,O
mechanisms,1075,O
remain,1075,O
unknown,1075,O
for,1075,O
most,1075,O
type,1075,B-DiseaseOrPhenotypicFeature
2,1075,I-DiseaseOrPhenotypicFeature
diabetes,1075,I-DiseaseOrPhenotypicFeature
genome-wide,1075,O
association,1075,O
study,1075,O
identified,1075,O
loci,1075,O
.,1075,O
Variants,1076,O
associated,1076,O
with,1076,O
type,1076,B-DiseaseOrPhenotypicFeature
2,1076,I-DiseaseOrPhenotypicFeature
diabetes,1076,I-DiseaseOrPhenotypicFeature
and,1076,O
fasting,1076,O
glucose,1076,B-ChemicalEntity
levels,1076,O
reside,1076,O
in,1076,O
introns,1076,O
of,1076,O
ADCY5,1076,B-GeneOrGeneProduct
",",1076,O
a,1076,O
gene,1076,O
that,1076,O
encodes,1076,O
adenylate,1076,B-GeneOrGeneProduct
cyclase,1076,I-GeneOrGeneProduct
5,1076,I-GeneOrGeneProduct
.,1076,O
Adenylate,1077,B-GeneOrGeneProduct
cyclase,1077,I-GeneOrGeneProduct
5,1077,I-GeneOrGeneProduct
catalyzes,1077,O
the,1077,O
production,1077,O
of,1077,O
cyclic,1077,B-ChemicalEntity
AMP,1077,I-ChemicalEntity
",",1077,O
which,1077,O
is,1077,O
a,1077,O
second,1077,O
messenger,1077,O
molecule,1077,O
involved,1077,O
in,1077,O
cell,1077,O
signaling,1077,O
and,1077,O
pancreatic,1077,O
b-cell,1077,O
insulin,1077,B-GeneOrGeneProduct
secretion,1077,O
.,1077,O
We,1078,O
demonstrated,1078,O
that,1078,O
type,1078,B-DiseaseOrPhenotypicFeature
2,1078,I-DiseaseOrPhenotypicFeature
diabetes,1078,I-DiseaseOrPhenotypicFeature
risk,1078,O
alleles,1078,O
are,1078,O
associated,1078,O
with,1078,O
decreased,1078,O
ADCY5,1078,B-GeneOrGeneProduct
expression,1078,O
in,1078,O
human,1078,B-OrganismTaxon
islets,1078,O
and,1078,O
examined,1078,O
candidate,1078,O
variants,1078,O
for,1078,O
regulatory,1078,O
function,1078,O
.,1078,O
rs11708067,1079,B-SequenceVariant
overlaps,1079,O
a,1079,O
predicted,1079,O
enhancer,1079,O
region,1079,O
in,1079,O
pancreatic,1079,O
islets,1079,O
.,1079,O
The,1080,O
type,1080,B-DiseaseOrPhenotypicFeature
2,1080,I-DiseaseOrPhenotypicFeature
diabetes,1080,I-DiseaseOrPhenotypicFeature
risk,1080,O
rs11708067-A,1080,B-SequenceVariant
allele,1080,O
showed,1080,O
fewer,1080,O
H3K27ac,1080,O
ChIP-seq,1080,O
reads,1080,O
in,1080,O
human,1080,B-OrganismTaxon
islets,1080,O
",",1080,O
lower,1080,O
transcriptional,1080,O
activity,1080,O
in,1080,O
reporter,1080,O
assays,1080,O
in,1080,O
rodent,1080,O
b-cells,1080,O
(,1080,O
rat,1080,B-OrganismTaxon
832/13,1080,B-CellLine
and,1080,O
mouse,1080,B-OrganismTaxon
MIN6,1080,B-CellLine
),1080,O
",",1080,O
and,1080,O
increased,1080,O
nuclear,1080,O
protein,1080,O
binding,1080,O
compared,1080,O
with,1080,O
the,1080,O
rs11708067-G,1080,B-SequenceVariant
allele,1080,O
.,1080,O
Homozygous,1081,O
deletion,1081,O
of,1081,O
the,1081,O
orthologous,1081,O
enhancer,1081,O
region,1081,O
in,1081,O
832/13,1081,B-CellLine
cells,1081,O
resulted,1081,O
in,1081,O
a,1081,O
64,1081,O
%,1081,O
reduction,1081,O
in,1081,O
expression,1081,O
level,1081,O
of,1081,O
Adcy5,1081,B-GeneOrGeneProduct
",",1081,O
but,1081,O
not,1081,O
adjacent,1081,O
gene,1081,O
Sec22a,1081,B-GeneOrGeneProduct
",",1081,O
and,1081,O
a,1081,O
39,1081,O
%,1081,O
reduction,1081,O
in,1081,O
insulin,1081,B-GeneOrGeneProduct
secretion,1081,O
.,1081,O
Together,1082,O
",",1082,O
these,1082,O
data,1082,O
suggest,1082,O
that,1082,O
rs11708067-A,1082,B-SequenceVariant
risk,1082,O
allele,1082,O
contributes,1082,O
to,1082,O
type,1082,B-DiseaseOrPhenotypicFeature
2,1082,I-DiseaseOrPhenotypicFeature
diabetes,1082,I-DiseaseOrPhenotypicFeature
by,1082,O
disrupting,1082,O
an,1082,O
islet,1082,O
enhancer,1082,O
",",1082,O
which,1082,O
results,1082,O
in,1082,O
reduced,1082,O
ADCY5,1082,B-GeneOrGeneProduct
expression,1082,O
and,1082,O
impaired,1082,B-DiseaseOrPhenotypicFeature
insulin,1082,I-DiseaseOrPhenotypicFeature
secretion,1082,I-DiseaseOrPhenotypicFeature
.,1082,O
Interleukin,1083,B-GeneOrGeneProduct
6,1083,I-GeneOrGeneProduct
(,1083,O
IL-6,1083,B-GeneOrGeneProduct
),1083,O
and,1083,O
Tumor,1083,B-GeneOrGeneProduct
Necrosis,1083,I-GeneOrGeneProduct
Factor,1083,I-GeneOrGeneProduct
alpha,1083,I-GeneOrGeneProduct
(,1083,O
TNF-alpha,1083,B-GeneOrGeneProduct
),1083,O
Single,1083,O
Nucleotide,1083,O
Polymorphisms,1083,O
(,1083,O
SNPs,1083,O
),1083,O
",",1083,O
Inflammation,1083,B-DiseaseOrPhenotypicFeature
and,1083,O
Metabolism,1083,O
in,1083,O
Gestational,1083,B-DiseaseOrPhenotypicFeature
Diabetes,1083,I-DiseaseOrPhenotypicFeature
Mellitus,1083,I-DiseaseOrPhenotypicFeature
in,1083,O
Inner,1083,O
Mongolia,1083,O
.,1083,O
BACKGROUND,1084,O
Gestational,1084,B-DiseaseOrPhenotypicFeature
diabetes,1084,I-DiseaseOrPhenotypicFeature
mellitus,1084,I-DiseaseOrPhenotypicFeature
(,1084,O
GDM,1084,B-DiseaseOrPhenotypicFeature
),1084,O
is,1084,O
common,1084,O
all,1084,O
over,1084,O
the,1084,O
world,1084,O
.,1084,O
GDM,1085,B-DiseaseOrPhenotypicFeature
women,1085,B-OrganismTaxon
are,1085,O
with,1085,O
inflammatory,1085,B-DiseaseOrPhenotypicFeature
and,1085,O
metabolisms,1085,B-DiseaseOrPhenotypicFeature
abnormalities,1085,I-DiseaseOrPhenotypicFeature
.,1085,O
However,1086,O
",",1086,O
few,1086,O
studies,1086,O
have,1086,O
focused,1086,O
on,1086,O
the,1086,O
association,1086,O
of,1086,O
IL-65-72C/G,1086,B-GeneOrGeneProduct
and,1086,O
TNF-alpha,1086,B-GeneOrGeneProduct
-857C/T,1086,B-SequenceVariant
single,1086,O
nucleotide,1086,O
polymorphisms,1086,O
(,1086,O
SNPs,1086,O
),1086,O
",",1086,O
inflammatory,1086,B-DiseaseOrPhenotypicFeature
biomarkers,1086,O
",",1086,O
and,1086,O
metabolic,1086,O
indexes,1086,O
in,1086,O
women,1086,B-OrganismTaxon
with,1086,O
GDM,1086,B-DiseaseOrPhenotypicFeature
",",1086,O
especially,1086,O
in,1086,O
the,1086,O
Inner,1086,O
Mongolia,1086,O
population,1086,O
.,1086,O
The,1087,O
aim,1087,O
of,1087,O
this,1087,O
study,1087,O
was,1087,O
to,1087,O
investigate,1087,O
the,1087,O
associations,1087,O
of,1087,O
IL-65-72C/G,1087,B-GeneOrGeneProduct
and,1087,O
TNF-alpha,1087,B-GeneOrGeneProduct
-857C/T,1087,B-SequenceVariant
SNPs,1087,O
",",1087,O
and,1087,O
inflammation,1087,B-DiseaseOrPhenotypicFeature
and,1087,O
metabolic,1087,O
biomarkers,1087,O
in,1087,O
women,1087,B-OrganismTaxon
with,1087,O
GDM,1087,B-DiseaseOrPhenotypicFeature
pregnancies,1087,O
.,1087,O
MATERIAL,1088,O
AND,1088,O
METHODS,1088,O
Blood,1088,O
samples,1088,O
and,1088,O
placentas,1088,O
from,1088,O
140,1088,O
women,1088,B-OrganismTaxon
with,1088,O
GDM,1088,B-DiseaseOrPhenotypicFeature
and,1088,O
140,1088,O
women,1088,B-OrganismTaxon
with,1088,O
healthy,1088,O
pregnancies,1088,O
were,1088,O
collected,1088,O
.,1088,O
Matrix-assisted,1089,O
laser,1089,O
desorption,1089,O
ionization,1089,O
time,1089,O
of,1089,O
flight,1089,O
mass,1089,O
spectrometry,1089,O
(,1089,O
MALDI-TOF-MS,1089,O
),1089,O
and,1089,O
MassARRAY-IPLEX,1089,O
were,1089,O
performed,1089,O
to,1089,O
analyze,1089,O
IL-65-72C/G,1089,B-GeneOrGeneProduct
and,1089,O
TNF-alpha,1089,B-GeneOrGeneProduct
-857C/T,1089,B-SequenceVariant
SNPs,1089,O
.,1089,O
Enzyme,1090,O
linked,1090,O
immunosorbent,1090,O
assay,1090,O
(,1090,O
ELISA,1090,O
),1090,O
was,1090,O
performed,1090,O
to,1090,O
analyze,1090,O
inflammatory,1090,B-DiseaseOrPhenotypicFeature
biomarkers,1090,O
and,1090,O
adipokines,1090,B-GeneOrGeneProduct
.,1090,O
RESULTS,1091,O
Distribution,1091,O
frequency,1091,O
of,1091,O
TNF-alpha,1091,B-GeneOrGeneProduct
-857CT,1091,B-SequenceVariant
(,1091,O
OR=3.316,1091,O
",",1091,O
95,1091,O
%,1091,O
CI=1.092-8.304,1091,O
",",1091,O
p=0.025,1091,O
),1091,O
in,1091,O
women,1091,B-OrganismTaxon
with,1091,O
GDM,1091,B-DiseaseOrPhenotypicFeature
pregnancies,1091,O
were,1091,O
obviously,1091,O
higher,1091,O
than,1091,O
that,1091,O
in,1091,O
women,1091,B-OrganismTaxon
with,1091,O
healthy,1091,O
pregnancies,1091,O
.,1091,O
Women,1092,B-OrganismTaxon
with,1092,O
GDM,1092,B-DiseaseOrPhenotypicFeature
were,1092,O
of,1092,O
older,1092,O
maternal,1092,O
age,1092,O
",",1092,O
had,1092,O
higher,1092,O
BMI,1092,O
",",1092,O
were,1092,O
more,1092,O
nulliparous,1092,O
",",1092,O
and,1092,O
had,1092,O
T2DM,1092,B-DiseaseOrPhenotypicFeature
and,1092,O
GDM,1092,B-DiseaseOrPhenotypicFeature
history,1092,O
",",1092,O
compared,1092,O
to,1092,O
women,1092,B-OrganismTaxon
with,1092,O
healthy,1092,O
pregnancies,1092,O
(,1092,O
p,1092,O
<,1092,O
0.05,1092,O
),1092,O
.,1092,O
Inflammatory,1093,B-DiseaseOrPhenotypicFeature
biomarkers,1093,O
in,1093,O
serum,1093,O
(,1093,O
hs-CRP,1093,O
",",1093,O
IL-6,1093,B-GeneOrGeneProduct
",",1093,O
IL-8,1093,B-GeneOrGeneProduct
",",1093,O
IL-6/IL-10,1093,B-GeneOrGeneProduct
ratio,1093,O
),1093,O
and,1093,O
placental,1093,O
(,1093,O
NF-kappaB,1093,B-GeneOrGeneProduct
",",1093,O
IL-6,1093,B-GeneOrGeneProduct
",",1093,O
IL-8,1093,B-GeneOrGeneProduct
",",1093,O
IL-6/IL-10,1093,B-GeneOrGeneProduct
ratio,1093,O
",",1093,O
IL-1b,1093,B-GeneOrGeneProduct
",",1093,O
TNF-alpha,1093,B-GeneOrGeneProduct
),1093,O
were,1093,O
significantly,1093,O
different,1093,O
(,1093,O
p,1093,O
<,1093,O
0.05,1093,O
),1093,O
between,1093,O
women,1093,B-OrganismTaxon
with,1093,O
GDM,1093,B-DiseaseOrPhenotypicFeature
and,1093,O
women,1093,B-OrganismTaxon
with,1093,O
healthy,1093,O
pregnancies,1093,O
.,1093,O
Differences,1094,O
were,1094,O
found,1094,O
for,1094,O
serum,1094,O
FBG,1094,O
",",1094,O
FINS,1094,O
",",1094,O
HOMA-IR,1094,O
",",1094,O
and,1094,O
HOMA-beta,1094,O
",",1094,O
and,1094,O
placental,1094,O
IRS-1,1094,B-GeneOrGeneProduct
",",1094,O
IRS-2,1094,B-GeneOrGeneProduct
",",1094,O
leptin,1094,B-GeneOrGeneProduct
",",1094,O
adiponectin,1094,B-GeneOrGeneProduct
",",1094,O
visfatin,1094,B-GeneOrGeneProduct
",",1094,O
RBP-4,1094,B-GeneOrGeneProduct
",",1094,O
chemerin,1094,B-GeneOrGeneProduct
",",1094,O
nesfatin-1,1094,B-GeneOrGeneProduct
",",1094,O
FATP-4,1094,B-GeneOrGeneProduct
",",1094,O
EL,1094,B-GeneOrGeneProduct
",",1094,O
LPL,1094,B-GeneOrGeneProduct
",",1094,O
FABP-1,1094,B-GeneOrGeneProduct
",",1094,O
FABP-3,1094,B-GeneOrGeneProduct
",",1094,O
FABP-4,1094,B-GeneOrGeneProduct
",",1094,O
and,1094,O
FABP-5,1094,B-GeneOrGeneProduct
.,1094,O
CONCLUSIONS,1095,O
TNF-alpha,1095,B-GeneOrGeneProduct
-857C/T,1095,B-SequenceVariant
SNP,1095,O
",",1095,O
hs-CRP,1095,O
",",1095,O
IL-6,1095,B-GeneOrGeneProduct
",",1095,O
IL-8,1095,B-GeneOrGeneProduct
",",1095,O
and,1095,O
IL-6/IL-10,1095,B-GeneOrGeneProduct
were,1095,O
associated,1095,O
with,1095,O
GDM,1095,B-DiseaseOrPhenotypicFeature
in,1095,O
women,1095,B-OrganismTaxon
from,1095,O
Inner,1095,O
Mongolia,1095,O
",",1095,O
as,1095,O
was,1095,O
serious,1095,O
inflammation,1095,B-DiseaseOrPhenotypicFeature
and,1095,O
disordered,1095,B-DiseaseOrPhenotypicFeature
lipid,1095,I-DiseaseOrPhenotypicFeature
and,1095,I-DiseaseOrPhenotypicFeature
glucose,1095,I-DiseaseOrPhenotypicFeature
metabolisms,1095,I-DiseaseOrPhenotypicFeature
.,1095,O
